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Radiotherapy (RT) is commonly used for the local control of many cancer 
types. Unfortunately, not all patients will achieve a therapeutic benefit, and some 
will develop loco-regional recurrences and/or metastatic disease. The hypoxic nature 
of the tumour microenvironment and the development of radioresistant cancer cells 
can contribute to these treatment failures. Understanding the mechanisms involved in 
acquired radioresistance and the development of techniques to identify and target 
hypoxic tumour areas has the potential to improve RT response rates. 
The first aim of this project was to investigate the development of acquired 
radioresistance and identify radiation-induced secreted biomarkers which could be 
used as indicators of a radiation response or radiosensitivity. Human radioresistant 
(RR) breast cancer cell lines were developed from parental MCF-7, ZR-751 and 
MDA-MB-231 cells. Parental and RR cells underwent genotypic, phenotypic and 
functional characterisation. RR cells exhibited enhanced migration and invasion, 
with evidence of epithelial-to-mesenchymal transition. MCF-7 RR and ZR-751 RR 
cell lines exhibited significant phenotypic changes, including loss of ERα and PgR 
expression and increased EGFR expression, which were associated with the down-
regulation of ER signalling genes and up-regulation of genes associated with PI3K, 
MAPK and WNT pathway activation. A change in subtype classification from 
luminal A to HER2-overexpressing (MCF-7 RR) and normal-like (ZR-751 RR) 
subtypes was also observed, consistent with radiation and endocrine therapy 
resistance and a more aggressive phenotype. 
To identify biomarkers secreted in response to radiation, human and canine 
breast and ovine lung cancer cell lines were radiated. Secretome samples were 
analysed by liquid chromatography-mass spectrometry. Using results from the MCF-
7 cell line, 33 radiation-induced secreted biomarkers were identified which had 
higher (up to 12-fold) secretion levels compared to untreated controls. Based on 
secretion profiles and functional analysis 9 candidate biomarkers were selected 
(YBX3, TK1, SEC24C, EIF3G, EIF4EBP2, NAP1L4, VPS29, GNPNAT1 and 
DKK1) of which the first 4 underwent in-lab validation. To identify biomarkers 
related to radiosensitivity transcriptomic analysis identified higher expression of 
genes encoding 7 of the candidate biomarkers in the MCF-7 cell line compared to its 
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radioresistant derivative. WB analysis identified increased levels of the 4 biomarkers 
in the conditioned media of parental cells 24 h post-radiation which was not seen in 
the RR cell lines. These biomarkers, which had differential gene expression and 
secretion profiles between parental and RR cell lines, may be useful for both 
predicting and monitoring a tumour’s response to RT. 
A further aim was to investigate the biocompatibility and functionality of an 
implantable electrochemical sensor, developed within the Engineering and Physical 
Sciences Research Council funded IMPACT project. This sensor was designed to 
measure tissue O2 tension (ptO2) within a tumour, enabling the identification and 
monitoring of radioresistant hypoxic tumour areas. This study developed a novel in 
vivo tumour xenograft model to evaluate the potential of 6 materials (silicon dioxide, 
silicon nitride, Parylene-C, Nafion, biocompatible EPOTEK epoxy resin and 
platinum) used in the construction of the sensor, to trigger a foreign body response 
(FBR) when implanted into a solid tumour. Following implantation none of the 
materials affected tumour growth and all mice remained healthy. 
Immunohistochemistry performed on the tumour showed no significant changes in 
necrosis, hypoxic cell number, proliferation, apoptosis, immune cell infiltration or 
collagen deposition around the implant site. The absence of a FBR supports their use 
in the construction of implantable medical devices. 
In vivo validation of the O2 sensor to provide real-time measurements on 
intra-tumoural ptO2 was performed using a novel large animal ovine model. To 
achieve this aim, we developed a novel computed tomography (CT) guided trans-
thoracic percutaneous implantation technique for the delivery of sensors into 
naturally occurring ovine pulmonary adenocarcinoma (OPA) tumours. This model 
successfully integrated techniques such as ultrasound, general anaesthesia, CT and 
surgery into the OPA model, all of which are techniques commonly used in the 
treatment of human lung cancer patients. This methodology resulted in the accurate 
implantation of sensors into OPA tumours with minimal complications and 
demonstrated the sensor’s ability to detect changes in intra-tumoural ptO2 following 
manipulation of the inspired fractional O2 concentration (FiO2). 
To investigate other possible clinical applications, sensors were validated for 
measuring intestinal ptO2 using a novel rat model. These experiments assessed the 
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potential of the sensor to monitor intestinal perfusion following an intestinal 
resection and anastomosis. The sensor was placed onto the serosal surface of the 
small intestine of anaesthetised rats that were subsequently exposed to ischaemic, 
hypoxaemic and haemorrhagic insults. Decreases in intestinal ptO2 were observed 
following superior mesenteric artery occlusion and reductions in FiO2; these changes 
were reversible after reinstating blood flow or increasing FiO2. These results 
provided evidence that the sensors could detect changes in intestinal perfusion which 
could be utilised in a clinical setting to monitor peri-anastomotic intestinal ptO2. 
Overall this PhD project has conducted both in vitro and in vivo work aimed 
at the investigation of mechanisms of radioresistance, identifying secreted 
biomarkers of radiosensitivity and validating the ability of an implantable sensor to 
measure real-time intra-tumoural and visceral surface O2 tension. Identification of 
factors contributing to poor RT responses, such as radioresistance development and 
hypoxic tumour areas could provide a means by which RT could become 
personalised. Patients identified as having radioresistant tumours or those not 
responding to RT based on radiation-induced secreted biomarkers, could be given 




Cancer is a disease characterised by the abnormal growth of cells within the 
body. The disease can cause patients to die either from cancer cells destroying the 
organ from which they started growing in or from spreading throughout the body. 
Radiotherapy (RT) is a commonly used cancer treatment that causes cancer cell 
death through irreparable DNA damage. Unfortunately, this treatment does not 
always work. Low O2 levels (hypoxia) within the tumour and the presence of 
radioresistant (RR) cancer cells can decrease the effectiveness of RT. 
Breast cancer is the most commonly diagnosed female cancer in the world, 
with 2 million cases and 0.7 million deaths occurring per year. Breast tumours can 
develop resistance to radiation, which leads to the development of aggressive cancer 
cells and disease recurrence. One of the aims of this project was to model the 
development of breast cancer radioresistance in the lab so that we can study changes 
in the cells which could warn doctors of the emergence of treatment resistant cancer 
cells. To do this, we treated breast cancer cells with high doses of radiation. While 
many cells died, some survived and were able to grow. These are the RR cells that 
would kick-start tumour growth after treatment. By developing these cells, in the 
laboratory setting, we can compare them to the original cells and determine how they 
are different. The main differences we observed were that the RR cells became more 
aggressive, with an increased ability to migrate and invade. These cells also showed 
resistance to endocrine therapy, meaning they had developed resistance to multiple 
treatment strategies. Differences in the proteins that were released from the original 
and RR cells in response to radiation were also seen. The main differences we 
identified were the increased release of EIF3G, SEC24C, YBX3 and TK1 from the 
original cells, which did not occur in the RR cells. We propose that monitoring the 
level of these proteins may help doctors monitor a patient’s response to RT and help 
them to alter the treatment plan accordingly. 
Using a sensor that can be implanted into a tumour to measure tissue O2 
concentrations could improve a patient’s treatment through the identification of RR 
hypoxic tumour areas. Unfortunately, when a foreign material is placed within the 
body a reaction can occur to isolate it from the surrounding tissues. This foreign 
body response (FBR) may limit the devices ability to function correctly. The 
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potential of materials used in the construction of an implantable miniaturised O2 
sensor to trigger this tissue reaction was assessed by implanting them into human 
tumours grown in mice. None of the materials tested had any effect on tumour 
growth or mice body weight, with the mice remaining healthy throughout the 
implantation period. Tumour analysis showed no significant tissue reactions, which 
supports the use of these materials for devices designed for implantation within 
tumours. To assess the ability of working sensors to measure O2 levels within a 
tumour, we implanted them into sheep lung tumours. In order to improve the model’s 
clinical usefulness, we used techniques commonly used in the treatment of human 
lung cancer patients (ultrasound, general anaesthesia, computed tomography and 
surgery). The method resulted in accurate implantation of sensors into lung tumours 
with minimal complications and demonstrated the sensor’s ability to detect changes 
in O2 levels within the tumour. 
The use of these O2 sensors is not only restricted to cancer patients. One 
alternative clinical use is for monitoring intestinal O2 levels as a means of assessing 
intestinal healing following surgery. To investigate this application sensors were 
placed onto the surface of the small intestine of anaesthetised rats. These sensors 
were able to detect lower intestinal O2 levels following ligation of the blood supply 
to the intestine and reduction in blood O2 levels. These results provided evidence that 
the sensors could detect changes in intestinal oxygenation which could be utilised in 
clinical settings following surgery. 
This PhD project has conducted both in vitro and in vivo work aimed at 
investigating mechanisms of radioresistance, identifying proteins released from 
cancer cells in response to radiation and testing the ability of an implantable sensor 
to measure O2 levels within a tumour. In the future, these techniques could be used to 
help personalise RT, whereby patients identified as having RR tumours could be 
given higher dose of radiation or drugs to improve treatment responses. We have also 
shown that these sensors could have multiple applications where the measurement of 
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This introduction chapter is an expanded version of 2 published review articles: 
1) Gray M, Meehan J, Ward C, Langdon SP, Kunkler IH, Murray A, Argyle D. 
Implantable biosensors and their contribution to the future of precision medicine. 
The Veterinary Journal 2018; 239: 21-29. 2) Gray M, Meehan J, Sullivan P, Marland 
JRK, Greenhalgh SN, Gregson R, Clutton RE, Ward C, Cousens C, Griffiths D, 
Murray A, Argyle D. Ovine Pulmonary Adenocarcinoma: A Unique Model to 
Improve Lung Cancer Research. Frontiers in Oncology - Molecular and Cellular 
Oncology 2019; 9(335): 1-11. These articles are open access with the authors 
retaining copyright to their work with permission to use published figures in this 
thesis. Sections of text and figures used from these articles have been referenced 
accordingly. 
1.1 The hallmarks of cancer 
Cancer (also referred to as a malignant tumour or neoplasm) is a term used to 
describe a large group of heterogenous diseases characterised by aberrant growth of 
abnormal cells with a potential to spread from the primary site of origin throughout 
the body (metastasis). Genetic and environmental factors (lifestyle, pathogens or 
carcinogens) can influence cancer development (carcinogenesis) and progression; 
however, carcinogenesis is likely due to a multistep process beginning with the 
accumulation of somatic mutations that eventually leads to an altered genome 
resulting in the transformation of normal cells into malignant ones1-3. 
Carcinogenesis can potentially occur in any cell in the human body that has 
replicative capabilities, because of this more than 100 different cancer types have 
been identified, each of which can have multiple subtypes4. Tumours originating 
from different tissues will be composed of specific cell types and stromal 
components; these factors in combination with malignant cells possessing unique 
genetic alterations make trying to understand cancer as a single disease entity very 
difficult. To overcome these issues Hanahan and Weinberg originally described 6 
essential cell physiology capabilities applicable to all cancer types that can cause 
malignant transformation. These ‘hallmarks’ are: growth signal self-sufficiency, 
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insensitivity to growth suppressors, resisting apoptosis, replicative immortality, 
increased angiogenesis and tissue invasion and metastasis3. With advances in 
understanding tumour biology, 2 further ‘hallmarks’ were subsequently described as 
energy metabolism reprogramming and avoiding immune system destruction5. 
These 8 functional capabilities are likely to develop in different tumour types 
through various mechanisms and at different stages in the process of carcinogenesis, 
these factors ultimately influence how cancer cells survive, proliferate, invade and 
metastasise. The development of these malignant capabilities requires certain cellular 
enabling characteristics, among which genomic instability and tumour promoting 
inflammation are considered important. Hanahan and Weinberg proposed that the 
study of tumour biology should not simply focus on cancer cells but should also 
include the investigation of recruited normal cells that make up the tumour-
associated stroma and the tumour microenvironment (TME), as these factors can also 
play roles in carcinogenesis and the development of hallmark capabilities5. 
1.2 Worldwide cancer incidence and mortality 
Cancer is a disease that occurs throughout the world, creating social and 
economic burdens for both developed and developing countries alike. Although 
advances in pre-clinical and clinical research are improving cancer diagnosis and 
treatment, the disease remains the most common cause of death throughout the 
world. It is estimated that 18.1 million new cancer cases and 9.6 million cancer-
related deaths occurred in 2018; combined data for both sexes showed that lung, 
breast, prostate and colon cancers account for approximately 40% of all newly 
diagnosed cases6. In males, lung cancer is the most frequently diagnosed cancer and 
leading cause of cancer-related deaths, whereas in females, breast cancer is the most 
common. Overall, the top 10 cancer types account for over 65% of newly diagnosed 
cases and deaths (Figure 1.1). If current trends in global population growth combined 
with the effects of an aging population continue, these figures could increase to 20.3 
million new cancer cases and 12.7 million deaths by 20307. 
1.3 United Kingdom cancer incidence and mortality 
Cancer incidence and mortality rates can vary between countries and 
continents. In the United Kingdom, approximately 360,000 new cancer cases and 
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165,000 cancer-related deaths occurred in 20154. Approximately 36% of these new 
cases were diagnosed in people above 75 years of age, giving an indication of the 
effect that the aging population can have on cancer incidence rates. In line with 
global incidences, the 4 most common cancer types in the UK are breast, prostate, 
lung and bowel, which account for approximately 53% of all new cancer cases and 
approximately 45% of all cancer-related deaths. Lung cancer is a major contributor 
to this mortality rate accounting alone for approximately 20% of deaths. The scale of 
the health problem that cancer creates is highlighted by the estimate that in 2016 
cancer accounted for 28% of all UK deaths; these figures are only likely to increase 
as UK cancer incidence rates are expected to rise by 2% by 20354. 
 
Figure 1.1. Pie charts representing the distribution of cancer cases and deaths 
for the 10 most common cancer types in the world in 2018. For each sex, the area 
of the pie chart reflects the percentage of the total number of cases or deaths6.  
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1.4 Precision medicine 
The terms precision and personalised medicine are interchangeable; however, 
concerns amongst clinicians that the term ‘personalised’ could be interpreted as 
treatments/drugs being developed specifically for individual patients has led to the 
term precision medicine being favoured8,9. Precision medicine is defined as the 
incorporation of disease biomarkers, phenotype, molecular signatures, lifestyle and 
environment into the prevention, investigation and treatment of diseases10. Patients 
can be classified according to their differences in disease susceptibility, treatment 
response and prognosis, information which can be used to select patients that are 
most likely to benefit from specific treatments to improve clinical outcome11. 
Precision medicine has gained increased awareness in recent years aided by world 
leaders such as the former President of the United States Barack Obama. His 
‘Precision Medicine Initiative’, announced in 2015 aimed ‘to bring us closer to 
curing diseases like cancer and diabetes – and to give us all access to the 
personalised information we need to keep ourselves and our families healthier’12. 
Dedicated centres such as The Personalised Medicine Coalition in the USA 
and The Centre for Personalised Medicine in the UK will help to improve the use of 
precision medicine into healthcare practices13; however, for precision medicine to be 
integrated into the field of oncology we will need to understand and map tumour 
heterogeneity at genomic, epigenomic and microenvironmental levels14,15. 
1.5 Breast cancer 
Breast cancer is the most common female cancer in the world, with 
approximately 2 million new cases and 0.7 million cancer-related deaths occurring 
per year6. Following a diagnosis of breast cancer, immunohistochemistry (IHC) is 
used to classify the tumour based on the expression of certain cellular receptors. 
These receptors typically include human epidermal growth factor receptor 2 (HER2), 
oestrogen receptor α (ERα), progesterone receptor (PgR) and epidermal growth 
factor receptor (EGFR) which can classify the tumour as hormone dependant or 
independent16. ER⍺ is the most important predictive biomarker, with approximately 
85% of breast cancers expressing this receptor. PgR is expressed in approximately 
67% of breast cancers and is known to regulate epithelial proliferation17 and can alter 
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which genes are stimulated by ER binding18,19. PgR expression is strongly dependent 
on the presence of ER, so the majority of ER+ cancers are also PgR+20. ER+ breast 
cancers are hormone dependent which rely on oestrogen for both carcinogenesis and 
tumour progression. 
1.5.1 Oestrogen signalling 
Oestrogen can modulate gene expression and promote cancer progression 
either directly through the genomic signalling pathway termed nuclear-initiated 
steroid signalling (NISS)21 or indirectly through the non-genomic signalling pathway 
termed membrane-initiated steroid signalling (MISS)22. In NISS oestrogen binds 
directly to ER⍺ causing the formation of an oestrogen-ER⍺ complex. This complex 
translocates to the nucleus where it interacts with co-activators and binds specific 
DNA regions called oestrogen response elements (EREs). These ERS regulate 
transcription of oestrogen responsive genes involved in angiogenesis, apoptosis, 
proliferation and invasion21. In MISS, following ligand binding, the oestrogen-ER⍺ 
complex can interact with and activate other transcription factors and signal 
transduction pathways, such as nuclear factor-κB (NF-κB), activating protein 1 
(AP1), p53, PI3K/AKT and ERK/MAPK. Following their recruitment and activation 
transcription of their target genes can occur22-24. Both the genomic and non-genomic 
pathways can also be activated through cross talk with other oncogenic pathways 
such as those involving the EGFR and HER tyrosine kinases23,25,26. Such interactions 
can lead to ER⍺ signalling activation even in the absence of oestrogen. 
1.5.2 Endocrine therapy 
Typically, early and locally advanced breast cancer is treated with surgery 
followed by adjuvant radiotherapy (RT), chemotherapy and/or endocrine therapy 
(ET). ET plays an important role in the treatment of patients with ER+ breast cancers 
and can be used either to stop oestrogen synthesis or reduce its effect by preventing 
its binding to ER. Although there are various ET strategies, treatment selection is 
usually based on menopausal status, clinicopathological factors and the presence of 
co-morbidities27,28. In pre-menopausal women, as the ovaries are the main source of 
oestrogen production, oestrogen synthesis blockade can be achieved either through 
removal of the ovaries (oophorectomy) or by chemical suppression (luteinising 
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hormone releasing hormone agonists, such as goserilin)16. In post-menopausal 
women the ovaries cease to be the main source of oestrogen production with 
oestrogen instead being synthesised from androgens in bone, fat, and breast tissue 
through a reaction catalysed by the enzyme aromatase29,30. Oestrogen synthesis can 
therefore be blocked through the administration of aromatase inhibitors such as 
anastrazole, letrozole, or exemestane. These inhibitors work either by competing 
with substrates binding to aromatase or by mimicking the substrates of aromatase 
and inactivating the enzyme. The overall result is to reduce the amount of oestrogen 
produced, thus inhibiting tumour growth31. To reduce the effect that oestrogen has on 
cancer cells ER function can also be chemically blocked in both pre- and post-
menopausal women using anti-oestrogens. These drugs include selective ER 
modulators (SERMs) and selective ER down-regulators or degraders (SERDs). 
Tamoxifen is an example of a SERM that acts as a partial oestrogen agonist which 
blocks the ER and removes the growth-promoting effects that oestrogen has on the 
tumour. Fulvestrant is an example of a SERD that acts as a full oestrogen antagonist, 
that both inhibits the ER and accelerates its degradation16. 
Overall, both ER and PgR have been used as diagnostic and predictive 
markers for response to ET treatment since the 1970s32,33 and their assessment by 
IHC is now a mandatory requirement in all breast cancer patients to assist treatment 
selection34. 
1.6 Radiotherapy 
RT remains a commonly used treatment modality for many different cancer 
types with approximately 50% of cancer patients receiving radiation either as a sole 
means of treatment or combined with surgery, ET or chemotherapy35. RT can be 
given as a neoadjuvant treatment with curative intent, such as in prostate36 or 
laryngeal cancers37, or to shrink a tumour before definitive surgery in cases such as 
locally advanced rectal cancer and various forms of head and neck cancers38. RT can 
also be given after surgery as an adjuvant treatment to improve patient outcome39. 
Unfortunately, not all patients obtain a therapeutic benefit from RT; factors such as 
innate40 and acquired radioresistance41 can contribute to treatment failures, resulting 
in local recurrences or metastatic disease. RT is also not a benign procedure; for 
example, in breast cancer known radiation-associated side effects include cardiac and 
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skin toxicities, lymphedema, secondary cancers, rib fractures and brachial 
plexopathy42. The use of RT in a patient’s treatment plan must therefore consider the 
potential therapeutic benefits against the potential patient risks. 
1.6.1 Breast cancer and radiotherapy 
RT with curative intent or as a palliative treatment is estimated to benefit up 
to 83% of breast cancer patients43. Multiple studies have also shown that whole 
breast RT following breast conserving surgery provides local control and survival 
rates equivalent to mastectomy39,44,45, with added advantages of improved cosmetic 
outcomes and reduced side effects. Although overall 5-year survival rates after RT 
are approximately 80%, it is estimated that 30% of these patients will develop loco-
regional recurrences or metastatic disease, the majority of which will die within 5 
years46. RT treatment plans typically involve the delivery of radiation to the tumour 
in multiple fractions over a period of several weeks; the standard adjuvant RT 
fractionation regime following breast conservation surgery is 25 fractions of 2 Gy 
over a 5 week period, or hypofractionated regimes consisting of a total of 40 Gy 
delivered in 15 fractions over 3 weeks47. 
Regardless of whether RT is given as a neoadjuvant or adjuvant treatment, 
the clinical effects of RT are only seen towards the end or even after the treatment 
course has finished, therefore patients who fail to respond to RT will initially go 
undetected. This delay in identifying non-responding tumours will expose patients to 
the risk of developing RT-induced side effects for no therapeutic gain, allow tumour 
progression, impact on long-term survival and delay the provision of alternative 
treatments48. One method being used in the management of cancer patients is the 
measurement of tumour-related biomarkers in serum and plasma. 
1.6.2 Using tumour biomarkers for precision radiotherapy 
Biomarkers can be defined as a characteristic which can be objectively 
measured and evaluated as indicators of normal biological processes, pathogenesis, 
or responses to therapy49. Biomarkers can be diagnostic and prognostic (estimating 
the likelihood of disease recurrence) but can also be used for predicting (identifying 
patients likely respond to a specific treatment) and monitoring treatment responses50. 
Post-operative reductions in the levels of the serum biomarkers carcinoembryonic 
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antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) have been shown to be 
prognostic for disease-free and overall survival in breast cancer patients51 and can 
improve the detection of recurrent/metastatic disease by 5–6 months52. However, 
these biomarker assays have limitations. For example, low biomarker concentrations 
in the presence of high abundance proteins (albumin and immunoglobulins) can 
make their detection difficult. Typically, biomarkers are also not specific for one 
cancer type and their levels can be altered in various disease conditions. The assays 
can also have low sensitivity and/or specificity and may not reflect a tumour’s 
response to therapy whilst a patient is on treatment. 
The ability of a biomarker to provide information on a tumour’s response to 
radiation could represent an important tool to help tailor a patient’s treatment plan; 
patients not responding to traditional RT regimens could be given alternative 
therapies at an earlier stage of the treatment process. This would help direct health 
services resources, ease the burden on RT machines and ultimately reduce the 
economic cost of cancer treatment. More importantly, this could potentially improve 
patient outcomes and survival rates. Unfortunately, at present, no robust or validated 
secreted biomarkers for monitoring a tumours response to RT whilst a patient is on 
treatment are available. To address this unmet clinical issue, research using the 
secretome of cancer cells/tissue is becoming more popular for the discovery of novel, 
clinically relevant biomarkers. 
1.6.3 Secretome analysis for biomarker discovery 
The term secretome was first used to describe both secretory pathways and 
secreted substances53, but has since been refined to include only the latter54. 
Approximately 10-15% of proteins encoded by the human genome are secreted, 
which play important roles in various cellular functions including immune responses, 
cell signaling and extra-cellular matrix remodeling. As research into the secretome of 
normal cells has increased, it has become clear that cancer cells have their own 
unique set of secreted substances. The term cancer secretome was first used in 2006 
in a study comparing the secretome of pancreatic cancer cells with that of non-
neoplastic pancreatic ductal cells55. Substances within the cancer secretome are now 
known to play roles in cancer pathogenesis including angiogenesis, differentiation, 
invasion and metastasis56. For proteins to be secreted into the extra-cellular space 
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they must pass through either the classical or non-classical secretory pathways. To 
undergo classical secretion, proteins are synthesised as precursors containing N-
terminus signal peptides that direct them to the translocation apparatus of the rough 
endoplasmic reticulum. Subsequent transfer to the Golgi apparatus allows the 
proteins to be released into the extracellular environment through fusion of Golgi-
derived secretory vesicles with the plasma membrane57. In contrast to this, at least 4 
non-classical secretory pathways have been identified for the release of proteins that 
lack the signal peptide for endoplasmic reticulum/Golgi-dependent secretion. 
Examples of non-classical secretion include intra-cellular vesicles undergoing 
endosomal recycling, direct translocation across the plasma membrane using 
transporter systems, membrane-anchored flip-flop mechanisms or exosomal 
secretion58. Exosomes are intralumenal vesicles (IVL) formed from inward budding 
of the membrane of multivesicular bodies (MVB). During their formation, cytosolic 
proteins and substances such as lipids, microRNAs and mRNA may be incorporated 
into the invaginating membrane and become contained within the ILV. As a result, 
when the MVB fuse with the plasma membrane, both ILV and their cytosolic 
contents are released into the extra-cellular space54. 
1.7 The tumour microenvironment 
Tumour physiology differs from normal tissue physiology in that tumours 
typically have areas of varying O2 tension, glucose and energy deprivation, extra-
cellular acidosis and high lactate levels. This TME, influenced by the tumours 
abnormal vasculature and heterogeneous microcirculation59, can affect a tumour’s 
response to RT and chemotherapy. The concepts of precision medicine are applicable 
to the idea of monitoring the TME. If TME parameters such as biomarkers, cancer 
metabolites, chemotherapeutic drug concentrations or intra-tumoural pH and O2 
could be safely and continuously measured throughout therapy without any or with 
minimal intervention from the patient or clinician, then this information could 
influence the management of a patient’s treatment60. 
1.7.1 Tumour hypoxia 
Tissue oxygenation is a balance between O2 supply and its use through 
cellular metabolic demands. Most normal mammalian tissues function in O2 
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concentrations of 2-9%, whereas hypoxic and severely hypoxic conditions are 
defined as ≤ 2% O2  and ≤ 0.02% O2 respectively
61. Intra-tumoural hypoxia is an 
important and common component of many cancers59, with up to 60% of solid 
tumours containing heterogeneously distributed areas of hypoxic tissue. Multiple 
pathogenic mechanisms can influence the formation of these hypoxic regions, largely 
due to the abnormal tumour vasculature. The first to be described in the literature 
was diffusion-limited hypoxia, when a connection between increasing distance from 
blood vessels and the development of necrotic tumour tissue was identified62. 
Diffusion-limited hypoxia largely influences the development of chronic hypoxia and 
occurs as a result of viable aerobic tumour cells near blood vessels utilising the 
available O2 carried in red blood cells (RBCs). O2 concentrations decrease as the 
distance from blood vessels increase, resulting in hypoxia63. Although the diffusion 
distance of O2 from a blood vessel is approximately 150-180 μm, the point at which 
hypoxia develops will depend upon the O2 carrying capacity of RBCs and the 
metabolic demands from cells closest to the blood vessel64. The second hypoxic 
mechanism is perfusion-limited or cycling hypoxia caused by interruptions to blood 
flow65,66. These interruptions can be acute and transient in nature and relate to the 
structural and functional abnormalities of tumour micro-vessels and 
collapse/blockade of these vessels by tumour cells67. Anaemic hypoxia is caused by 
tumour-associated and/or therapy-induced anaemia, leading to a reduced RBC O2 
transport capacity63,68. Macroscopic regional hypoxia is a recent term used to 
describe the situation where hypoxic cancer cells are found situated near a blood 
vessel69,70. This occurs due to the production of an O2 gradient along the length of a 
blood vessel contained within the tumour. Blood at the arterial end of a vessel will 
contain the highest O2 concentration which will be readily used by cells present in 
this region. As the distance from the arterial end of the blood vessel increases the O2 
concentration of blood will decrease, so cells situated at the distal end of the vessel, 
even if near it, may still be hypoxic. 
1.7.2 Hypoxia and its effect on treatment responses 
The abnormal tumour blood supply leading to hypoxia can affect the response 
of a tumour to RT and chemotherapy. The irregular tumour vasculature can reduce 
the effective delivery of systemic drugs such as chemotherapeutic, hormone or 
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targeted therapies, leading to heterogeneous drug distribution within the tumour71. 
Hypoxic conditions can also reduce cancer cells proliferation rates72 which can 
reduce the effectiveness of cytotoxic agents that predominantly target rapidly 
dividing cells73. Tissue O2 concentrations at the time of radiation can also influence 
the degree of cellular radiosensitivity; studies have demonstrated that radiated anoxic 
cells are less sensitive to the effects of radiation than those which are well 
oxygenated74. When exposed to a given dose of radiation, cancer cells in low O2 
conditions can withstand a dose 2-3 times higher than aerobic cells. This 
phenomenon is known as the O2 enhancement effect. The pivotal role of O2 in the 
effectiveness of RT is described through the O2 fixation hypothesis
61,75. The clinical 
effects from RT arise largely through its DNA damaging ability which occurs via the 
indirect route due to the production of free radicals or through the direct route due to 
DNA ionisation. O2 present at the time of radiation can react with radiation-induced 
DNA radicals producing chemically irreparable peroxy radicals; however, in the 
absence of O2 this reaction cannot occur, and DNA damage can be repaired by 
radical scavengers such as endogenous thiols76 giving these hypoxic cells a 
significant survival advantage. 
1.7.3 Cellular response to hypoxia 
Although it seems intuitive that hypoxia would generate an unfavourable 
environment for cellular survival, cancer cells can produce a hypoxic response 
through changes in gene expression, which protect them against cell death77. Those 
cancer cells not able to adapt to hypoxia will die, leading to the selection of cancer 
cells with genetically-fixed features of this ‘hypoxic phenotype’78. This process, 
termed hypoxia-driven malignant progression, can cause cancer cells to become 
more invasive, metastatic and treatment resistant79. 
Key transcription factors involved in the hypoxic response are the hypoxia-
inducible factors (HIF). The most extensively studied is hypoxia inducible factor-1 
(HIF-1), composed of a constitutively expressed HIF-1β subunit and a regulated 
HIF-1α subunit. In normoxic conditions HIF-1α is degraded by the von Hippel-
Lindau (VHL)-mediated ubiquitin-proteasome pathway; however, in hypoxic 
conditions VHL cannot bind to HIF-1α, preventing its degradation. Accumulation 
and nuclear translocation of HIF-1α leads to heterodimerisation with HIF-1β and 
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binding to specific DNA sequences within hypoxia-response elements to promote 
target gene transcription. Approximately 40 HIF-1 regulated genes have been 
identified80. In combination with other inducible transcription factors81-83 it is 
estimated that approximately 1.5% of the genome is transcriptionally responsive to 
hypoxia84. These hypoxia-regulated genes are involved in processes such as 
angiogenesis, erythropoiesis, iron homeostasis, cell survival, proliferation, apoptosis, 
glucose metabolism and invasion; it is these adaptive changes that improve a cancer 
cell’s ability to survive in the hostile hypoxic TME85. 
1.7.4 Endoplasmic reticulum stress and the unfolded protein 
response 
The unfolded protein response (UPR) consists of signalling pathways that 
attempt to protect a cell from the accumulation of misfolded or unfolded proteins 
within the endoplasmic reticulum86. Accumulation of these proteins can occur as a 
result of cellular stress from hypoxia, alterations in pH and nutrient deprivation87. 
The UPR can also be activated by radiation88,89 and can promote cancer cell survival 
in hypoxic conditions by regulating the translation of angiogenic factors87. The UPR 
is mediated through protein kinase RNA (PKR)-like ER kinase (PERK), inositol-
requiring enzyme 1α (IRE1α) and activating transcription factor 6 (ATF6)90 
signalling pathways. These endoplasmic reticulum membrane-bound transducer 
proteins are inactive under non-stressed states through binding of their luminal 
domains with chaperone immunoglobulin heavy-chain binding proteins (BiP). 
However, during endoplasmic reticulum stress unfolded proteins bind directly to the 
transducer proteins or to BiP (causing their sequestration) leading to transducer 
activation (Figure 1.2). 
PERK homodimerises and autophosphorylates when activated, which 
mediates the phosphorylation of the eukaryotic initiation factor 2α (eIF2α), leading 
to translation suppression and reduced protein transport into the endoplasmic 
reticulum91. PERK activation can also induce the translation of activating 
transcription factor 4 (ATF4) which controls the transcription of endoplasmic 
reticulum chaperone proteins, along with those involved in amino acid production 
and transport. IRE1α activation splices X-box-binding protein 1 (XBP1) mRNA, 
leading to the transcription of endoplasmic reticulum stress genes that promote 
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misfolded protein degradation, correct protein folding and secretion92. Activated 
ATF6 functions as a transcription factor; following its transport to the Golgi 
apparatus in COPII vesicles93 it is cleaved by proteases before translocating to the 
nucleus and inducing the transcription of endoplasmic reticulum stress genes94-96. 
The combined function of these pathways is to reduce endoplasmic reticulum 
protein translocation, increase misfolded protein degradation and improve 
endoplasmic reticulum protein folding and secretion. However, prolonged stress with 
insurmountable accumulation of misfolded proteins can overwhelm these responses, 
causing a switch of UPR signalling to initiate apoptosis. Typically, endoplasmic 
reticulum stress-induced apoptosis is mediated by the PERK/eIF2α /ATF4 UPR 
pathway90,97. ATF4 can induce expression of the transcription factor C/EBP 
homologues protein (CHOP)98,99, which increases the expression of Bim, (pro-
apoptotic member of the Bcl-2 family)100 and decreases the expression of Bcl-2 (an 
anti-apoptotic protein)101. Radiation-induced PERK activation can also cause cell 
death through autophagy in caspase 3/7-deficient cells102. 
 
Figure 1.2. PERK, IRE1 and ATF6 pathways of the unfolded protein response. 
The UPR is comprised of 3 signalling pathways: protein kinase RNA (PKR)-like ER 
kinase (PERK), inositol-requiring enzyme 1α (IRE1α), X-box binding protein 1 
(XBP1) and activating transcription factor 6 (ATF6) (GADD34, growth arrest and 
DNA damage-inducible protein 34; CHOP, C/EBP homologous protein; JNK, JUN 
N-terminal kinase; RIDD, regulated IRE1-dependent decay; XBP1s transcriptionally 
active XBP1, XBP1u; P, phosphorylation)103. 
1.7.5 Clinical relevance of tumour hypoxia 
Tumour hypoxia has been shown to influence tumour progression and 
prognosis in a range of tumour types. One large international study demonstrated that 
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pre-treatment tumour O2 status for head and neck cancer patients was prognostic for 
survival after RT (+/- surgery, chemotherapy, or radiosensitiser)104. Another study 
showed that low O2 levels measured in squamous cell carcinoma lymph node 
metastasis was associated with poor or no response to RT; this study concluded that 
O2 levels could be used to identify patients who would benefit most from additional 
treatments105. The prognostic significance of tumour hypoxia has also been shown in 
cervical cancer106 where patients with hypoxic tumours had worse disease-free and 
overall survival rates compared to patients with non-hypoxic tumours107. Similar 
results have been observed in patients with soft tissue sarcomas108. 
1.7.6 Tumour hypoxia functional imaging 
 To target hypoxic, treatment-resistant tumour areas, clinicians need to be able 
to detect them. Multiple direct or indirect methods are available to detect hypoxic 
areas within tumours, but none are used routinely either due to their invasive nature 
or difficulties in incorporating them into clinical practice (Table 1.1). One of the first 
approaches for direct measuring of intra-tumoural O2 levels used polarographic 
electrodes, such as the Eppendorf O2 electrode
109. This technique showed 
associations between hypoxia and treatment responses in numerous cancer 
types105,107,110-113 and that O2 concentrations within breast cancer tissue can be lower 
than that of normal breast tissue109. However, this technique is invasive and only 
applicable to readily accessible tumours and is not used routinely in the clinic. 
Indirect methods for assessing tumour hypoxia include the use of molecular 
reporters of O2 such as pimonidazole, which forms adducts with intra-cellular 
macromolecules at low O2 levels
114. Pimonidazole has been used in trials for hypoxia 
assessment to determine the use of hypoxia modifying drugs with accelerated RT; 
results demonstrated that patients with hypoxic laryngeal tumours benefited from 
additional treatments115. Other indirect assessment methods include the evaluation of 
genes and proteins whose levels are regulated by O2 (HIF-1, CA9 and GLUT1)
116,117. 
Hypoxic gene signatures have also been identified which can be prognostic118 and 
predictive of response to radiosensitising agents119. All these indirect methods 
require a biopsy sample which can be challenging or impossible to obtain; recurrent 
measurements using repeat biopsies are also difficult to perform and justify 
clinically. Blood samples assessing biomarkers of hypoxia, such as osteopontin, can 
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be used to circumvent the issue of repeat biopsy sampling. These ‘liquid biopsies’ 
have been used to assess head and neck patients undergoing RT. Results showed that 
high osteopontin plasma concentrations were associated with a poor prognosis which 
could be improved with O2 mimetic drugs
120. However, hypoxia assessment through 
biopsy samples only allows the analysis of specific tumour areas at specific times 
and hypoxia assessment through blood samples does not analyse the tumour at all. 
These limitations mean that the hypoxic heterogeneity of the entire tumour and the 
changing distribution of O2 that occurs during treatment are not evaluated. 
Advanced imaging techniques provide a non-invasive way of assessing 
hypoxia throughout the whole tumour volume and a means by which serial 
measurements can be obtained. The most common methods used are positron 
emission tomography (PET) and magnetic resonance imaging (MRI). PET hypoxia 
imaging uses tracers such as nitroimidazoles, copper-complexed 
dithiosemicarbazone (Cu-ATSM) derivatives, fluorodeoxyglucose or endogenous 
markers such as CA9 labelled with radioisotopes that allow images depicting 
hypoxia to be obtained. Each tracer has its own specific disadvantages; for example, 
the expression of CA9 can be induced by factors other than hypoxia and at reduced 
O2 levels that are not low enough to have a radiobiological effect. Nitroimidazole-
based tracers also require cells to be hypoxic for significant periods of time, meaning 
levels of acute hypoxia may be underestimated. Resolution may also be a problem; 
voxel size (3D representation of a pixel – determined by slice thickness and pixel 
size) tends to be much larger than potential hypoxic areas, so areas of low hypoxia 
that contain hypoxic hotspots could be classified as negative if the average value for 
that region falls below a cut-off point. Therefore, the actual PET image may not 
accurately reflect tumoural hypoxic heterogeneity at the microregional level. 
Most MRI-based techniques use either dynamic contrast-enhanced MRI 
(DCE-MRI) or blood O2 level-dependent (BOLD) imaging. In DCE-MRI, a 
gadolinium-based contrast agent is injected into a vein and its passage is tracked 
through the tumour vasculature; signal changes identified by MRI give an estimation 
of perfusion. BOLD techniques detect signal differences induced by regional changes 
in deoxygenated haemoglobin levels and are carried out with dynamic challenges to 
alter oxygenated and deoxygenated haemoglobin ratios to map hypoxic regions121.  
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Table 1.1. Methods used for measuring tumour hypoxia. Advantages and 
disadvantages of each method used to measure tumour hypoxia121. 
Microelectrode 
Method: An O2 electrode is placed directly into a solid tumour. 
Advantages: Direct measurement of ptO2. Easy to use. Real-time measurements can be obtained. 
Disadvantages: Invasive. Can only be used in accessible tumours. Inability to distinguish tumour 
areas with viable hypoxic cells from regions of necrosis. 
Tissue based biomarkers 
Method: Nitroimidazole compounds (pimonidazole) are administered systemically which are 
converted into protein adducts in hypoxic cells. Proteins are detected by IHC using biopsy samples. 
Advantages: IHC can estimate hypoxia heterogeneity within different tumour areas. 
Disadvantages: Indirect measurement of ptO2. Invasive as requires a biopsy. Compounds may not 
be sensitive enough to detect intermediate hypoxic phenotypes as HIF-1 is stabilised at higher ptO2 
than those at which nitroimidazole adducts are formed. Does not provide real-time measurements. 
Tissue based biomarkers 
Method: Evaluating the expression levels of hypoxia-induced proteins (CA9, GLUT1). 
Advantages: IHC can identify the location of protein expression and provide information on 
functional status. IHC can estimate hypoxia heterogeneity within different tumour areas. 
Disadvantages: Indirect measurement of ptO2. Invasive as requires a biopsy. Protein expression 
can be influenced by other factors not just hypoxia. Antibody specificity and sensitivity can limit 
the technique to a small number of biomarkers. Does not provide real-time measurements. 
Tissue based biomarkers 
Method: Evaluating gene expression signatures (HIF-1α, CA9). 
Advantages: Prognostic and predictive of responses to agents that radiosensitise hypoxic cells. 
Disadvantages: Indirect measurement of ptO2. Invasive as requires a biopsy. Genes can be 
up/down-regulated by other factors not just hypoxia. Does not provide real-time measurements. 
Serological based biomarkers 
Method: Measurement of serum biomarkers (osteopontin, hepatocyte growth factor, IL-8). 
Advantages: Non-invasive. Real-time measurements can be obtained. 
Disadvantages: Indirect measurement of ptO2. Biomarker expression can be influenced by other 
factors not just hypoxia. Does not give information about hypoxia heterogeneity within different 
areas of a tumour. 
Positron emission tomography 
Method: Nitroimidazole or copper-complexed dithiosemicarbazone compounds are administered 
systemically which are taken up by hypoxic cells. Compounds are labelled with radiotracers (F-
fluoromisonidazole used for nitroimidazole compounds) which can be detected using PET imaging. 
Advantages: Non-invasive. Real-time measurements can be obtained. PET imaging can give an 
estimation of hypoxia heterogeneity within different areas of a tumour. 
Disadvantages: Indirect measurement of ptO2. Compounds may not be sensitive enough to detect 
intermediate hypoxic phenotypes as HIF-1 is stabilised at higher ptO2 than those at which 
nitroimidazole adducts are formed. Safety concerns over using radioisotopes. 
Magnetic resonance imaging 
Method: Most MRI studies either use dynamic contrast-enhanced MRI (DCE-MRI), blood oxygen 
level-dependent (BOLD) imaging or oxygen-enhanced MRI (OE-MRI). 
Advantages: Non-invasive. Real-time measurements can be obtained. MRI can give an estimation 
of hypoxia heterogeneity within different areas of a tumour. Avoids radiation exposure. 
Disadvantages: Potential for artefacts. The biological meaning of the parameters used to reflect 
hypoxia and the link with the hypoxic phenotype has yet to be established. 
1.7.7 Using hypoxic imaging for precision radiotherapy 
Identification of tumours containing significant levels of hypoxia would 
enable patient selection for additional treatments to overcome hypoxia-related 
radioresistance. Options include increasing tumour oxygenation through patients 
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breathing O2 at higher than normal partial pressures (hyperbaric O2 treatment), 
improving haemoglobin levels with blood transfusions, erythropoietin, and 
erythropoiesis-stimulating agents and administering hypoxia targeting drugs. 
Hyperbaric O2 treatment, largely from studies conducted in the 1970s, has been 
shown to have a therapeutic benefit in patients with head and neck squamous cell 
carcinomas (HNSCC)122; however, inconsistent clinical trial data for other cancer 
types and logistical issues have impeded its widespread use. Another approach to 
increasing tumoural oxygenation is by administering carbogen with nicotinamide. 
Carbogen, a mixture of O2 and CO2 gas, can reduce diffusion-limited hypoxia, 
whereas nicotinamide, an amide derivative of vitamin B6, is a vasoactive agent 
which counteracts perfusion-related acute hypoxia. Accelerated RT with carbogen 
and nicotinamide (ARCON) has been evaluated in numerous clinical trials with 
studies showing improved loco-regional control and disease-free survival rates115,123. 
Similarly, clinical trials of nitroimidazole derivatives that act as O2 mimetics such as 
doranidazole and nimorazole have yielded survival benefits when used in 
combination with chemoradiotherapy in HNSCC patients124 and non-small cell lung 
cancer (NSCLC) patients125 or with RT alone126,127. Nimorazole in combination with 
RT is a standard of care treatment in Denmark for head and neck cancers128. Pro-
drugs have been developed that are given to patients in an inactive form and are 
converted to their pharmacologically active form within hypoxic cells, thus enabling 
the selective killing of hypoxic cells. Numerous pro-drugs are undergoing pre-
clinical or clinical trials129. Although studies involving the pro-drug tirapazamine 
have shown disappointing results in terms of improving progression-free or overall 
survival130,131; these studies failed to identify patients with hypoxic tumours that may 
gain the most benefit from this treatment. Another hypoxia-activated prodrug, TH-
302, is showing promise in improving progression-free survival in phase II trials in 
combination with chemotherapy for pancreatic cancer132 and soft tissue sarcomas133, 
providing evidence for further evaluation in phase III trials. 
An important aspect of clinical trials evaluating the potential benefit of 
hypoxia-modifying therapies is case selection. Most historical studies failed to 
specifically identify hypoxic tumours and so treatments would inevitably be given to 
patients who were unlikely to benefit from hypoxic modification. A hypoxic tumour 
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classifier based on a hypoxic gene signature has been used in a large cohort of 
HNSCC patients; tumours classified as hypoxic were associated with a significantly 
poorer outcome; however, outcomes were improved for patients with hypoxic 
tumours who received nimorazole134. These results are also supported by studies that 
specifically identified hypoxic tumours in HNSCC patients through methods such as 
18F-fluoromisonidazole–positron emission tomography (FMISO-PET) imaging135, 
osteopontin120 or immunohistochemical analysis of pimonidazole labelling115,123; 
with their results showing better tumour responses to nimorazole, tirapazamine, or 
ARCON, compared with standard treatments emphasising the need for accurate 
assessment of tumour hypoxia before treatment. One large meta-analysis study 
looked at the results of 64 clinical trials from HNSCC patients who received RT with 
curative intent and found that the addition of hypoxic modification improved loco-
regional control, disease-free and overall survival136. 
Hypoxic imaging can also be used to enable more effective delivery of 
radiation to a tumour. Tumours identified as having large areas of hypoxia could be 
treated with increased radiation doses across the entire gross tumour volume (GTV); 
however, this technique could increase the risk of damage to the surrounding tissues. 
A more refined approach would be to determine a biological target volume (BTV) 
based on hypoxia. In this situation, the total radiation dose delivered to the GTV 
would remain the same, but the dose redistributed; raising the dose received by the 
hypoxic regions while reducing that received by the higher oxygenated regions. 
Alternatively, the BTV could receive boost doses of radiation either uniformly 
spread throughout the hypoxic sub-volume or varied according to the regional levels 
of hypoxia. Advancements in radiation-delivery machines, such as image-guided RT 
(IGRT) and intensity-modulated RT (IMRT), that allow highly conformal and 
accurate radiation delivery have meant that dose painting by numbers (DPBN) or 
sculpturing techniques are becoming more attainable137. These techniques also have 
the advantage of limiting the radiation dose received by the nearby normal tissues. 
If GTV or BTV dose escalation is to be used clinically, then determining how 
much additional radiation is required to obtain an increase in the benefit-to-risk ratio 
will need to be determined. Modelling studies have begun to investigate this 
question. One study combined PET imaging with IMRT planning as a means of 
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delivering a boost dose of 10 Gy to the hypoxic sub-volume of patients with HNSCC 
for those prescribed 70 Gy to the planned target volume (PTV). This study reported 
that this boost dose would provide a tumour control probability (TCP) increase of 
17% without increasing complication risks within the surrounding normal tissues138. 
Another study has shown that dose escalation using DPBN to the BTV would 
provide improved TCP compared with uniform dose escalation (both methods used 
the same mean dose). This study also showed that DPBN may be especially 
beneficial in cases with tumour regions of chronic hypoxia139. Uniform BTV dose 
escalations of 10% have also been compared with DPBN in 13 scans from patients 
with HNSCC. DPBN again showed significantly improved TCP (70.2%) compared 
to conventional IMRT (55.9%) and uniform BTV (57.7%) dose escalation140. These 
improved TCP rates are comparable with that seen using ARCON. 
Although these results are promising, they are only radiobiological modelling 
studies and validation in clinical trials is needed. A potential significant limitation to 
using dose escalation plans based on functional imaging such as PET or MRI is that 
they fail to account for the dynamic nature of tumour hypoxia and the spatial and 
temporal changes that occur to the hypoxic volume during treatment. Serial images 
before and during treatment may provide an indication of changes but they still only 
provide a static indication of hypoxia at the time of image capture. Real-time data 
acquisition is currently not possible, and these techniques do not provide information 
on acute versus chronic hypoxia. Therefore, despite advances, approaches that give 
an accurate 3D map of hypoxic areas within the entire tumour volume in real-time 
are still not available. A potential solution to this unmet clinical need is the use of an 
implantable sensor that is designed to measure intra-tumoural O2 tension at the time 
of treatment, which would also be able to provide information on the spatial and 
temporal changes that can occur during a patient’s treatment course. 
1.7.8 Electrochemical oxygen sensors 
The electrochemical reduction of O2 was first demonstrated at the end of the 
19th century by Danneel and Nerst141. However, in 1965 Clark was the first to be 
credited with the development of the amperometric ‘Clark electrode’ O2 sensor 
capable of detecting O2 at a platinum electrode
142. Here, at the electrode, O2 
undergoes electrochemical reduction which generates a measurable electric current 
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proportional to the partial pressure of O2 contained in the environment surrounding 
the sensor. This sensor used a gas permeable membrane to separate the electrodes 
and the liquid electrolyte in which they worked from the external environment. This 
technique prevented environmental proteins and electrolytes interfering with O2 
detection and reduction thus improving the sensor’s function in biological media141. 
Unfortunately, these conventional Clark electrodes are unsuitable as implantable 
medical devices due to their large size and use of liquid electrolytes. 
The Implantable Microsystems for Personalised Anti-Cancer Therapy 
(IMPACT) project is developing a miniaturised implantable solid-state Clark O2 
sensor to overcome limitations with conventional Clark-type electrodes143. The 
project’s primary aim is to develop an implantable sensor that can monitor intra-
tumoural O2. However, the ability of a sensor to continually measure tissue O2 
tension could prove to be a valuable monitoring tool for clinicians in a wide range of 
pathological and traumatic conditions where the measurement of organ perfusion is 
required. The IMPACT sensor is a 3-electrode cell composed of a platinum working 
electrode (WE), a Ag/AgCl reference electrode (RE) and a platinum counter 
electrode (CE), all microfabricated on silicon wafers143. Oxygen reduction occurs at 
the WE against a fixed electrochemical potential provided by the RE. The function of 
the CE is to supply current to balance the WE reactions144. A potential of -0.5 V 
(measured against the RE) is typically required to cause O2 reduction at the WE. 
Nafion, a perfluorinated ion exchange resin, is O2 permeable and can conduct protons 
between the electrodes and is used to coat the sensor surface, acting as both a gas 
permeable membrane and as a replacement for the traditional liquid electrolyte; this 
solid polymer membrane also helps prevents rapid electrode deterioration, increasing 
the sensors longevity145,146. The silicon wafers are diced into 2.0 mm x 3.0 mm chips 
which each carry a single sensor. Individual chips are then bonded to a 1.7 mm x 200 
mm long flexible printed circuit board (lead wire) and the chips are sealed in epoxy 
resin, resulting in an overall sensor size of approximately 2.6 mm x 5.0 mm x 1.4 
mm (width x length x height). A window clear of epoxy resin over the central active 
sensor area permits interaction with the tissue environment (Figure 1.3). 
Although several previous studies have designed microfabricated 
electrochemical O2 sensors
147-150, IMPACT’s use of silicon-based microfabrication 
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techniques is currently unique. As well as having reproducibility and reduced 
manufacturing costs, silicon-based systems allow the integration of built-in 
complementary metal oxide semiconductor instrumentation electronics. This can 
create a fully autonomous ‘smart sensor’ eliminating the requirement of bulky 
external equipment, both of which are desirable characteristics for its use as an 
implantable medical device143. 
 
Figure 1.3. Microscopic and macroscopic images of the IMPACT O2 sensor. (a) 
High magnification image documenting the position of the working, reference and 
counter electrodes covered by the Nafion membrane. (b) Macroscopic image 
documenting the chip covered in epoxy resin and bonded to the lead wire (images 
kindly provided by Dr J. Marland). 
1.7.9 Cancer treatment and implantable technology 
The concept of integrating implantable medical devices into cancer diagnosis, 
treatment and disease monitoring is becoming attainable due to advances in 
electronics and microfabrication techniques. Although most cancer studies using 
implantable devices are experimental or pre-clinical, promising results highlight their 
potential use in the field of precision medicine. 
Pre-clinical studies have investigated the use of short-term implantable 
devices for high-throughput drug sensitivity testing within tumours. One study used a 
device containing multiple reservoirs which were capable of releasing drugs into 
distinct tumour regions at systemically achievable concentrations. Removal of 
tumour tissue surrounding the device 24 h after implantation allowed assessment of 
the anti-neoplastic effect of each drug through immunohistochemical analysis151. 
This type of device could be employed to improve the identification of optimal drug 
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treatment before definitive systemic treatment commences. Releasing drugs directly 
within the TME could also reduce the severity of side effects seen with systemically 
administered drugs, whilst still achieving effective therapeutic doses. A tumour type 
that would benefit from a localised drug delivery system would be malignant brain 
tumours. The presence of the blood-brain barrier is a limitation to the development of 
effective brain tumour therapies, as it prevents the transfer of substances larger than 
500 KDa and non-lipid soluble molecules into the brain152. Because of this, 
chemotherapeutic systemic toxicity is often reached before obtaining effective 
therapeutic concentrations in the brain. The use of an implanted intra-cranial micro-
electro-mechanical system (MEMS) to deliver the chemotherapy drug temozolomide 
to gliosarcoma brain tumours in rats has shown that implantation was safe and that 
drug delivery from the MEMS improved survival times. This silicon microchip was 
composed of 3 separate temozolomide containing reservoirs; each reservoir was 
covered by a membrane that could be independently opened by applying an electrical 
current. This study provided evidence that drugs can be locally administered to brain 
tumours at specific time points, allowing for active control over drug release rates. 
This concept could have applications for a range of tumours that require additional 
local treatments153. 
This MEMS type of implantable drug delivery systems also has potential for 
use in a wide range of diseases in which treatment regimens are difficult to 
implement. The first-in-human testing of a wirelessly-controlled drug delivery 
silicon microchip was used in the treatment of osteoporosis as a means of 
overcoming long-term daily injections of human parathyroid hormone fragment 1-34 
(hPTH(1-34))154. The device consisted of multiple individual reservoirs filled with 
concentrated hPTH(1-34) solution. Even though a fibrous capsule developed around 
the device following implantation, pharmacokinetic evaluation showed similar bone 
formation results as compared to repeated daily hPTH(1-34) injections. This study 
provided evidence of an implantable device being utilised to overcome difficult 
treatment regimens and poor patient compliance15. 
Implantable devices are not restricted to chemotherapeutic applications; they 
also have potential to be used in combination with RT. As previously mentioned, 
newer external beam RT techniques, such as 3D conformal RT can accurately 
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conform and deliver radiation to the shape of the PTV. As the clinical success of RT 
will depend upon the accuracy of delivering the calculated dose to the target area, it 
is important to be able to verify that the planned radiation dose is accurately 
delivered to the tumour. This has traditionally been achieved through regular 
calibration of the radiation source, using predictive algorithms and through placing 
diodes, thermo-luminescence dosimeters or metal oxide semiconductor field-effect 
transistor (MOSFET) dosimeters on the patient’s skin surface155,156. However, a 
novel and potentially more accurate way to achieve dose monitoring has been 
achieved using an implantable dosimeter. This dose verification system (DVS) has 
undergone clinical testing and received Food and Drug Administration (FDA) 
approval for use in breast and prostate cancer. This device can verify the radiation 
dose received by the PTV for each fraction157 and provides the ability for radiation 
oncologists to verify and optimise radiation treatment on an individual basis. 
As well as influencing a patient’s treatment, implantable sensors are suited 
for sampling the local tissue environment. Placed within a tumour or in surrounding 
tissue at the time of surgery or biopsy, sensors could play a role in monitoring the 
response of a tumour to treatment or in detection of recurrence or metastasis by 
measuring specific biomarkers. This would be especially useful in areas where 
imaging (MRI/CT) makes it difficult to distinguish between tumour recurrence, 
fibrosis, necrosis or benign lesions from previous surgery or chemoradiotherapy 
(gliomas)158. The first in vivo description of such a device was used to detect the  
subunit of human chorionic gonadotrophin (hcG-β)159, a known soluble cancer 
biomarker, which shows elevated secretion levels in testicular and ovarian cancers. 
This study used an implantable device containing nanoparticle magnetic relaxation 
switches (MRSw) conjugated with antibodies for hcG-β. The device was implanted 
in tissue near hcG-β producing JEG-3 (human choriocarcinoma) xenografts. 
Aggregation of these MRSw through hcG-β antibody binding was detected through 
MRI, showing that the device was able to detect the biomarker in peri-tumoural 
tissue. MRSw can be functionalised to detect a variety of molecules, providing 
opportunities for their use in a variety of monitoring purposes160. 
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1.7.10 Regulations governing implantable medical devices 
In 1992, Canada, the USA and Great Britain formed the International 
Standards Agency (ISO), which developed and published international standards on 
the Biological Evaluation of Medical Devices: ISO 10993. These standards classify 
implantable sensors as devices that are in contact with body tissues for geater than 30 
days and describes pre-clinical in vitro and in vivo biocompatibility testing. In vitro 
tests include those for genotoxicity, cytotoxicity, carcinogenicity, developmental and 
reproductive toxicity, haemocompatibility, degradation assessment and 
biofunctionality (cellular adhesion and spreading); whereas in vivo tests focus on 
evaluating ethylene oxide residues, material degredation, sensitisation and irritation, 
local tissue effects and systemic toxicity161. 
The Active Implantable Medical Devices Directive 90/385/ECC, developed by 
the Medicines and Healthcare products Regulatory Agency, aims to protect patient 
safety by ensuring manufacturers provide evidence of device safety and performance. 
This is essential for devices to gain market approval but also continues through post-
market surveillance so adverse incidents can be identified by clinicians and patients. 
For a device to gain market approval manufactures can use ‘equivalence data’ and 
published clinical work of similar devices. This can decrease costs and the time 
required to get a product to market but can potentially lead to safety concerns, as 
each device is not fully evaluated; even high risk medical devices have been certified 
as safe without any supporting evidence in human trials162. 
1.8 Biocompatibility and the foreign body response 
During the development of implantable medical devices they must undergo 
biocompatibility evaluation to assess the device in terms of its biofunctionality 
(performance) and biosafety (local and systemic tissue responses and the absence of 
carcinogenesis, mutagenesis and cytotoxicity)15,163-165. Following implantation 
medical devices can lose functionality, this failure is largely due to biofouling (non-
specific protein adsorption) that occurs around the device. This process results in a 
tissue reaction known as the foreign body response (FBR)165-167 and represents a 
clinical challenge in implantable technology design and development. It is the 
surface properties of the device that will influence the extent of the FBR that occurs 
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during the initial weeks following implantation, although the reaction at the 
tissue/surface interface will be present for the in vivo lifetime of the device. 
1.8.1 Acute inflammatory response 
Acute inflammation starts immediately after the implantation of a medical 
device within the body and typically resolves within 5 days168. The magnitude of this 
initial response is related to the trauma caused by the insertion device, whereas the 
subsequent chronic inflammatory responses and fibrous encapsulation are largely 
affected by sensor size169. Tissue injury at the implantation site will activate the 
intrinsic and extrinsic coagulation systems, complement and fibrinolytic system, 
kinin-generating system and platelets, causing the formation of a provisional matrix 
around the device170. The device surface characteristics will affect the extent and 
type of proteins, such as albumin, fibrinogen, complement, fibronectin, vitronectin, 
and γ globulin that adhere to it167,171-173. These proteins at the tissue/device interface 
provide structural, biochemical and cellular components that contribute to the 
ongoing inflammation through cytokine, chemoattractant and growth factor 
release174. These substances can further regulate activation of the coagulation 
cascade, complement system, platelets and the subsequent immune responses 
through interacting with adhesion receptors present on inflammatory cells. Mast cell 
degranulation, with histamine release and fibrinogen adsorption, is also important 
during this stage for the recruitment of inflammatory cells175,176. 
Polymorphonuclear (PMN) leukocytes (neutrophils, granulocytes) are the 
predominant inflammatory cell type present for up to 2 days post-implantation167. 
These cells play roles in microorganism phagocytosis and pathogen killing through 
the secretion of proteolytic enzymes and reactive O2 species. However, these 
enzymes may also be damaging to implanted materials and increase the duration of 
the acute inflammatory response. Prolonged PMN activation, due to the continual 
presence of the implanted medical device, can lead to metabolic exhaustion and 
depletion of oxidative resources. This situation can reduce their microbial killing 
ability and can contribute to the development of implant-related infections177. PMNs 
secrete immunoregulatory signals such as IL-8178,179, monocyte chemoattractant 
protein-1 and macrophage inflammatory protein-1 which recruit further PMNs, 
monocytes, macrophages, lymphocytes and immature dendritic cells into the 
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area180,181. Continued chemokine release leads to suppression of PMN infiltration and 
their numbers begin to fall as they are engulfed by macrophages or become 
apoptotic182. 
1.8.2 Chronic inflammatory response 
The continued presence of an implanted medical device within the body leads 
to the development of chronic inflammation; this phase is characterised by the 
presence of monocytes, macrophages, fibroblasts, neovascularisation and the 
production of granulation and fibrous tissue around the implanted device167. 
Macrophages are the predominant cell type present for up to 3 weeks following 
resolution of acute inflammation and will drive the ongoing immune response, 
enhancing the propagation of chemoattractive signals through the production of 
factors such as: PDGF, fibroblast growth factor, tumour necrosis factor-α (TNF-α), 
IL-1, IL-6, granulocyte-colony stimulating factor (G-CSF), transforming growth 
factor-β, transforming growth factor-α, chemokine (C-C motif) ligand 2 (CCL2) and 
granulocyte macrophage colony stimulating factor (GM-CSF)174,183. Macrophages 
are only capable of phagocytosing particles up to 5 μm in size; as a consequence of 
this, macrophages, in an attempt to deal with large implanted materials, fuse together 
to form foreign body giant cells (FBGCs) which spread over the material’s surface 
through integrin binding184,185. 
In vitro and in vivo studies have shown that FBGC formation can be induced 
by the cytokines IL-4 and IL-13186-188; although, the exact source of these cytokines 
is under debate, natural killer cells (NK), natural killer-T cells (NKT) cells189,190, 
mast cells, eosinophils, and basophils are all potential sources191. However, the 
functions of these cell types in FBGC formation is unknown, as mouse models 
deficient in NK or NKT lymphocytes, mast cells or IL-4 receptor- can still form 
FBGC in response to implanted materials192. Activated T lymphocytes (CD4+ cells), 
transiently present at the implant site during chronic inflammation167, are another 
possible source of these cytokines. In vivo lymphocyte/macrophage co-cultures have 
shown the ability of lymphocytes to increase macrophage adhesion to material 
surfaces and enhance FBGC formation, while macrophages can stimulate 
lymphocytes to proliferate193. However, as the FBR has been shown to occur in the 
absence of T cells, the role of lymphocytes in FBGC formation remains unclear194. 
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1.8.3 Consequences of foreign body giant cell formation 
A unique environment exists between the device surface and the 
FBGC/macrophage cell membranes. Following failed attempts of classically 
activated macrophages and FBGC to phagocytose the material, they release 
degradative substances such as reactive O2 intermediates, free radicals, enzymes and 
acids into the microenvironment; this process is termed ‘frustrated phagocytosis’195-
197. The slow rate at which buffers and inhibitors of these substances gain access to 
this environment results in the surface of the device being exposed to high 
concentrations of these degradative agents198. It is these reactions that can lead to 
material degradation and device failure167. 
1.8.4 Extracellular matrix remodelling 
Macrophages are involved in angiogenesis, fibroproliferation and tissue 
remodelling through the secretion of growth and angiogenic factors and matrix 
metalloproteinases167,199. Alternatively activated macrophages produce profibrogenic 
factors leading to fibrogenesis by fibroblasts200, which can lead to the deposition of a 
collagenous and vascular fibrous capsule around the device. This capsule is the end 
stage of the FBR201 and can be 50–200 µm thick165. It is this capsule, in combination 
with FBGC on the device surface, that can contribute to loss of device function 
through the creation of a barrier that confines and prevents the implant from 




Figure 1.4. Sequence of inflammatory responses leading to FBGC formation 
and fibroblast infiltration. The result of the FBR is the production of granulation 
tissue with subsequent fibrous capsule formation. This reaction causes ‘walling-off’ 
of the sensor from its immediate surrounding area. This reaction combined with the 
degradative chemicals released from the FBGC can lead to loss of sensor function15. 
1.9 Pre-clinical in vitro models used in the development of 
cancer therapeutics 
The development and assessment of anti-cancer agents follow a stepwise 
process from in vitro and in vivo testing through to phase 0, I, II, III and IV clinical 
trials. A typical development plan would involve the assessment of compounds 
through in vitro cell-based assays investigating cell survival, proliferation, death, 
migration and invasion. Compounds would then progress onto in vivo studies 
assessing anti-tumour activity and pharmacological studies to define drug absorption, 
distribution, metabolism and elimination before progressing into clinical trials. This 
process is expensive and time consuming; from concept to completion of phase III 
trials, may take over 10 years and several hundred million pounds202. Time and 
expense are not the only issues with cancer drug development; attrition rates for new 
cancer therapeutics are very high, with only 5% of agents that show pre-clinical 
promise gain a license to be used in patients203. 
Most pre-clinical studies assessing the efficacy of cancer agents rely on cancer 
cells grown in 2D cultures. Unfortunately, these models lack tumour heterogeneity 
and extended culturing may select for clones which survive and grow best in these 
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conditions. Using large panels of cell lines, such as the National Cancer Institute-60 
panel (NCI-60)204, or the expansion of cell lines derived directly from tumour tissue 
may partially overcome this problem205. However, 2D cultures cannot replicate 
complex stromal components, interactions with immune cells/inflammatory 
mediators/growth factors or the acidic/hypoxic TME206. The development of 3D cell 
culture and co-culture systems such as multicellular tumour spheroids (MTS) and 
organoids aim to better mimic the structural and functional properties of normal and 
tumour tissue and to bridge the gap between cell-based assays and animal studies207. 
High-throughput assays have also been developed using MTS cultured in microwells 
with non-adherent hydrogels208,209. MTS from cervical, breast and HNSCC cells 
form within 3-6 days, allowing high-throughput drug assays to be performed210. 
The National Cancer Institute’s (NCI) Developmental Therapeutics Program 
has developed in vivo rodent screening models to select agents for evaluation as 
clinical candidates. Common in vivo models include the hollow fibre assay211, human 
tumour xenograft models, carcinogen-induced models, genetically-engineered 
models and inbred strains with high rates of spontaneous tumour development212. 
Murine models have historically dominated medical research due to ease of breeding 
and housing and the availability of a large number of genetically identical strains and 
genetically-engineered models. 
Subcutaneous and orthotopic xenograft murine tumour models can be 
established by inoculating human tumour cells grown in vitro or by implantation of 
patient tumour tissue into immunodeficient mice (athymic, severe combined 
immunodeficient (SCID), or non-obese diabetic/SCID); these models allow in vivo 
monitoring of tumour growth, drug toxicity, efficacy and pharmacokinetic studies, 
and reflect the O2 and pH gradients found in solid tumours
213. These models have 
increased our molecular understanding of cancer and have been used successfully in 
pre-clinical cancer drug development; their use as predictors of clinical activity has 
also been validated for numerous cytotoxic agents214,215. A retrospective analysis of 
39 compounds using data from both xenograft testing and phase II clinical trials was 
performed by the NCI. This study showed that 15/33 agents with activity in more 
than one-third of cell line derived xenografts showed clinical activity. However, with 
the exception of NSCLC, activity within a particular xenograft histological type did 
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not predict for clinical activity in the same tumour type in patients216. A further study 
using patient-derived xenografts (PDX) showed similar results217. 
Unfortunately, these murine models have limitations and reliance on them has 
contributed to high attrition rates in cancer drug development. Subcutaneous 
xenografts, particularly those established from cell lines, do not represent the primary 
tumour from which they are derived in terms of heterogeneity, tumourigenesis and 
metastasis218,219. Orthotopic transplantation models are thought to be more 
representative of clinical tumours in terms of the development of metastatic 
disease220. However, stromal tumour components in both models will be murine in 
origin and therefore the effects of drugs on the TME may not be representative of 
human tumours. This limitation may be minimised by using PDX, although even in 
this model human stromal elements are progressively lost over time. Other 
limitations include poor uptake of PDX and difficulties in obtaining patient 
material221. Importantly, the growth rates of human xenografts are higher than that of 
primary tumours, as a result of this, they are much more likely to respond to anti-
proliferative agents and so might provide a false indication of drug efficacy219. The 
use of immunocompromised models hinders the testing of immunomodulatory 
agents; although immunocompetent genetically-engineered murine models, 
carcinogen-induced models or strains that have spontaneously-occurring tumours can 
overcome some of these limitations they still suffer from having murine-derived 
stroma. It can also be difficult to extrapolate drug doses to human trials as maximum 
tolerated murine doses may be far higher than those used in human patients222. 
Rodents also differ considerably from humans in size, physiology, anatomy, 
lifespan and immunology, all of which can reduce their usefulness215. Their small 
size precludes their use for the development of human surgical procedures223. It is 
also difficult to scale down equipment such as imaging technologies or surgical 
instrumentation. Samples can also only be collected in small quantities, which can be 
insufficient for detailed analyses. Modelling treatment protocols commonly used in 
human patients such as RT is hampered in rodents by uncertainties regarding the 
scaling of energy doses. An approach to overcome these limitations would be to 
combine murine studies with comparative cancer studies in other species to optimise 
the development of the most effective cancer therapies. 
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1.10 Comparative oncology 
Comparative oncology is a field of research that uses naturally occurring 
cancers in animals as a means of investigating similar cancers in human patients. 
This approach can include all aspects of cancer research including pathogenesis and 
the evaluation of cancer treatments. Dogs, cats and large animals with naturally-
occurring tumours that have incidence rates, clinicopathological features and risk 
factors similar to specific human cancers are regarded as excellent translational 
models of human disease224-226. These models are particularly important as these 
cancers develop in the presence of an intact immune system where tumour, TME and 
host have developed together227. 
Dogs and sheep have many features that make them suitable for a range of 
comparative studies. The shorter lifespan of these species compared to humans 
enables tumours that develop after a few years instead of decades to be studied more 
readily; this can allow clinical trials to be performed rapidly whilst still providing a 
sufficient time course to allow comparison of treatment responses. Similarities in 
anatomy, size, physiology, immunology and metabolism to humans allow procedures 
or drugs that are commonly used in human medicine to be used in translational 
studies. Recent canine genome sequencing228 has also shown significant similarities 
between dog and human genetic sequences; which is far greater than that seen 
between human and mice sequences229. Dogs have also been shown to be a highly 
predictive model for human drug development224,226,230. As a result of these factors 
various canine and ovine translational models have become popular in pre-clinical 
trials as they can overcome the limitations associated with murine models. 
1.11 Comparative human and canine breast cancer 
Mammary tumours are the most commonly diagnosed cancer in female dogs 
with the disease accounting for approximately 50% of all canine neoplasms231. The 
peak incidence age for dogs to develop mammary tumours is between 8-11 years old 
which is comparable to that seen in humans (50-58 years)232-236. Canine mammary 
tumours (CMT) are known to have a hormonal aetiology with one study showing that 
the disease developed in approximately 0.5% of female dogs that were spayed before 
their first season compared with 8% and 26% of dogs spayed after their first or 
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second season237. Other risk factors for disease development include diet and 
obesity238,239. In humans, obesity has been suggested to increase the risk breast 
cancer by raising circulating oestrogen levels and increasing local oestrogen 
production by aromatases240,241. 
Approximately 50% of canine mammary carcinomas will metastasise to 
regional lymph nodes, lungs and bone242,243. This clinical course is similar to that 
seen in humans where approximately 37% of women will either present with or 
develop metastatic disease244. In both human and canine patients tumour size, age, 
clinical stage, the presence of local/distant metastases and histological subtype can 
be used as prognostic markers that can identify patients at higher risk of recurrence 
or mortality245,246. Studies have also shown that there are significant similarities in 
the transcriptome247 and proteome248 of metastatic canine and human mammary 
carcinomas. These results suggest that similar mechanisms of mammary 
carcinogenesis may occur between the 2 species and that metastatic canine 
carcinomas are a suitable model for human breast tumours in order to identify 
prognostic molecular signatures and potential therapeutic targets. 
1.11.1 Molecular markers and signalling pathways 
The assessment of hormone or signalling receptor expression in human breast 
cancer has been shown to provide prognostic information and predict which patients 
will most likely respond to certain treatments. Although these markers are not 
routinely used in veterinary medicine, increasing evidence suggests that these 
human-derived molecular markers might be similarly useful for CMT evaluation. 
ER and PgR expression occur in approximately 70% of benign and 60% of 
malignant CMT249-251, this is similar to that seen in human breast cancer where 
approximately 85% express ER and 67% express PgR17. Several studies have now 
shown that ER and PgR expression can be prognostic and predictive of disease-free 
and overall survival, with a decrease in hormonal dependency commonly seen in 
canine malignant mammary tumours and metastatic disease250,252-254. One recent 
study showed that dogs with ER+/PgR+ tumours had better survival rates compared 
with ER-/PgR+ tumours and that ER-/PgR- tumours had the worst prognosis of all255. 
HER2 expression occurs in approximately 30% of all human breast cancers 
and is associated with high metastatic rates and poor prognosis256. Several studies 
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have identified HER2 expression in approximately 35% of malignant CMT257-259; 
however, the use of HER2 as a marker of CMT malignancy is unclear. Although 
some studies have shown HER2 expression is associated with high proliferation 
rates, histological grade, tumour size and poor prognosis257,259-261 others have shown 
no difference in HER2 expression between benign and malignant tumours258,262,263. 
EGFR has been suggested as a prognostic marker in human triple negative 
breast cancer (ER−/PgR−/HER2−)264. In CMT high EGFR expression has been 
associated with tumour size, angiogenesis, proliferation rate, tumour necrosis, 
histological grade and clinical stage265-267. However, its role in carcinogenesis or 
prognosis is unclear. Although a tendency toward shorter disease-free survival and 
overall survival has been identified in dogs with CMT expressing EGFR, these 
associations failed to reach statistical significance266. EGFR downstream signalling 
pathways have also been implicated in human breast cancer pathogenesis; results 
from the first genome-wide comparative analysis of canine and human mammary 
cancers demonstrated that tumours from both species had up-regulation of pathways 
related to proliferation, whereas pathways related to cell development, cell matrix 
adhesion and cell communication were down-regulated. Furthermore, this study 
demonstrated a great degree of homology between human and canine mammary 
tumours with respect to many cancer-related pathways including PI3K/AKT, KRAS, 
PTEN, WNT-β-catenin, and MAPK268. Other molecular markers which have been 
investigated for similarities between human and canine mammary tumours include 
insulin-like growth factor, growth hormone, mucins, heat shock proteins, P53, CEA, 
CA 15-3, VEGF and cyclooxygenases261,269-272. 
The similarities in aetiology, histopathology, pathogenesis, oncogenic drivers, 
target genes and molecular signalling pathways observed between canine and human 
mammary cancers supports the use of spontaneously occurring canine mammary 
tumours as a model for human disease. This model has great potential to not only 
advance the molecular understanding of breast cancer, but also improve pre-clinical 
research and treatment of canine and human breast cancer patients. 
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1.12 Comparative human and ovine lung anatomy and 
physiology 
  Sheep are excellent models for investigating human lung function and disease 
largely due to their similarities in terms of lung physiology and anatomy273. Both 
species have 2 lungs, in humans the left is divided into superior and inferior lobes 
and the right is divided into superior, inferior and middle lobes; whereas, in sheep the 
left divided is into cranial and caudal lobes and the right is divided into cranial, 
caudal, middle and accessory lobes274 (Figure 1.5). Although the right cranial lobe 
bronchus originates proximal to the tracheal bifurcation275 and bronchioles are less 
well developed in sheep274, the remaining tracheobronchial anatomy is very similar 
to humans. Both species show an irregular dichotomous tracheobronchial branching 
pattern with similar distribution of differentiated respiratory epithelial cells276, mast 
cells277 and airway smooth muscle278. Although fewer intra-vascular pulmonary 
macrophages are seen in human lungs, increased numbers can be induced after 
endotoxic insults279. Lung development between the species is also comparable, with 
lamb and human infant lungs showing prenatal alveologenesis and the same 
tracheobronchial branching pattern. Type II alveolar epithelial cell (pneumocytes) 
development and number of bronchiolar club cells and airway submucosal glands is 
also similar280. Similarities in lung size also allow sheep to be used in ways not 
achievable using rodent models. Techniques used in the treatment of human patients 
such as endoscopy, advanced imaging281, ultrasound282 and surgery can be performed 
in sheep, providing the model with excellent translational potential283. Repeated 
blood and tissue collection are easier in sheep and their increased lifespan compared 
to rodents allows chronic conditions to be modelled whilst enabling long-term 
treatments to be evaluated. These factors have made sheep excellent models for 
human respiratory diseases275 such as asthma284, cystic fibrosis, chronic obstructive 




Figure 1.5. Human and ovine comparative gross anatomy. (a) Ovine lower 
respiratory tract. (b) Human lower respiratory tract273. 
1.12.1 Human lung cancer 
  Global estimates indicate that lung cancer accounts for approximately 2 
million new cases and 1.8 million cancer-related deaths per year, making it the most 
commonly diagnosed cancer in the world6. Unfortunately, 5-year survival rates are 
only 15%; this low rate is largely due to patients being diagnosed with advanced 
disease, when poor responses to chemotherapy and RT are seen. Lung cancer is a 
highly heterogenous disease and is divided into multiple subtypes273. These subtypes 
undergo periodic review and in 2011 a multidisciplinary classification system was 
suggested by the European Respiratory Society (ERS) and International Association 
for the Study of Lung Cancer (IASLC)288. Based on pathogenesis, biology and 
histopathology, this system rendered previous terms such as bronchioloalveolar 
carcinoma (BAC), including its non-mucinous and mucinous forms redundant. Lung 
cancer is broadly classified into non-small cell lung cancer (NSCLC), originating 
from epithelial lung cells and small-cell lung cancer (SCLC), originating from 
neuroendocrine bronchial cells. NSCLC accounts for 80% of lung cancer cases and is 
further subtyped into adenocarcinomas, squamous cell carcinomas, large-cell 
carcinomas, undifferentiated and mixed tumours289. Adenocarcinomas are the most 
common form of lung cancer, accounting for 40% of all cases. 
  Adenocarcinoma tumourigenesis is complex but is thought to begin with 
cellular changes occurring through hyperplasia of lung epithelial cells. The cells 
making up these pre-malignant lesions, known as ‘atypical adenomatous 
hyperplasia’290, accumulate genetic abnormalities causing them to become 
pleomorphic resulting in a lepidic, non-invasive, growth pattern along alveolar walls. 
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Lesions less than 30 mm in diameter are known as adenocarcinoma-in-situ; if treated 
at this stage by complete surgical resection, almost 100% of cases will achieve 5-
year disease-free survival. Untreated/undiagnosed lesions will continue to grow and 
develop into invasive adenocarcinomas. Minimally invasive adenocarcinoma is a 
term used to describe lesions less than 30 mm in diameter with an invasive 
component of less than 5 mm; lesion resection is still likely to give excellent disease-
free survival rates. Invasive adenocarcinomas greater than 30 mm in diameter are 
classified on the predominant cellular growth pattern present within the lesion 
(lepidic, acinar, papillary or solid); it is these invasive subtypes that are most 
commonly diagnosed in patients. Lepidic-predominant adenocarcinoma describes an 
invasive adenocarcinoma subtype that has a predominant lepidic growth pattern with 
an invasive component greater than 5 mm; these subtypes can be non-mucinous or 
mucinous (previously termed non-mucinous and mucinous BAC). The mucinous 
form can be non-invasive, minimally-invasive or invasive and is often bilateral and 
multifocal with extensive mucous production. Patients suffering from this subtype 
present with a cough and extensive mucous production which can lead to death from 
respiratory failure without any evidence of invasive disease288. 
1.12.2 Models of human lung cancer 
  Although numerous animal models are available for lung cancer research 
(hamsters, mice, dogs, primates)291,292, mice have been considered the model of 
choice due to their ease of genetic manipulation and cost-effectiveness293. These 
factors have led to numerous mouse models being developed. Inbred strains with 
high rates of spontaneous lung tumour development are commonly used in 
chemoprevention studies294-296. Chemical297, carcinogen291 and environmental-
induced lung cancer models allow for the study of tumourigenesis and 
progression298, whereas orthotopic xenograft models are used to investigate both 
primary and metastatic disease299-302. Transgenic mouse strains incorporating genetic 
mutations that occur in human lung cancers such as tumour suppressor gene 
inactivation (p53, retinoblastoma and p16), oncogene activation (K-ras), altered 
growth factor expression303 and amplification of specific chromosomal regions304,305 
will produce tumours with greater similarity to those seen in humans and can be used 
to identify genes that drive lung cancer development and progression304. Mouse 
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models using fluorescent or bioluminescent reporters have also been described306,307 
which can be used for the identification of oncogenes involved in tumourigenesis and 
determination of tumour cell type origin308. 
  Despite their uses, these mouse models do not accurately represent advanced 
stages of human lung cancer and suffer from the same general limitations as mouse 
models for other cancer types, as described in section 1.9. The perceived advantages 
of having numerous models available can also be a significant limitation, as no one 
single model can be used to investigate all stages of the disease. 
1.12.3 Ovine pulmonary adenocarcinoma 
  Ovine pulmonary adenocarcinoma (OPA) is becoming regarded as a valuable 
translational model for studying human lung cancer309. OPA is a naturally occurring 
neoplastic lung disease caused by the jaagsiekte sheep retrovirus (JSRV)310-313; the 
disease was first described in the 19th century in sheep flocks in South Africa314. 
Since then, JSRV infection has been identified throughout the world in numerous 
sheep breeds and small ruminants (including goats) but has never been identified in 
humans315,316. Endemic within the UK, OPA is an economic and animal welfare 
concern317. Although within-flock disease incidence can be as high as 30%, levels of 
2-5% are more common309. Mortality rates tend to reduce from 50%, following 
initial disease diagnosis within the flock318, to approximately 1-5% as it becomes 
endemic314,319. Apart from increased mortality, production losses occur through 
decreased weight gain and reduced fertility312. Disease transmission occurs most 
commonly through the aerosol route314,318,320, although the virus has also been 
isolated from the milk and colostrum of infected ewes321. 
1.12.4 JSRV biology 
  JSRV is the only known betaretrovirus capable of lung adenocarcinoma 
tumourigenesis. Each JSRV particle contains 2 single-stranded positive sense RNA 
copies containing a genome of approximately 7,460 nucleotides. Four genes encode 
viral proteins312, gag (encoding structural proteins), pro (encoding aspartic protease), 
pol (encoding reverse transcriptase and integrase enzymes) and env (encoding 
surface and transmembrane envelope glycoproteins)322,323. Although an additional 
open reading frame, known as orfX, has also been identified, its function remains 
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unclear as it is not required for cellular transformation324 or oncogenesis325-327. The 
cellular mechanism underlying neoplastic transformation following JSRV infection 
involves the Env glycoprotein acting as a viral oncoprotein; this transforming ability 
has been shown using in vitro systems324,328 and in vivo mice327 and sheep326 models. 
It is thought that plasma membrane localised Env glycoprotein may interact with 
protein kinases, adapter proteins and signalling molecules that are capable of 
triggering cellular proliferation and survival pathways329. The Ras-MEK-ERK and 
PI3K-AKT-mTOR287 pathways are commonly activated in OPA and human lung 
adenocarcinomas but others may include RON-HYAL2, EGFR and heat shock 
proteins330. Further mutations such as telomerase activation331, inactivation of 
tumour-suppressor genes or activation of additional oncogenes287 are likely to be 
required if tumours are to develop following initial pathway activation273. 
1.12.5 Endogenous retrovirus and immune responses 
  Endogenous retroviruses are viruses that have become integrated into host 
germ-line DNA and are passed to subsequent generations. Numerous endogenous 
JSRV (enJSRV) have been found in the sheep genome which have over 90% 
sequence homology to exogenous JSRV (exJSRV)332,333. Although enJSRV are non-
oncogenic310,322,334,335, viral RNA and proteins have been identified in the female 
reproductive tract and in foetal tissues, providing evidence of their transcriptional 
potential335,336. Viral proteins may protect from exJSRV infection by receptor 
competition or through the prevention of exJSRV transport and cellular exit336,337. 
  Although JSRV infection can induce the production of neutralising 
antibodies338,339, cellular or humoral adaptive immune responses typically do not 
occur. This is likely the result of immunological tolerance to JSRV antigens due to 
enJSRV protein expression in the foetal thymus during T lymphocyte development. 
Ineffective immune responses are also thought to occur through overproduction of 
surfactant proteins combined with tumour cells down-regulating major 
histocompatibility complex class I antigens preventing cellular recognition by CD8+ 
T lymphocytes. Alveolar macrophages can also produce large amounts of interferon 
gamma, which can inhibit T cell activation and JSRV-specific immune responses340. 
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1.12.6 OPA diagnosis 
  OPA cases are typically diagnosed in sheep aged 2-4 years of age. Diagnosis 
of clinical cases can be obtained from a physical examination; common clinical signs 
include weight loss, pneumonia, tachypnoea and dyspnoea341. Thoracic auscultation 
may identify adventitious lung sounds342; however, a pathognomonic sign of OPA is 
copious amounts of fluid draining from the nostrils343 which typically occurs when 
tumours occupy more than 30% of the lung volume341. Although these advanced 
stage tumours may develop over many months or years341, new evidence indicates 
that some tumours can develop quickly344. Pre-clinical antemortem OPA diagnosis is 
important for removing infectious sheep from flocks but also for identifying cases for 
research. Unfortunately, this pre-clinical diagnosis is difficult to achieve, as many 
sheep never develop clinical signs during their commercial lifespan345. Diagnostic 
serological assays are not useful, as JSRV-infected sheep fail to produce humoral 
immune responses346. Virus detection in the blood is possible through PCR 
technology347 but due to low numbers of virally infected blood cells (monocytes, T 
and B lymphocytes) high false negative results are seen348. Despite this, PCR testing 
is useful for identifying infected flocks rather than individual animals. The same 
PCR technique has been used successfully to detect JSRV-infected cells in 
bronchoalveolar343 and lung fluid349 samples. This PCR test offers better sensitivity 
compared to blood samples; although, early cases can be missed as the procedure 
only samples a small region of the lung. The procedure also requires sedation and so 
is not practical for routine large-scale on-farm testing. Because of these factors, the 
standard diagnostic test for pre-clinical and clinical OPA cases is gross pathology 
and histology performed at the post-mortem examination. 
1.12.7 OPA histology and comparison with human lung 
adenocarcinomas 
  Histological examination of OPA lesions reveal non-encapsulated tumours 
originating from JSRV-transformed alveolar and bronchiolar epithelial cells273,350,351. 
Lesions are composed predominantly of type II pneumocytes, involved with alveolar 
surfactant production, with smaller numbers of undifferentiated cells and bronchiolar 
club cells that are involved with producing proteins that line bronchioles352. Tumours 
can be highly heterogenous, with typical areas composed of columnar or cuboidal 
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cells with a low mitotic rate, whereas other areas show higher degrees of malignancy 
with high mitotic rates and necrosis352,353. Tumour cells become surrounded by 
fibrovascular connective tissue which aids the influx of inflammatory cells. Although 
large numbers of macrophages are seen340, neutrophil numbers can be variable, 
which is largely determined by whether a bacterial infection is present. Cancer cells 
spread along alveolar septa (lepidic growth) before forming acinar or papillary 
proliferations within bronchioles. JSRV virions, released from infected cells, cause 
the formation of new foci of infection throughout the lung354 and as neighbouring 
neoplastic foci enlarge, they coalesce to form a single large tumour. Although not 
common, intra-thoracic and extra-thoracic metastasis has been identified in 
approximately 10% of cases355-358. Initial histological classification systems 
described OPA as having similarity to human BAC; however, under the revised lung 
classification system early OPA lesions closely resemble those of minimally invasive 
adenocarcinoma or lepidic-predominant adenocarcinoma, whereas advanced disease 
would fit a description of adenocarcinoma with an acinar or papillary growth pattern 
with or without mucinous features. An important consideration is that OPA has 
significant similarities to the rare non-invasive, multifocal subtypes of human lung 
adenocarcinoma (such as the mucinous forms), where clinical samples are difficult to 
obtain, and is less similar to the more common metastatic forms of the disease287. 
1.13 Hypothesis and aims 
The radiation response of a tumour depends not only on innate radiosensitivity 
but also on the TME and the development of acquired radioresistance. For RT to 
become integrated into the concept of precision medicine we require a detailed 
understanding of the mechanisms that contribute to cancer cells gaining 
radioresistance, as well as the development of novel methods by which tumour 
hypoxia can be monitored in real-time. This would provide a means by which these 
treatment resistant areas can be targeted. Monitoring patients during therapy would 
allow assessment of response to treatment and would assist the early identification of 
non-responding patients; more effective therapies could then be instigated sooner 
whilst sparing the patient from RT-induced side effects. With these currently unmet 





The overriding hypothesis that forms the basis for the body of work within 
this thesis is that complementary in vitro and in vivo research is required to advance 
the understanding of radioresistance and investigate means by which RT can become 
tailored to individual patients. 
We hypothesise that developed in vitro radioresistant (RR) cell lines will 
undergo phenotypic and genotypic changes with respect to their original parental cell 
lines. Alterations in signalling pathways are hypothesised to identify therapeutic 
targets to reverse radioresistance; whereas changes in secretion profiles can be used 
to identify biomarkers related to radiation response and radioresistance. These 
biomarkers, when validated, could provide a means by which the radiation response 
of a tumour can be monitored either through blood samples or more locally using a 
sensor implanted into the tumour itself. 
For medical devices to be implanted into tumours the in vivo biocompatibility 
of sensor components must be assessed. We hypothesise that a murine xenograft 
model can be developed to obtain intra-tumoural biocompatibility data for materials 
being consideration for use in the IMPACT O2 sensor. Previous studies have 
suggested that these materials, commonly used in medical devices, have good 
biocompatibility when implanted into healthy tissues. We therefore hypothesise that 
these materials when implanted into xenografted tumours will be biocompatible and 
produce a minimal FBR. These results could be used in conjunction with previous 
studies to justify the use of these materials in the construction of implantable devices 
for a range of medical conditions. For validation of ability of the IMPACT O2 sensor 
to be able to be implanted into a tumour and provide real-time intra-tumoural O2 
measurements we hypothesise that an ovine lung cancer model would not only 
answer these questions but would also be an excellent novel translational model of 
human lung cancer. 
Our final hypothesis is that although the IMPACT O2 sensor was originally 
designed for intra-tumoural use, this sensor could also be utilised for real-time 
monitoring of visceral surface O2 levels in a range of medical conditions. One such 
application would be monitoring post-operative intestinal perfusion following an 
intestinal resection and anastomosis. The use of the sensor in this way could detect 
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peri-anastomotic tissue hypoxia and enable goal-directed treatments to be provided 
to restore intestinal oxygenation and prevent anastomotic dehiscence. We hypothesis 
that a developed murine model will provide proof-of-concept for this application. 
1.13.2 Aims 
1. To develop and characterise radioresistant breast cancer cell lines 
• Develop novel RR breast cancer cell lines using ER+ and ER- cell lines 
representing different molecular breast cancer subtypes. 
• Undertake genotypic, phenotypic and functional characterisation of parental 
and RR cell lines to demonstrate cellular differences at gene, protein and 
functional levels. 
• Identify differential phenotypic and signalling pathways between parental and 
RR cell lines to highlight potential mechanisms of radioresistance. 
2. To develop a method to identify and validate radiation-induced cancer cell 
secreted biomarkers 
• Obtain secretome samples from cancer cells up to 24 h post-radiation 
treatment from a variety of species and cancer types. 
• Use liquid chromatography-mass spectrometry to characterise the MCF-7 
secretome in both untreated and radiation-treated samples. 
• Select candidate radiation-induced secreted biomarkers for further validation 
and examine their secretion patterns in other human and canine breast and 
ovine lung cancer cell lines. 
• Combine secretomic results with whole-transcriptome gene expression data 
from both radiation-treated parental and RR cell lines to identify biomarkers 
of radiosensitivity and validate them through western blot, 
immunofluorescence and immunohistochemistry. 
3. To develop a method to investigate the biocompatibility of implantable 
sensor materials in a tumour model 
• Assess the intra-tumoural biocompatibility of materials under consideration 
for use in the IMPACT O2 sensor. 
• Develop a novel in vivo murine biocompatibility model whereby materials 
are implanted into human breast cancer xenograft tumours and their effects 
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assessed through tumour immunohistochemistry (necrosis, proliferation, 
apoptosis, hypoxic markers, innate immune responses and fibrosis). 
• Provide evidence to justify the use of these materials in the IMPACT O2 sensor. 
4. To validate functionality of the IMPACT O2 sensor to measure tissue O2 
tension for clinical applications 
• Develop an in vivo murine model for validation of the IMPACT O2 sensor to 
provide real-time measurements of intestinal and muscular ptO2. 
• Investigate the sensor’s ability to detect changes in intestinal ptO2 following 
ischaemic, hypoxic and haemorrhagic challenges and its ability to detect 
changes in muscular ptO2 following hypoxic challenges. 
• Provide evidence to justify further development of the IMPACT O2 sensor 
towards clinical applications in man. 
5. To develop a pre-clinical translation large animal model of human lung 
cancer and validate functionality of the IMPACT O2 sensor to measure 
tissue O2 tension within a solid tumour 
• Develop a novel in vivo ovine pulmonary adenocarcinoma model for the 
surgical implantation and validation of the IMPACT O2 sensor. 
• Develop a novel CT-guided trans-thoracic percutaneous implantation 
procedure with integration of techniques such as ultrasound, general 
anaesthesia, CT and surgery into the model. 
• Assess the sensor’s ability to detect changes in intra-tumoural ptO2 following 
hypoxic challenges. 
• Provide evidence to justify further development of the IMPACT O2 sensor 






2 Materials and Methods: In Vitro Experiments 
2.1 Introduction 
All cell tissue culture and laboratory experiments were performed in the 
Division of Pathology Laboratories, Western General Hospital (University of 
Edinburgh). 
2.2 Cell tissue culture 
2.2.1 Cell lines 
A panel of 4 human breast cancer cell lines, MCF-7, ZR-751, MDA-MB-231 
and HBL-100, were chosen for this study due to their differing molecular 
classifications and phenotypic traits. For comparative studies involving different 
species and cancer cell types, 1 canine breast cancer cell line, REM-134, and 1 ovine 
lung cancer cell line, JS7, were chosen. The characteristics of these cell lines are 
outlined in Table 2.1. 
All human breast cancer cell lines were obtained from the American Type 
Culture Collection (LGC Standards, Teddington, UK) and were authenticated by 
short tandem repeat (STR) profiling performed at Health England (Porton Down, 
Salisbury, UK). All cell line DNA samples matched 9 of 9 tested core alleles in DNA 
from known cell line samples confirming their identity. The canine breast cancer cell 
line was a kind gift from Professor R.W. Else (College of Veterinary Medicine, 
University of Edinburgh) and the ovine lung cancer cell line was a kind gift from Dr 
D. Griffiths (Moredun Research Institute, Pentlands Science Park, UK). All cells 
were maintained at a low passage number from frozen stocks with mycoplasma 
testing performed at 6 monthly intervals.  
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Table 2.1. Human, canine and ovine cell lines used in this study. (ER, oestrogen 
receptor; wt, wild type; PgR, progesterone receptor; HER2, human epidermal growth 
factor receptor 2; TNBC, triple negative breast cancer; SV40, Simian Virus 40). 
Cell line Origin Classification Description 
MCF-7 Human breast cancer: pleural 
effusion from a 69-year-old female 
suffering from metastatic disease 
originating from a luminal mammary 
adenocarcinoma359. 
Luminal A ER+ (wt and variants)/ 
PgR+/HER2-360 
ZR-751 Human breast cancer: ascitic 
effusion from a 63-year-old female 
suffering from metastatic disease 
originating from a ductal mammary 
adenocarcinoma361. 
Luminal A ER+/ PgR+/HER2- 
MDA-
MB-231 
Human breast cancer: pleural 
effusion from a 51-year-old female 
suffering from metastatic disease 
originating from a basal mammary 
adenocarcinoma362. 
Basal B ER-/PgR-/HER2- (TNBC) 
HBL-100 Human breast cancer: primary 
cultures of epithelial cells from an 
early lactation sample of human 
milk363. 
Basal B ER-/PgR-/HER2- (TNBC) 
HBL-100 harbours the 
SV40 genome and exhibits 
characteristics of 
transformation including 
the ability to form colonies 
in soft agar, an aneuploid 
chromosome complement 
and continuous replication 
in culture 
REM-134 Canine breast cancer: primary 
cultures of a mammary carcinoma364. 
Unknown ER-/PgR-/HER2- (TNBC) 
JS7 Ovine lung cancer: primary cultures 






2.2.2 Cell culture 
Cell culture procedures were performed inside a category II biological safety 
hood using aseptic techniques. Media was stored at 4oC and was used or discarded 
within 4 weeks of the addition of supplements. Foetal calf serum (FCS) used for cell 
culture was inactivated by heating for 15 min at 37oC, then for 30 min at 56oC. For 
routine cell culture, all cell lines were grown using the appropriate media (Table 2.2) 
in an incubator at 37oC in a humidified atmosphere at 21% O2 with 5% CO2. Media 
was changed every 48-72 h. Cells were used for no more than 15 passages, after 
which new cells were obtained from frozen stocks. Periodic recording of morphology 
and doubling times was undertaken to ensure maintenance of phenotype. Phase 
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contrast images of cells were captured with a monochrome digital Axiocam camera 
fitted to a Zeiss Axiovert S100 (Carl Zeiss Ltd, UK) microscope. 
Table 2.2. Growth media and supplements required for each cell line. 





Dulbecco’s Modified Eagle 
Media (Gibco Life 
Technologies, Invitrogen, UK) 
10% heat-inactivated FCS 
1% Penicillin/Streptomycin (100 
IU/ml) 
REM-134 Dulbecco’s Modified Eagle 
Media-high glucose (Gibco Life 
Technologies, Invitrogen, UK) 
10% heat-inactivated FCS 
1% Penicillin/Streptomycin (100 
IU/ml) 
JS7 Iscove's Modified Dulbecco's 
Media (Sigma-Aldrich, UK) 
10% heat-inactivated FCS 
1% Penicillin/Streptomycin (100 
IU/ml) 
4mM L-glutamine 
2.2.3 Recovery of cells from liquid nitrogen storage 
Cell stocks were stored in freezing mix media (90% FCS, 10% DMSO) 
within cryovials in liquid nitrogen storage tanks at -196oC. To recover cells from 
storage, cryovials were defrosted as rapidly as possible in a water bath at 37oC. Cells 
were transferred into 10 ml of warmed media and centrifuged at 1000 x g for 5 min. 
The supernatant containing DMSO was removed and the cell pellet re-suspended in 8 
ml of media and transferred to a T25 flask. Cells were used in experiments after a 
minimum period of 2 weeks after recovery from liquid nitrogen storage. 
2.2.4 Cell passage 
Cells were passaged when they reached 75-85% confluency. Media was 
removed and cells were washed twice with sterile phosphate-buffered saline (PBS). 
An appropriate volume of 0.05% trypsin ethylenediaminetetraacetic acid (EDTA) 
(Table 2.3) was added and the cells incubated for 3-5 min at 37oC until they detached 
from the flask surface. FCS-containing media was then added to neutralise the 
trypsin. Cells were centrifuged at 1000 x g for 5 min and the supernatant removed. 
Cells were then re-suspended in media and seeded into new culture vessels (Table 
2.3) or counted as required. All experiments were performed using sub-confluent 
cultures in the log-phase of growth.  
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Table 2.3. Summary of culture vessels used. Data includes volumes of media and 



























1 5 3-5 2.5x106 
T75 7,500 1-3x106 2 7 8-15 8x106 
T175 16,200 4x106 3 7 15-30 18x106 
Plates 
75 mm 2,100 1x105 2 5 5-10 3x106 
150 mm 15,200 1-2x106 3 7 15-30 20x106 
6 well 900 0.23-
1x106 
1 3 2-5 1x106 
96 well 320 1.5-
10x102 
N/A N/A 0.2 N/A 
Spinner Flasks      
100 ml N/A 1.5-
3x106 
N/A N/A 90 N/A 
250 ml N/A 3-6x106 N/A N/A 150 N/A 
2.2.5 Cell counting and determination of cell viability 
Following trypsinisation and the addition of FCS-containing media the cell 
suspension was transferred to a Falcon tube and centrifuged at 1000 x g for 5 min. 
The supernatant was removed, and the cell pellet re-suspended in media. A single 
cell suspension was created by passing the cell suspension 3 times through a 21G 
needle attached to a 10 ml syringe. 10 µl of this cell suspension was added to 10 µl 
of 0.4% trypan blue (Sigma-Aldrich, UK) and incubated for 2 min. 10 µl of this 
trypan blue cell suspension was then added to a haemocytometer. The total number 
and the number of dead cells were then counted (Table 2.4). 
Table 2.4. Formulas used for cell counting and viability assessment. (*0.1 µl is 
the volume contained within the haemocytometer counting chamber). 
Dilution factor = (volume of cell suspension + volume of trypan blue)/volume of 
new cell suspension 
Cell density (cells/ml) = total cell count/0.1 µl* x dilution factor x103 
Total number of cells = cells/ml x volume of cell suspension 
Percentage cell viability = total number of live cells/total cell count x100 
2.2.6 Cryopreservation of cells and storage into liquid nitrogen 
Surplus cells were allowed to reach 80-90% confluency in a T175 flask 
before undergoing routine trypsinisation and counting as described in sections 2.2.4 
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and 2.2.5. Cells were re-centrifuged at 1000 x g for 5 min and the supernatant 
removed. Cells were then re-suspended in freezing media at a density of 2-5x106 
cells per 0.5 ml freezing media, transferred into separate cryovials and placed into a 
freezing container (Nalgene Mr. Frosty, Sigma-Aldrich, UK) containing 100% 
isopropyl alcohol and stored overnight at -70oC. Cryovials were then transferred to a 
liquid nitrogen tank for long term storage (Institute of Genetics and Molecular 
Medicine, University of Edinburgh). 
2.2.7 Irradiation of cells 
Cells were irradiated using a Faxitron cabinet X-ray system 43855D 
(Faxitron X-ray Corporation, IL, USA). Dosimetry and dose-rate [mGy/s] checks 
were conducted at least once a year (NHS Medical Physics Department, Western 
General Hospital, Edinburgh, UK) using an Innovision Dosimeter 35050A and 150cc 
ion chamber 96020C. The Faxitron cabinet used no extra filtration, with x-rays 
passing through a 1.6 mm beryllium window. Culture vessels were placed in the 
centre of the glass shelf which rotates at 2 rpm to ensure uniform dosing. The 
distance from the focal spot of the x-ray tube to the culture vessels was 40.6 cm and 
when operated at 130 kV it produces a central dose of 1 Gy/min. For all experiments 
that involved radiation treatment, control cells were included that consisted of cells 
undergoing mock radiation treatment being placed within the Faxitron cabinet for the 
desired length of time without undergoing radiation treatment. 
2.2.8 Development of radioresistant cell lines 
Radioresistant cell lines (MCF-7 RR, ZR-751 RR, MDA-MB-231 RR, REM-
134 RR and JS7 RR) were developed from their respective parental cell lines by 
weekly exposure to single fractions of radiation. An initial dose of 2 Gy was 
followed by weekly incremental doses of 0.5 Gy for 12 weeks. During this period 
cells received a total radiation dose of 57 Gy. Cells were subsequently maintained 
with further weekly doses of 5 Gy. Radioresistant cell lines were maintained in 
routine media. Following exposure to radiation, cells were left at least 24 h before 
undergoing trypsinisation and passage. 
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2.2.9 Generation of multicellular tumour spheroids 
Numerous cancer cell line models are available to increase the complexity of 
cell culture systems that more accurately replicate the in vivo TME. The use of 
multicellular tumour spheroids (MTS) represents one such commonly used model366. 
A single cell suspension from a T175 flask (approximately 15x106 cells) was 
created and transferred into a spinner flask (Cellcontrol Spinner Flask, Integra, 
Switzerland) containing 100 ml of media and incubated routinely on a magnetic 
stirrer platform (Cellspin, Integra, Switzerland) to provide convective mixing of the 
culture media and cell suspension to generate MTS. Flasks were checked daily for 
MTS formation, the media was changed as required. When MTS had reached a 
sufficient size (generally 7-14 d) they were removed from the spinner flask using a 
25 mL serological pipette. 
2.3 Cellular assays 
2.3.1 Sulforhodamine B proliferation (SRB) assay 
The SRB assay was originally described in 1990 as a new technique for anti-
cancer drug screening367. The SRB assay measures cellular proliferation based on the 
ability of the SRB dye to bind the basic amino acids of fixed proteins in a pH-
dependent manner367-369; colorimetric evaluation provides an estimate of total 
protein, which is related to cell number369. 
Due to differences in proliferation rates between cell lines, initial 
optimisation experiments were conducted to identify cell seeding numbers to ensure 
optical density (OD) saturation did not occur over the time course of the 
experiments. If the OD values produced by the assay are below 3.5, the relationship 
between OD and cell number is linear. However, if the OD values are greater than 
3.5 there is a risk saturation may be occurring with values becoming inaccurate. 
Seeding densities used for each cell line gave a confluency of approximately 10-30% 
at 24 h post-seeding and produced OD values less than 3.5 up to 144 h post seeding. 
Cells were seeded into flat-bottom 96 well plates and incubated for 24 h 
before treatment with drugs or radiation in a final volume of 200 µl in each well. 
Controls included untreated and drug vehicle (DMSO or ethanol) treated cells. Drug 
vehicle controls were treated corresponding to the highest drug concentration used in 
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each experiment (final concentration of DMSO/ethanol was not greater than 1%). 
Media only controls were also included to allow background readings to be assessed. 
Six replicates of each treatment group were performed in each experiment. Cellular 
proliferation was assessed at 0, 24, 48, 72, 96, 120 and 144 h following drug or 
radiation treatment. To perform the SRB assay, cells were fixed with 50 µl/well of 
cold 25% trichloracetic acid (TCA) (Sigma-Aldrich, UK) for 60 min at 4oC and 
subsequently washed 10 times with water to remove the TCA, media, metabolites 
and serum proteins. Plates were dried, and the fixed cells stained with 50 µl of 0.4% 
SRB dye solution (Sigma-Aldrich, UK) dissolved in 1% acetic acid (VWR 
International) for 30 min at room temperature. The SRB solution was removed and 
the plates washed in 1% glacial acetic acid 4 times to remove unbound dye. Once the 
plates were dry, the protein-bound SRB was solubilised with 150 µl of 10 mM Tris-
NaOH buffer (pH 10.5) for 60 min at room temperature before measuring the OD of 
each well at 540 nm using a Biohit BP800 spectrophotometer (Biohit Ltd, UK) and 
Wallac 1420 Manager. OD values were corrected by subtracting average values of 
blanks and normalising to vehicle controls. Mean values and standard deviations 
were calculated from the technical replicates. IC50 values were generated through 
sigmoidal concentration response curves fitted using Prism 7 (GraphPad Software, 
San Diego, CA, USA). 
2.3.2 Colony formation assay 
Cells were seeded into 75 mm plates (1x103 cells/plate) and incubated for 24 
h before radiation treatment. Untreated cells were used as controls; once visible 
colonies (approximately 50 cells/colony) had formed in the untreated control group 
(approximately 10-14 d post-seeding) the cells were fixed and stained for counting. 
The media was discarded, and the cells washed twice in PBS. Clonogenic reagent 
(1,9-dimethyl-methylene blue zinc chloride double salt, Sigma Aldrich, UK; 0.5 g 
methylene blue dissolved in 100 ml ethanol and 100 ml H2O) was added to the 
plates, which were then left to incubate for 45 min at room temperature. The plates 
were washed twice in H2O then left to dry before manually counting the colonies; 
only colonies greater than 50 cells were counted. Analysis was performed by 
calculating plating efficiencies (PE) and survival fractions (SF) for untreated and 
radiation treated cells. PE, which indicates the proportion of cells seeded into the 
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plate that grew to form a colony, was calculated by dividing the number of colonies 
counted by the initial number of cells seeded. Following determination of PE, the 
fraction of cells surviving a given radiation treatment was calculated; this SF was 
calculated by dividing the PE of the treated cells by that of the PE of the untreated 
control cells. 
2.3.3 Scratch (migratory) assays 
The migratory capabilities of parental and RR cell lines were investigated 
through 2D scratch assays. Cells were seeded into 6 well plates to achieve 100% 
confluence after 24 h. Scratch assays were performed as described by Liang et al,. 
2007370. A scratch was made in the monolayer of cells using a p1000 pipette tip. 
Media was discarded and the cells were washed in PBS until all floating cells were 
removed and a clean, sharp edged scratch could be identified by phase contrast light 
microscopy. 0.1% FCS-supplemented media was then added (lower percentage FCS-
supplemented media was used to minimise cell proliferation while preventing 
apoptosis and/or cell detachment). Controls included untreated and drug vehicle 
(DMSO or ethanol) treated cells. For drug assays, the drug or drug vehicle was added 
to the 0.1% FCS-supplemented media. Photographs were taken using the 2.5x 
objective lens at regular intervals until the cells had migrated across the scratch (or 
up to a maximum of 48 h post-scratch). At each time point the area remaining of the 
scratch was calculated using FIJIJ software and expressed as a percentage of the 
scratch area at 0 h, giving a final relative migratory distance at each time point. 
2.3.4 MTS invasion assays 
The invasive capabilities of parental and RR cell lines were investigated 
through 3D invasion assays as the movement of cells through a 3D matrix more 
closely mimics in vivo invasion371. A collagen gel solution was made by mixing 
0.1% filtered acetic acid, cell matrix type 1-A (an acid soluble type 1 collagen 
solution produced from porcine tendon, pH 3, 3 mg/ml, Alphalabs, UK), 0.22 M 
NaOH (Sigma-Aldrich, UK), FCS and 10x DMEM (Sigma-Aldrich, UK) at 
concentrations of 45%, 25%, 10%, 10% and 10% respectively. All solutions were 
kept on ice to prevent collagen polymerisation. A single MTS was added with 500 ul 
of collagen mix into a well of a 24 well plate and incubated for 1 h at 37oC to allow 
53 
 
the collagen to polymerise. Following polymerisation, a p200 pipette tip was used to 
release the collagen gel from the edges of the well and a further 500 ul of DMEM 
was added to each well. Controls included untreated and drug vehicle (DMSO or 
ethanol) treated cells. For drug assays, the drug or drug vehicle was added to both the 
collagen mix and the media. Photographs were taken using a 2.5x objective lens at 
regular intervals up to 120 h post-seeding. MTS invasion was measured using a 
macro programme developed by Matthew Pearson (Light Microscopy Application 
Specialist, IGMM, University of Edinburgh). This macro processes the image to find 
the edges of the MTS and highlights the cells using morphological filters and 
intensity thresholding. This macro programme provided 3 readings after analysis; the 
total area, the MTS area and the invasive area. To assess invasion the total MTS area 
at each time point was expressed as a percentage of the MTS area at 0 h (Figure 2.1). 
 
Figure 2.1. MTS invasion measurement. MCF-7 RR MTS are shown at (a) 0 h and 
(b) 96 h post-seeding into collagen. Images are shown pre- and post-macro analysis 
using FIJI software. The green lines outline the MTS and the invasive front. 
2.4 Protein recovery and detection 
2.4.1 Whole cell protein extraction from adherent cells 
Protein extraction was carried out on ice to minimise protein degradation. 
Cells were washed twice in ice cold PBS before the addition of ice-cold isotonic lysis 
buffer (Table 2.5). Using a cell scraper, the cells were scraped off the surface of the 
culture vessel and mixed with the lysis buffer. The cells were left on ice for 10-15 
min to allow lysis to occur. The lysate was collected and transferred to a cold 1.5 ml 
Eppendorf tube then centrifuged at 13,000 x g for 6 min at 4oC. The supernatant 
(lysate) was removed and transferred to a new Eppendorf tube, which was then either 
frozen and stored at -70oC or placed on ice for immediate use. 
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Table 2.5. Lysis buffer. Volumes of lysis buffer used were dependent on the size of 
culture vessel: 400 µls per T175 flask or 150 mm petri dish; 200 µl per T75 flask or 
75 mm petri dish; 100 µl per well in a 6 well plate. 
Lysis buffer Lysis buffer additives per 10 ml lysis buffer 
50 mM Tris (pH 7.5), 
5 mM EGTA (pH 
8.5), 150 mM NaCl 
• 1 complete ‘protease inhibitor tablet’ (Roche, UK) 
• 100 µl phosphatase inhibitor cocktail 2 (Sigma-Aldrich, UK) 
• 100 µl phosphatase inhibitor cocktail 3 (Sigma-Aldrich, UK) 
• 50 µl aprotinin (Sigma-Aldrich, UK) 
• 100 µl Triton-X (Sigma-Aldrich, UK) 
2.4.2 Protein quantification using the bicinchoninic acid assay 
Protein concentrations from cellular lysates were determined using the 
bicinchoninic acid (BCA) assay. A 1 mg/ml bovine serum albumin (BSA) (Sigma-
Aldrich, UK) standard was used to create an 8-point standard curve. Known BSA 
protein standards were made up to a final volume of 50 µl. The standard curve was 
produced using the same plate on which the samples were assayed. 5 µl of each 
protein sample was diluted into 45 µl of distilled water in borosilicate glass tubes. 
Fresh BCA solution was made by adding 1 ml of copper (II) sulphate (Sigma-
Aldrich, UK) into 49 ml of BCA (Sigma-Aldrich, UK). 1 ml of this BCA solution 
was added to each 50 µl aliquot of sample or BSA standard. The samples were 
briefly vortexed and incubated for 15 min at 60oC then allowed to cool. In a 96 well 
plate, 200 µl of each solution (sample or known BSA protein standard) was added to 
a designated well. All samples were performed in duplicate. OD values were 
measured at 540 nm using a Biohit BP800 spectrophotometer (Biohit Ltd, UK) and 
Wallac 1420 Manager program (PerkinElmer, UK). Protein concentrations were 
determined from the standard curve generated using the known BSA concentrations. 
2.4.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Protein samples were resolved in sodium dodecyl sulphate-polyacrylamide 
gels using electrophoresis. Different percentage SDS-polyacrylamide gels (5-15%) 
were used according to the size of the protein of interest. Lower percentage gels were 
used to separate high molecular weight proteins and higher percentage gels were 
used for lower molecular weight proteins. All SDS-polyacrylamide gels were 
prepared using the Bio-Rad Protean II mini-gel system (Bio-Rad Laboratories, UK). 
The resolving gel was prepared (Table 2.6) and approximately 8 ml was poured 
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between the plates; this was overlaid with isopropanol to remove air bubbles. The gel 
was allowed to set at room temperature, the isopropanol was discarded, and the top 
of the gel was washed with dH2O. The stacking gel (Table 2.6) was prepared and 
approximately 1.5 ml was poured on top of the resolving gel. A loading comb was 
then inserted into the stacking gel and allowed to set at room temperature. Once set, 
the comb was removed, and the wells were washed with dH2O. The gel was placed 
into a running module which was then immersed in SDS-PAGE running buffer 
(Table 2.6). Protein samples were prepared into 40 µg aliquots by adding the 
appropriate volume of 4x Laemmli sample buffer (Bio-Rad Laboratories, UK) and 
lysis buffer to cell lysates as determined by the BCA assay. Samples were heated for 
5 min at 95oC to denature the proteins, which were then loaded into the wells in the 
stacking gel. A pre-stained protein marker (broad range ladder, 11-190 KDa, Cell 
Signalling Technology, UK) was run in parallel to allow identification of the protein 
bands by size. The gel was subjected to electrophoresis at 80 V for 15 min (which 
allows the samples to move through the stacking gel), then at 150 V until the dye 
front had run off the bottom of the resolving gel (approximately 45 min). 
2.4.4 Immunoblotting 
Resolved proteins were electrophoretically transferred onto methanol-
activated polyvinylidene difluoride nitrocellulose membranes (Immobilon-P PVDF, 
0.45 µm, Merck Millipore, UK) in ice-cold transfer buffer (Table 2.6) using the 
Protean Transfer Cell equipment (Bio-Rad laboratories, UK). Transfer was 
performed at 100 V for 90 min at 4oC. Nitrocellulose membranes were stained with 
Revert total protein stain for 5 min, then washed twice in Revert wash solution for 30 
s each time to allow visualisation of protein bands and confirm equal loading (Li-
COR Biotechnology, UK). Membranes were visualised using the LI-COR Odyssey 
Infrared Imager (LI-COR, Bioscience, UK) using the 700 nm channel (as described 
below). Membranes were then washed with Revert reversal solution (Li-COR 
Biotechnology, UK) for 10 min until the stain was no longer visible. Non-specific 
antibody binding was blocked by incubating membranes in Li-COR Odyssey 
blocking buffer solution (Li-COR Biotechnology, UK) for 1 h at room temperature. 
Primary antibodies (targeting the protein of interest and loading control) were diluted 
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in Li-COR Odyssey blocking buffer solution (Table 2.7). The membranes were 
subsequently probed with primary antibodies and incubated overnight at 4oC. 
Table 2.6. Gels and solutions required for SDS-PAGE and immunoblotting. 
Reagent Composition 
Resolving gel 5-15% acrylamide gels were made according to the size of protein 
of interest. 390mM Tris-HCL (pH 8.8), 0.1% SDS. Polymerisation 
was initiated by the addition of 0.1% ammonium persulphate and 
0.08% TEMED immediately prior to pouring the gel 
SDS-PAGE running buffer  25mM Tris, 190mM glycine, 0.1% (v/w) SDS 
Stacking gel 5% acrylamide, 123mM Tris-HCL (pH 6.8), 0.1% SDS. 
Polymerisation was initiated by the addition of 0.1% ammonium 
persulphate and 0.1% TEMED immediately prior to pouring the gel 
Transfer buffer 25mM Tris, 190mM glycine, 20% (v/v) methanol 
Following overnight incubation, the primary antibodies were removed, and 
the membrane washed 3 times in phosphate-buffered saline-Tween 20 (PBST, 
1:1000 solution of Tween20) 5 min per wash. Fluorescently labelled secondary 
antibodies IRDye 800CW and IRDye 680LT (LI-COR, Bioscience, UK) were 
diluted in Li-COR Odyssey blocking buffer solution (1:10,000) with the addition of 
0.01% SDS. These fluorescently labelled secondary antibodies are susceptible to 
photo-bleaching, therefore subsequent steps were performed in the dark. The 
membranes were probed with the secondary antibodies and incubated for 45 min at 
room temperature. Following incubation, the secondary antibody was removed, and 
the membrane washed 3 times in PBST, followed by a further 3 washes with PBS (5 
min per wash). Membranes were visualised using the LI-COR Odyssey Infrared 
Imager (LI-COR, Bioscience, UK) using the 700 and 800 nm channels to detect the 
loading control and protein of interest bands respectively. Images were saved as 
TIFF files for quantification. For storage, membranes were washed in PBST for 10 
min and frozen at -20oC. Membranes required the following day were covered in 
PBS and stored at 4oC. 
2.4.5 Protein quantification using infra-red radiation 
Relative protein intensities were measured by quantifying infra-red radiation 
emitted from labelled antibodies using Odyssey software (Image Studio Lite, Li-
COR Biosciences, UK). Protein intensities were normalised to loading controls. 
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Table 2.7. Primary antibodies. Primary antibodies used for western blotting (WB), 
immunocytochemistry (ICC) and immunohistochemistry (IHC). 
Primary antibody 
target antigen 




Anti-α tubulin Mouse mAb; Abcam; ab7291  1:10,000 (WB) N/A 
Anti-β actin Rabbit pAb; Abcam; ab8227 1:10,000 (WB) N/A 
Anti-GAPDH Mouse mAb; Abcam; ab8245 1:5000 (WB) N/A 
Anti-ERα Mouse mAb; Dako; M7047 1:50 (WB, ICC, IHC) Sodium citrate 
Anti-EGFR Rabbit mAb; Cell Signaling 
Technology; 4267 
1:1000 (WB); 1:50 
(ICC, IHC) 
EDTA 
Anti-Phospho EGFR Mouse mAb; Abcam; ab24918 1: 1000 (WB) N/A 
Anti-HER2 Rabbit mAb; Cell signaling 
Technology; 2242 
1:1000 (WB); 1:50 
(ICC, IHC) 
Sodium citrate 
Anti-PgR (A/B) Rabbit mAb; Cell Signaling 
Technology; 8757 
1:1000 (WB) N/A 
Anti-PgR Mouse mAb; DAKO; M3569 1:150 (ICC, IHC) EDTA 
Anti-AKT Mouse mAb; Cell Signaling 
technology; 2920 
1:1000 (WB) N/A 
Anti-Phospho AKT Rabbit pAb; Cell Signaling 
technology; 9271 
1:1000 (WB) N/A 
Anti-ERK Rabbit pAb; Cell Signaling 
Technology; 9102 
1:1000 (WB) N/A 
Anti-Phospho ERK Mouse mAb; Cell Signaling 
Technology; 9106 
1:1000 (WB) N/A 
Anti-Ki67 Mouse mAb; DAKO; M7240 1:150 (ICC, IHC) Sodium citrate 
Anti-E-cadherin Mouse mAb; BD 
Transduction; 610182 
1:50 (ICC, IHC) Sodium citrate 
Anti-N-cadherin Mouse mAb; BD 
Transduction; 610921 
1:150 (ICC, IHC) Sodium citrate 
Anti-vimentin Mouse mAb; Abcam; ab8069 1:50 (ICC, IHC) Sodium citrate 
Anti-SNAIL Rabbit pAb; Abcam; 
ab128530 
1:250 (ICC, IHC) Sodium citrate 
Anti-SEC24C Rabbit pAb; Atlas Antibodies; 
HPA040196 
1:500 (WB); 1:500 
(IHC) 
Sodium citrate 
Anti YBX3 Mouse mAb; Novus 
biologicals; H00008531-MO6 
1:500 (WB); 1:100 
(IHC) 
Sodium citrate 
Anti-EIF3G Rabbit pAb; Atlas Antibodies; 
HPA041997 
1:1000 (WB); 1:250 
(IHC) 
Sodium citrate 
Anti-TK1 Rabbit mAb; Abcam; ab76495 1:500 (WB); 1:500 
(IHC) 
Sodium citrate 
Anti-PERK Rabbit mab; Cell Signaling 
Technology; 5683 
1:500 (WB) N/A 
Anti-Phospho PERK Rabbit pAb; Thermo 
Scientific; PA5-30294 
1:500 (WB) N/A 
Anti-PhosphoEIF2α Rabbit pAb; Cell Signaling 
Technology; 9721 
1:500 (WB) N/A 
Anti-Phospho IRE1 Rabbit pAb; Thermo 
Scientific; PA1-16927 
1:500 (WB) N/A 
Anti-WNT5a Mouse mAb; Thermo 
Scientific; MA5-15502 
1:500 (WB, ICC) Sodium citrate 
58 
 
2.4.6 Membrane Stripping 
Membranes required for re-probing were stripped using NewBlot PVDF 
Stripping Buffer (LI-COR Biosciences, UK). Membranes were first washed in PBST 
then covered in stripping buffer (diluted 1:5 with dH2O) for 20 min at room 
temperature. The membranes were visualised using the LI-COR Odyssey Infrared 
Imager to ensure the secondary antibodies had been removed. Blots were then re-
probed with secondary antibodies for 45 min at room temperature and re-visualised 
to ensure the primary antibody had also been removed. Blots were washed in PBS 
then blocked and probed as previously described in section 2.4.4. 
2.4.7 Assessment of the effects of radiation on pathway activation 
Cells were seeded into 75 mm plates at a density of 1x106 cells per plate and 
incubated for 24 h. Cells were washed twice with PBS before 7 ml of FCS-free 
media was added into the wells. The cells were serum starved for 2 h then exposed to 
2 Gy radiation (control cells were not treated with radiation). All cells underwent 
routine harvesting and lysis collection at 0, 5, 10- and 30-min post-radiation. The 
lysate was snap frozen on dry ice and stored at -70oC for subsequent western blot 
(WB) analysis. 
2.5 Immunohistochemistry 
2.5.1 Fixation and sectioning of MTS and tissue for 
immunohistochemistry 
MTS were fixed for 24 h in 4% formaldehyde (Genta Medical, UK). After 
fixation, the formaldehyde was removed and 100-200 µl of molten 2% agarose was 
added. A 1 ml pipette tip was then used to gently stir the agarose and MTS, being 
careful to conserve the integrity of the MTS. The suspension was allowed to set at 
room temperature before being processed. Harvested xenograft tumours and OPA 
tissue were fixed for at least 24 h (depending on tissue thickness) in 4% 
formaldehyde before being processed. Processing of MTS and tissue for IHC was 
performed using the Thermo Scientific Excelsior AS Tissue Processor (Thermo 
Scientific, UK). Once processed, MTS and tissue were embedded in paraffin blocks 
and stored at room temperature. Sectioning of samples was performed using the 
Leica RM2235 rotary microtome (Leica Microsystems Ltd, UK). Microtome sections 
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of 4 µm were placed on SuperFrost Plus glass slides (Thermo Scientific, UK) and 
allowed to dry for a minimum of 4 h at 53oC for H&E and Masons trichrome staining 
or overnight at 37oC for IHC. Sections cut for IHC were stored at 4oC. 
2.5.2 Haematoxylin and eosin staining 
Sections were deparaffinised by 3 changes in 100% xylene for 5 min each 
time, then rehydrated by placing into decreasing concentrations of alcohol; 2 changes 
in 100% ethanol, followed by 80% then 50% for 2 min each time. The slides were 
then washed in running water for 2 min, before placing in haematoxylin (Shandon 
Harris Haematoxylin, Thermo Scientific, UK) for a maximum of 10 min. Slides were 
washed in running water for 2 min before being placed into Scott’s tap water 
substitute for a maximum of 10 min until the tissue sections turned blue. Sections 
were counterstained by placing them into Eosin Y (Shandon Eosin Y Cytoplasmic 
Counterstain, Thermo Scientific, UK) for 5 min. The slides were dehydrated by 
placing them into increasing concentrations of alcohol; 50% ethanol for 30 s, 80% 
ethanol for 30 s, then 2 changes in 100% ethanol for 2 min each time. The slides 
were placed in xylene for 10 min before being mounted with coverslips using DXP 
mountant (Sigma-Aldrich, UK). Mounted slides were given a brief wash in 100% 
xylene before being left to dry at room temperature. 
2.5.3 Masson’s trichrome staining 
All solutions for Masson’s Trichrome staining were obtained from TCS 
Biosciences Ltd, UK. Sections were routinely deparaffinised and rehydrated then 
washed in running water for 2 min. Slides were mordanted with Bouin solution for 
24 h at room temperature, before washing in running water for 60 s or until free of 
yellow colouration. Slides were then stained in Weigert iron haematoxylin for 5 min, 
washed for 5 min in running water and rinsed in distilled water. Slides were stained 
with Masson’s Trichrome for 5 min, rinsed in distilled water and then treated with 
phosphotungstic/phosphomolybdic acid solution for 5 min. Slides were counter 
stained in aniline blue for 5 min, immersed in 1% acetic acid, then routinely 
dehydrated and mounted. 
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2.5.4 Vertical immunohistochemistry for paraffin embedded MTS 
and tissue samples 
Sections were routinely deparaffinised and rehydrated. The slides were 
washed in running water for 10 s before being placed into a pressure cooker and 
covered with pre-warmed antigen retrieval solution. The pressure cooker was placed 
into a microwave and heated on maximum power for 5 min. Following heating, the 
slides were left to cool for 20 min, then washed twice in PBST for 5 min. Cover 
plates were added and the slides placed into a Sequenza rack (Thermo Scientific, 
UK) before washing in PBST for 5 min. Following this wash endogenous peroxidase 
activity was blocked by the addition of 120 µl of 3% H2O2 (Dako, UK) for 10 min, 
followed by 2 washes in PBST for 5 min each time. Non-specific staining was 
blocked by the addition of Total Protein Block (Dako, UK) for 10 min at room 
temperature. Primary antibodies were diluted in Dako antibody diluent (Dako, UK), 
added to the slides and incubated for 1 h at room temperature. Negative controls 
consisted of adding antibody diluent containing no primary antibodies. Following 
incubation, the slides were washed twice in PBST for 5 min each time and then 
incubated with Dako Envision labelled polymer or IgG specific secondary antibody 
for 30 min at room temperature. Following incubation, the slides were washed twice 
in PBST for 5 min followed by the addition of Dako chromophore/substrate solution 
(1:50) to the slides, which were incubated for 10 min at room temperature. The slides 
were then removed from the Sequenza rack and cover plates and placed into a slide 
rack submerged in water. The slides were counterstained in haematoxylin for 60 s, 
rinsed in water for 60 s until the purple colour had washed away then placed in 
Scott’s tap water substitute for 30 s before rinsing in water. The slides were then 
routinely dehydrated and mounted. 
2.5.5 Horizontal immunocytochemistry and immunofluorescence 
using chamber slides 
Cells were seeded into 2-well chamber slides (Lab-Tek II, Scientific 
Laboratory Supplies, UK) to achieve confluences of approximately 80% at 24 h 
(total of 2 ml media/chamber). Following incubation, the media was discarded, and 
the cells washed twice in cold PBS. The cells were fixed in cold acetone (500 
µl/chamber) for 10 min at 4oC and then washed twice in PBS for 10 min each time. 
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For immunocytochemistry the slides underwent the same protocol as described for 
paraffin embedded MTS/tissue starting with the addition of the H2O2 solution. To 
perform immunofluorescence the slides also underwent the same protocol as 
described for paraffin embedded MTS/tissue starting with the addition of the H2O2 
solution, continuing up to the addition of the labelled polymer. At this point 
secondary antibodies conjugated with fluorescent dyes (AlexaFluro 568, IgG. Life 
Technologies, UK), diluted to 1:300 in Dako antibody diluent (Dako, UK), were 
added to the chambers and incubated in the dark for 1 h at room temperature. 
Following incubation, the slides were washed 3 times in PBST for 5 min each time. 
Slides were then mounted using anti-fade mounting media containing DAPI 
(Vetorshield, Vector Laboratories Inc, Burlingame, CA, USA). 
2.5.6 Image acquisition 
High resolution digital scans of the entire microscope slide were obtained 
using the NanoZoomer ER slide scanner (Hamamatsu Photonics, UK) and viewed 
using NanoZoomer Digital Pathology software. All mounted slides were stored at 
room temperature. 
2.6 RNA interference 
2.6.1 ERα knockdown using siRNA 
An individual pre-designed ERα siRNA (J-003401-12; ESR1), a combined 
mixture of 4 siRNAs (L-003401-00-0005; Smart pool ESR1) and a non-targeting 
siRNA (D-001810-01) were purchased from the ON-TARGET plus series (GE 
Healthcare Dharmacon, UK). siRNAs were re-suspended to create 20 µM stock 
solutions using siRNA buffer (Dharmacon, UK) and RNase-free water. The solutions 
were mixed by pipetting and placed on an orbital shaker for 30 min at room 
temperature. The concentration of the reconstituted siRNA was then verified using 
the NanoDrop Spectrophotometer ND1000 (Thermo Fischer Scientific, UK) at 260 
nm (for siRNAs 1 µM = 13.3 ng/µl). Aliquots of the stock solution were made and 




2.6.2 Liposome-mediated transfection optimisation 
MCF-7 cells were seeded into either 96 or 6 well plates at a density of 1.5x 
103 or 2.3x 105 respectively using antibiotic-free, 10% FCS-supplemented DMEM. 
Cells were seeded to achieve confluences of approximately 20-30% by 24 h. 
Transfections were performed using the manufacturer’s transfection protocol; briefly, 
24 h post-seeding the media was removed, and the cells washed in PBS. Antibiotic-
free DMEM was then added to the wells (1 ml for 6 well plate, 100 µl for 96 well 
plate). The transfection protocol consisted of diluting DharamaEFECT 1 transfection 
reagent (GE Healthcare Dharmacon,UK) into serum and antibiotic-free DMEM and 
incubating the solution for 5 min at room temperature. Required amounts of siRNA 
were also diluted into serum and antibiotic-free DMEM which was also incubated for 
5 min at room temperature. siRNA was diluted to achieve the desired concentration 
in the wells (Table 2.8). The 2 solutions were combined and incubated for 20 min at 
room temperature. The solution was diluted with antibiotic-free 10% FCS-
supplemented DMEM then added drop wise to the appropriate wells. Cells were 
incubated routinely with the media changed to routine DMEM (containing antibiotics 
and FCS) 24 h post-transfection. 
For each experiment controls included; untreated cells, mock transfected cells 
(cells treated only with transfection reagent but no siRNA) and non-targeted 
transfected cells (cells transfected with a non-targeting siRNA sequence). Lysates of 
transfected samples were collected, and efficiency of knockdown was assessed at 
protein level through western blotting. The expression of the targeted protein in the 
transfected cells was compared to the expression in the mock and non-targeted 
treated cells. All transfection reactions were optimised for individual experiments to 
achieve the maximum knockdown while preserving cell viability.  
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Table 2.8. siRNA transfection concentrations and volumes required for 96 and 6 
well plate formats. Data provided is to achieve siRNA end concentrations of 25 nM. 
Reagent Concentration/volume per well 
 96 Well Plate 6 Well Plate 
siRNA 0.25 µl 2.5 µl 
Volume of FCS and antibiotic-free DMEM used for 
siRNA dilution 
9.75 µl 197.5 µl 
Total volume of diluted RNA 10 µl 200 µl 
 
DharmaFECT 1 transfection reagent 0.1 µl 4 µl 
Volume of FCS and antibiotic-free DMEM used for 
DharmaFECT 1 transfection reagent dilution 
9.9 µl 196 µl 
Total volume of diluted transfection reagent 10 µl 200 µl 
 
Volume of antibiotic-free 10% FCS DMEM added to 
the combined transfection mixture 
80 µl 600 µl 
Total end volume of media, transfection reagent and 
siRNA solution per well 
200 µl 2 ml 
2.7 Nucleic acid isolation and quantification 
2.7.1 RNA extraction and assessment of nucleic acid purity 
The RNeasy Mini Kit using QIAshredder technology (Qiagen, UK) was used 
to extract total RNA from cells following the manufacturer’s protocol for the 
purification of RNA from cells using spin technology. The protocol included the 
addition of a genomic DNA (gDNA) eliminator column for the removal of gDNA. 
Cells were seeded into 75 mm plates at a density of 3x106 cells per plate and 
incubated for 24 h. Cells were washed twice with PBS before 7 ml of FCS-free 
media was added. The cells were serum starved for 2 h after which the treatment 
groups were exposed to 2 Gy radiation. The cells underwent routine trypsinisation at 
0, 2 and 8 h post-radiation. A cell suspension containing up to 1x107 cells (the 
maximum number of cells recommended for each spin column) was centrifuged at 
1000 x g for 5 min. The supernatant was removed, and the cell pellet was snap frozen 
on dry ice and stored at -70oC for subsequent RNA extraction. 
For RNA extraction the cell pellet was defrosted on ice and re-suspended in 
350-600 µl (depending on cell number) of RLT lysis buffer. The lysate was 
transferred into a QIAshredder placed into a 2 ml collection tube; the assembled 
QIAshredder was centrifuged for 2 min at full speed. To eliminate gDNA 
contamination the homogenised lysate was then transferred to a gDNA eliminator 
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spin column placed into a 2 ml collection tube and centrifuged for 30 s at 13000 x g. 
The spin column was discarded but the flow through was saved. 
Depending on cell number, 350 or 600 µl of 70% ethanol was added to the 
homogenised and gDNA-removed lysate before the solution was transferred to a 
RNeasy spin column placed in a 2 ml collection tube and centrifuged for 15 s at 
13000 x g. The flow through was discarded and 700 µl of buffer RW1 was added to 
the RNeasy spin column and centrifuged for 15 s at 13000 x g to wash the spin 
column membrane. The flow through was discarded and care was taken to ensure the 
RNeasy spin column collection tube did not contact the flow through. Two further 
washes using 500 µl of buffer RPE containing 80% ethanol with centrifugation steps 
of 15 s and 2 min at 13000 x g were performed to wash the spin column membrane. 
The RPE buffer dissolves RNA salts but nucleic acids are left behind. After each 
wash the flow through was discarded. To ensure that no RPE buffer was carried over, 
the RNeasy spin column was placed in a new 1.5 ml collection tube and centrifuged 
at full speed for 1 min. The RNeasy spin column was then placed in a new 1.5 ml 
collection tube and 30-50 µl of RNase-free water was added directly to the spin 
column membrane, the RNA was eluted by centrifugation for 1 min at 13000 x g. 
The eluted RNA was used immediately or stored at -20oC. 
Extracted RNA samples were assessed for quality and quantified using the 
NanoDrop Spectrophotometer ND1000 (Thermo Fischer Scientific). Nucleic acid 
purity was assessed using the A260:A280 and A260:A230 ratios. An A260:A280 ratio value 
of approximately 2.0 is accepted as pure for RNA. Only good quality RNA with 
acceptable A260:A280 ratios were used in subsequent experiments. 
2.7.2 Whole-transcriptome gene expression analysis 
Gene expression analysis was performed using Lexogen QuantSeq 
sequencing (Edinburgh Clinical Research Facility, University of Edinburgh). 
Analysis was performed by Dr A. K. Turnbull (Cancer Research UK, University of 
Edinburgh). Full genome expression read-counts were generated using Lexogen 
QuantSeq 3’ FWD sequencing technology on an Illumina flow cell which was 
scanned using an Illumina HiScanSQ system. NGS reads were generated towards the 
poly(A) tail and read 1 directly reflects the mRNA sequence. RNA integrity number 
(RIN) was generated for each sample to assess RNA quality (Agilent Bioanalyzer); 
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all samples had RIN values above 9.7. FASTQ files of raw read-count data were pre-
processed using the Lexogen recommended BlueBee high-performance NGS 
analysis software which implemented poly(A) tail trimming and alignment to the 
Genome Reference Consortium Human genome build 38 reference genome using the 
Spliced Transcripts Alignment to a Reference (STAR) algorithm372. Prior to analysis, 
data were log2 transformed and quantile normalised in R (Bioconductor) software 
and packages373. Differentially expressed genes were identified using a log2 fold-
change increase or decrease cut-off of greater than 1. Gene enrichment and multi-
dimensional scaling analysis were performed using R (Bioconductor) software and 
packages373. Pathway-focused analyses, heatmap and cluster analysis were 
performed using TM4 MeV (multiple experiment viewer) software374. Heatmap 
clustering was carried out using Pearson correlation with average linkage. For 
integration of gene expression data with public datasets, correction for integration 
batch effects was performed in R using ComBat375,376. Hierarchical clustering of 
parental and RR cell lines was performed using a published list of genes whose 
expression profile denotes the breast cancer intrinsic subtypes (basal, normal-like, 
HER2, luminal A and luminal B)377. Assignment of individual samples to intrinsic 
subtypes was performed using the genefu R package378. Genefu implements a Single 
Sample Predictor algorithm which is a nearest-centroid classifier. The centroids 
representing the breast cancer molecular subtypes were identified through 
hierarchical clustering using the same intrinsic gene list that were used for cluster 
analysis. Venn diagrams were generated using jvenn379. All datasets generated and/or 
analysed during the study are available in the NCBI's Gene Expression Omnibus380 
and are accessible through GEO Series accession number GSE120798. 
2.8 Cancer cell secretome analysis 
2.8.1 Assessment of the effects of radiation on secretome profiles of 
cancer cells 
Cells were seeded into 6 well plates to achieve approximately 40–50% 
confluency at 24 h. Cells were washed 3 times with PBS before 2 ml of FCS-free 
media was added. The cells were serum starved for 2 h. Cells were then exposed to 
radiation (0, 2, 4, 6, 8 or 10 Gy) and the conditioned media (CM) was harvested at 1, 
2, 4, 8 and 24 h post-radiation for each radiation dose. Secretome samples underwent 
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processing for liquid chromatography-mass spectrometry (LC-MS) or WB analysis 
immediately following collection. Following CM harvesting cells were routinely 
trypsinised and counted using a haemocytometer with trypan blue exclusion (Sigma-
Aldrich, UK). Secretome samples were stored at -80oC. 
2.8.2 Secretome sample preparation 
CM samples were centrifuged at 1000 x g for 5 min at 4oC to remove dead 
cells and large debris then passed through a 0.22 µm filter (Millex, Merck Millipore, 
UK). The samples were further centrifuged at 100,000 x g for 60 min at 4oC 
(Beckman Coulter Optima L-90K Ultracentrifuge with SW 55 Ti rotor); the 
supernatant was removed and placed into a new universal container. Proteins were 
concentrated from the supernatant using the Amicon Ultra-0.5 Centrifugal Filter Unit 
with Ultracel-3 membrane (Merck Millipore, UK) as per the manufacturer’s 
protocol. Briefly, 500 µl of the CM was added to the Amicon Ultra filter device and 
the sample was centrifuged at 14,000 x g for 30 min at 4oC. The filter was removed 
and placed upside down into a new 1.5 ml microcentrifuge tube. The sample was 
centrifuged at 1000 x g for 2 min at 4oC to elute the concentrated protein. Protein 
concentrations were determined using the BCA assay. The ultrafiltrate was then 
stored at -80oC prior to undergoing LC-MS or WB analysis. 
2.8.3 Liquid chromatography-mass spectrometry (LC-MS) and 
sample analysis 
Secretomic samples underwent in-solution digests for LC-MS analysis, which 
was performed by Dr J. Wills (Mass Spectrometry Facility, IGMM, University of 
Edinburgh). Using 96 well plates with silicon lids, 50 µg of protein was added to 2 M 
urea/100 mM tris/10 mM DTT and heated for 30 min at 50oC. 55 mM iodoacetamide 
was then added and incubated in the dark for 30 min at room temperature. Trypsin at 
1:100 was then added and incubated overnight at room temperature. 10 µg of the 
resulting peptide solution was loaded onto an activated (20 µl methanol) and 
equilibrated (100 µl 0.1% trifluoroacetic acid (TFA)) C18 StAGE tip, and washed 
with 100 µl of 0.1% TFA. Bound peptides were eluted into Protein LoBind tubes 
with 20 µl of 80% acetonitrile (ACN) and 0.1% TFA solution and concentrated to 
less than 4 µl in a vacuum concentrator. The final volume was adjusted to 6 µl with 
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0.1% TFA. Online LC was performed using a Dionex RSLC Nano. Following the 
C18 clean-up, 5 µg of the peptide solution was injected onto a C18 packed emitter 
and eluted over a gradient of 2-80% ACN for 120 min with 0.1% TFA. Eluted 
peptides were ionised at +2 kV before data-dependent analysis on a Thermo Q-
Exactive Plus. MS1 was acquired with mz range 300-1650 and resolution 70,000, 
and the top 12 ions were selected for fragmentation with normalised collision energy 
of 26, and an exclusion window of 30 s. MS2 were collected with resolution 17,500. 
The AGC targets for MS1 and MS2 were 3x 106 and 5x 104 respectively, and all 
spectra were acquired with 1 microscan without lockmass. 
Pre-processing and analysis of data was performed by Dr A. K. Turnbull 
(Cancer Research UK, University of Edinburgh). Data were analysed using 
MaxQuant in conjunction with uniport fasta database with match between runs. Prior 
to analysis all data were log2 transformed. For fold change analysis, data were 
normalised to untreated controls at each time point using R (Bioconductor) software 
and packages373. Venn diagrams were generated using jvenn379. Heatmap and cluster 
analysis were performed using TM4 MeV (multiple experiment viewer) software374. 
Heatmap clustering was carried out using Pearson correlation with average linkage 
For integration of gene expression data with public datasets, correction for 
integration batch effects was performed in R using ComBat375,376. Protein interaction 
networks of candidate biomarkers were generated using the STRING protein 
interaction database381 and Markvo clustering algorithms382. 
2.9 Immunohistochemistry and statistical analysis 
Image analysis software QuPath383 version 0.1.2 was used to analyse Ki67, 
ERα and WNT5a target protein expression. Two-way ANOVA with Holm-Šídák 
multiple comparisons test was used to test for differences between 2 groups in CF, 
SRB, invasion and migration assays and WB experiments. Unpaired two-sample t-
test was used to test for differences between 2 groups in IHC analysis. p values <0.05 
were deemed statistically significant. Data are shown as mean ± SEM with all 
statistical analysis and graphs generated using Prism 7 (GraphPad Software, San 
Diego, CA, USA).  
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3 Materials and Methods: In Vivo Experiments 
3.1 Introduction 
The murine and ovine experiments were performed in accordance with a UK 
Home Office Project Licence. The murine study was carried out in the BRF facility 
(University of Edinburgh), with the ovine study performed at the Large Animal 
Research and Imaging Facility (LARIF) at Dryden Farm (University of Edinburgh) 
and at the Royal (Dick) School of Veterinary Studies (University of Edinburgh). The 
rat experiments were conducted at the Institute for Biomedical Research (University 
College London). All studies were performed using my own personal licence gained 
through the Scottish Accreditation Board in accordance with the Animals (Scientific 
Procedures) Act 1986. All projects were approved by either the University of 
Edinburgh or University College London Animal Ethics Committee. The 
recommended guidelines for welfare and use of animals in research were followed. 
The following materials and methods sections will cover general procedures 
relating to each animal model. The development of specific novel techniques will be 
described in-depth in the relevant result chapters. 
3.2 Biocompatibility assessment of common implantable 
sensor materials in a tumour xenograft model 
3.2.1 Background 
CD-1 female nude mice (Charles River Laboratories, Tranent, UK) were used 
in all experiments. The mice were allowed a period of adaptation of at least 7 days 
before use in experiments and were housed in cages of 6 on an alternating 12 h light 
cycle in a sterile and specific pathogen-free environment, with ad libitum access to 
food and water. As nude mice are immunocompromised, they were housed in 
individually ventilated cages in a barrier environment. 
3.2.2 Generation of MDA-MB-231 stock xenograft tumours 
MDA-MB-231 cells were grown routinely, trypsinised and counted as 
previously described in sections 2.2.4 and 2.2.5. Approximately 2x 109 cells were re-
suspended in 1 ml of FCS-free DMEM. Using a 21G needle, 0.1 ml of this cell 
suspension was injected bilaterally into subcutaneous tissue of the flanks of 5 mice. 
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Mice were monitored for the development of xenograft tumours which occurred 
within 6-8 weeks post-injection. 
3.2.3 Generation of MDA-MB-231 xenograft tumours for 
biomaterial implantation 
Once stock tumours had grown to an adequate size (approximately 0.7-1.2 cm 
in length), mice were euthanised by cervical dislocation. In a sterile cabinet, 
xenograft tumours were harvested and placed into DMEM with no additives and 
sectioned into small fragments, approximately 1-2 mm in length. Implantation of 
tumour fragments into experimental mice was performed under local anaesthetic 
(ethyl chloride) using a 12G trocar. Each mouse received 1 tumour fragment injected 
bilaterally into subcutaneous tissue of the flanks. Mice were monitored for the 
development of xenograft tumours which occurred within 6-8 weeks post-
implantation. The tumour uptake success rate was approximately 90%. 
3.2.4 General anaesthesia for biomaterial implantation procedures 
Mice underwent general anaesthesia using 5% isoflurane (IsoFlo, Abbot 
Animal Health, Maidenhead, UK) gaseous anaesthesia delivered in room air. 
Animals were positioned onto a heat mat to maintain rectal temperature between 
36.5–37.5oC and adequate depth of anaesthesia was maintained using end-tidal 
concentrations of 1.5-2.0% isoflurane. All animals were euthanised when required by 
cervical dislocation. 
3.2.5 Biomaterial fabrication 
The outward-facing materials of the IMPACT sensor were selected for 
testing; the materials chosen were silicon dioxide (SiO2), silicon nitride (Si3N4), 
Parylene-C, Nafion, OG116-31 resin (Epoxy Technology) and platinum (Pt). 
Materials were prepared in the Scottish Microelectronics Centre Class 10 cleanroom 
facility (Kings Buildings, University of Edinburgh) and comprised of 3–7 mm long 
pieces of titanium (Ti) wire, diameter 0.4 mm, coated with the material to be tested. 




3.2.6 Biomaterial manufacture 
Manufacture of materials for xenograft implantation was performed by Dr E. 
Blair and Dr J. Marland (School of Engineering, University of Edinburgh). For all 
coated materials Ti wire was first cleaned in isopropyl alcohol at 50℃ with 
ultrasonic agitation for 15 min, followed by the same treatment in deionised water, 
then dried using an N2 gun; Cu wire was also cleaned using the same protocol. 
Parylene-C samples were produced using a vapour deposition system SCS 
(Speciality Coating Systems 2010 Labcoater), ensuring a conformal coating of 5 μm 
of Parylene-C. SiO2 and Si3N4 samples were prepared using Plasma Enhanced 
Chemical Vapour Deposition (PECVD); a 1 μm layer of each material was 
deposited. Pt samples were produced using electron-beam evaporation in an ANS 
Cluster tool which deposited a 50 nm thick Pt film onto the wire. Nafion samples 
were created by dipping Ti wire in a solution of 5% by weight Nafion in lower 
aliphatic alcohols and water, before air curing for 5 min; the process was repeated 5 
times before curing for 1 h at 120℃145. Resin samples were produced by dip coating 
the Ti wire in OG116-31 resin which were then cured for 800 s under ultraviolet 
light. After completion of each coating process wires were optically inspected to 
ensure uniformity. All wires were sterilised prior to implantation. Nafion coated 
wires were sterilised by routine autoclaving; all other biomaterials were sterilised in 
100% ethanol for 10 min, rinsed in deionised water and stored in penicillin and 
streptomycin. All wires were washed in sterile distilled water immediately before 
implantation. 
3.2.7 Immunohistochemistry 
Sections for IHC underwent routine vertical IHC and counterstaining in 
haematoxylin as described in section 2.5.4. Primary antibodies used in the murine 
study are described in Table 3.1. Appropriate positive and negative controls were 
included in all IHC staining protocols (Figure 3.1). The staining pattern of each 
antibody was verified by a board-certified veterinary pathologist (Dr L. Morrison, 
The Royal (Dick) School of Veterinary Studies, University of Edinburgh). 
Additional sections were also routinely stained with haematoxylin and eosin (H&E) 
or Masson’s Trichrome as described in sections 2.5.2 & 2.5.3.  
71 
 











Anti-Ki67 Proliferation384-387 Rabbit mAb  
Sodium citrate 
Abcam; ab92742 1:1000 
Anti-carbonic 
anhydrase 9 
Hypoxia117,388,389 Rabbit pAb 
Sodium citrate 









Anti-Ly-6G  Neutrophil394-397 Rat mAb 
EDTA 
Abcam; ab25377 1:50 
Anti-F4/80  Macrophage398-401 Rat mAb 
Enzymatic 
Biolegend; 123101 1:100 





3.2.8 Immunohistochemical analysis 
QuPath version 0.1.2383 was used to analyse target protein expression and the 
percentage area of tumour necrosis using the entire tumour area contained within 
whole slide images. The image analysis pipeline was comprised of several steps. The 
initial step required, for both target protein expression and percentage area of tumour 
necrosis analysis, was to isolate the diagnostically relevant areas within the tissue in 
each whole slide image. Extraneous tissue such as subcutaneous fat and skin was 
excluded from image analysis and all areas of necrosis were identified. H&E stained 
sections were used to calculate the percentage area of tumour necrosis; the area of 
necrosis was divided by the total tumour area (tumour tissue and necrotic area) and 
then multiplied by 100 (Figure 3.2 & Figure 3.3). Further steps were required for 
target protein expression analysis. Intensity thresholds and detection parameters for 
positive and negatively stained cells for each antibody were optimised (Table 3.2). 
DAB‐positive cells were detected using positive cell detection and negative cells 
were detected by haematoxylin staining. These antibody specific parameters were 
then applied to every section stained using that antibody. All results were visually 
assessed for accuracy in all tumour sections following analysis. Examples of this 
method of cell detection are shown for each antibody in Figure 3.4-Figure 3.15. To 
calculate the percentage of positively stained cells, the number of positively stained 
cells was divided by the total number of cells and then multiplied by 100.  
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Table 3.2. QuPath parameters for cell detection. Intensity threshold values were 
optimised for each specific antibody other values remained as default settings. 
Parameter Setting Parameter Setting 
Scan magnification 20x Max. background intensity 2 
Stain vectors QuPath default Split by shape on 
Detection image Haematoxylin OD Exclude DAB off 
Pixel size 0.5 μm Cell expansion 5 
Background radius 8 μm Include cell nucleus  on 
Median filter radius 0 μm Smooth boundaries on 
Sigma 1.5 μm Make measurements on 
Minimum area 10 μm Score compartment Nucleus DAB OD mean 
Maximum area 400 μm Threshold 1+ Antibody specific 
Intensity threshold 0.1 single threshold on 
 
Threshold 1+ 
Ki67, CA9, Ly-6C, 
F4/80 
0.2 
Caspase 3 0.1 
ER-TR7 0.45 
Image J (NIH, Bethesda, MD, USA) was used to analyse the percentage area 
of collagen using the entire tumour area contained within whole slide images. A  
colour deconvolution macro programme developed by Dr L. Murphy (IGMM, 
University of Edinburgh) was used in conjunction with Image J for this purpose.  
Following the isolation of the diagnostically relevant areas (as was performed with 
the QuPath analysis) and colour deconvolution, thresholds were set to detect collagen 
appearing as red on a white background. This stain specific threshold was then 
applied to every section. All results were visually checked for accuracy in all tumour 
sections following analysis. Examples for collagen detection using whole slide 
images are shown in Figure 3.16 & Figure 3.17. To calculate the percentage area of 




Figure 3.1. Positive controls used for verifying murine immune antibodies. (a) Liver used for F4/80 (macrophage), (b) SKOV 
xenograft tumour used for ER-TR7 (fibroblast), (c) Spleen used for Ly-6G (neutrophil). Negative controls underwent the same IHC 
procedure as for positive controls, with the exception that antibody diluent containing no primary antibodies was added to the slides. 
Positive DAB staining is seen for each antibody at the expected cellular localisation region and in the correct cell type: positive F4/80 
staining is seen predominately at the cell membrane in hepatic macrophages, ER-TR7 staining is seen predominantly in the cytoplasm in 




Figure 3.2. Representative H&E stained sections from tumours harvested at day 
7. (a) Untreated, (b) Parylene-C implanted. 
 
Figure 3.3. Representative H&E stained sections for QuPath analysis of the area 
of necrosis. Yellow line is outlining the total tumour area including the necrotic area, 





Figure 3.4. Representative CA9 stained sections from tumours harvested at day 
7. (a) Negative control, (b) Untreated, (c) Nafion implanted. 
 
Figure 3.5. Representative CA9 stained sections for QuPath analysis of hypoxia. 




Figure 3.6. Representative Ki67 stained sections from tumours harvested at day 
7. (a) Negative control, (b) Untreated, (c) Silicon dioxide implanted. 
 
Figure 3.7. Representative Ki67 stained sections for QuPath analysis of 




Figure 3.8. Representative caspase 3 stained sections from tumours harvested at 
day 7. (a) Negative control, (b) Untreated, (c) Copper implanted. 
 
Figure 3.9. Representative caspase 3 stained sections for QuPath analysis of 





Figure 3.10. Representative Ly-6G stained sections from tumours harvested at 
day 7. (a) Negative control, (b) Untreated, (c) Silicon nitride implanted. 
 
Figure 3.11. Representative Ly-6G stained sections for QuPath analysis of 





Figure 3.12. Representative F4/80 stained sections from tumours harvested at 
day 7. (a) Negative control, (b) Untreated, (c) Parylene-C implanted. 
 
Figure 3.13. Representative F4/80 stained sections for QuPath analysis of 
macrophage numbers. F4/80 staining, as expected, is predominantly localised to 




Figure 3.14. Representative ER-TR7 stained sections from tumours harvested at 
day 7. (a) Negative control, (b) Untreated, (c) Platinum implanted. 
 
Figure 3.15. Representative ER-TR7 stained sections for QuPath analysis of 





Figure 3.16. Representative Masson’s trichrome stained sections from tumours 
harvested at day 7. (a) Untreated, (b) Silicon dioxide implanted. 
 
Figure 3.17. Representative Masson’s trichrome stained sections for Image J 
analysis of collagen deposition. Following colour devolution, the collagen is 
highlighted in red against a white background. 
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3.3 Validation of functionality of the IMPACT oxygen 
sensor to measure tissue oxygen tension for clinical 
applications 
3.3.1 Background 
Male Wistar rats (Charles River Laboratories, Margate, UK) of 
approximately 400 g body weight were used in all experiments. Prior to 
instrumentation, the rats were allowed a period of adaptation of at least 7 days and 
were housed in cages of 4 on an alternating 12 h light cycle in a specific pathogen-
free environment, with ad libitum access to food and water. 
3.3.2 Anaesthesia, arterial and venous cannulation and 
tracheostomy tube placement 
Rats underwent general anaesthesia using 5% isoflurane (IsoFlo, Abbot 
Animal Health, Maidenhead, UK) gaseous anaesthesia delivered in room air and 
were positioned onto a heat mat to maintain rectal temperature between 36.5–37.5oC, 
which was continuously recorded using a temperature sensor (Harvard Apparatus, 
Cambridge, UK). Adequate depth of anaesthesia was maintained using end-tidal 
concentrations of 1.5-2.0% isoflurane. Placement of arterial and venous cannulas 
was performed in accordance with a previous study406. A 2 cm ventral midline 
cervical incision was made with cervical dissection to identify the right internal 
jugular vein and left common carotid artery. Both vessels were cannulated using 0.96 
mm external diameter PVC catheters (Scientific Commodities Inc., Lake Havasu 
City, AZ, USA) (Figure 3.18 & Figure 3.19) and secured in place with 1 metric 
braided silk (Ethicon, UK). The arterial line was subsequently connected to a 
pressure transducer (Powerlab, AD Instruments, Chalgrove, UK) for continuous 
monitoring and recording of mean arterial blood pressure and heart rate; this was 
performed by connecting the transducer to a computer using a 16-channel Powerlab 
system and Chart 5 acquisition software (AD Instruments, Charlgrove, UK). The 
arterial line was also used for intermittent blood sampling; when required, 0.1 ml of 
arterial blood was taken into heparinised capillary tubes for immediate blood-gas 
(pH, pCO2, pO2, HCO3
-, arterial base deficits and paO2), biochemical (glucose, 
lactate, Na+, K+, Cl-, Ca2+) and haematological (tCO2, Hct, Hgb) analysis (ABL90 
Analyser; Radiometer, Copenhagen, Denmark). The venous line was used for the 
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administration of fluids; all animals received surgical doses of crystalloid fluids 
throughout the procedures, which consisted of a continuous infusion of 10-
20/ml/kg/h compound sodium lactate (Aqupharm No 11, Animalcare, York, UK) to 
sustain cardiac preload and replace lost fluids and electrolytes. Mean arterial blood 
pressure was maintained at approximately 100 mmHg. A tracheostomy was created 
using 2.08 mm external diameter polythene tubing (Portex Ltd, Hythe, UK); this was 
attached to a T-piece breathing circuit to secure the airway, maintain anaesthesia and 
allow changes in the inspired fractional oxygen concentration (FiO2) to be delivered 
(Figure 3.20). All animals were euthanised with intravenous sodium pentobarbitone 
(Pentoject; Animalcare, York, UK). 
 
Figure 3.18 Intra-operative photographs depicting cannulation of the right 
jugular vein. (a) A 2 cm ventral cervical skin incision is made. (b&c) Cervical 
dissection is performed to allow identification and mobilisation of the right jugular 
vein. (d) One untied suture is placed distally around the jugular vein and a second is 
placed proximally and tied securely, leaving about 1 cm of vein between the 2 
sutures. (e) A venotomy is created just distal to the proximal suture; the cannula is 
inserted and advanced 2-3 cm into the vein before tying the distal suture around the 




Figure 3.19. Intra-operative photographs depicting cannulation of the left 
carotid artery. (a) Cervical dissection is performed to allow identification of the left 
carotid artery. (b) The carotid artery is dissected from the vagus nerve. (c) One 
untied suture is placed distally around the carotid artery and a second is placed 
proximally and tied securely leaving about 1.5 cm of artery between the 2 sutures. A 
clamp is added just proximal to the distal suture before placing a third untied suture. 
(d) An arteriotomy is created between the 2 sutures and the cannula is inserted and 
advanced up to the clamp. (e) The third suture is tied loosely over the cannula and 
the clamp is removed. (f) The cannula is advanced a further 2 cm before tying the 
distal suture around the artery and cannula. 
 
Figure 3.20. Intra-operative photographs depicting placement of a tracheostomy 
tube. (a) Cervical dissection is performed to allow identification of the trachea. (b) 
The trachea is elevated and maintained in position with a piece of sterile paper and 
an untied suture is placed distally. (c) An incision is made between tracheal cartilage 
rings through which the tracheostomy tube is inserted. The tubing is advanced 1 cm 
before tying the distal suture around the trachea and tracheostomy tube. The tubing is 
attached to a 3-way tap connected to the inflow of anaesthetic gases. 
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3.4 Development of a pre-clinical ovine pulmonary 
adenocarcinoma model for human lung cancer and 
validation of intra-tumoural functionality of the 
IMPACT oxygen sensor 
3.4.1 Background 
For initial protocol development, post-mortem carcasses were obtained 
through the Royal (Dick) School of Veterinary Studies Large Animal Practice 
(University of Edinburgh). All experimental OPA sheep were obtained in 
collaboration with Dr C. Cousens at the Moredun Institute (Pentland Science Park, 
UK) through an on-farm ultrasound eradication programme run by Dr P. Scot. 
Eight post-mortem carcases were used for initial protocol development. A 
total of 12 adult female sheep diagnosed with OPA were used in the study. Of these 
cases, 3 were used to refine the model and 9 were used in experimental procedures. 
All sheep weighed between 39-76 kg and were transported direct from the farm of 
origin to Dryden farm. Sheep were bedded on straw, with ad libitum access to food 
and water in groups of at least 2 animals and were allowed a period of adaptation of 
at least 24 h before undergoing anaesthesia. Anaesthesia, CT imaging, sensor 
placement and post-mortem examinations were carried out at the Large Animal 
Research and Imaging Facility (LARIF) at Dryden Farm (University of Edinburgh). 
3.4.2 General anaesthesia for CT imaging and sensor implantations 
All sheep underwent pre-anaesthetic assessment, which included distant 
observation of demeanour and breathing, followed by physical examination. Only 
animals that passed veterinary assessment underwent anaesthesia and surgery. Food 
was withheld for 12 h before anaesthesia, but access to water was permitted until 
pre-anaesthetic medication was administered. Anaesthesia was managed by a 
specialist team of anaesthetists at the LARIF. 
All sheep received pre-anaesthetic sedation to reduce stress, facilitate the 
induction of anaesthesia and decrease induction agent dose requirements. To limit 
the risk of sedation-induced respiratory decompensation, intravenous sedative 
administration was followed by induction of general anaesthesia within 10 min. This 
pre-anaesthetic sedation was achieved by the intravenous injection of medetomidine 
in combination with midazolam. Following sedation, the head was elevated to limit 
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respiratory secretions and rumen contents entering the upper airway. Once sedative 
effects were evident, generally within 5 min, intravenous propofol was given to 
effect to allow endotracheal intubation. Intubation was assisted by a laryngoscope 
with a long (350 mm) blade and a rigid atraumatic stylet; suction was also used when 
required to aid larynx visualisation; once intubated, the endotracheal tube cuff was 
inflated and secured in place. Generally, a 10 mm internal diameter endotracheal 
tube was required for a 30-60 kg sheep. Oropharyngeal and tracheobronchial suction 
was used as required. Morphine in combination with flunixin was given pre-
emptively, either at the time of sedation or immediately post-induction, to provide 
analgesia for the duration of anaesthesia (Table 3.3). 
Anaesthesia was maintained with isoflurane (IsoFlo, Abbot Animal Health, 
Maidenhead, UK) vaporised in an O2/air mixture administered via a Bain or circle 
breathing system connected to the endotracheal tube; end-tidal concentrations of 1.5-
2.0% isoflurane were used to maintain adequate depth of anaesthesia. After tracheal 
intubation, intermittent positive pressure, volume controlled, ventilation was 
provided using a mechanical ventilation system to achieve adequate tidal volumes of 
8-10 ml/kg. Respiratory rate was adjusted to maintain normocapnia (PaCO2 range 
4.7–6 kPa). To aid ventilation sheep were positioned in sternal recumbency; 
however, animals were placed temporarily in lateral recumbency, with OPA lesion(s) 
uppermost, for CT imaging and sensor implantation (Figure 3.21). 
Body temperature was monitored using rectal and oesophageal temperature 
sensors and maintained between 38.5–39.5oC. A central (jugular) venous 14G 
cannula was placed which was used for the administration of drugs and crystalloid 
fluids. Animals received surgical doses of fluids throughout anaesthesia and surgery, 
which consisted of a continuous infusion of 5-10/ml/kg/hr compound sodium lactate 
(Aqupharm No 11, Animalcare, York, UK) to maintain cardiac preload and replace 
lost fluids and electrolytes. Mean arterial blood pressure was maintained at 
approximately 70-80 mmHg. An arterial cannula was placed in the central auricular 
artery which was used for intermittent blood sampling; when required, 1 ml of 
arterial blood was taken into heparinised syringes for immediate blood-gas (pH, 
pCO2, pO2, HCO3
-, arterial base deficits and paO2), biochemical (glucose, lactate, 
creatinine, Na+, K+, Cl-, Ca2+) and haematological (tCO2, Hct, Hgb) analysis (Epoc 
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portable blood-gas electrolyte and critical care analyser; Woodley Equipment 
Company Ltd, Lancashire, UK). A multiparameter patient monitoring device (Datex-
Ohmeda S/5, SOMA Technology, Madison, USA) was used to continuously monitor 
pulse rate and blood pressure along with pulse oximetry, capnography, temperature, 
spirometry, electrocardiography and inspired and expired gases (O2, CO2 and 
inhalant anaesthetic agent). All animals were euthanised with intravenous sodium 
pentobarbitone (Pentoject; Animalcare, York, UK). 
Table 3.3. Anaesthesia and analgesia options in sheep diagnosed with OPA. 
*Until conditions for endotracheal intubation are present (i.m., intramuscular; i.v., 
intravenous) (information provided by Professor E. Clutton and Dr S. Greenhalgh). 
Phase Drug Manufacturer Dose (mg/kg) Route 
Sedation Medetomidine ‘Sedator’; Dechra Veterinary 
Products, Shrewsbury, UK 
0.003-0.01 i.v. 
 in combination with   
Midazolam ‘Hypnovel’; Roche, Welwyn 
Garden City, UK 
0.25-0.5 i.v. 
  
Induction Propofol ‘Propofol’; Fresenius Kabi, 
Cheshire, UK 
To effect* (e.g. 3-10) i.v. 
  




Analgesia Flunixin ‘Flunixin Injection’; Norbrook, 
Newry, UK 
2.2 i.v. 
 Morphine ‘Morphine Sulphate’; Martindale 
Pharmaceuticals, Essex, UK 
0.1-0.3 i.v./i.m 
 
Figure 3.21. Photographs of an anaesthetised sheep undergoing sensor readings. 
Sheep are positioned in sternal recumbency with the head elevated above the thorax. 
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3.4.3 Computed tomography 
CT imaging was performed by Mrs L. Grant (The Royal (Dick) School of 
Veterinary Studies, University of Edinburgh). A single-section SOMATOM 
Definition AS 64 slice helical CT machine (Siemens Healthcare Ltd, Camberley, 
UK) was used for all advanced imaging procedures. Imaging parameters of the 
scanner were 120 kVp, 35 mA, 3-5 mm collimation with 1 mm section thickness. 
The window width and level were approximately 2000 and -500 HU respectively, 
allowing simultaneous visualisation of the implantation needle, blood vessels, 
lesions, pneumothorax, bone, muscle and fat. All scans were obtained through the 
entire thoracic cavity from the first to the last rib using a section thickness of 1 mm 
to improve the visualisation of the needle tip and sensor in relation to the OPA lesion 
(Figure 3.22). 
 
Figure 3.22. Photographs of imaging and surgical facilities. (a) The sheep is 
anaesthetised and positioned on the gantry, rump first, for CT scanning in lateral 
recumbency, with the OPA affected lungs uppermost. (b) Surgical equipment 
required for sensor implantation including a general surgical kit and Jamshidi 
insertion needle. An IMPACT O2 sensor can be seen in a bottle of sterile saline at the 
top right-hand side of the image. 
3.4.4 Oxygen sensor recordings 
Oxygen sensor recordings in both the rat and ovine experiments were 
performed by Dr J. Marland (School of Engineering, University of Edinburgh). 
Following sensor implantation, the lead wire was connected to an EmStat3 Blue 
potentiostat (PalmSens BV, Netherlands). Periodic O2 measurements were performed 
using chronoamperometry at -0.5 V (versus the on-chip Ag/AgCl reference 
electrode) for 20 s, followed by a rest period of 20 s. These cycles were repeated 
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continuously for the duration of the experiments. The working electrode current over 
the final 5 s of each 20 s chronoamperometry recording was analysed using 
MATLAB R2017a (MathWorks, Natick, MA, USA) to derive the mean current. The 
measured working electrode current is directly proportional to the ptO2 at the sensor 
surface. 
3.4.5 Statistical Analysis 
Data for all murine and ovine experiments were analysed with either one-way 
or two-way ANOVA with Holm-Šídák multiple comparisons tests to test for 
differences between 2 groups; p values <0.05 were deemed statistically significant. 
Data are shown as mean ± SEM with all statistical analysis and graphs generated 






4 Development and Characterisation of Acquired 
Radioresistant Breast Cancer Cell Lines 
This results chapter is an expanded version of a published research article: Gray 
M, Turnbull AK, Ward C, Meehan J, Martínez-Pérez C, Bonello M, Pang LP, 
Langdon SP, Kunkler IH, Murray A, Argyle D. Development and characterisation of 
acquired radioresistant breast cancer cell lines. Radiation Oncology 2019; 14(64): 1-
19. This article is open access with the authors retaining copyright to their work with 
permission to use published figures in this thesis. Sections of text and figures used 
from this article have been referenced accordingly. 
4.1 Abstract 
Background: The response of a tumour to radiotherapy will be influenced by the 
tumour’s innate radiosensitivity and the development of acquired radioresistance. 
Research into understanding and targeting the mechanisms involved in acquired 
radioresistance is required if patient outcomes are to be improved. Methods: 
Radioresistant breast cancer cell lines (RR) were established by treating ZR-751, 
MCF-7 and MDA-MB-231 parental cells with weekly fractions of radiation. Parental 
and radioresistant cell lines underwent phenotypic, functional and genotypic 
characterisation. Intrinsic differences between parental and RR cells were 
investigated by gene expression analysis to identify differentially expressed or 
activated signalling networks. Results: Radioresistance was confirmed through 
colony formation and proliferation assays. Radioresistant cells exhibited evidence of 
epithelial-to-mesenchymal-transition with enhanced invasion and migration. ZR-751 
RR and MCF-7 RR cell lines demonstrated loss of ERα and PgR expression with an 
increase in EGFR expression. Based on gene analysis, these cell lines changed 
classification from luminal A (parental) to normal-like (ZR-751 RR) or HER2-
overexpressing (MCF-7 RR) subtypes. Gene expression analysis identified that RR 
cell lines derived from ER+ cells demonstrated down-regulation of ER signalling 
genes and up-regulation of genes associated with WNT, MAPK and PI3K pathway 
activation; this was confirmed by western blot. Conclusions: This study has 
successfully developed 3 novel radioresistant breast cancer cell lines which 
underwent phenotypic, functional and genotypic characterisation. Comparisons made 
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with their parental cells identified multiple differentially expressed or activated 
signalling networks which warrant further investigation as potential targets for 
overcoming acquired radioresistance. 
4.2 Introduction 
Tumour recurrence following RT can be due to the survival of a population of 
cells that have either greater intrinsic (innate) resistance to radiation (e.g. hypoxic or 
cancer stem cells) or acquire resistance. Ultimately, through clonal selection, it is 
these radioresistant cells that can repopulate the tumour site, leading to recurrence 
and treatment failure. Research into understanding and targeting the mechanisms 
involved in cancer cells acquiring radioresistance is therefore required to improve 
patient outcome. Previous studies have identified multiple factors which are likely to 
be involved in radioresistance development, including increased oncogenic miRNA 
production, epithelial-to-mesenchymal transition (EMT), signalling pathway 
activation (EGFR, PI3K/AKT, MAPK, NF-ƙB), improved DNA damage responses, 
cancer stem cell repopulation and changes in cancer cell metabolism. The TME 
(including hypoxia) can also influence the effectiveness of RT407. Unfortunately, 
these studies tend to focus on isolated pathways which fail to appreciate the complex 
and likely interconnected cellular changes that are required for cancer cells to 
become radioresistant. Hypoxia, for example, can cause cancer cells to adopt a more 
undifferentiated phenotype characterised by increased stem cell marker expression 
and can also affect the expression of genes and pathways controlling stemness, such 
as Oct4, Notch and EMT408,409. 
In comparison with studies investigating chemoresistance, research into 
understanding radioresistance is currently limited; this is partly due to a lack of 
radioresistant model systems. To overcome this, RR models are required that can be 
used with techniques capable of studying multiple pathways simultaneously. This 
research could provide an overview of complex interrelated biological systems and a 
detailed understanding of cellular changes involved in the development of 
radioresistance. This could ultimately lead to a more effective way of identifying 
pathways which could be targeted to overcome radioresistance409,410. 
This chapter describes the development of novel in vitro radioresistant ER 
positive (ER+) and ER negative (ER-) breast cancer cell lines. Analysis of gene 
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expression data was performed by Dr A. K. Turnbull (Cancer Research UK, 
University of Edinburgh). Parental cell lines were chosen to represent different 
molecular subtypes of breast cancer and included MCF-7 and ZR-751 cell lines 
(ER+, PgR+, HER2-), which are hormone-dependent, and the MDA-MB-231 cell line, 
which is triple negative (ER-, PgR-, HER2-) and consequently hormone-independent. 
Genotypic, phenotypic and functional characterisation of the RR model was 
undertaken, allowing validation of results at gene, protein and functional levels. This 
approach identified multiple differences between paired parental and RR cell lines 
and between the different breast cancer subtypes (ER+ and ER-), resulting in an in-
depth characterisation of the RR model. To our knowledge, this is the first 
description of a developed ZR-751 RR cell line and the use of MTS derived from RR 
cells in IHC and functional assays. 
4.3 Results 
4.3.1 Development and confirmation of acquired radioresistance in 
human ER+ and ER- breast cancer cell lines 
Parental cells (MCF-7, ZR-751 and MDA-MB-231) were used to develop 
radioresistant cell lines (MCF-7 RR, ZR-751 RR and MDA-MB-231 RR). Parental 
cells were exposed to weekly single fractionated doses of radiation, increasing by 0.5 
Gy per week over a 12-week period; cells were subsequently maintained by weekly 
doses of 5 Gy. Although this maintenance radiation dose still caused cell death in all 
3 RR cell lines, this was significantly less than the level seen during the 12-week 
development period and did not appear to change with chronic radiation exposure. 
Following the 12-week development period, CF and SRB assays were used to 
confirm radioresistance. All RR cell lines had significantly higher CF ability than 
their parental cell lines when exposed to a single dose of radiation up to 6 Gy (Figure 
4.1). Proliferation of the RR cell lines was inhibited less than that of their parental 
cell lines when exposed to a single dose of radiation up to 10 Gy (Figure 4.2, Figure 
4.3 & Figure 4.4), with correspondingly higher IC50 values seen in the RR cell lines 
(Table 4.1). MCF-7 RR and MCF-7 rr cells (a MCF-7 RR cell line which had not 
received radiation for 6 months), showed comparable radioresistance when exposed 
to a single dose of radiation up to 6 Gy in CF assays and up to 4 Gy in SRB assays. 
Both cell lines showed significantly greater resistance to the effects of radiation in 
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terms of proliferation and CF ability compared to the parental MCF-7 cell line, 
suggesting maintenance of their acquired phenotype (Figure 4.5). 
 
Figure 4.1. Radioresistant cell lines have increased colony formation ability. 
Colony formation assays at 10-14 d post-radiation comparing MCF-7 RR, ZR-751 
RR and MDA-MB-231 RR cell lines with their respective parental cell lines (two-
way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± 
SEM, n=3, ****p≤0.0001). 
 
Figure 4.2. Proliferation of the ZR-751 RR cell line is inhibited less than its 
parental cell line following exposure to radiation. SRB proliferation assay 
comparing ZR-751 RR with its parental cell line at 144 h post-radiation (two-way 
ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± 




Figure 4.3. Proliferation of the MCF-7 RR cell line is inhibited less than its 
parental cell line following exposure to radiation. SRB proliferation assays 
comparing MCF-7 RR with its parental cell line up to 120 h post-radiation (two-way 
ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± 




Figure 4.4. Proliferation of the MDA-MB-231 RR cell line is inhibited less than 
its parental cell line following exposure to radiation. SRB proliferation assays 
comparing MDA-MB-231 RR with its parental cell line up to 120 h post-radiation 
(two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as 
mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05). 
Table 4.1. IC50 values for each parental and RR cell line up to 144 h post-
radiation. If no value is recorded this indicates that a reduction in proliferation by 
50% had not occurred at that time point; MCF-7 and MDA-MB-231 cell lines were 
evaluated up to 120 h post-radiation, whereas the ZR-751 cell line was evaluated up 
to 144 h post-radiation. 
Time post-
radiation (h) 




24 - - - - - - 
48 - - - - - - 
72 4.98 9.64 - - - - 
96 3.27 5.36 - - 3.53 9.71 
120 3.74 5.22 - - 3.13 7.11 




Figure 4.5. CF and SRB assays comparing MCF-7, MCF-7 RR and MCF-7 rr 
cell lines. MCF-7 rr is a radioresistant cell line not radiated for 6 months (24 
passages). (a) Colony formation assay at 14 d post-radiation. (b) SRB assay at 120 h 
post-radiation (two-way ANOVA with Holm-Šídák multiple comparisons test; data 
expressed as mean ± SEM, n=3, **p≤0.01). 
4.3.2 Development and confirmation of acquired radioresistance in 
a canine ER- breast cancer and an ovine lung cancer cell line 
Parental cells (REM-134 and JS7) were used to develop radioresistant cell 
lines (REM-134 RR and JS7 RR). These cell lines were developed for use in the 
secretomic experiments (described in chapter 5). Following the 12-week radiation 
protocol, as previously described, SRB assays were used to confirm radioresistance 
(CF assays were not used, as both cell lines would not form colonies from single 
cells). Proliferation of the JS7 RR and REM-134 RR cell lines was inhibited less 
than that of their parental cell lines when exposed to a single dose of radiation up to 
4 and 10 Gy respectively (Figure 4.6 & Figure 4.7), with corresponding higher IC50 
values seen in the RR cell lines (Table 4.2). REM-134 RR and REM-134 rr cells (a 
REM-134 RR cell line which had not received radiation for 6 months), showed 
comparable radioresistance when exposed to radiation doses of up to 10 Gy in SRB 
assays. Both cell lines showed significantly greater resistance to the effects of 
radiation in terms of proliferation compared to the parental REM-134 cell line, 




Figure 4.6.Proliferation of the JS7 RR cell line is inhibited less than its parental 
cell line following exposure to radiation. SRB proliferation assay comparing JS7 
RR with its parental cell line at 144 h post-radiation (two-way ANOVA with Holm-
Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, **p≤0.01; 
*p≤0.05). 
 
Figure 4.7. Proliferation of the REM-134 RR cell line is inhibited less than its 
parental cell line following exposure to radiation. SRB proliferation assays 
comparing REM-134 RR with its parental cell line up to 120 h post-radiation (two-
way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± 
SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05). 
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Table 4.2. IC50 values for each parental and RR cell line up to 144 h post-
radiation. If no value is recorded this indicates that a reduction in proliferation by 
50% at that time point had not occurred; REM-134 cell line was evaluated up to 120 
h post-radiation whereas JS7 cell line was evaluated up to 144 h post-radiation. 
Time post-radiation (h) REM-134 REM-134 RR JS7 JS7 RR 
24 - - - - 
48 - - - - 
72 3.85 10.34 - - 
96 3.32 4.98 - - 
120 1.7 3.6 - - 
144 N/A N/A 2.82 4.12 
 
Figure 4.8. SRB assays comparing REM-134, REM-134 RR and REM-134 rr 
cell lines. REM-134 rr is a radioresistant cell line not radiated for 6 months (24 
passages). (a) SRB assay at 96 h post-radiation. (b) SRB assay at 120 h post-
radiation (two-way ANOVA with Holm-Šídák multiple comparisons test; data 
expressed as mean ± SEM, n=3). 
4.3.3 Gene expression analysis identifies inherent similarities 
between radioresistant cell lines derived from ER+ cells 
A large number of genes were found to be inherently differentially expressed 
(using a log2 fold-change cut-off of 1) between ER+ parental and RR cell lines. 
These changes were consistent between both MCF-7 RR and ZR-751 RR cell lines. 
Fewer differentially expressed genes were observed between the MDA-MB-231 
parental and RR cell lines. Cluster analysis using differentially expressed genes 
(n=8796) identified that the MDA-MB-231 and RR cell lines clustered closely 
together, having similar expression patterns. Parental ZR-751 and MCF-7 cells also 
had a similar pattern of gene expression to the MDA-MB-231 cells except for 2 gene 
clusters, 1 enriched for focal adhesion and tight junctions and 1 enriched for glycan 
biosynthesis. MCF-7 RR and ZR-751 RR cell lines clustered together and separately 
from all the other cell lines, with lower expression of ribosomal genes and genes 
involved in proliferation, metabolism and DNA repair and higher expression of 




Figure 4.9. Global gene expression analysis identifies significant inherent 
similarities between RR cell lines derived from ER+ cells. (a) Venn-diagrams 
comparing all 3 cell lines, showing the overlap of up-regulated (left) and down-
regulated (right) genes with log2 fold changes >1 between paired parental and RR 
untreated cell lines. (b) Log2 mean-centered gene expression heatmap, labelled with 
cluster-enriched gene ontology, showing expression of the most differentially 
expressed genes, taken from the Venn-diagram analysis (red=higher expression, 
black=no change, green=lower expression, n=1). Heatmap clustering was carried out 
using Pearson correlation with average linkage. 
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4.3.4 Radioresistant cell lines have concurrent lower expression of 
cell cycle associated genes and modified basal proliferation 
rates 
SRB assays using cells grown in 2D cultures showed lower proliferation rates 
in the MCF-7 RR and MDA-MB-231 RR cell lines and higher rates in the ZR-751 
RR cell line in comparison to their respective parental cells (Figure 4.10a). Gene 
expression analysis from 2D cultures characterised the MCF-7 RR and ZR-751 RR 
cell lines as having lower expression of genes involved in DNA repair and 
replication and those related to G1/S-phase transition and cell cycle regulation, along 
with higher expression of cell cycle arrest genes. Changes were less marked in the 
MDA-MB-231 parental and RR cell lines, both of which clustered next to each other 
and to the MCF-7 and ZR-751 parental cell lines (Figure 4.10b). To investigate the 
apparent differences between the gene expression and SRB proliferation data in the 
ZR-751 RR cell line, Ki67 staining by IHC was performed using MCF-7 and ZR-751 
parental and RR MTS (MDA-MB-231 cells failed to form MTS that could withstand 
IHC processing). Quantitative analysis showed that RR MTS contained lower 
percentages of positively stained Ki67 cells compared with parental MTS, suggesting 




Figure 4.10. Radioresistant cell lines have modified proliferation rates relative 
to their parental cells. (a) SRB assays showing differences in proliferation rates 
between parental and RR cell lines grown in 2D cultures over 120 h (two-way 
ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± 
SEM, n=3, ****p≤0.0001; ***p≤0.001; *p≤0.05). (b) Log2 mean-centered gene 
expression heatmap showing differences in expression between parental and RR cell 
lines in respect of proliferation genes taken from the KEGG database cell cycle 
pathway411 (red=higher expression, black=no change, green=lower expression, n=1). 




Figure 4.11. MCF-7 RR and ZR-751 RR MTS show decreased expression of 
Ki67. IHC of MTS stained for Ki67 using MCF-7 and ZR-751 parental and RR cell 
lines with quantitative analysis of the % of positively stained cells. Ki67 staining, as 
expected, is localised to the cell nucleus (unpaired two-sample t-test; data expressed 
as mean ± SEM, n=3, ****p≤0.0001). 
4.3.5 Radioresistant cell lines have increased invasion and 
migration potential 
Considered to be a normal feature of embryonic development, epithelial -to-
mesenchymal transition (EMT) is a process involved in cellular movement and 
morphogenesis412. However, cancer cells can also undergo EMT, causing them to 
develop a more invasive and migratory phenotype413. Here, using a 3D collagen 
invasion assay, we showed a statistically significant increase in the invasive potential 
of MTS derived from MCF-7 RR and ZR-751 RR cells compared to parental MTS 
(which demonstrated no invasive capabilities); although at 72 h the MDA-MB-231 
RR MTS showed a small increase in invasiveness, this was not statistically 
significant (Figure 4.12). However, results from 2D scratch assays demonstrated that 
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all 3 RR cell lines had significantly enhanced migratory ability compared to their 
parental cells (Figure 4.13, Figure 4.14 & Figure 4.15). 
The morphology of parental ER+ cell lines was typically epithelial-like, 
consisting of clumps of tightly packed cells forming cobblestone-like monolayers. 
The cells themselves consisted of a small amount of cytoplasm and a single large 
nucleus. However, following the initial 12 weeks of radiation exposure significant 
morphological changes were evident in the RR derivatives. Single cells or those 
within small clusters gained a spindle-shaped morphology with cellular contact 
between cells occurring via focal points rather than along their entire perimeter. 
Parental MDA-MB-231 cells originally exhibited a mesenchymal-like phenotype, 
therefore phenotypic changes in its RR derivate were not obvious (Figure 4.16). 
These morphological changes that occurred with the acquisition of 
radioresistance were consistent with EMT and this process was initially investigated 
using IHC and ICC to examine the expression levels of EMT markers. Increased 
expression of vimentin, N-cadherin and SNAIL, along with the partial down-
regulation of E-cadherin was identified in the MCF-7 RR and ZR-751 RR cell lines 
compared with their parental cells. No differences between the MDA-MB-231 
parental and RR cell lines were identified, with these cell lines exhibiting high 
vimentin along with low N-cadherin and E-cadherin expression (Figure 4.17). The 
IHC results were mirrored in the gene expression data, firstly by investigating the 
expression of the vimentin, E- and N-cadherin genes (VIM, CDH1 and CDH2) 
(Figure 4.18a) and secondly by using a published EMT signature (Figure 4.18b)414. 
This pan-cancer EMT-associated gene expression signature was from a study that 
combined bioinformatic expression data from 7 tumour types using The Cancer 
Genome Atlas and Cancer Cell Line Encyclopaedia databases (the gene lists used are 
provided in the appendix). In our analysis, as expected, MCF-7 and ZR-751 parental 
cell lines had a gene expression pattern consistent with an epithelial genotype, 
whereas the MDA-MB-231 parental and RR cell lines had higher mesenchymal gene 
expression. A mixed pattern of gene expression was identified in the MCF-7 RR and 
ZR-751 RR cell lines, with higher expression of both epithelial and mesenchymal 
genes; this suggested a transition from an epithelial towards a more mesenchymal-




Figure 4.12. Radioresistant cell lines have increased invasion potential. 3D 
invasion assays comparing MCF-7 RR, ZR-751 RR and MDA-MB-231 RR MTS 
with their respective parental MTS. Following placement in collagen MTS invasion 
was assessed up to 120 h. Area of MTS at each time point was calculated and 
expressed as a % of the initial MTS area at day 0 (two-way ANOVA with Holm-





Figure 4.13. MCF-7 RR cell line has increased migration potential. 2D migration 
scratch assays comparing MCF-7 RR with its parental cell line. Relative migratory 
distance was calculated at each time point and expressed as a % area devoid of cells 
based on the initial scratch area at day 0 (two-way ANOVA with Holm-Šídák 
multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001). 
 
Figure 4.14. ZR-751 RR cell line has increased migration potential. 2D migration 
scratch assays comparing ZR-751 RR with its parental cell line. Relative migratory 
distance was calculated at each time point and expressed as a % area devoid of cells 
based on the initial scratch area at day 0 (two-way ANOVA with Holm-Šídák 




Figure 4.15. MDA-MB-231 RR cell line has increased migration potential. 2D 
migration scratch assays comparing MDA-MB-231 RR with its parental cell line. 
Relative migratory distance was calculated at each time point and expressed as a % 
area devoid of cells based on the initial scratch area at day 0 (two-way ANOVA with 
Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, 
****p≤0.0001). 
 
Figure 4.16. MCF-7 RR and ZR-751 RR cells show phenotypic changes 
consistent with EMT. H&E staining of parental and RR cell lines detailing their 








Figure 4.17. MCF-7 RR and ZR-751 RR cell lines show increased expression of vimentin, N-cadherin and SNAIL with partial 
down-regulation of E-cadherin. IHC staining for EMT markers (vimentin, N-cadherin, SNAIL and E-cadherin) in MCF-7, ZR-751 and 
MDA-MB-231 parental and RR cells. Positive DAB staining is seen for each antibody at the expected cellular localisation region: positive 
vimentin and SNAIL staining is seen predominately in the cytoplasm whereas E and N-cadherin staining is seen predominantly in the cell 




Figure 4.18. MCF-7 RR and ZR-751 RR cell lines show increased gene 
expression of vimentin and N-cadherin with the partial down-regulation of E-
cadherin. (a) Log2 mean-centered gene expression heatmap showing relative 
inherent gene expression differences between parental and RR cell lines in respect of 
classical EMT markers; VIM=vimentin, CDH1=E-cadherin, CDH2=N-cadherin 
(red=higher expression, green=lower expression). (b) Log2 mean-centered gene 
expression heatmap showing expression differences in respect of a published cancer 
cell EMT-signature414 (red=higher expression, black=no change, green=lower 
expression, n=1). Heatmap clustering was carried out using Pearson correlation with 
average linkage. The gene list and the order in which they appear in the heatmap is 
shown in the appendix. 
4.3.6 WNT signalling is increased in radioresistant cell lines derived 
from ER+ cells 
WNT signalling has been reported to be involved in EMT and 
radioresistance415. To investigate this, the expression levels of WNT pathway-related 
genes was determined in the ER+ parental and RR cell lines. To perform this analysis 
panels of WNT signalling pathway members and their down-stream targets were 
taken from the KEGG database411 (the gene lists used are provided in the appendix). 
The majority of genes in these panels, including WNT5a, WNT5b and FRIZZLED 
family members 1/2/5/7/8, showed increased expression in the RR cell lines derived 
from ER+ cells (Figure 4.19a & Figure 4.19b); WNT5a showed a log2 5-fold and 15-
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fold increase in count-number in the ZR-751 RR and MCF-7 RR cell lines 
respectively when compared to their parental cell lines. IHC and quantitative analysis 
using MCF-7 and ZR-751 parental and RR MTS showed increased WNT5a 
expression in the RR cell lines (Figure 4.20a). Further validation through WB 
experiments using whole cell lysates from serum-starved cells (in accordance with 
conditions for the gene expression experiments) also showed increased WNT5a 
expression in the RR cell lines at 0 and 24 h post-serum starvation (Figure 4.20b). 
 
Figure 4.19. WNT signalling is increased in RR cell lines derived from ER+ cells. 
Log2 mean-centered gene expression heatmaps showing differences between 
parental and RR cell lines. (a) WNT pathway-related genes with highlighted WNT 
and FRIZZLED genes. (b) WNT target genes, taken from the KEGG pathway 
database411 (red=higher expression, black=no change, green=lower expression, n=1). 
Heatmap clustering was carried out using Pearson correlation with average linkage. 





Figure 4.20. WNT signalling is increased in RR cell lines derived from ER+ cells. 
(a) IHC of WNT5a expression using MCF-7 and ZR-751 parental and RR MTS; 
WNT5a staining, as expected, is predominantly localised to the cytoplasm. (b) WB 
analysis showing the levels of WNT5a in untreated MCF-7 and ZR-751 cell lines in 
comparison with their RR derivatives (samples were obtained at 0 and 24 h after 2 h 
serum starvation), (unpaired two-sample t-test; data expressed as mean ± SEM, n=3, 
****p≤0.0001; ***p≤0.001, ** p≤0.01). 
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4.3.7 Radioresistant MCF-7 and ZR-751 cell lines show loss of ERα 
and PgR expression and gain in EGFR expression 
Breast cancers can be characterised into subtypes by the expression of certain 
signalling receptors (ERα, PgR, HER2 and EGFR)416-418. IHC showed that the 
phenotype of the RR cell lines derived from ER+ cells was characterised by ERα and 
PgR expression loss in combination with a gain in EGFR expression (Figure 4.21 & 
Figure 4.22). MDA-MB-231 parental and RR cells maintained their TNBC 
phenotype with no significant EGFR expression changes (Figure 4.23); these IHC 
results were confirmed by WB (Figure 4.24a). ICC with quantitative analysis 
confirmed reduction in the percentage of ERα positive staining cells in the MCF-7 
RR cell line (0.27 ± 0.17%) compared with the parental MCF-7 cell line (81 ± 1.1%) 
and in the ZR-751 RR cell line (0.52 ± 0.36%) compared with the parental ZR-751 
cell line (96.5 ± 1.8%). Loss of ERα in the MCF-7 RR cell line was associated with 
tamoxifen resistance; after 72 h of tamoxifen treatment a statistically significant 
increase in proliferation of the MCF-7 RR cell line was evident compared to the 
parental cells at concentrations ranging from 0.01–3 μM (Figure 4.24b). Tamoxifen 
at concentrations of 1 and 3 μM had no effect on migration in the MCF-7 RR cells, 
whereas an inhibition of migration was seen in the parental cell line (Figure 4.24c). 
To investigate the cellular effects of increased EGFR expression on 
proliferation, invasion and migration, parental and RR cells were treated with the 
EGFR inhibitor, gefitinib (Selleckchem, Munich, Germany). A statistically 
significant decrease in MCF-7 RR proliferation was seen after 72 h of treatment with 
gefitinib at concentrations ranging from 0.1-15 μM compared to MCF-7 parental 
cells. A significant reduction in migration of the MCF-7 RR cells was also seen, with 
a concentration of 5 µM decreasing their migratory potential to that of the parental 
cells (Figure 4.25a & Figure 4.25b). Similar results were also seen in the ZR-751 
parental and RR cell lines (Figure 4.25c & Figure 4.25d). Although only a small 
decrease in MDA-MB-231 RR proliferation was seen at higher gefitinib 
concentrations compared to the parental cells, a significant reduction in migration 
was seen, with a concentration of 5 µM decreasing the migratory potential of the RR 
cell line below that of the parental cells (Figure 4.25e & Figure 4.25f). IC50 values 
were reduced in all RR cell lines but were more pronounced in the MCF-7 RR and 
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ZR-751 RR cell lines (Table 4.3). The effects of gefitinib on invasion were also 
investigated in the ER+ cell lines, with results showing a significant reduction in 
invasion of the MCF-7 RR and ZR-751 RR cell lines with a concentration of 5 μM 
(Figure 4.26). 
 
Figure 4.21. MCF-7 RR cells show loss of ERα and PgR and gain in EGFR 
expression. ICC and IHC expression profiles of signalling receptors, ERα, PgR and 
EGFR in MCF-7 and MCF-7 RR cell lines using 2D monolayer of cells and MTS. 
Positive DAB staining is seen for each antibody at the expected cellular localisation 
region: positive ERα and PgR staining is seen in the nucleus whereas EGFR is seen 




Figure 4.22. ZR-751 RR cells show loss of ERα and PgR and gain in EGFR 
expression. ICC and IHC expression profiles of signalling receptors, ERα, PgR and 
EGFR in ZR-751 and ZR-751 RR cell lines using 2D monolayer of cells and MTS. 
Positive DAB staining is seen for each antibody at the expected cellular localisation 
region: positive ERα and PgR staining is seen in the nucleus whereas EGFR is seen 




Figure 4.23. MDA-MB-231 parental and RR cells show similar EGFR 
expression. ICC expression profiles of EGFR in MDA-MB-231 and MDA-MB-231 
RR cell lines using 2D monolayer of cells. Positive DAB staining is seen at the 
expected cellular localisation region: positive EGFR staining is seen predominantly 
in the cell membrane (representative images, n=3). 
 
Figure 4.24. MCF-7 RR and ZR-751 RR cell lines show loss of ERα and PgR 
expression and gain in EGFR expression. (a) WB analysis showing parental and 
RR cell lines. The ZR-751 Rr cell line shows results from cells only receiving 6 
weeks radiation as opposed to the 12 week course of radiation required for the 
development of confirmed radioresistance. (b) SRB at 72 h and (c) scratch assay up 
to 24 h showing the effects of tamoxifen in MCF-7 and MCF-7 RR cell lines (two-
way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± 




Figure 4.25. Radioresistant cell lines show increased sensitivity to gefitinib. (a) 
SRB at 72 h and (b) scratch assay up to 48 h showing the effects of gefitinib in 
MCF-7 and MCF-7 RR cell lines. (c) SRB at 72 h and (d) scratch assay up to 24 h 
showing the effects of gefitinib in ZR-751 and ZR-751 RR cell lines. (e) SRB at 72 h 
and (f) scratch assay up to 24 h showing the effects of gefitinib in MDA-MB-231 
and MDA-MB-231 RR cell lines (two-way ANOVA with Holm-Šídák multiple 
comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; 
**p≤0.01). 
Table 4.3. IC50 values of gefitinib for each parental and RR cell line 72 h post-
treatment. 
Time post gefitinib 
treatment (h) 
MCF-7 MCF-7 RR ZR-751 ZR-751 RR MDA-MB-231 MDA-MB-231 RR 




Figure 4.26. Gefitinib inhibits MCF-7 RR and ZR-751 RR invasion. 3D invasion 
assay showing the effects of gefitinib in (a&b) MCF-7 and MCF-7 RR MTS and 
(c&d) ZR-751 and ZR-751 RR MTS. MTS were placed in collagen and invasion was 
assessed up to 120 h post-seeding. Area of MTS at each time point was calculated 
and expressed as a % of the initial MTS area at day 0 (two-way ANOVA with Holm-
Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, 
****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05). 
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4.3.8 Radioresistant MCF-7 and ZR-751 cell lines show activation 
of PI3K and MAPK pathways 
Increased total EGFR expression was further investigated through the 
evaluation of downstream signal transduction pathways of the HER/ERBB tyrosine-
kinase receptor family. WB analysis of time course experiments up to 30 min after 2 
Gy radiation showed increased p-ERK levels in MCF-7 RR and ZR-751 RR cell 
lines 5 min post-radiation, whereas only smaller increases were seen in the parental 
cells at a much later time point (Figure 4.27). Although p-AKT did not show a 
response with radiation, the MCF-7 RR and ZR-751 RR cell lines had overall higher 
expression levels compared to those of their parental cell lines (Figure 4.28). No 
differences were seen in the MDA-MB-231 and RR cell lines. 
MAPK pathway activity was investigated by integrating the transcriptomic 
data with a published gene expression signature419, whereas PI3K activity was 
assessed using genes taken from the KEGG pathway database411 in combination with 
FOXO-regulated genes (which have an inverse expression pattern to PI3K 
activity)420. Analysis suggested that active MAPK and inactive PI3K signalling were 
constitutive in the MDA-MB-231 parental and RR cell lines and expression of genes 
related to these pathways were not affected by radiation. Untreated ER+ cell lines 
were characterised by inactive MAPK and PI3K pathway signalling, whereas their 
RR derivatives showed significant changes in gene expression patterns suggesting a 




Figure 4.27. Western blot results showing activation of MAPK signalling in RR 
cell lines derived from ER+ cells. WB analysis showing the levels of p-ERK in 
response to 2 Gy of radiation in MCF-7, ZR-751 and MDA-MB-231 cell lines in 
comparison with their RR derivatives (two-way ANOVA with Holm-Šídák multiple 




Figure 4.28. Western blot results showing activation of PI3K signalling in RR 
cell lines derived from ER+ cells. WB analysis showing the levels of p-AKT in 
response to 2 Gy of radiation in MCF-7, ZR-751 and MDA-MB-231 cell lines in 
comparison with their RR derivatives (two-way ANOVA with Holm-Šídák multiple 




Figure 4.29. Gene analysis showing activation of MAPK signalling in RR cell 
lines derived from ER+ cells. Log2 mean-centered gene expression heatmap 
showing differences between parental and RR cell lines in respect to a MAPK 
pathway activity gene signature419 (red=higher expression, black=no change, 
green=lower expression, n=1). Heatmap clustering was carried out using Pearson 
correlation with average linkage. 
 
Figure 4.30. Gene analysis showing activation of PI3K signalling in RR cell lines 
derived from ER+ cells. Log2 mean-centered gene expression heatmap showing 
differences between parental and RR cell lines in respect of the PI3K pathway; 
associated genes taken from the PI3K KEGG pathway411 (upper heatmap) and 
FOXO-regulated genes420 (lower heatmap) (red=higher expression, black=no change, 
green=lower expression, n=1). Heatmap clustering was carried out using Pearson 
correlation with average linkage. 
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4.3.9 ERα knockdown in MCF-7 cells results in EGFR expression, 
reduced proliferation and enhancement of radiosensitivity 
siRNA optimisation was performed using SRB and WB analysis to select the 
appropriate transfection reagent concentration and the most efficient ERα siRNA to 
achieve maximum knockdown while preserving cell viability. Using the MCF-7 cell 
line, 0.1 µl of transfection reagent had no detrimental effect on proliferation up to 96 
h post-transfection in mock and non-targeting transfected cells. This volume was 
sufficient to produce a significant reduction in proliferation when transfected with 
ERα siRNA (Figure 4.31). The J-003401-12, ESR1 siRNA was chosen for use in 
siRNA experiments over the Smart pool siRNA as lower concentrations could be 
used to achieve the same knockdown efficiency. WB results showed that ERα siRNA 
transfection lasted for 120 h, although at 120 h post-transfection ERα expression 
began to increase. No statistical difference in ERα expression was identified between 
the mock and non-targeting transfected cells, whereas ERα expression was 
statistically lower in the ERα siRNA transfected cells (Figure 4.32 & Table 4.4). 
 
Figure 4.31. SRB assay showing proliferation of the MCF-7 cell line when 
exposed to different volumes of transfection reagent. Transfection volumes of 0.1, 
0.14 and 0.25 µl were used in (a) Mock transfected, (b) Non-targeting transfected 
(25 nM) and (c) ERα siRNA transfected (25 nM) (two-way ANOVA with Holm-
Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, 




Figure 4.32. Validation of ERα siRNA knockdown in MCF-7 transfected cells. 
(two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as 
mean ± SEM, n=3, ***p≤0.001; **p≤0.01; *p≤0.05). 
Table 4.4. ERα percentage knockdown compared to non-targeting transfected 
cells. Excellent reductions in ERα expression was seen using both the Smart pool 
and J12 ESR1 siRNAs based on WB analysis. 
Time post-ERα siRNA transfection (h) 24 48 72 96 120 
Smart pool ERα siRNA (50 nM) 62.51 78.45 70.55 74.55 40.64 
J12 ERα siRNA (25 nM) 75.63 82.68 73.30 73.07 43.59 
J12 ERα siRNA (50 nM) 79.45 86.70 83.71 85.83 63.08 
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ERα loss in the MCF-7 RR cell line was further investigated using ERα 
siRNA knockdown. At 72 h post ERα siRNA knockdown (25 nM) or tamoxifen 
treatment (0.05 µM) results showed significant reductions in MCF-7 proliferation, 
whereas no change was identified in the MCF-7 RR cell line (Figure 4.33). An 
additional reduction MCF-7 proliferation was observed when ERα knockdown or 
tamoxifen treatment was combined with radiation 24 h post-transfection/tamoxifen 
treatment, suggesting acute loss of ERα provides a radiosensitising rather than a 
radioprotective effect (Figure 4.34). WB analysis also showed increased EGFR 
expression at 96 and 120 h post-ERα knockdown (Figure 4.35). 
 
Figure 4.33. ERα siRNA transfection or tamoxifen treatment reduces MCF-7 
proliferation. SRB assays showing the effect of ERα siRNA (25 nM) or tamoxifen 
(0.05 µM) on proliferation 72 h after treatment in (a) MCF-7 cells and (b) MCF-7 
RR cells (two-way ANOVA with Holm-Šídák multiple comparisons test; data 




Figure 4.34. Radiation treatment combined with either ERα siRNA transfection 
or tamoxifen treatment results in an additional reduction in MCF-7 
proliferation. Cells were exposed to 1.5 Gy radiation 24 h following either (a) ERα 
siRNA transfection or (b) tamoxifen treatment (two-way ANOVA with Holm-Šídák 
multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; 
***p≤0.001; **p≤0.01). 
 
Figure 4.35. EGFR expression increases in MCF-7 cells following ERα siRNA 
transfection. WB results showing EGFR and ERα expression following ERα siRNA 
knockdown (5, 10 and 25 nM) with quantitative analysis at 96 and 120 h post-
transfection (graphs document the relative intensity of EGFR normalised to the 
loading controls) (one-way ANOVA with Holm-Šídák multiple comparisons test; 
data expressed as mean ± SEM, n=3, ****p≤0.0001; **p≤0.01). 
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4.3.10 Radioresistant cell lines exhibit cellular plasticity within the 
context of intrinsic breast cancer subtyping 
ER signalling was investigated further through the integration of a published 
ER signalling gene expression signature with the transcriptomic data421. As expected, 
both ER+ parental cell lines were characterised by high expression of ER signalling 
genes in comparison to the ER- parental and RR cell lines which had several-fold 
lower expression of the same genes. Interestingly, using hierarchical clustering 
analysis both MCF-7 RR and ZR-751 RR cell lines clustered closely with the ER- 
cell lines, although they still maintained higher expression levels for a subset of these 
genes, similar to their parental cells. Radiation treatment did not affect the expression 
of these genes (Figure 4.36a). 
Gene expression data was further integrated with a public gene expression 
dataset (GSE50811) of 67 breast cancer cell lines422. Untreated and radiation treated 
MDA-MB-231 parental and RR cell lines clustered tightly with each other in the 
dendrogram branch enriched for the basal breast cancer subtype. MCF-7 and ZR-751 
parental cell lines obtained a luminal A classification whereas their RR derivates 
clustered independently and were enriched for HER2-overexpressing (MCF-7 RR) 




Figure 4.36. Radioresistant cell lines derived from ER+ cells exhibited a change 
in oestrogen signalling associated genes and a change in intrinsic breast cancer 
subtype classification. (a) Log2 mean-centered gene expression heatmap showing 
differential expression of oestrogen-signalling associated genes421 (red=higher 
expression, black=no change, green=lower expression). Heatmap clustering was 
carried out using Pearson correlation with average linkage. (b) Transcriptomic data 
integrated with a public gene expression dataset (GSE50811). Hierarchical clustering 
of parental and RR cell lines based on Pearson correlation to centroids of Sørlie 2003 
intrinsic genes377 (red=basal, dark blue=luminal A, light blue=luminal B, 
purple=HER2-overexpressing, green=normal-like, n=1). 
4.3.11 Radioresistant cell lines derived from ER+ cells show reduced 
activation of the PERK/eIF2α signalling pathway 
Endoplasmic reticulum stress leading to the UPR has been shown to be 
implicated in radiation-induced cell death88,89,102. To investigate the 3 arms (PERK, 
IRE1, ATF6) of the UPR, gene and/or protein expression levels of UPR transducers 
and mediators were investigated, assessing both their inherent levels and changes in 
response to radiation between MCF-7 and ZR-751 parental and RR cell lines. 
Selected UPR components included: endoplasmic reticulum chaperone BIP, primary 
UPR transducer IRE1α and its target XBP1, UPR transducer ATF6, UPR transducer 




Gene analysis of endoplasmic reticulum stress markers identified inherently 
higher expression of genes encoding for BiP, ATF4, ATF6, XBP1 and PERK in 
MCF-7 cells compared to MCF-7 RR cells. Gene expression in both parental and RR 
cell lines was not altered by 2 Gy radiation at either 2 or 8 h post-treatment. 
Conversely, the expression of CHOP and IRE1 was inherently higher in the MCF-7 
RR cells compared with their parental cells and again their expression levels did not 
change in response to radiation (Figure 4.37a). To investigate activation of 
components of the UPR, phosphorylated levels of IRE1, total PERK and its down-
stream target EIF2α were examined through WB analysis in both MCF-7 and ZR-
751 parental and RR cell lines. Results confirmed statistically higher levels of total 
PERK (p≤0.0001), p-PERK (p≤0.0083), and p-eIF2α (p≤0.0068) in the MCF-7 
parental cells compared to the MCF-7 RR cell line. These results were mirrored in 
the ZR-751 parental and RR cell lines, with statistically higher levels of total PERK 
(p≤0.0001), p-PERK (p≤0.0056), and p-eIF2α (p≤0.0469) in the ZR-751 parental cell 
line. An almost complete loss of total and p-PERK was seen in both RR cell lines. 
MCF-7 parental cell lines also demonstrated increased p-PERK expression at 8 h 
post-radiation returning to baseline levels at 24 h; this radiation response did not 
occur in the MCF-7 RR cell line. Statistically lower levels of p-IRE1 were seen in 
MCF-7 (p≤0.0009) and ZR-751 (p≤0.0114) parental cells compared with their RR 




Figure 4.37. Gene expression and western blot analysis show inherent 
differences in UPR pathway activation between MCF-7 and MCF-7 RR cell 
lines. (a) Log2 mean-centered gene expression heatmap showing differences in 
respect of endoplasmic reticulum markers between untreated and radiation treated 
MCF-7 and MCF-7 RR cell lines (red=higher expression, black=no change, 
green=lower expression, n=1). Heatmap clustering was carried out using Pearson 
correlation with average linkage. (b) WB analysis showing the levels of p-PERK, p-
eIF2α and p-IRE1 in untreated MCF-7 and MCF-7 RR cell lines in comparison to 2 
Gy treated cells at 0, 8 and 24 h post-radiation (two-way ANOVA with Holm-Šídák 
multiple comparisons test; data expressed as mean ± SEM, n=3, **p≤0.01). 
 
Figure 4.38. Western blot analysis shows inherent differences in UPR pathway 
activation between ZR-751 and ZR-751 RR cell lines. WB analysis showing the 
levels of p-PERK, p-eIF2α and p-IRE1 in untreated ZR-751 and ZR-751 RR cell 
lines in comparison to 2 Gy treated cells at 0, 8 and 24 h post-radiation (two-way 





Cancer cells that possess innate radioresistance or those that acquire it can 
contribute to treatment failures and poor patient outcomes. Treatment failures can 
occur through tumours not responding or only partially responding to RT or due to 
the development of recurrent loco-regional and/or metastatic disease. Through the 
identification of genes, proteins and signalling pathways that are related to the 
acquisition of radioresistance, targets can be identified, and therapeutic approaches 
developed to overcome the clinical issue of radioresistance. The generation of in 
vitro RR cancer cell line models can help study, and subsequently target, the 
mechanisms involved in the development of acquired radioresistance. However, only 
a small number of previous studies have developed RR cell lines to investigate 
acquired radioresistance and these focused on single specific pathways, which 
limited their ability to determine the complex interrelated systems that govern 
radioresistance development410,423-427. 
This chapter describes the development of novel RR breast cancer cell lines 
from both ER+ hormone-responsive (MCF-7 and ZR-751) and ER- hormone non-
responsive (MDA-MB-231) molecular subtypes and the characterisation of their 
inherent differences and responses to radiation. Using genetic, molecular and 
functional assays, in 2D and 3D model systems, a more global characterisation of 
this RR model was achieved. 3D culture systems were incorporated into the 
experiments to increase the complexity of the RR model. These MTS models more 
accurately represent the TME within a solid tumour, as they develop O2, nutrient and 
pH gradients, producing a central necrotic core with an outer mantle of proliferating 
cells428. The novel MTS derived from RR cells developed in this study have not been 
described before in the literature and serve as excellent in vitro RR tumour models 
which were used to investigate invasiveness and protein expression through IHC. 
Following the 12-week development period, all RR cell lines were confirmed 
as radioresistant through proliferation and CF assays with respect to their sensitivity 
to a single, clinically relevant, dose of radiation. These initial experiments validated 
the use of these cell lines as in vitro models to characterise the radioresistant 
phenotype and investigate the mechanisms involved in its development. Using the 
same assays, the radioresistant phenotype was also shown to be maintained in MCF-
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7 RR (and REM-134 RR) cells that had not been exposed to radiation for 6 months. 
This indicated RR models were generated in which the acquisition of radioresistance 
was not transient. This is in contrast to a previous study that showed that 
radioresistant MCF-7 cells lost their resistant phenotype 12 weeks after a final dose 
of radiation424. The difference in maintenance of the RR phenotype could be due to 
the fact that we developed our model by increasing weekly radiation doses by 0.5 Gy 
or due to cell lines being exposed to radiation over a longer period of time. These 
factors could contribute to the generation of a more stable phenotype. Varying results 
from different RR models highlights the importance of regular confirmation of 
maintained radioresistance through CF/SRB assays. 
The cell cycle of a cancer cell can significantly influence the effects of 
radiation. Cells during the G2/M phase are most sensitive to radiation-induced DNA 
damage whereas those in late S-phase are most resistant. Fractionated RT treatment 
plans can help overcome this cell cycle-associated radioresistance by allowing 
radioresistant S-phase cells to progress into a more sensitive cell cycle phase in 
between the daily fractions of radiation. Quiescent cells or those that only progress 
slowly through the cell cycle are known to be more radioresistant, as they have more 
time to activate DNA damage response pathways and repair DNA damage before 
cellular division occurs. Results from our study suggested reduced proliferation in 
terms of cell cycle arrest genes and Ki67 staining in MTS, which is in accordance 
with other studies showing reduced proliferation rates of in vitro prostate cancer RR 
cell lines429. In clinical terms, reduced cancer cell proliferation rates as demonstrated 
by Ki67 staining has been associated with poor local control of HNSCC tumours430. 
Among breast cancer patients, metastatic disease accounts for more than 90% 
of cancer-related deaths431, so understanding the processes involved in breast cancer 
metastasis and treatment failure is of clinical importance. Results obtained using 
functional assays identified that MCF-7 RR and ZR-751 RR cell lines had 
significantly increased migration and invasion ability compared with their parental 
cells, whereas the MDA-MB-231 RR cell line exhibited increased migration with 
only a marginal and non-significant increase in invasion compared to its parental cell 
line. These results suggested that the RR cell lines had developed a more aggressive 
phenotype, which was more evident in the RR cell lines derived from ER+ cells. 
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Clinically these results could lead to a greater potential for local tissue invasion and 
metastasis. These functional changes are likely to be orchestrated by EMT. EMT is a 
critical process involved in malignant cellular transformation leading to reduced 
cell–cell contacts, increased cell motility and metastasis432-434. In addition, EMT can 
influence other cellular processes such as enhanced survival435, genomic 
instability436, cancer stem cells425,437 and resistance to chemotherapy and RT415,425,438. 
The loss of epithelial morphology that occurs during EMT has been shown to be a 
prognostic indicator that correlates with poor prognosis439. We evaluated known 
biomarkers for breast cancer EMT440 in our RR model and demonstrated, at both 
gene and protein levels, down-regulation of E-cadherin and up-regulation of 
vimentin, N-cadherin and SNAIL in the MCF-7 RR and ZR-751 RR cell lines. These 
results supported the morphological and functional changes identified in these RR 
cells, which developed a more mesenchymal-like phenotype with increased invasive 
and migratory potential. In contrast to the epithelial-like ER+ cell lines, the MDA-
MB-231 cell line has a much more mesenchymal-like phenotype with constitutively 
low E-cadherin and high vimentin expression; because of this, further development 
of EMT in its RR derivative was difficult to ascertain. Multiple signalling pathways 
can activate EMT in both normal and cancer cells, including receptor tyrosine kinase 
signalling, WNT-β-catenin and Notch signalling441,442. Radiation alone can also 
induce EMT through the expression of TGFβ443,444. Both EGFR downstream 
signalling pathways and WNT signalling were found to be activated in MCF-7 RR 
and ZR-751 RR cell lines suggesting possible mechanisms by which EMT may be 
activated. WNT signalling has been shown to play a role in EMT, with one study 
using MCF-7 cells showing that WNT signalling could inhibit Snail phosphorylation, 
causing an increase in Snail protein and activity levels resulting in the MCF-7 cells 
gaining a mesenchymal-like phenotype441. It is interesting to note that in our results 
the same population of cells, predominantly those around the periphery of the MTS 
formed from RR cells from ER+ cell lines, showed increased co-expression of 
vimentin, Snail, N-cadherin and WNT5a409. 
Breast cancers can be characterised and subtyped using IHC and gene 
expression analysis. Expression of receptors such as HER2, ERα, PgR and EGFR 
can be assessed by IHC, whereas gene expression profiling can be used to identify 
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cancer cell molecular profiles and classify them into 5 specific tumour subtypes: 
basal, luminal A, luminal B, HER2-overexpressing and normal-like416,445. These 
subtypes exhibit differential sensitivities to radiation and have distinct clinical 
outcomes417,418. The clinical usefulness of breast cancer molecular subtyping is 
undeniable, as it can help influence a patient’s treatment plan and give an indication 
of prognosis. However, its usefulness in subtyping in vitro cell lines remains 
controversial. This issue has been previously investigated by comparing genomic and 
transcriptional characteristics of primary breast tumours with those of cancer cell 
lines. One study showed that genome aberrations and transcriptional changes 
identified in 51 cancer cell lines (including MCF-7, ZR-751 and MDA-MB-231) 
were well preserved compared to those found in primary tumours of a similar 
subtype446. Although the cell lines carried more genome aberrations, possibly related 
to certain cell lines having been derived from pleural effusions or late stage tumours, 
the study concluded that cell lines can show stable genomic patterns which do not 
necessarily accumulate significant numbers of new mutations during extended 
culture. This study also reported that cell lines are well suited to assess the functional 
consequences of genome aberrations-mediated gene deregulation and are useful in 
the identification of molecular features that predict sensitivity/resistance to agents 
targeting these changes. However, it is important to understand that profiling cell 
lines does not consider the TME, which includes normal stromal tissue and epithelial 
cells, nor will it reflect intra-tumoural heterogeneity. With these caveats in mind, the 
purpose of subtyping the parental and RR cell lines in this study was to demonstrate 
that radioresistance development is consistent with a change in intrinsic subtype to a 
prognostically less favourable classification409. 
Transcriptional profiles of the parental and RR cell lines were used to assign 
each one to an intrinsic breast cancer subtype. Both parental and RR MDA-MB-231 
cell lines were triple negative and transcriptional subtyping identified them both as 
basal377,445,447,448. Treatment of basal breast cancers mainly relies on chemotherapy, 
as targeted therapies are lacking. Unfortunately, basal breast cancer is associated 
with lower disease-specific survival rates and a higher risk of local and regional 
recurrence compared with luminal subtypes445,447,448. It is therefore not surprising 
that no significant changes were identified in the MDA-MB-231 RR cell line as the 
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parental MDA-MB-231 cell line is inherently aggressive in nature. A change in 
subtype classification was identified in both RR cell lines derived from ER+ cells, 
with a shift from luminal A for both MCF-7 and ZR-751 cell lines towards a non-
luminal classification. The MCF-7 RR cell line closely correlated with the HER2-
overexpressing subtype while the ZR-751 RR cell line correlated with the normal-
like subtype. Although the MCF-7 RR cell line did not express HER2 in IHC 
assessment, it is likely that it gained its HER2-overexpressing classification due to its 
gain in EGFR expression in combination with MAPK and PI3K activity, which are 
also found in HER2 positive breast cancers. Normal-like breast cancers resemble 
normal breast tissue with high expression of genes associated with adipocytes and 
non-epithelial cell types, and low expression of genes related to luminal epithelial 
cells. Both HER2-overexpressing and normal-like subtypes carry a worse prognosis 
compared to luminal A tumours, with HER2-overexpressing tumours having a higher 
risk of locoregional recurrence377,445,447,448. Luminal A tumours also respond well to 
hormone and radiation treatment447, and so a shift away from this subtype would be 
consistent with endocrine therapy resistance, reduced radiosensitivity and a more 
aggressive phenotype. These results show that the acquisition of radioresistance can 
be linked with cellular plasticity through extensive alterations in gene expression 
resulting in a change in molecular subtype classification. 
Investigation of common breast cancer signalling receptors demonstrated that 
MCF-7 RR and ZR-751 RR cell lines lost ERα and PgR expression and gained 
EGFR expression. Furthermore, when siRNA transfection was used in the MCF-7 
cell line to knockdown ERα this resulted in increased EGFR expression, suggesting a 
direct relationship between ERα loss and EGFR expression. Gene analysis also 
corroborated ERα loss, with lower expression of ER driven genes in the RR cell lines 
derived from ER+ cells. An inverse relationship between ER activity and EGFR and 
HER2 expression has been reported in clinical breast cancers and overexpression of 
these receptor tyrosine kinases is associated with reduced sensitivity to endocrine 
therapy and worse prognosis449-451. This apparent switch from ER signalling to 
EGFR-mediated signalling in the RR cell lines derived from ER+ cells was 
investigated using the EGFR inhibitor gefitinib and the anti-oestrogen tamoxifen. 
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Gefitinib treatment produced greater concentration-dependent reductions in 
cell proliferation, migration and invasion in the MCF-7 RR and ZR-751 RR cell lines 
compared with their parental cells. The calculated IC50 values were 6.43 (MCF-7 
RR) and 13.12 µM (ZR-751 RR); although these values were approximately half that 
of the parental cells (13.34 µM for the MCF-7 and 22.02 µM for the ZR-751), these 
concentrations are still relatively high compared to clinically relevant doses452-454. 
Therefore, these results suggest that, although the MCF-7 RR and ZR-751 RR cell 
lines are still relatively insensitive to the effects of gefitinib, a significant 
sensitisation was seen in comparison to their parental cell lines. Results also showed 
that the MCF-7 RR cells developed simultaneous resistance to tamoxifen at clinically 
relevant doses. In the clinic, patients with ER+ breast cancer may be treated with 
tamoxifen for 5-10 years following surgery and RT. If radioresistant cells survive 
following completion of the RT course then, as our results suggest, these 
radioresistant cells may also gain tamoxifen resistance. Repopulation of the tumour 
site with endocrine therapy-resistant and radioresistant cancer cells could 
significantly limit treatment options and have a negative impact on patient outcome. 
Mechanisms for acquired tamoxifen resistance are complex, since resistant tumours 
do not usually lose ERα expression and the receptor remains functional455. This is 
demonstrated by patient cohorts with recurrent disease still being able to respond to 
second line endocrine therapy456,457. Studies have suggested that this form of 
resistance could work through ER function modification by growth factor 
pathways458,459. Another study investigated tamoxifen resistance in MCF-7 RR cells, 
showing resistance occurred without a change in the expression levels of ER but with 
enhanced AKT phosphorylation. This study suggested that sequential tamoxifen 
treatment post-radiation treatment could be more effective than providing the 
treatments concurrently427. Conversely, results from our study showed an additional 
inhibition of proliferation when radiation was delivered 24 h after tamoxifen 
treatment or ERα knockdown in the MCF-7 cells. Suggesting that the use of 
tamoxifen before and during a patient’s RT treatment would be advantageous. 
Another study determined that tamoxifen-resistant MCF-7 cells showed increased 
EGF sensitivity, with oestradiol stimulating MAPK activation. Tamoxifen was able 
to elicit rapid MAPK phosphorylation in the MCF-7 resistant cells, whereas 
137 
 
inhibition of the EGFR/MAPK pathway caused a significant inhibition of 
proliferation. Although ERα was not lost in these tamoxifen-resistant cells, it became 
redistributed to extra-nuclear sites (cytoplasmic translocation). It was postulated that 
the enhanced function of ERα was due to cooperation with EGFR and is a possible 
mechanism for the development of acquired resistance to tamoxifen460. Similar 
results have also been shown in anti-oestrogen-resistant MCF-7 cell lines developed 
through continuous culture in fulvestrant. These resistant cells developed reduced 
ERα expression and loss of PgR with a shift towards dependence on EGFR/MAPK-
mediated signalling461. Our RR model is the first to report a link between acquired 
radioresistance and the loss of ERα and PgR and resistance to tamoxifen. Therefore, 
this suggests that tamoxifen resistance secondary to acquired radioresistance may 
involve different pathways compared to the development of tamoxifen resistance 
from chronic drug exposure and that additional targeted therapy may be required in 
these cells to overcome both endocrine and radiation resistance. 
Following the identification of increased EGFR expression in the RR cell 
lines, downstream signal transduction pathways of the HER tyrosine-kinase receptor 
family were investigated. Increased activation of the PI3K/AKT/mTOR cascade is 
frequently seen in a wide range of cancer types and can trigger downstream pathway 
responses related to cell survival, apoptosis, proliferation, migration, invasion, and 
metabolism462,463. This pathway can be activated by radiation and has been 
associated with resistance mechanisms, with constitutively activated AKT being 
linked to intrinsic radioresistance464,465. In this study we found that the gene 
expression signature in the MCF-7 RR and ZR-751 RR cell lines fitted with 
activation of the PI3K pathway. Although p-AKT did not increase in response to 
radiation, expression levels were statistically higher than in the parental cell lines, 
suggesting a constitutively activated PI3K/AKT/mTOR signalling pathway in these 
RR cell lines, which may play an important role in their radioresistant phenotype. 
These pathways have also been shown to be activated in RR prostate cancer cell lines 
(androgen responsive and non-responsive) in combination with enhanced 
EMT/cancer stem cell phenotypes and activation of checkpoint proteins425. 
In breast and other cancers, EGFR activation with stimulation of the 
downstream components of the MAPK cascade, including phospholipase-C, Ras, and 
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Raf-1, has been linked with radiation-induced cancer cell proliferation466-469 and is 
considered to be a cytoprotective response470 and a mechanism by which cancer cells 
can cause tumour repopulation during fractionated RT. Results at gene and protein 
level from this study suggest that MAPK signalling is activated in the MCF-7 RR 
and ZR-751 RR cell lines. Basal expression levels of p-ERK1 and p-ERK2 were 
significantly higher in MCF-7 RR and ZR-751 RR cell lines compared with their 
parental cells. Radiation-induced ERK1 and ERK2 phosphorylation also occurred 
more quickly and to a greater degree following a 2 Gy dose of radiation in these RR 
cell lines. These results suggest that EGFR signalling, and multiple components of its 
downstream pathways are activated in the MCF-7 RR and ZR-751 RR cell lines. 
This finding could have clinical implications, as multiple pathways may need to be 
targeted to improve therapeutic responses to radiation and overcome resistance409. 
The UPR is an important cellular process that enables cells to respond to 
endoplasmic reticulum stress, resulting in either restoration of normal cellular 
functions and endoplasmic reticulum homeostasis or cell death471. The UPR of ER+ 
parental and RR cell lines was characterised because previous studies have shown 
that radiation can induce endoplasmic reticulum stress and UPR activation88,89. If 
differential pathway activation is occurring in the RR cell lines, then this may 
provide a radiation-induced pro-survival mechanism rather than activating 
endoplasmic reticulum-induced apoptotic or autophagic cell death pathways. The 
most striking finding from our results was an almost complete loss of total and p-
PERK expression and significantly reduced expression of eIF2α in both RR cell lines 
derived from ER+ cells. A previous study using MDA-MB-231 cells showed that, 
although endoplasmic reticulum stress markers and CHOP levels were not elevated 
following radiation, the PERK-eIF2α pathway did become activated; these results led 
the authors to conclude that PERK-dependent radiation-induced apoptosis was not 
CHOP mediated. Furthermore, PERK down-regulation using siRNA resulted in 
lower levels of radiation-induced apoptosis, leading to increased radioresistance472. 
Although this study used an ER- cell line, it provides an important comparison with 
our results, as our RR cell lines derived from ER+ cells have some ER- phenotypic 
characteristics. As endoplasmic reticulum stress-induced apoptosis is primarily 
mediated by the PERK/eIF2α UPR pathway90,97, these results support our findings 
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that a reduction in PERK-eIF2α pathway activation may be contributing to the RR 
phenotype. 
Although apoptosis is considered the main mechanism by which irreversibly 
endoplasmic reticulum stressed cells are removed, typical apoptotic pathways may 
not occur in the MCF-7 cell line since, although it possesses caspase 6 and 7, it is 
deficient in functional caspase 3. One study showed that PERK and radiation-
induced phosphorylation of eIF2α were essential for autophagy and radiosensitivity 
in caspase 3/7-deficient cells102. Although our study reported almost identical results 
for MCF-7 and ZR-751 cell lines, further work would be required to determine if 
they are undergoing similar caspase 3-independent autophagy or some other cell 
death mechanism. The increased gene and protein expression levels of IRE1 in the 
RR cell lines warrant further investigation, as this part of the UPR can be protective 
or lead to apoptosis. If the MCF-7 and MCF-7 RR cell lines are predominantly 
relying on PERK-mediated radiation-induced autophagy, then IRE1 activation may 
suggest the pathway is being used as a pro-survival mechanism, as this pathway has 
not been shown to be involved in cell death through autophagy. Although expression 
signatures of the major UPR genes differ among tissues and diseases, BiP, PERK, 
IRE1α and ATF6 have been shown to have increased expression in breast 
carcinomas473. Inherent expression of these markers could explain the base line gene 
and protein levels seen in our experiments, especially in the MCF-7 and ZR-751 
parental cells. 
4.5 Conclusion 
This chapter has described the development of novel RR models which 
incorporated the use of both 2D and 3D culture systems. Characterisation of these 
RR breast cancer cell lines was performed using multiple different techniques 
including gene, protein and functional experiments. This in-depth characterisation 
allowed results to be validated through independent means and provided a more 
global approach to understanding the cellular changes that occur following the 
acquisition of radioresistance. The development of RR cells from both ER+ and ER- 
parental cell lines allowed for comparisons to be made between not only paired 
parental and RR cell lines but also between the different molecular breast cancer 
subtypes. The most striking cellular changes were identified in the RR cell lines 
140 
 
derived from ER+ cells; these RR cells were characterised by a shift towards a more 
invasive mesenchymal phenotype, with changes in oestrogen-regulated signalling 
pathways, gain of EGFR signalling and a change in subtype classification. The ER- 
cell line possessed these characteristics at the outset and hence its phenotype changed 
relatively little with radioresistance development. 
Well characterised models of resistant disease, as developed and examined in 
this chapter, are needed if continued progress is to be made in understanding the 
mechanisms and signalling pathways involved in the development of radioresistance. 
Future studies using this RR model can now target the differentially activated 
pathways identified in the RR cell lines to focus on radioresistance reversal. The use 
of paired parental and RR cell lines can also be used to identify genetic and 
secretomic signatures to assess a tumour’s response to radiation. This type of study 
will likely be instrumental in the development of new therapeutic strategies for 
patients who either fail to respond to treatment or develop recurrent disease.  
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5 Identification of Biomarkers Released from 
Cancer Cells in Response to Radiation – A Pilot 
Study 
5.1 Abstract 
Background: Identification of patients that fail to respond to radiotherapy during 
treatment could decrease the number of patients receiving radiation treatment for no 
therapeutic gain and allow the use of alternative therapies at an earlier stage. 
Monitoring radiation-induced secreted cancer biomarkers could assess a tumours 
response to radiotherapy, determine radiosensitivity and provide a means of 
identifying non-responding patients. Methods: To identify radiation-induced 
secreted biomarkers, cancer cells were exposed to radiation and liquid 
chromatography-mass spectroscopy was performed on conditioned media samples. 
To identify biomarkers related to radiosensitivity, gene expression analysis was 
performed using parental and radioresistant cell lines. Results: Using the MCF-7 cell 
line, 33 biomarkers were identified as having up to a 12-fold increase in secretion in 
response to radiation compared to controls at 24 h. Based on secretion profiles and 
functional analysis 9 candidate biomarkers were selected (YBX3, TK1, SEC24C, 
EIF3G, EIF4EBP2, NAP1L4, VPS29, GNPNAT1 and DKK1), of which the first 4 
underwent in-lab validation. Gene analysis identified higher expression of genes 
encoding 7 of the candidate biomarkers in the MCF-7 cell line compared to its 
radioresistant derivative. Western blot identified increased levels of the 4 biomarkers 
in the conditioned media of parental cells 24 h post-radiation which was not seen in 
the RR cell lines. Conclusions: The identification of biomarkers that have 
differential gene expression and secretion profiles in response to radiation between 
sensitive and RR cell lines has provided initial evidence that these biomarkers may 
be useful for predicting and/or monitoring the response to radiotherapy. 
5.1 Introduction 
Monitoring a tumours response to radiation whilst a patient is undergoing RT 
could provide a means by which a patient’s treatment could become tailored, with 
patients not responding to traditional RT given alternative therapies at an earlier 
stage of the treatment process. One method through which response could be 
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measured is through the detection of tumour secreted biomarkers, either in the blood 
or within the tumour itself using an implanted sensor. Research using the secretome 
of cancer cells is likely to aid the discovery of these clinically relevant biomarkers. 
Although the term ‘cancer secretome’ should be used to describe all substances 
secreted by cancer cells and cancer-associated stromal cells through the classical or 
non-classical pathways it is more commonly applied to proteins identified by mass 
spectrometry in the conditioned media (CM) of cancer cell lines474. Although these 
types of experiments do not accurately re-create the complex TME, the CM obtained 
with these experiments is less complex than that of biological fluids, which increases 
the likelihood of identifying low abundance substances. Several secretomic studies 
have used CM from breast cancer cell lines as in vitro model systems475-479. Many of 
these studies are comparative, using non-tumourigenic and tumourigenic cell lines to 
investigate differentially secreted proteins related to malignant transformation, with 
the aim of identifying secreted biomarkers for early breast cancer diagnosis475-477. 
The MCF-10 isogenic cell line has been used in various secretomic studies to help 
identify differentially secreted proteins from cell lines representing different 
tumourigenic stages, ranging from the non-tumourigenic MCF-10A through to the 
tumourigenic/metastatic MCF-10CA cl. Differential secretome profiles between non-
tumorigenic and malignant cell lines have been confirmed in numerous studies475,477, 
providing evidence that secreted proteins within the cancer secretome can be used to 
predict the aggressiveness of breast cancer cells. Cancer cell line in vitro secretomic 
results have also been validated using clinical samples; following in vitro 
identification that activated leukocyte cell adhesion molecule (ALCAM) was 
secreted in higher levels in non-invasive and metastatic breast cancer cell lines 
compared with breast epithelial cells480, a clinical study investigated its use as a 
serum biomarker for breast cancer diagnosis. This study showed ALCAM serum 
concentrations were statistically higher in breast cancer patients compared with 
normal women, with the test having higher diagnostic sensitivity compared to other 
serum biomarker assays currently used (CA15-3 and CEA)481. 
Secretomic studies have also been used for the investigation of predictive 
biomarkers of chemotherapy resistance. For example, one study characterised the 
secretomes from MCF-7 doxorubicin sensitive and resistant cell lines478; a total of 
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2084 proteins were identified in the 2 cell lines, of which 89 were differentially 
secreted. In vitro validation showed that doxorubicin resistance could be induced by 
IL-18, whereas doxorubicin sensitivity was restored upon IL-18 inhibition. In vivo 
validation using breast cancer lysates from patients resistant to neoadjuvant 
doxorubicin showed higher IL-18 levels compared to responding patient samples, 
demonstrating the functional role of IL-18 in doxorubicin resistance. 
Although these secretomic studies have identified novel biomarkers of 
aggressive phenotypes or as therapeutic predictors, no study has investigated the 
immediate effects of radiation on the cancer secretome as a means of assessing a 
cancer cells response to RT and/or determining their radiosensitivity. This chapter 
describes the development of an in vitro secretomic screening and validation method 
to identify such biomarkers. Analysis of gene expression and secretomic data was 
performed by Dr A. K. Turnbull (Cancer Research UK, University of Edinburgh). 
Parental cell lines were used to investigate the secretome of cancer cells and 
characterise the changes that occur in response to radiation. These cell lines, unlike 
their RR derivatives, have not received any prior exposure to radiation and therefore 
could be considered a more appropriate model for monitoring a naive cellular 
response to radiation as would be the case in most tumours in patients receiving RT 
for the first time. Characterisation of the cancer secretome was performed using LC-
MS on CM samples from untreated and radiation-treated parental cells up to 24 h 
post-treatment. Secretion patterns of candidate biomarkers were initially identified 
using the MCF-7 cell line, which were then investigated in CM samples obtained 
from other human breast, canine breast and ovine lung cancer cell lines. The aim was 
to identify differentially secreted biomarkers that were secreted in response to 
radiation within 24 h of treatment, and to investigate whether these biomarkers could 
be found in different cancer types and species. Further investigations were performed 
using both parental and RR cell lines to assess the expression of candidate 
biomarkers at gene and intra-cellular protein level, along with their secretion levels 
up to 24 h following 2 Gy radiation. The aim was to assess the biomarkers potential 
for use as an indicator of radiosensitivity. To our knowledge, this is the first 
description of the use of secretomic experiments to identify radiation-induced 




5.2.1 Characterisation of the MCF-7 secretome 
The ER+ MCF-7 cell line was chosen as the initial model system for 
biomarker discovery as it is an extremely well characterised cell line, with previous 
studies successfully demonstrating and validating its use in secretomic experiments. 
Preliminary characterisation of the untreated MCF-7 secretome identified a total of 
927 secreted proteins in CM samples up to 24 h post-serum starvation (provided in 
the appendix). Although at each secretomic analysis time point (1, 2, 4, 8 and 24 h) a 
unique set of proteins (proteins detected only at one specific time point) were 
identified, the number of unique proteins remained low up to 8 h post-serum 
starvation (Figure 5.1a). By 24 h, 160 unique proteins were identified. In total, 239 
secreted proteins (provided in the appendix) were common to all time points, and 
although their secretion levels did vary over time, overall absolute changes in 
secretion were minimal (only around 2-fold). At later time points lower secretion was 
seen for proteins functionally enriched for metabolism, including glycolysis and the 
citrate cycle, whereas higher secretion was found for proteins associated with 




Figure 5.1. Characterisation of the untreated MCF-7 secretome identified 927 
unique proteins up to 24 h post-serum starvation. (a)Venn diagram showing the 
overlap between the total number of detected secreted proteins in the CM of 
untreated MCF-7 cells at each time point. (b) Log2 mean-centered protein heatmap 
showing secretion levels for the 239 proteins common to all time points 
(yellow=higher secretion, black=no change, blue=lower secretion, n=1). Heatmap 
clustering was carried out using Pearson correlation with average linkage. 
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Following characterisation of the MCF-7 untreated secretome we wished to 
identify differentially secreted proteins in response to radiation. To achieve this 
MCF-7 cells were treated with a single dose of radiation (2–10 Gy) and CM samples 
were obtained up to 24 h post-radiation. To ensure that radiation treatment was not 
causing significant cell death, cell counts using trypan blue exclusion were 
performed at the time of the experiments. Although some cell lines did show a 
statistically significant increase in cell number between untreated samples at 0 h and 
24 h, no difference in total cell number or number of dead cells was seen between 
any of the untreated and radiation treated (up to 10 Gy) groups at 24 h (Figure 5.2) 
(the proportion of dead cells in each treatment group was less than 5%). 
 
Figure 5.2. Cell numbers were not affected by a single dose of radiation up to 10 
Gy at 24 h post-treatment. Cells were seeded at varying numbers to achieve a 
confluency of 40% at 24 h (MCF-7 and MCF-7 RR 40x104; ZR-751 and ZR-751 RR 
60x104; MDA-MB-231, MDA-MB-231 RR, HBL-100 and REM-134 30x104; JS7 
20x104). After secretome collection, cells were counted routinely using trypan blue 
exclusion (two-way ANOVA with Holm-Šídák multiple comparisons test; data 
expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05). 
MCF-7 secretomic analysis subsequently focused on CM samples obtained at 
24 h post-radiation treatment. This time point was chosen as it was deemed most 
suitable for use in clinical situations where patients routinely receive daily radiation 
doses approximately 24 h apart. Characterisation of untreated and radiation treated 
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CM samples at 24 h identified a total of 765 secreted proteins, of which 530 were 
common to both the untreated and radiation treated samples (Figure 5.3). 
Investigation of protein secretion fold changes between untreated and radiation 
treated samples identified 147 proteins which had a >2-fold increase in secretion 
levels in radiation treated cells (provided in the appendix). 
 
Figure 5.3. Characterisation of the untreated and radiation treated MCF-7 
secretome identified 530 common proteins at 24 h. Venn diagram showing the 
overlap between the total number of detected secreted proteins in the CM of MCF-7 
untreated and radiation treated cells (2-10 Gy) at 24 h. 
5.2.2 Criteria used for candidate biomarker selection 
Using secretomic data initially obtained from the MCF-7 model, several 
criteria were applied to the biomarkers in order to identify those most appropriate to 
be taken forward for validation. We had already focused on biomarkers that were 
released by cells which were detectable at 24 h post-radiation exposure, as this was 
likely to be the most clinically relevant time point; patients typically receive daily 
radiation fractions, therefore biomarkers detectable at 24 h post-radiation would 
allow for ease of monitoring between daily doses. We also wished to identify 
biomarkers that showed a simple secretion profile whereby levels were low at early 
time points, then showed a dramatic increase at 24 h, as this would potentially 
increase the likelihood of successful validation. Selected biomarkers were also 
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investigated in multiple radiosensitive cancer types from different species. The 
identification of common biomarkers in several species would give the biomarkers 
wider application and would allow for large animal model testing, and possible 
veterinary uses. Following the initial selection based on secretion profiles, final 
biomarker selection was performed using functional analysis; any biomarkers that 
played roles in common pathways were preferentially selected. 
Although not part of the selection process, further assessment of candidate 
biomarkers at gene and intra-cellular protein level in parental and RR cell lines was 
performed to investigate whether a gene/protein expression signature could be 
obtained to predict radiosensitivity. 
5.2.3 MCF-7 preliminary biomarker selection based on increased 
secretion at 24 hours post-radiation identified 33 candidate 
biomarkers 
Using the 147 biomarkers with >2-fold increase in secretion levels in 
radiation treated cells, hierarchical clustering with Euclidean distance was 
performed. A cluster of 33 biomarkers emerged which had higher (up to 12-fold) 
secretion levels at all radiation doses in treated compared to untreated controls 
(Figure 5.4) (provided in the appendix). Secretion levels of all 33 biomarkers were 
then investigated at the earlier time points. Although a small number of the 
biomarkers had early increased or decreased secretion compared to untreated 
controls the secretion levels of most of the biomarkers did not change with radiation 
at the earlier time points (Figure 5.5). A literature search of theses 33 candidates was 
performed to investigate whether these biomarkers were previously known to be 
secreted either through the classical or non-classical routes. Cross referencing 
through Vesiclepaedia482 identified that all 33 biomarkers have previously been 




Figure 5.4. Hierarchical clustering identified a cluster of 33 biomarkers with 
dramatic increase in secretion in response to radiation. Heatmap of log2 fold 
changes showing the 147 proteins whose increased secretion had fold changes 
greater than 2 between controls and matched treated samples at 24 h across all doses. 
Hierarchical clustering identified a cluster of 33 proteins, shown at the top of the 
heatmap in red, which had increased (up to 12-fold) secretion at all radiation doses in 
treated compared to untreated controls (red=higher secretion, blue=no change, n=1). 




Figure 5.5. MCF-7 secretion patterns of the 33 candidate biomarkers remained 
stable up to 8 hours post-radiation treatment. Heatmap of log2 fold changes 
showing secretion levels of the 33 biomarkers compared to untreated controls at each 
time point up to 24 h post-radiation for each radiation dose (red=higher secretion, 
green=no change, blue=lower secretion, n=1). Heatmap clustering was carried out 
using Pearson correlation with average linkage. 
5.2.4 No common set of biomarkers were identified between 
different cancer types 
To investigate whether the 33 candidate biomarkers could be found in 
different cancer types and species, their secretion patterns up to 24 h post-radiation 
exposure were investigated using secretomic data generated from ER- human breast 
(MDA-MB-231 and HBL-100), canine breast (REM-134) and ovine lung (JS7) 
cancer cell lines. In total across all time points, 20 of the 33 biomarkers were 
identified in both MDA-MB-231 and HBL-100 cell lines; however, this number 
reduced to 12 and 6 respectively when including the criteria of increased secretion at 
the 24 h time point, as was done with the MCF-7 secretomic data. Across all time 
points only 5 and 4 of the 33 biomarkers were identified in the REM-134 and JS7 
cell lines respectively. Most of the biomarkers also had more complicated secretion 




Figure 5.6. Secretion patterns of the 33 candidate biomarkers in multiple cancer 
cell types and species identified no common set of candidate biomarkers. 
Heatmap of log2 fold changes showing secretion levels of the 33 biomarkers 
compared to untreated controls at each time point up to 24 h post-radiation for each 
radiation dose (yellow=higher secretion, black=no change, blue=lower secretion, 
n=1). Heatmap clustering was carried out using Pearson correlation with average 
linkage. 
5.2.5 MCF-7 final biomarker selection based on functional analysis 
of the 33 biomarkers identified 9 candidate biomarkers 
Final candidate biomarkers were selected based on secretion profiles and 
functional analysis. Using the Markov clustering algorithm382, incorporating the 
initial 33 candidate biomarkers selected based on secretion profiles, this program 
identified 3 functionally enriched clusters that included protein transport, 




Figure 5.7. Protein interaction networks identified protein transport, 
transcription and translation as enriched clusters within the 33 candidate 
biomarkers. Protein interaction network of the 33 candidate biomarkers plus the 10 
most closely associated interacting partners using the STRING protein interaction 
database381. Using the Markov clustering algorithm382, 3 functional clusters were 
identified: protein transport (green), transcription (yellow) and translation (red). 
Any biomarkers identified as playing roles within these 3 functional 
pathways were selected. Biomarkers involved in signalling pathways that were 
determined as inherently different between the MCF-7 parental and RR cell lines 
(described in chapter 4) were also considered as these could potentially be used as 
biomarkers to determine radiosensitivity; these included UPR, WNT and 
proliferation. This analysis identified 9 candidate biomarkers that either had excellent 
secretion profiles (GNPNAT1, YBX3), or played roles in translation (EIF3G, 
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EIF4EBP2, NAP1L4), proliferation (TK1), protein transport from the ER to the 
Golgi (SEC24C, VPS29) or WNT signalling (DKK1). 
Out of these 9 candidate biomarkers, 4 were selected for initial validation. 
These were EIF3G, TK1, SEC24C and YBX3. MCF-7 log2 secretion levels were 
calculated relative to untreated controls at each time point and for each radiation 
dose (Figure 5.8). The secretion of both TK1 and YBX3 increased 4-fold at 24 h with 
all doses of radiation, with no detected secretion at the earlier time points. Both 
EIF3G and SEC24C also had approximately a 4-fold increase in secretion by 24 h. 
EIF3G had an early secretion peak at 4 h post-radiation at higher doses (6-8 Gy) and 
increased secretion at 8 h with lower doses (2 and 4 Gy) which was maintained at 24 
h. SEC24C had reduced secretion at 8 h compared to the untreated controls prior to a 
dramatic increase by 24 h post-radiation. 
 
Figure 5.8. The 9 candidate biomarkers show increased secretion levels at all 
radiation doses at 24 h post-treatment. Graphs of log2 secretion levels of each of 
the candidate biomarkers relative to untreated controls at each time point and for 
each radiation dose. 
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5.2.6 Similarities in secretion patterns of the 4 biomarkers between 
ER- and ER+ cell lines were identified 
To specifically investigate the 4 candidate biomarkers in the different cancer 
types and species their secretion patterns at 8 and 24 h post-radiation were 
investigated using the secretomic data presented in Figure 5.6. These 4 biomarkers 
alone are shown in Figure 5.9. Whereas YBX3 was detected in all these cell lines, the 
other biomarkers were detected only in some of them (Figure 5.9a). In the MDA-
MB-231 cell line, except for YBX3, all biomarkers were found to have increased 
secretion above that of the untreated controls at all doses of radiation at 24 h and at 
the earlier time point of 8 h for SEC24C and TK1. Only EIF3G was found to have 
increased secretion in HBL-100 cells at 24 h with all doses of radiation. In the REM-
134 cell line only EIF3G and YBX3 were detected, both of which had increased 
secretion with 3 of the 5 radiation doses. In the JS7 cell line only YBX3 was 
detected, with increased secretion at 24 h with all doses of radiation. In total 14 
members of the EIF family were detected at 24 h in CM samples in the MCF-7, 
MDA-MB-231 and HBL-100 cell lines, several of which had higher secretion levels 
in radiation-treated samples compared to untreated controls. Investigation of SEC 
family members showed that only SEC24C had consistently higher secretion levels 




Figure 5.9. Similarities in secretion patterns of the 4 biomarkers at 24 h post-
radiation treatment were identified between ER- and ER+ cell lines. (a) Heatmap 
of log2 fold changes showing changes in secretion levels of each of the 4 candidate 
biomarkers compared to untreated controls in MDA-MB-231, HBL-100, REM-134 
and JS7 cell lines at 8 and 24 h for all radiation doses (yellow=higher secretion, 
black=no change, blue=lower secretion, n=1). (b) Heatmap of log2 fold changes 
showing secretion levels compared to untreated controls at 24 h for detected 
members of the EIF family (upper) and Sec23/24 family (lower) in MCF-7, MDA-
MB-231 and HBL-100 cell lines (red=higher secretion, white=no change, and 
green=lower secretion, n=1). Heatmap clustering was carried out using Pearson 
correlation with average linkage. 
5.2.7 Radioresistant cell lines have lower gene and intra-cellular 
protein expression of the 4 biomarkers 
To investigate the potential of the biomarkers for use as an indicator of 
radiosensitivity, parental and RR cell lines were used to assess differential expression 
of candidate biomarkers at gene and intra-cellular protein level. Although these 
results would not give an indication of secretion, increased gene expression levels 
may suggest higher amounts of intra-cellular protein, which may lead to increased 
secretion. As our secretomic results have shown that at least in the MCF-7 model the 
biomarkers all have increased secretion at 24 h post-radiation, we investigated 
whether gene changes could be detected up to 8 h post-exposure to 2 Gy. 
Analysis of gene expression data investigating the 33 secreted biomarkers 
from ER+ and ER- human breast cancer cell lines using both parental and their RR 
156 
 
derivatives identified higher YBX3, EIF3G, EIF4EBP2, TK1, DKK1 NAP1L4 and 
GNPNAT1 gene expression in the MCF-7 parental cell line compared with the MCF-
7 RR cell line; conversely the expression of SEC24C was the opposite with higher 
levels in the RR cells compared with the parental cells, VPS29 showed little change 
between the cell lines. These results showed that in total 7 of the 9 candidate 
biomarkers had higher gene expression levels in the parental cell line. Similar results 
were seen in the ZR-751 parental and RR cell lines, although higher gene expression 
levels for both SEC24C and DKK1 were seen in the RR cell line. Gene expression 
differences between the MDA-MB-231 parental and RR cell lines identified higher 
YBX3, EIF3G, EIF4EBP2, VPS29, DKK1 and GNPNAT1 expression in the MDA-
MB-231 parental cell line. Again, the expression of SEC24C as well as TK1 and 
NAP1L4 was the opposite with higher levels in the RR cells compared with the 
parental cell line. A single radiation dose of 2 Gy had little/no effect on gene 
expression at 2 and 8 h post-treatment in all cell lines (Figure 5.10). 
To compare basal intra-cellular protein expression levels of each of the 4 
biomarkers in parental and RR cell lines IF was performed using untreated MCF-7 
and MCF-7 RR cell lines grown in 2D monolayers. Higher expression levels for all 4 
biomarkers were identified in the parental cell line in comparison to the RR 
derivative (Figure 5.11). To investigate this result further, expression levels were 
also evaluated using MCF-7, ZR-751 and REM-134 parental and RR MTS (MDA-
MB-231 cells failed to form MTS that could withstand IHC processing). 
Experiments produced similar results to those seen using IF, with higher expression 
levels identified in the parental cell lines compared to the RR derivatives; the 
exception was for EIF3G in which the parental MCF-7 cell line had lower expression 




Figure 5.10. MCF-7 and ZR-751 show higher expression of genes encoding 7 of 
the 9 candidate biomarkers compared with their RR derivatives. Log2 mean-
centered gene expression heatmap showing differences in expression of the genes 
encoding the 33 candidate biomarkers in the human parental and RR breast cancer 
cell lines at 2 and 8 h post-2 Gy radiation treatment (red=higher expression, 
black=no change, green=lower expression, n=1). Heatmap clustering was carried out 




Figure 5.11. MCF-7 cells grown in 2D monolayers show higher intra-cellular 
expression of EIF3G, SEC24C, TK1 and YBX3 compared with its RR 
derivative. IF of the 4 candidate biomarkers in MCF-7 and MCF-7 RR cell lines. For 
each antibody immunofluorescence signal is detected at the expected cellular 
localisation region: the strongest signal for EIF3G, SEC24C, TK1 and YBX3 is seen 








Figure 5.12. MCF-7, ZR-751 and REM-134 MTS show higher intra-cellular expression of SEC24C, TK1 and YBX3 compared with 
their RR derivatives. IHC of the 4 candidate biomarkers in MCF-7, ZR-751 and REM-134 parental and RR cell lines. Positive DAB 
staining is seen for each antibody at the expected cellular localisation region: positive EIF3G, SEC24, TK1 and YBX3 staining is seen in 
the cytoplasm (representative images, n=3). 
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5.2.8 Differential secretion patterns of the candidate biomarkers 
occur between sensitive and radioresistant cell lines in 
multiple species in response to radiation 
To validate the secretomic results and to further investigate the potential use 
of these proteins as biomarkers of radiosensitivity, parental and RR cell lines were 
used in WB experiments. To achieve this, WB analysis was performed using CM 
samples to assess the secretion levels obtained from parental and RR cell lines 24 h 
after the cells had received a single radiation dose of 2 or 4 Gy. Unfortunately, due to 
time restraints and antibody availability only EIF3G, SEC24C and TK1 validation 
was performed. GAPDH was used with CM samples to assess for the presence of 
intra-cellular proteins that could be released into the CM from cell lysis; 2 µg of 
whole cell lysates were also run in parallel to CM samples to act as positive controls. 
Revert total protein stain (Li-COR Biotechnology, UK) was used to confirm equal 
loading of the samples. 
Secretion levels of SEC24C, EIF3G and TK1 were found to be significantly 
increased from MCF-7 cells treated with 2 Gy of radiation at 24 h compared to 24 h 
untreated controls. Biomarker levels in the CM from radiation-treated and untreated 
MCF-7 RR cells remained low (Figure 5.13). Similar results were found in ZR-751 
parental and RR cell lines with secretion levels of SEC24C and TK1 found to be 
significantly increased from ZR-751 cells treated with 2 or 4 Gy of radiation at 24 h 
compared to the 24 h untreated controls. A dose dependent effect was seen for TK1. 
Biomarker levels in CM from radiation-treated and untreated ZR-751 RR cells 
remained low. EIF3G was not detected in the CM from the ZR-751 or ZR-751 RR 




Figure 5.13. MCF-7 secretion levels of SEC24C, EIF3G and TK1 increase in 
response to radiation. WB analysis of candidate biomarkers in MCF-7 and MCF-7 
RR cell lines using CM samples obtained up to 24 h following exposure to a 2 Gy 
dose of radiation. NS is a non-specific band identified using the total protein stain 
used to confirm equal loading (two-way ANOVA with Holm-Šídák multiple 




Figure 5.14. ZR-751 secretion levels of SEC24C and TK1 increase in response to 
radiation. WB analysis of candidate biomarkers in ZR-751 and ZR-751 RR cell 
lines using CM samples obtained up to 24 h following exposure to a 2 or 4 Gy dose 
of radiation. NS is a non-specific band identified using the total protein stain used to 
confirm equal loading (two-way ANOVA with Holm-Šídák multiple comparisons 
test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001). 
Only SEC24C was detected in the CM of MDA-MB-231 and MDA-MB-231 
RR cell lines. Although SEC24C secretion in the MDA-MB-231 cell line did occur 
in response to 2 Gy of radiation at 24 h compared to the 24 h untreated controls, a 
much larger and statistically significant increase was seen in the MDA-MB-231 RR 





Figure 5.15. MDA-MB-231 RR secretion levels of SEC24C increase in response 
to radiation. WB analysis of candidate biomarkers in MDA-MB-231 and MDA-
MB-231 RR cell lines using CM samples obtained up to 24 h following exposure to a 
2 Gy dose of radiation. NS is a non-specific band identified using the total protein 
stain used to confirm equal loading (two-way ANOVA with Holm-Šídák multiple 
comparisons test; data expressed as mean ± SEM, n=3, *p≤0.05). 
Secretion levels of SEC24C and EIF3G were found to be significantly 
increased in the CM of REM-134 cells treated with 2 Gy of radiation at 24 h 
compared to the 24 h untreated controls. SEC24C and EIF3G levels in CM from 
radiation treated and untreated REM-134 RR cells remained low. TK1 was not 
detected in the CM from the REM-134 or REM-134 RR cell lines (Figure 5.16). 
SEC24C was detected at all time points and treatment groups in both the JS7 and JS7 
RR cell lines, however secretion levels were not altered with exposure to radiation. 
Although EIF3G secretion increased in both the JS7 and JS7 RR cell lines in 
response to 2 Gy of radiation at 24 h compared to the 24 h untreated controls, a 
larger and statistically significant increase was seen from the parental JS7 cells. TK1 
secretion was also increased in both the JS7 and JS7 RR cell lines in response to 2 
Gy of radiation, however these increases were not statistically significant (Figure 
5.17). A summary of all validation experiments for all cell lines is provided in Table 




Figure 5.16. REM-134 secretion levels of SEC24C and EIF3G increase in 
response to radiation. WB analysis of candidate biomarkers in REM-134 and REM-
134 RR cell lines using CM samples obtained up to 24 h following exposure to a 2 
Gy dose of radiation. NS is a non-specific band identified using the total protein stain 
used to confirm equal loading (two-way ANOVA with Holm-Šídák multiple 




Figure 5.17. JS7 secretion levels of EIF3G increase in response to radiation. WB 
analysis of candidate biomarkers in JS7 and JS7 RR cell lines using CM samples 
obtained up to 24 h following exposure to a 2 Gy dose of radiation. NS is a non-
specific band identified using the total protein stain used to confirm equal loading 
(two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as 
mean ± SEM, n=3, *p≤0.05).  
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Table 5.1. Summary of validation experiments in human breast cancer cell lines. 
The WB results show whether each biomarker had increased secretion (↑↑), low 
levels (-) or were not detected in the CM of cells 24 h following a 2 Gy dose of 
radiation. IF and IHC results show intra-cellular expression levels of each biomarker 
(results for WB, IF and IHC depict comparisons between each paired parental and 
RR cell line). 





SEC24C ↑↑ - ↑↑ - ↑ ↑↑ 
EIF3G ↑↑ - Not detected Not detected Not detected Not detected 
TK1 ↑↑ - ↑↑ - Not detected Not detected 
  
IF 
SEC24C ↑↑ Lower levels 
EIF3G ↑↑ Lower levels 
TK1 ↑↑ Lower levels 
YBX3 ↑↑ Lower levels 
  
IHC 
SEC24C ↑↑ Lower levels ↑↑ Lower levels 
EIF3G Lower levels ↑↑ ↑↑ Lower levels 
TK1 ↑↑ Lower levels ↑↑ Lower levels 
YBX3 ↑↑ Lower levels ↑↑ Lower levels 
Table 5.2. Summary of validation experiments in canine breast and ovine lung 
cancer cell lines. The WB results show whether each biomarker had increased 
secretion (↑↑), low levels (-) or were not detected in the CM of cells 24 h following a 
2 Gy dose of radiation. IF and IHC results show intra-cellular expression levels of 
each biomarker (results for WB, IF and IHC depict comparisons between each paired 
parental and RR cell line). 
 REM-134 REM-134 RR JS7 JS7 RR 
WB 
SEC24C ↑↑ - ↑↑ ↑↑ 
EIF3G ↑↑ - ↑↑ ↑ 
TK1 Not detected Not detected ↑ ↑ 
  
IHC 
SEC24C ↑↑ Lower levels 
EIF3G ↑↑ Lower levels 
TK1 ↑↑ Lower levels 
YBX3 ↑↑ Lower levels 
5.2.9 Increased expression of genes encoding EIF3G, SEC24, YBX3 
and those involved in ER stress and the UPR is seen in breast 
cancer tissue following radiotherapy treatment 
Characterisation of the ER+ parental and RR cell lines previously identified 
differential activation of UPR pathways, with MCF-7 RR and ZR-751 RR cell lines 
showing reduced PERK/EIF2α signalling in comparison to their parental cells 
(described in chapter 4). The UPR is involved in the suspension of translation 
168 
 
following endoplasmic reticulum stress and as we had identified translation 
components enriched in our candidate biomarkers, we sought to preliminarily 
investigate any potential relationship between the UPR and our candidate 
biomarkers. A publicly available data set (GSE59733) was analysed to investigate 
changes in gene expression that occur following RT. In that study, 9 patients with 
breast cancer who were at least 55 years old and diagnosed with invasive carcinomas 
received pre-operative partial breast RT of either 15, 18 or 21 Gy. Surgical resection 
was performed on patients within 10 days of treatment. As part of the study both pre- 
and post-radiation biopsy tumour samples were obtained and profiled using 
Affymetrix whole transcriptome expression analysis with HTA 2.0 arrays. For our 
analysis, expression of genes encoding the 4 candidate biomarkers and 6 genes 
involved with ER stress and the UPR were compared in patient samples taken before 
and after pre-operative RT. Hierarchical cluster analysis using the 4 candidate 
biomarkers produced 2 clear clusters, 1 enriched for pre-treatment and 1 enriched for 
post-treatment samples. The post-treatment cluster was characterised by higher 
expression levels of EIF3G, SEC24 and YBX3, and lower expression levels of TK1 
when compared to the pre-treatment cluster. Higher expression of genes involved in 





Figure 5.18. Increased expression of genes encoding EIF3G, SEC24 and YBX3 is 
seen in patient breast cancer tissue following RT. Log2 mean-centered gene 
expression heatmap showing differential expression of genes encoding the 4 
candidate biomarkers and 6 genes involved with ER stress and the UPR using a 
public gene expression dataset (GSE50811). Gene expression differences are shown 
from biopsy samples taken before and after pre-operative RT (red=higher expression, 
black=no change, green=lower expression). Heatmap clustering was carried out 
using Pearson correlation with average linkage. 
5.3 Discussion 
The cancer secretome is a potential source of biomarkers suitable for use not 
only in cancer diagnosis and prognosis but also as a monitoring tool to assess the 
response of a tumour to treatment. A major advantage of studying the secretome over 
the cellular proteome is that proteins secreted by tumour cells have the potential to be 
detected in the blood or locally through the implantation of a sensor into the tumour 
itself. This chapter describes the characterisation of the cancer secretome using 
untreated and radiation treated MCF-7 cells and the investigation of selected 
candidate biomarkers in various other cancer cell lines from multiple species. The 
aim was to identify biomarkers that were differentially secreted in response to 
radiation within 24 h of treatment. The incorporation of our novel RR cell lines into 
validation experiments also allowed the potential of the biomarkers to be used as 
indicators of radiosensitivity to be assessed. 
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Several secretomic studies have used CM from breast cancer cell lines as in 
vitro model systems. Most of these studies use non-tumourigenic and tumourigenic 
cell lines to investigate differentially secreted proteins related to malignancy; results 
from these studies have shown that secretomic analysis can identify biomarkers 
related to an aggressive phenotype or predict chemotherapeutic response. One study 
has investigated secreted biomarkers related to radiation sensitivity by analysing the 
secretome from various breast cancer cell lines 6 days after exposure to a single 
radiation dose of 10 Gy479. Comparison of the secretomes between untreated cells 
and those cells that survived radiation identified 17 differentially secreted proteins, 
including cyclophilin A (CyPA), which was subsequently validated by WB. Further 
investigation using untreated cell lines with varying radiosensitivities showed that 
CyPA cellular protein expression was consistent between the cell lines, however 
higher secretion levels were observed in the most radiosensitive cell lines, 
demonstrating that CyPA secretion, independent of intra-cellular protein levels, is 
related to intrinsic radiosensitivity; this led the authors to suggest that secretion 
levels of CyPA were regulated by post-translation mechanisms. This study provided 
evidence that protein secretion can be increased following radiation treatment and 
can relate to radiosensitivity; however, the study did not assess acute changes to the 
cancer secretome following radiation exposure. 
The first step in our experimental design was to obtain CM samples for LC-
MS. We chose the technique of using CM from cells grown in serum-free media 
(SFM). This protocol is simple and can increase the identification of secreted 
proteins as the presence of serum proteins can mask and dilute the cancer secretome 
and confound the identification of secreted proteins due to its high abundance or 
close sequence homology483. Although the effect that serum starvation has on cells is 
under debate484-487, studies have shown that under correct culture conditions cell 
death is minimised477,488 and that serum-free culture does not significantly affect the 
composition of secreted proteins489,490. In order to reduce cytosolic protein 
contamination from cell death, studies have suggested that optimal cell number and 
incubation times are required; SFM incubation up to 30 h with cell confluency under 
70% are considered optimal cell culture conditions to minimise cell lysis and the 
release of cytoplasmic proteins477,488. These culture conditions were adhered to in our 
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experiments. An extensive wash step was also performed prior to incubating cells in 
SFM to remove both cytosolic and serum proteins; this has been shown to reduce 
CM contamination by serum proteins and increase the number of secreted proteins 
identified, while not affecting cell growth or viability491. As secreted proteins present 
in the CM are usually at low concentrations they were concentrated before 
secretomic analysis. All CM samples underwent filtering and centrifugation to 
reduce contamination by dead cells and debris, with ultrafiltration performed to 
enrich and concentrate secreted proteins; this method has been successfully used in 
numerous studies492,493 despite the potential for column blockade with prolonged 
centrifugation periods and the loss of low molecular weight proteins488. In our 
experiments control samples were also included at each time point to account for the 
potential effects from serum starvation. Cell counts, using trypan blue, for each cell 
line following CM harvesting identified no significant differences in viable cell 
number between controls and samples treated with up to 10 Gy 24 h post-radiation. 
This method of assessing cell viability has been used in previous secretomic studies, 
the results of which are in accordance with our survival data, showing the absence of 
any significant cell death up to 24 h post 10 Gy radiation494. 
Initial analysis to identify MCF-7 radiation-induced secreted biomarkers 
involved the 24 h time point. As cancer patients typically receive daily radiation 
fractions, identification of biomarkers at this time point would be more applicable for 
use in the clinics; biomarker levels could in theory be measured just prior to daily 
treatment i.e. 24 h after a patient’s previous dose. Using only biomarkers whose 
levels dramatically rose at 24 h reduced the number of potential biomarkers from 765 
to 33. Subsequent investigation of the secretion levels of the 33 biomarkers at earlier 
time points identified that the majority had low secretion levels up to 8 h post-
radiation. Literature searches and cross referencing through Vesiclepaedia482 
identified that all 33 biomarkers have previously been shown to be secreted in 
microvesicles or exosomes by cancer cells. As our results had previously confirmed 
that the total number and percentage of dead cells did not change with radiation, and 
that the total number of unique secreted biomarkers also did not change with 
radiation, it is unlikely that the identified changes in the secretome up to 24 h post-
radiation was related to radiation-induced membrane damage and cell death. Instead, 
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it is more likely that these biomarkers are either actively secreted or secreted via 
microvesicles or exosomes, and that the rate of secretion may be increased by 
radiation treatment. Exosomes (30-150 nm) and microvesicles (100-1000 nm), 
together with apoptotic bodies (>1 µm), are collectively termed extra-cellular 
vesicles and are utilised by normal cells for the transmission of proteins, lipids, 
mRNAs, microRNA and DNA495,496. Cancer cells can also use these vesicles to 
communicate with other cancer and stromal cells through various cytokines and 
growth factors (VEGF, FGF, TGFβ), enabling then to modify the TME to sustain 
tumour progression, angiogenesis and promote metastasis497,498. Exosome markers 
and exosome-related proteins have been found in the cancer secretome and in the 
blood of patients; this exosome cargo is one explanation for the identification of 
nuclear, cytoplasmic and unconventional secreted biomarkers found in tumour 
secretomes499. Further investigations from our results would be to specifically isolate 
microvesicles and exosomes and validate the presence of our biomarkers within 
them; advantages of using the microvesicle/exosome proteome is that it is relatively 
stable in blood, making it suited for blood-based detection methods. 
Although all 33 biomarkers identified from the preliminary MCF-7 
characterisation could have been taken forward for validation based on their 
excellent secretion profiles, we wanted to reduce the numbers further; this was done 
first by investigating the secretion patterns in other cancer cell types from different 
species and then through functional analysis. A common set of biomarkers that are 
released from multiple cancer types and in different species that are sensitive to 
radiation would allow for wider applications of the biomarkers and would allow for 
large animal model validation and possible veterinary uses. Unfortunately, from the 
33 MCF-7 candidate biomarkers only a small number were identified as having 
similar secretion patterns in the other cell lines. Using the ER- human breast cancer 
cell lines (MDA-MB-231 and HBL-100) only EIF3G, SEC24C, CAP1 and VPS29 
shared similar secretion patterns with those found in the MCF-7 secretome. Even 
fewer similarities in secretion patterns compared with the MCF-7 secretome were 
seen using the canine breast cancer (REM-134; YBX3 and EIF3G) and ovine lung 
cancer (JS7; YBX3, VPS29 and FAM49B) cell lines. These results suggest that 
secretome patterns may be cell line and species specific which is supported by 
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previous studies that have identified specific secretomes related to aggressive 
phenotypes. Further investigation of this would require secretome characterisation of 
untreated and radiation treated samples to be performed from each individual cell 
line separately, with a subsequent analysis assessing for any biomarker similarities. 
Unfortunately, time restraints prevented this from being performed, but this analysis 
may in the future be a means of identifying common biomarkers across cell lines, or 
at least ones common to specific cancer subtypes i.e. ER- versus ER+. 
Final candidate biomarker selection was based on those with known roles in 
the 3 functional pathways identified through Markov clustering. Biomarkers were 
also selected if they were involved in signalling pathways previously determined as 
inherently different between the MCF-7 parental and RR cell lines (consisting of 
proliferation, UPR and WNT pathways). Incorporating these factors into the 
biomarker selection process could enable the identification of biomarkers that may 
provide an indication of radiosensitivity. This analysis identified 9 candidate 
biomarkers that either had excellent secretion profiles (GNPNAT1, YBX3) or had 
roles in translation (EIF3G, EIF4EBP2, NAP1L4), proliferation (TK1), protein 
transport from the ER to the Golgi (SEC24C, VPS29) or WNT signalling (DKK1). 
Following the selection of lead candidate biomarkers in-lab validation was 
conducted on 4 of the 9 biomarkers. Validation experiments aimed to confirm that 
biomarker secretion occurred in response to radiation and to assess whether 
differential secretion occurred between radiosensitive and radioresistant cell lines. 
This was achieved predominantly through WB experiments using CM samples and 
was supported through the investigation of gene and intra-cellular biomarker 
expression levels. All these validation experiments were performed using paired 
parental and RR cell lines which had been previously developed and characterised. A 
brief description of the function of the 4 biomarkers, highlighting their potential roles 
in cancer and secretion pathways, is discussed in the following sections. 
The eukaryotic translation initiation factor 3 (EIF3) complex plays an 
essential role in RNA transport and protein synthesis through its control of 
translation initiation500. Although essential for normal cellular functions, aberrant 
EIF3 subunit expression has been shown in several cancer types to be associated 
with proliferation, invasion, metastasis and prognosis501-505. Specifically, increased 
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EIF3G expression has been shown in vitro to enhance the ability of breast cancer 
cells to proliferate, migrate and invade, whist in vivo studies have shown increased 
expression to correlate with lymph node metastasis and drug resistance506. EIF3G has 
also been found to be secreted via extra-cellular vesicles in numerous cancer types507-
509, breast milk510 and mesenchymal stem cells511. Validation using CM samples 
identified increased EIF3G secretion levels in response to radiation at 24 h in MCF-
7, REM-134 and JS7 parental cell lines, whereas significantly lower or no secretion 
was observed in the RR cell lines. EIF3G gene expression was also higher in ER- and 
ER+ parental cell lines compared with RR derivatives, which was supported by IHC 
and IF results. Overall these results provided evidence that EIF3G is secreted in 
response to radiation, but only in radiosensitive cell lines, and that EIF3G gene 
expression and intra-cellular protein levels may be related to radiosensitivity. 
Protein transport from the endoplasmic reticulum to the Golgi apparatus is an 
essential component of the classical protein secretion pathway. Transport occurs 
through the production of Coat Protein Complex II (COPII) vesicles512, which are 
composed of 5 proteins (Sar1, Sec23, Sec24, Sec13 and Sec31) that assemble on the 
cytosolic face of the endoplasmic reticulum membrane513-515. Four isoforms of Sec24 
exist (A-D) which serve as cargo-binding adaptor molecules in COPII vesicles516-520. 
Cellular kinases may also play a role in post-translational modification of Sec24; 
AKT has been shown in vitro to phosphorylate Sec24C which can decrease its 
binding affinity with SEC23, thus reducing correct COPII formation and transport 
ability521. This may be an important finding, as our previous characterisation of the 
MCF-7 RR cell line identified increased AKT pathway activity. The effects of AKT 
inhibition on SEC24 could warrant further investigation. Increased SEC24C 
expression has been shown in colorectal cancer522 and has been found to be secreted 
via extra-cellular vesicles in numerous cancer types507,523-526, breast milk510 and 
mesenchymal stem cells511. Validation using CM samples identified increased 
SEC24C secretion levels in response to radiation at 24 h in MCF-7, ZR-751, MDA-
MB-231 and REM-134 parental cell lines, whereas significantly lower or no 
secretion was observed in the RR cell lines. The only exception was in the MDA-
MB-231 RR cell line, which showed a significant increase in secretion levels. 
SEC24C gene expression was lower in ER- and ER+ parental cell lines compared 
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with RR derivatives, although this result was not supported by IHC and IF results, 
which identified higher expression in the parental cell lines. Overall, these results 
provided evidence that SEC24C is secreted in response to radiation, but secretion 
may only provide evidence of radiosensitivity in ER+ cell lines. Differences between 
SEC24C gene expression and intra-cellular protein levels would require further 
investigation to determine if levels could relate to radiosensitivity. 
Y-box binding protein 3 (YBX3) has been shown to act as a transcription 
factor, regulating translation527 and influencing processes such as differentiation, 
proliferation and survival528. YBX3 overexpression and nuclear localisation has been 
correlated with poor prognosis in hepatocarcinomas529-531 and is involved with the 
pathogenesis of gastric cancer through increased invasion and chemoresistance532. 
YBX3 has also been found to be secreted via extra-cellular vesicles in numerous 
cancer types507,533,534 and mesenchymal stem cells535. Unfortunately, time restraints 
did not allow for validation using CM samples; however, YBX3 gene expression was 
higher in ER- and ER+ parental cell lines compared with RR derivatives, which was 
supported by IHC and IF results. Overall these results provided evidence that YBX3 
gene expression and intra-cellular protein levels may be related to radiosensitivity. 
TK1 is a cell cycle regulator536 which catalyses the addition of a gamma-
phosphate group to thymidine creating thymidine monophosphate, which is the first 
step in the synthesis of deoxythymidine triphosphate and DNA replication537. Intra-
cellular TK1 levels vary depending on the stage of the cell cycle, with low 
concentrations in the G1 phase and higher levels in S/G2 phases. A dramatic fall in 
concentration is seen in the M-phase as a result of degradation pathways538. 
Increased TK1 expression has been identified in breast tumours and has been shown 
to correlate with disease stage and grade539. TK1 has also been found to be secreted 
via extra-cellular vesicles in numerous cancer types507,526,533,534. Serum TK1 has 
shown promise as a biomarker of proliferation540 with diagnostic and prognostic 
potential in numerous cancer types536,541. Serum TK1 has also been investigated for 
monitoring the response of breast cancer patients to treatment542 and for predicting 
the risk of developing distant and/or regional recurrence post-surgery543. Validation 
using CM samples identified increased TK1 secretion levels in response to radiation 
at 24 h in MCF-7 and ZR-751 parental cell lines, whereas significantly lower or no 
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secretion was observed in the RR cell lines. Increased secretion levels were seen in 
both JS7 and JS7 RR cell lines. TK1 gene expression was also higher in the ER+ 
parental cell lines compared with RR derivatives, which was supported by IHC and 
IF results. Gene expression in the ER- MDA-MB-231 parental and RR cell lines 
identified higher expression in the RR derivatives. Overall, these results provided 
evidence that TK1 is secreted in response to radiation but may only provide evidence 
of radiosensitivity (based on gene analysis) in ER+ cell lines. 
Currently only 4 of the 9 lead biomarkers have undergone preliminary 
validation and further work will be needed to investigate the remaining candidates. 
Gene analysis of the REM-134 and JS7 parental and RR cell lines has also not yet 
been completed; performing this analysis would provide further information of the 
ability of these biomarkers to be used for predicting radiosensitivity. Another area of 
future research would involve investigating the mechanisms of biomarker secretion 
and what roles their secretion plays in terms of radiation response. One speculative 
mechanistic theory for biomarker secretion that incorporates both protein transport 
and translation would involve the UPR. From our previous characterisation of the 
ER+ parental and RR cell lines we know that there is differential activation in UPR 
pathways. MCF-7 RR and ZR-751 RR cell lines seemingly lose PERK/EIF2α 
signalling as opposed to parental cells which show higher expression of total and p-
PERK and EIF2α at both gene and protein level. If parental radiosensitive cells block 
translation in response to radiation, then this could perhaps lead to a build-up of 
complexes required for translation initiation (EIF3G, EIF4EBP2, NAP1L4) and 
protein transport from the endoplasmic reticulum to the Golgi (SEC24C, VPS29) 
within the cytoplasm. While translation is inhibited these biomarkers are no longer 
required by the cell and so may be preferentially secreted. Although currently there is 
no direct evidence to support this theory, investigation of UPR associated genes and 
genes encoding the 4 biomarkers using a publicly available data set (GSE59733) 
provided preliminary evidence that radiation can increase the expression of UPR 
response genes and genes encoding EIF3G, SEC24C and YBX3. These results 
identified a gene signature similar to that seen in MCF-7 and ZR-751 parental cell 
lines as opposed to their RR derivatives. Further work investigating the UPR would 
177 
 
help to investigate the mechanisms of radioresistance and assess its potential role in 
radiation-induced secreted biomarkers. 
5.4 Conclusion 
This chapter has described the preliminary development of an in vitro 
secretomic experiment using CM from cancer cells with the aim of detecting and 
validating radiation-induced acutely secreted biomarkers. To our knowledge, this is 
the first description of secretomic experiments being used to identify radiation-
induced secreted biomarkers which are released within 24 h of treatment, the results 
of which were validated using novel RR cell lines. By using these paired parental 
and RR cell lines we have shown that biomarkers can be released in response to 
radiation and that differential biomarker secretion profiles can indicate the 
radiosensitivity of a cancer cell. Furthermore, investigation of differential gene 
expression and intra-cellular protein levels of the candidate biomarkers also provided 
an indication of radiosensitivity. In clinical terms, the identification of a panel of 
biomarkers whose gene expression signature or intra-cellular expression levels 
predict the likelihood of a tumour responding to RT could be combined with 
measuring on-treatment secreted levels of the same biomarkers; this may provide a 
means by which the response of a tumour could both be predicted and also 
continually assessed. The use of biomarkers for both predicting and monitoring the 
response to treatment would provide a potential way in which RT could become 






6 Biocompatibility Assessment of Common 
Implantable Sensor Materials in a Tumour 
Xenograft Model 
This results chapter is an expanded version of a published research article: Gray 
M, Meehan J, Blair EO, Ward C, Langdon SP, Morrison L, Marland JRK, Tsiamis 
A, Kunkler IH, Murray A, Argyle D. Biocompatibility of common implantable 
sensor materials in a tumour xenograft model. Journal of Biomedical Materials 
Research Part B: Applied Biomaterials 2018; 1-14. This article is open access with 
the authors retaining copyright to their work with permission to use published figures 
in this thesis. Sections of text and figures used from this article have been referenced 
accordingly. 
6.1 Abstract 
Background: Interest in the use of implantable devices for a wide range of medical 
conditions is increasing. Unfortunately, following implantation within the body these 
devices can lose functionality due to biofouling caused by the foreign body response 
(FBR). To accurately assess the FBR induced by an implanted medical device then 
biocompatibility evaluation should be performed within tissues where implantation is 
intended; sensors designed for implantation into solid tumours should be evaluated 
within a tumour microenvironment. Methods: A novel serial sacrifice murine 
xenograft model was developed to evaluate the potential of 6 biomaterials, used in 
the construction of the IMPACT O2 sensor (silicon dioxide, silicon nitride, Parylene-
C, Nafion, biocompatible EPOTEK epoxy resin and platinum), to trigger a FBR 
when implanted into human breast cancer xenograft tumours. Novel protocols were 
developed to process, and section harvested tumours that allowed identification of 
the implant site. Results: No detrimental effects from implantation of any of the 
biomaterials on mice body weight or on tumour growth were identified. 
Immunohistochemistry showed no significant changes in tumour necrosis, hypoxic 
cell number, proliferation, apoptosis, immune cell infiltration or collagen deposition. 
Conclusions: The lack of biofouling from the implantation of these biomaterials 
within a solid tumour supports their use in implantable medical devices. To our 
knowledge, this is the first documented investigation of the effects of modern 
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biomaterials used in the production of implantable sensors within a tumour 
microenvironment. 
6.2 Introduction 
Interest in the development and use of implantable medical devices has 
increased in recent years due to advances in microfabrication techniques and through 
the development of novel biocompatible materials. As precision medicine becomes 
integrated into healthcare practices, the roles of implantable medical devices as 
diagnostic, therapeutic and monitoring aids will likely become more important in 
achieving better patient outcomes in a variety of disease conditions. Major 
challenges in the development of any implantable medical device include the 
activation of tissue and immune responses that occur post-implantation. These 
reactions can contribute to device failure or host toxicity and are largely attributed to 
biofouling and the FBR165-167. The extent of these processes can be influenced by the 
implantation procedure itself as well as the biocompatibility of the device. 
Although in vitro tests as outlined in the Biological Evaluation of Medical 
Devices: ISO 10993161 are excellent screening processes, in vivo animal models are 
required to evaluate tissue reactions, the results of which can influence the selection 
of materials used in the development of implantable medical devices. In vivo models 
provide a means by which the FBR can be evaluated in a situation similar to that 
which would occur following implantation into patients. Obtaining tissue or fluid 
exudates adjacent to the implanted material allows assessment of cellular interactions 
which occur in the presence of stromal and immune cells; these factors greatly 
increase the complexity of in vivo models compared with in vitro testing systems544. 
The cage implant system involves placing candidate materials into stainless-
steel cages which are then subcutaneously implanted into an animal. Tissue exudates 
can be collected from the cage and examined for inflammatory cells, enzymes, 
fibrous encapsulation and infection545. Although no tissue is obtained from this 
model, it allows for serial exudate samples to be obtained without animal sacrifice. 
Serial sacrifice models, such as the chamber system, allow for tissue harvesting for 
histological evaluation of the inflammatory response, fibrous encapsulation and 
vascularisation. This system utilises a lightweight aluminium or titanium frame 
fastened to 2 skin folds on the back of a rat or hamster. Candidate materials can then 
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be implanted into the skin fold. Real-time visualisation can also be achieved with this 
model by removing a skin section and replacing it with glass546,547. The 
chorioallantoic membrane (CAM) of a developing chick embryo is a simple and 
cost-effective method of observing tissue responses to materials. Acute and chronic 
inflammatory responses have been shown to be elicited in a manner similar to that in 
other animal models. Materials coated in ovalbumin or egg white are placed on top 
of the CAM, which can become incorporated into it within 7 days. Visualisation of 
the material is also possible due to the transparent nature of the CAM548,549. 
These models have all been used to evaluate medical devices designed for 
implantation into normal healthy tissues. However, it has been suggested that 
biocompatibility is a characteristic of a system rather than of a material and that 
individual materials may affect different biological systems in different ways. 
Therefore, materials should undergo biocompatibility testing in the tissue they are 
designed to be implanted into166,544,550,551. This is an important consideration for the 
IMPACT sensor, designed for implantation into solid tumours, or any device 
developed for intra or peri-tumoural implantation. For these devices, the FBR must 
be evaluated within the diseased tissues, rather than relying on published data from 
implantation studies within healthy tissues. The in vitro and in vivo biocompatibility 
of the constituent materials used in the construction of the IMPACT sensor has been 
previously documented. Various in vivo studies have shown that the materials are 
well tolerated and induce only a minimal FBR. Some of the materials have gained 
ISO 10993 accreditation, while all have been used in the construction of a variety of 
medical devices (Table 6.1). However, all these biocompatibility studies used in vivo 
models in which the materials were implanted into healthy, non-diseased tissue; their 
effects within a tumour have never been evaluated. 
This chapter describes the assessment of the intra-tumoural biocompatibility 
of 6 modern biomaterials that were under consideration for use in the IMPACT 
sensor. The biomaterials investigated were silicon nitride, silicon dioxide, platinum, 
Parylene-C, biocompatible EPOTEK epoxy resin and Nafion. Copper was chosen as 
a positive control implantation material due to its recognised previously published 
cytotoxic effects552,553. Through the development of a novel serial sacrifice murine 
model, biomaterials were implanted into human breast cancer xenograft tumours and 
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their biocompatibility assessed up to 14 days post-implantation. Novel protocols 
were developed to process, and section harvested tumours that allowed identification 
of the implant site. The effects of the biomaterials were investigated through changes 
in mean tumour volumes and mouse body weights, while histopathology was used to 
assess proliferation, apoptosis, hypoxia and necrosis, as well as innate immune 
responses and collagen deposition occurring within the tumour. To our knowledge, 
this is the first description of the interaction of modern biomaterials, used in the 
fabrication of implantable devices within a TME. 
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Table 6.1. Previously published studies investigating the in vivo and in vitro biocompatibility testing of IMPACT component 
biomaterials. (taken from551). 
Biomaterial In vitro testing In vivo testing Implantable devices Regulations 
Parylene-C Haemocompatibility testing554 
Cell culture biocompatibility555-557 
Cytotoxicity, hemocompatibility 
testing161 
Systemic toxicity, sensitisation, intracutaneous 
reactivity testing161 
Neural electrodes biocompatibility: mice556,558, 




Platinum Cell culture biocompatibility566  Arterial stents567,568 
Embolization coils569,570 
Pacemaker leads, implantable 







Non-toxic, encourage cell adhesion 
and cellular differentiation573-577 
Systemic toxicity, sensitisation and 
intramuscular reactivity testing161,578 
Fracture repair and evaluation of 
osteoconduction573,576,579-581 
Cage implant biocompatibility testing582,583 







Biocompatibility and antibacterial 
testing577,587 
Intramuscular reactivity testing161,578 
Nerve electrodes biocompatibility: rat588 
Cage implant biocompatibility testing582 
Nanomedicine drug delivery systems 
and diagnostic probes589,590 
ISO 10993578 
Nafion Biocompatibility and antibacterial 
testing591 
Non-cytotoxic and allows cellular 
differentiation592 
Subcutaneous, intraperitoneal and intravenous 
biocompatibility: mice591,593, dogs594 
Intracerebral biocompatibility145,595-597 
Nervous system biocompatibility592 








Systemic toxicity, sensitisation, intracutaneous 
and intramuscular reactivity testing161 
 
Pacemakers, ophthalmic and 
neurostimulators, insulin pumps, 






6.3.1 Development of a percutaneous biomaterial implantation 
technique 
To develop a technique whereby biomaterials could be safely, reliably and 
quickly implanted into a xenograft tumour, we began to investigate protocols using 
ex-vivo MDA-MB-231 xenograft tumours. A 21G needle was introduced through the 
skin overlying the tumour but not into the tumour tissue itself. The needle was 
withdrawn, noting its skin entry position and any blood seeping from the wound. 
Using needle holders, a length of Cu wire (400 µm in diameter and approximately 7 
mm in length) was introduced through the needle-created insertion hole and 
advanced into tumour tissue until the wire was completely buried under the skin 
(Figure 6.1). Tumours containing the implanted wires then underwent fixing in 
formalin, processing and edge embedding in paraffin for IHC. 
 
Figure 6.1. Photographs of ex-vivo MDA-MB-231 xenograft tumours used in the 
development of a biomaterial implantation protocol. (a) Dorsal aspect of MDA-
MB-231 xenograft tumour, a 1 cm Cu wire is shown for implantation. (b) Ventral 
aspect of MDA-MB-231 xenograft tumour. (c) A 21G needle was introduced through 
the skin overlying the tumour. (d) A length of Cu wire was then introduced into the 
tumour through the insertion hole created by the needle. 
6.3.2 Development of an IHC sectioning protocol for xenograft 
tumours containing implanted biomaterials 
Blocks of paraffin-embedded xenograft tumours were sectioned until the tip 
of the implanted wire was reached. If the wire was flush with the cut surface of the 
block it was removed, and sectioning continued through the implant site. However, if 
the trajectory of the wire was directed further into the tumour, sectioning stopped, 
and the paraffin was melted. The tumour was then trimmed from its sectioned edge 
as parallel as possible to the path of the wire. The wire was then carefully removed 
before re-embedding the tumour in paraffin. Once cooled and set, sectioning 





Figure 6.2. Photographs depicting the position of an implanted biomaterial 
within a xenograft tumour following harvesting and processing for IHC. The 
dashed box is outlining an OG116-31 resin wire. (a) Lateral and (b) Dorsal views 
showing the biomaterial positioned centrally within the tumour; photographs were 
taken following tumour processing but before paraffin embedding. (c) Following 
edge embedding in paraffin, the tumour was sectioned until the biomaterial was 
identified. The wire was then removed, and sectioning continued through the 
implantation site. 
 
Figure 6.3. Histological appearance of xenograft tumour sections containing the 
biomaterial implantation site. These H&E stained sections are from 2 xenograft 
tumours used for development of the sectioning protocol. The implant site can be 
clearly identified centrally positioned within the tumour. 
6.3.3 Refined procedure for biomaterial implantation into xenograft 
tumours 
Following development of the implantation procedure using ex vivo xenograft 
tumours we progressed onto experimental cases. All biomaterials were implanted 
under general anaesthesia using the same percutaneous technique. MDA-MB-231 
human xenograft tumours were generated subcutaneously in CD-1 female nude mice 
as described in sections 3.2.2 & 3.2.3. Once tumours had developed to an adequate 
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size (0.7-1.2 mm) mice were randomly assigned into treatment or control groups. 
Treatment groups consisted of tumours implanted with a single biomaterial, whereas 
control groups consisted of untreated tumours and those that received a needle tract 
(NT) injury to mimic the implantation procedure. The generation of bilateral 
subcutaneous flank xenograft tumours enabled each mouse to act as its own control. 
This reduced the total number of mice required as 1 tumour received biomaterial 
implantation or NT injury whilst the contralateral tumour remained untreated. 
All mice underwent general anaesthesia as described in section 3.2.4 (defined 
as day 0). Mice were positioned in dorsal recumbency and the skin immediately 
surrounding the xenograft tumour was aseptically prepared for surgery using 
chlorohexidine solution. The biomaterials were implanted using a percutaneous 
technique based on the developed protocol described in section 6.3.1. A 21G needle 
was used to penetrate the skin overlying the tumour but not into the tumour 
parenchyma itself. This entry point was positioned at the caudal aspect of the 
tumour, so introduction of the biomaterial would be along the long axis. The needle 
was removed, and a single biomaterial wire was then introduced into the tumour 
through the pre-made entry point and advanced until the entire length of the wire was 
within tumour tissue. Tissue adhesive (Vetbond, 3M, Bracknell, UK) was then 
applied to the skin (Figure 6.4). For NT injury control tumours, a 21G needle was 
used to penetrate the skin as previously described but was then advanced into the 
tumour tissue, stopping just short of penetrating the contralateral side of the tumour. 
The needle was removed, and tissue adhesive was applied to the skin (Figure 6.5). 
Following surgery all mice were placed into an incubator at 30-35oC until recovered. 
Anaesthetic duration, including induction and maintenance, aseptic skin preparation, 
implantation/NT injury and recovery lasted approximately 5 min. No anaesthetic 




Figure 6.4. Intra-operative photographs depicting percutaneous biomaterial 
implantation. (a) Under general anaesthesia mice were placed in dorsal recumbency 
and the skin surrounding the tumour was aseptically prepared. (b) A 21G needle was 
used to make an entry point in the skin overlying the tumour. (c) An appropriately 
sized length of biomaterial was chosen for each tumour. (d) Needle holders were 
used to introduce the biomaterial into the tumour through the pre-prepared hole. 
 
Figure 6.5. Intra-operative photograph depicting needle tract injury. A 21G 
needle was introduced through the skin overlying the tumour and into the tumour 
parenchyma itself. The needle was advanced as far as possible through the tumour to 
ensure the creation of a long NT. The needle stopped short of penetrating the 
contralateral side of the tumour. 
Day 0 mice were euthanised immediately following anaesthesia, whilst the 
remaining mice were monitored up to 14 days post-implantation. All mice were 
assessed for signs of ill health with body condition score, body weight and tumour 
size measured 3 times a week. Relative mouse body weight was calculated by 
dividing the body weight measured on each day by the weight on day 0. Tumour size 
(width and length) was measured using Vernier callipers and tumour volume was 
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calculated as π/6 x width2 x length. Relative tumour volume was calculated by 
dividing the tumour volume on each day by its volume on day 0. Immediately 
following euthanasia, xenograft tumours were removed and fixed in formalin for 
subsequent processing and edge embedding in paraffin for IHC. 
6.3.4 The percutaneous implantation procedure resulted in a high 
success rate of biomaterial delivery into xenograft tumours 
The mean body weight of each mouse group at day 0 was similar, averaging 
26.76  ± 1.2 g. The developed percutaneous implantation procedure resulted in a high 
success rate of delivering biomaterial wires to the centre of the xenograft tumours. 
Out of 47 implantations, following harvesting 1 wire was found to have migrated 
from within the tumour to lie in subcutaneous fat and 1 was found to be peripherally 
located within the tumour during sectioning; the remainder were all well positioned 
within central tumour tissue. The method for sectioning biomaterial-containing 
tumours was also highly successful, with all implant sites identified and every 
implanted wire successfully recovered (Figure 6.6 & Figure 6.7). The number of 
mice used in each control and treatment group is provided in Figure 6.8 & Figure 
6.9. 
 
Figure 6.6. Representative H&E stained sections from untreated tumours 
harvested at day 7. 
 
Figure 6.7. Representative H&E stained sections from biomaterial implanted 
tumours harvested at day 7 post-implantation. (a) Nafion implanted. (b) SiO2 
implanted. (c) Pt implanted. 
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6.3.5 Implanted biomaterials have no effect on mouse body weights 
and tumour volumes 
Body weights of biomaterial (Si3N4, SiO2, Parylene-C, Nafion, Pt and 
OG116-31 resin) implanted and untreated mice remained stable throughout the 7-day 
experimental period, with no statistically significant changes in body weight 
identified within any individual treatment group (Figure 6.8). The body weights of 
mice whose xenograft tumours were implanted with Cu also remained stable. 
Furthermore, no statistically significant differences were identified between any of 
the groups measured at each time point. Mean tumour volumes for untreated, NT 
injury and all biomaterial implanted and Cu implanted tumours, all showed growth 
over the 7 days, with no statistically significant differences identified between any 
group at any time point (Figure 6.8). Similar results were found when Parylene-C 
was implanted for 14 days; body weights remained stable with no statistically 
significant changes in body weight observed between implanted and control tumours. 
Although at day 7 the mean tumour volume of NT injury tumours was statistically 
lower compared to the untreated control group (p= 0.0211) their volumes increased 
on subsequent days with differences between the groups becoming non-significant. 
Tumour volumes for Parylene-C implanted tumours showed no statistical differences 
between untreated and NT injury tumours at any of the time points up to 14 days 




Figure 6.8. Biomaterials have no effect on mice body weights or xenograft 
tumour growth up to 7 days post-implantation. (a&b) Mice body weights for 
untreated tumours and Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and SiO2 
implanted tumours. Body weights are normalised to the day 0 measurement. (c&d) 
Mean tumour volumes for untreated and NT injury tumours, along with Cu, OG116-
31 resin, Parylene-C, Nafion, Pt, Si3N4 and SiO2 implanted tumours. Tumour 
volumes are normalised to the day 0 measurement. Number of mice in each control 




Figure 6.9. Parylene-C has no effect on mice body weights or xenograft tumour 
growth up to 14 days post-implantation. (a) Mice body weights for untreated 
tumours and Parylene-C implanted tumours. Body weights are normalised to the day 
0 measurement. (b) Mean tumour volumes for untreated and NT injury tumours, 
along with Parylene-C implanted tumours. Tumour volumes are normalised to the 
day 0 measurement. Number of mice in each control and treatment group is provided 
in each figure legend (two-way ANOVA with Holm-Šídák multiple comparisons 
test; data expressed as mean ± SEM, *p≤0.05). 
6.3.6 Implanted biomaterials have no effect on tumour necrosis and 
CA9 staining 
The area of tumour necrosis was calculated as a percentage of the total 
xenograft tumour area. At 7 days post-implantation xenograft tumours implanted 
with Cu wires showed a statistically significant increase in the percentage area of 
necrosis compared to NT injury (p= 0.0288) and untreated (p= 0.0141) control 
groups. No significant differences in the area of necrosis were identified between 
biomaterial implanted xenograft tumours and the control tumours, including 
Parylene-C up to 14 days post-implantation (Figure 6.10 & Figure 6.11). As a 
hypoxic marker, CA9 expression was investigated to identify the number of hypoxic 
cancer cells in each xenograft tumour. No significant differences in the percentage of 
CA9 positive cells were identified between any of the biomaterial implanted, Cu 
implanted and control tumours up to 7 days post-implantation (Figure 6.12). CA9 
staining was not undertaken in Parylene-C implanted tumours up to 14 days due to 




Figure 6.10. Biomaterials have no effect on the percentage area of tumour 
necrosis up to 7 days post-implantation. (ai&aii) Representative H&E stained 
sections from tumours harvested at day 7. (ai) Untreated. (aii) Cu implanted. 
(bi&bii) Percentage area of necrosis for untreated and NT injury tumours, along with 
Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and SiO2 implanted tumours 
(one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as 




Figure 6.11. Parylene-C has no effect on the percentage area of tumour necrosis 
up to 14 days post-implantation. Percentage area of necrosis for untreated and NT 
injury tumours, along with Parylene-C implanted tumours. 
 
Figure 6.12. Biomaterials have no effect on xenograft cancer cell CA9 staining 
up to 7 days post-implantation. (ai&aii) Representative CA9 stained sections from 
tumours harvested at day 7. (ai) Untreated. (aii) Nafion implanted. (bi&bii) 
Percentage of CA9 positive staining cells for untreated and NT injury xenograft 




6.3.7 Implanted biomaterials have no effect on xenograft cancer cell 
proliferation and apoptosis 
As a marker of cells present in active phases of the cell cycle (G1, S, G2) and 
mitosis, Ki67 expression was investigated to identify the number of proliferating 
cancer cells in each xenograft tumour. No significant difference in the percentage of 
Ki67 positive staining cells was identified between any of the biomaterial implanted, 
Cu implanted and control tumours up to 7 days post-implantation. (Figure 6.13). 
When Parylene-C implantation was investigated up to 14 days a statistically 
significant higher percentage of Ki67 positive staining cells was identified in the 
Parylene-C implanted xenograft tumours compared with NT injury tumours at 2 days 
post-implantation (p= 0.0037). The numbers of Ki67 positive staining cells increased 
in the NT injury control group on subsequent days with differences between the 
groups becoming non-significant (Figure 6.15). As a marker of cells activating death 
proteases, cleaved caspase 3 expression was investigated to identify the number of 
apoptotic cancer cells in each xenograft tumour. Only Cu implanted xenograft 
tumours had a statistically significant increase in the percentage of cleaved caspase 3 
positive staining cells compared to untreated (p= 0.0025) and NT (p= 0.0020) control 
groups at 7 days post-implantation (Figure 6.14). Parylene-C implanted tumours 
showed no statistical differences in the percentage of caspase 3 positive staining cells 
between untreated and NT injury tumours at any of the time points up to 14 days 




Figure 6.13. Biomaterials have no effect on xenograft cancer cell proliferation 
up to 7 days post-implantation. (ai&aii) Representative Ki67 stained sections from 
tumours harvested at day 7. (ai) Untreated. (aii) SiO2 implanted. (bi&bii) Percentage 
of Ki67 positive staining cells for untreated and NT injury tumours, along with Cu, 




Figure 6.14. Biomaterials have no effect on xenograft cancer cell apoptosis up to 
7 days post-implantation. (ai&aii) Representative caspase 3 stained sections from 
tumours harvested at day 7. (ai) Untreated. (aii) Cu implanted. (bi&bii) Percentage 
of caspase 3 positive staining cells for untreated and NT injury tumours, along with 
Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and SiO2 implanted tumours 
(one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as 




Figure 6.15. Parylene-C has no effect on xenograft cancer cell proliferation and 
apoptosis up to 14 days post-implantation. (a) Percentage of Ki67 positive staining 
cells for untreated and NT injury tumours, along with Parylene-C implanted tumours. 
(b) Percentage of caspase 3 positive staining cells for untreated and NT injury 
tumours, along with Parylene-C implanted tumours (two-way ANOVA with Holm-
Šídák multiple comparisons test; data expressed as mean ± SEM, **p≤0.01). 
6.3.8 Implanted biomaterials have no effect on neutrophil and 
macrophage infiltration within xenograft tumours 
Using Ly6G, a glycosylphosphatidylinositol-anchored protein and the 
glycoprotein F4/80, cellular expression levels of each target was investigated to 
identify the number of murine neutrophils and macrophages within each xenograft 
tumour. No significant differences in the percentage of Ly6G or F4/80 positive 
staining cells were identified between any of the biomaterial implanted, Cu 
implanted and control tumours up to 7 days post-implantation or up to 14 days with 
Parylene-C implantation. Only small numbers of Ly6G positive cells were identified 
in any of the tumours (Figure 6.16, Figure 6.17 & Figure 6.18). Two types of 
macrophage distribution patterns were identified in implanted and control tumours. 
In approximately 50% of tumours, a localised region of F4/80 positive stained cells 
was identified round the periphery of the tumour, whereas the remaining tumours 




Figure 6.16. Biomaterials have no effect on neutrophil infiltration within 
tumour tissue up to 7 days post-implantation. (ai&aii) Representative Ly6G 
stained sections from tumours harvested at day 7. (ai) Untreated. (aii) Parylene-C 
implanted. (bi&bii) Percentage of Ly6G positive staining cells for untreated and NT 
injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and 




Figure 6.17. Biomaterials have no effect on macrophage infiltration within 
tumour tissue up to 7 days post-implantation. (ai&aii) Representative F4/80 
stained sections from tumours harvested at day 7. (ai) Untreated. (aii) Si3N4 
implanted. (bi&bii) Percentage of F4/80 positive staining cells for untreated and NT 
injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and 




Figure 6.18. Parylene-C has no effect on neutrophil and macrophage infiltration 
within tumour tissue up to 14 days post-implantation. (a) Percentage of Ly6G 
positive staining cells for untreated and NT injury tumours, along with Parylene-C 
implanted tumours. (b) Percentage of F4/80 staining cells for untreated and NT 
injury tumours, along with Parylene-C implanted tumours. 
 
Figure 6.19. Macrophage distribution patterns within untreated xenograft 
tumours. (a) Macrophages are identified both at the periphery of the tumour and 




6.3.9 Implanted biomaterials have no effect on fibroblast 
infiltration and collagen deposition within xenograft tumours 
Using ER-TR7, an antigen expressed in the cytoplasm of fibroblasts, cellular 
expression levels were investigated to identify the number of murine fibroblasts 
within each xenograft tumour. Compared to untreated tumours at day 0, there was a 
significantly higher percentage of ER-TR7 positive staining cells in both untreated 
(p= 0.0073) and NT injury tumours (p= 0.0445) at day 7. However, no significant 
differences in the percentage of ER-TR7 positive staining cells were identified 
between any of the biomaterial implanted, Cu implanted tumours and control 
tumours at 7 days post-implantation (Figure 6.20) or up to 14 days with Parylene-C 
implantation (Figure 6.22). Untreated tumours at 7 days post-implantation had a 
statistically significant higher percentage area of collagen compared to untreated 
tumours at day 0 (p= 0.0086) (Figure 6.21). However, no significant differences in 
the percentage area of collagen were identified between any of the biomaterial 
implanted and control tumours at 7 days post-implantation. Cu implanted tumours, 
on the other hand, did have a statistically significant increase in collagen compared 
to untreated (p= 0.0217) and NT (p= 0.0314) control groups at day 7 post-
implantation (Figure 6.21). Although a trend for an increase in the percentage area of 
collagen was noted over the 14-day period for Parylene-C implantation, this was not 




Figure 6.20. Biomaterials have no effect on fibroblast infiltration within 
xenograft tumour tissue up to 7 days post-implantation. (ai&aii) Representative 
ER-TR7 stained sections from tumours harvested at day 7. (ai) Untreated. (aii) Pt 
implanted. (bi&bii) Percentage of ER-TR7 positive staining cells for untreated and 
NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 
and SiO2 implanted tumours (one-way ANOVA with Holm-Šídák multiple 




Figure 6.21. Biomaterials have no effect on collagen deposition within xenograft 
tumour tissue up to 7 days post-implantation. (ai&aii) Representative Masson’s 
trichrome stained sections from tumours harvested at day 7. (ai) Untreated. (aii) SiO2 
implanted. (bi&bii) Percentage area of collagen for untreated and NT injury 
tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and SiO2 
implanted tumours (one-way ANOVA with Holm-Šídák multiple comparisons test; 




Figure 6.22. Parylene-C has no effect on fibroblast infiltration and collagen 
deposition within tumour tissue up to 14 days post-implantation. (a) Percentage 
of ER-TR7 positive staining cells for untreated and NT injury tumours, along with 
Parylene-C implanted tumours. (b) Percentage area of collagen for untreated and NT 
injury tumours, along with Parylene-C implanted tumours. 
6.4 Discussion 
Implantable medical devices are becoming increasing used in pre-clinical 
research for a variety of disease conditions (Table 6.1) including cancer151. With the 
first implantable device for monitoring radiation dose delivery now used in the 
clinics157, it is likely more and more devices will become available as their roles in 
precision medicine become more defined. However, for an implantable device to 
attain regulatory approval, component materials or, ideally, the complete working 
device must undergo pre-clinical in vitro and in vivo biocompatibility testing. Well 
documented and commonly used biocompatibility models typically implant devices 
into healthy, non-diseased tissue; to date only limited published information is 
available regarding biofouling and the FBR that occurs within tumour tissue. Only 
one historical paper, published in 1962, has investigated the FBR induced following 
the implantation of cotton into murine tumours. Results showed that following 
implantation, the FBR seen within the tumours was minimal compared to that of 
normal tissues, indicating that the induced FBR may be decreased within a TME601. 
This chapter describes the investigation of the effects of selected modern 
biomaterials within a solid tumour and provides important biocompatibility data. 
Using human breast cancer xenograft tumours, biocompatibility was assessed up to 
14 days following implantation through the development of a novel percutaneous 
implantation technique and IHC processing and sectioning protocols. The 
implantation procedure was highly reproducible and minimally invasive. 
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Approximately 95% of implants were successfully placed within the centre of 
xenograft tumours with no mice showing signs of inflammation or discomfort around 
the implantation/NT injury site. 
For validation of the results obtained from biomaterial implanted tumours 
positive control implants were required, Cu wires were used in the experiments for 
this purpose. Although not previously reported within a TME, Cu has been shown to 
be cytotoxic552,553,595, these toxic effects are mediated through a variety of different 
mechanisms602,603. Cu and Cu ions can be involved in the generation of ROS604, 
leading to DNA strand breaks, base oxidation and ultimately cell death605. Apoptosis 
induced by Cu2+ has also been shown to be mediated through the induction of Bax, 
NF-ƙB inactivation and ROS formation606. In accordance with these results, Cu 
implanted xenograft tumours in our study had increased percentages of caspase 3 
positive staining cells and larger areas of tumour necrosis. Although the mechanisms 
by which Cu-induced apoptosis were not investigated, the increased levels of caspase 
3 expression within Cu implanted tumours agrees with these previously published 
findings. In vivo models have also shown that Cu can generate more severe 
inflammatory responses and fibrosis compared to non-Cu containing materials201,607. 
Our results demonstrated that, although the absolute percentage of fibroblasts 
remained the same in Cu implanted tumours, the percentage area of collagen was 
higher compared to control tumours; increasing to 1.05% in Cu implanted tumours 
compared with 0.49% in NT injury tumours and 0.48% in untreated tumours. These 
changes identified in the Cu implanted tumours (apoptosis, necrosis and fibrosis), 
reflecting the known cytotoxic effects of Cu, provided confidence in the implantation 
procedure and the method used for quantitative analysis and validated our results 
seen in the biomaterial implanted xenograft tumours551. 
Potential systemic effects caused by the implanted biomaterials was 
investigated by monitoring changes in body weight and condition score. No systemic 
toxicities were identified in mice that underwent biomaterial or Cu implantation, as 
indicated by maintenance of their body weight and condition score. Localised 
tumoural effects were investigated by calculating relative mean tumour volumes 
throughout the experimental period, results showed that all implanted tumours 
increased in size over 7 or 14 days in accordance with the controls. This result was 
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further assessed through histopathology by evaluating MDA-MB-231 cancer cell 
proliferation, apoptosis, necrosis and hypoxia within the xenograft tumours. 
Assessment of proliferation and apoptosis was performed through Ki67 and 
caspase 3 staining respectively. Only Parylene-C implanted tumours had a 
statistically greater percentage of Ki67 positive cells compared to NT injury tumours 
at 2 days post-implantation. No further differences in cellular proliferation or 
apoptosis were observed between the other biomaterials at any of the remaining time 
points. CA9 is a protein whose expression is induced in hypoxic conditions117; 
expression levels were investigated, as the IMPACT sensor is ultimately designed to 
monitor intra-tumoural O2 concentrations. No significant differences in the 
percentage of CA9 positive staining cells were observed between any of the 
implanted and control tumours, indicating that the biomaterials did not affect intra-
tumoral O2 levels. MDA-MB-231 xenograft tumours are heterogeneous, containing 
areas that are normoxic, hypoxic and necrotic608. The necrosis that develops can be a 
result of the tumour outgrowing its blood supply, increased levels of cell death and 
failure of clearance of these dead cells. Although necrotic areas were identified 
around the implanted biomaterials, the percentage area of necrosis was not 
significantly different from that of the control tumours. This suggests that the 
biomaterials did not increase the levels of necrosis from that seen within untreated 
xenograft tumours. Together, assessment of these 4 cellular parameters (Ki67, 
caspase 3, CA9 and necrosis) indicate that the implanted biomaterials did not affect 
the viability of the MDA-MB-231 cancer cells within the xenograft tumours551. 
Acute inflammation begins immediately after a material has been implanted 
within the body and can continue for 5 days168. The initial trauma caused by the 
insertion device will largely determine the severity of the acute inflammatory 
response, whereas the size of the implanted device will have a more significant effect 
on chronic inflammation and fibrosis169. During acute inflammation, 
polymorphonuclear leukocytes predominate, these cells are typically found in tissues 
at the implant site immediately following and up to 2 days post-implantation167. This 
component of the acute inflammatory response was investigated through the 
measurement of murine neutrophil numbers in the xenograft tumours using a primary 
antibody targeting the Ly6G antigen, a glycosylphosphatidylinositol-anchored 
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protein (also known as the myeloid differentiation antigen Gr1). Although transiently 
expressed in eosinophils and bone marrow monocytes609, Ly6G is predominantly 
expressed on neutrophils and is a common marker used for murine neutrophil 
identification610. Our study showed that the percentage of Ly6G positive stained cells 
was considerably lower than that seen using the F4/80 antibody (murine macrophage 
marker), indicating that cross reactivity between these cell types was unlikely to have 
occurred. Minimal numbers of neutrophils were identified in both the implanted and 
control xenograft tumours at day 0 and day 7 post-implantation. Even in the 
Parylene-C serial sacrifice study at 2 days post-implantation minimal numbers were 
identified. These results suggest that the acute inflammatory response resolved 
normally in the presence of the biomaterials. 
Chronic inflammation develops following the resolution of acute 
inflammation because the causative agent (the biomaterial) remains within the tissues 
at the implantation site. Monocytes, macrophages and fibroblasts are the major cell 
types present in the first 3 weeks of chronic inflammation, leading to 
neovascularisation with granulation and fibrous tissue production167,195. Macrophages 
take the lead role in orchestrating events involved with the ongoing immune 
responses through the formation of FBGCs185 and production of profibrogenic 
factors that lead to enhanced fibrogenesis by fibroblasts200. The potential of the 
implanted biomaterials for influencing these chronic immune responses was 
investigated through the measurement of murine macrophage and fibroblast numbers 
in the xenograft tumours using primary antibodies targeting the F4/80 and ER-TR7 
antigens respectively, while also assessing the area of collagen deposition with 
Masson’s trichrome staining. No significant differences in the percentage of F4/80 
positive staining cells were identified between any of the implanted and control 
tumours up to 7 days post-implantation or up to 14 days with Parylene-C 
implantation. Both tissue-resident macrophages and tumour-associated macrophages 
(TAMs) can be present within a tumour. Identification of the separate types can be 
advantageous, as TAMs have been shown to promote cancer cell invasion, migration, 
metastasis and angiogenesis; however, differentiating the 2 types of macrophages 
can be challenging611. In our study, macrophage identification was performed using 
an antibody reactive to murine F4/80, a protein that has been widely used as a pan-
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macrophage marker612,613; as a result of this, we did not distinguish between the 
different macrophage types. However, as the percentage of positive staining cells 
between implanted and control tumours was similar, our results indicated that the 
biomaterials did not lead to the recruitment of additional macrophages. An 
association between the percentage number of ER-TR7 positive staining cells and the 
percentage area of collagen was identified with a statistically significant increase in 
both parameters occurring between day 0 untreated and day 7 untreated/NT injury 
tumours, this result was likely due to ongoing tumour growth. Importantly no 
differences were identified in ER-TR7 positive staining cells and the percentage area 
of collagen between implanted and control tumours. 
When considering the FBR generated by an implanted material, it has been 
suggested that the physical structure of the material, including its modulus 
(resistance to elastic (recoverable) deformation), mechanics and stiffness may 
influence the extent of the inflammatory reactions, with materials of lower moduli 
producing less fibrosis than more rigid materials614. Tissue damage may also be 
increased in the presence of stiffer materials615, therefore the use of softer materials 
with properties more similar to the tissue in which it is implanted may reduce 
interfacial strain and improve biocompatibility616. However, as no significant 
differences were seen in the FBR between the softest (Nafion, Youngs modulus 600 
MPa) and hardest (Pt, Youngs modulus 168 GPa) biomaterials in our study, the 
results indicate that a material’s modulus is not be a major contributing factor to the 
FBR in this tumour model551. 
Following implantation, a layer of host proteins immediately acquires on the 
materials surface. The specific types and amounts of these adsorbed proteins is 
determined by the materials surface charge and hydrophilicity617. Adsorbed proteins 
such as such as albumin, vitronectin, fibronectin, fibrinogen, complement and γ 
globulin are known influencers of the FBR as they can dictate the adhesion and 
survival of monocytes, macrophages and FBGCs on the materials surface167,618,619. 
These proteins can also desorb rapidly from the materials surface causing time-
dependent fluctuations in protein levels620. Various methods could have been used to 
investigate differences in adsorbed proteins between the materials tested in our study. 
One method would have been to use the cage implant system whereby exudates 
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could be examined for these specific proteins. The advantage of using this method 
would have meant multiple samples could have been obtained without the need for 
animal sacrifice. Serial samples from the same animal would also mean that levels of 
specific proteins across time would be directly comparable to each other. A second 
method would have been to use the serial sacrifice IHC method we developed but 
harvest mice immediately following implantation and at a greater number of time 
points within the first 48 h post-implantation. These tumours could then be 
specifically stained for a range of these adsorbed proteins. These experiments would 
allow characterisation of the adsorbed proteins for each implanted material which 
could provide information with regards to the subsequent immune and FBRs that 
occurred in the surrounding tissues. 
Adherent macrophages and FBGC can lead to degradation of materials with 
subsequent device failure. An important clinical example of this was seen following 
the replacement of silicon rubber as the insulating material on pacemaker leads for 
mechanically superior polyether polyurethane (PEU) elastomers167. PEU was thought 
to be biocompatible but following its use in pacemaker leads increased rates of 
device failure were seen. Initial investigations suggested that environment stress 
cracking and metal ion oxidation were responsible for these failures with later studies 
demonstrating that adherent macrophages and FBGC were involved in the 
mechanisms underlying both these failure mechanisms621-626. To investigate the 
effects of adherent macrophages and FBGC in our model, scanning electron 
microscopy could have been used on recovered implanted materials. This technique 
has been previously used to study the progression of the FBR in terms of monocyte 
adhesion, monocyte-to-macrophage development, macrophage fusion and FBGC 
formation and so could have been applied to our model167. Scanning electron 
microscopy would also have provided visual information on the presence of any 
degradation occurring on the materials surface due to the ongoing FBR. 
Numerous mouse models (including CD-1 nude mice, SCID and NOD SCID) 
have been developed specifically to investigate tumourigenesis and pathogenesis of 
human cancers through the production of xenograft tumours218,219. Due to the relative 
ease, speed and reproducibility of producing human xenograft tumours, CD-1 nude 
mice were used in our model. Although this model uses athymic nude mice, deficient 
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in thymus-derived T lymphocytes, they are far from being immunodeficient. T 
lymphocytes can be produced via thymus-independent pathways (although in 
diminished numbers), allowing for some T cell-dependent immunity627. CD-1 nude 
mice also demonstrate near-normal responses to T cell-independent antigens, have 
high, naturally occurring antibody titres that can react with cancer cells628, have 
tumouricidal macrophages629 and have high levels of natural killer (NK) cell 
activity630. As a result of these studies demonstrating the ability of CD-1 nude mice 
to generate both innate and adapted immune responses, T cell-deficient mice 
(BALB/c nude mice) have been used in the investigation of the FBR to implanted 
materials194. This study demonstrated that, although the BALB/c nude mice had 
lower total leukocyte concentrations in the region of the implanted material, FBGC 
number and morphology were comparable to the control BALB/c mice. This 
suggests that pathways independent of thymus-matured T lymphocytes can still 
induce a normal FBR. Using non-immunosuppressed mice models, such as 
carcinogen-induced or spontaneously occurring tumours, would allow for the 
generation of tumours in the presence of an intact immune system. However, a 
significant disadvantage of these models would be the loss of using xenografted 
human cancer cells; this would mean the FBR induced by the implanted biomaterial 
would be assessed within murine rather than human cancer cells. 
Functional differences between murine and human immune systems need to 
be considered when evaluating the data presented in this murine study if the results 
are to be considered comparable to what would be expected to occur in human 
tissue551. Immune system differences in a range of species, including human and CD-
1 mice, have been previously investigated which identified significant species 
differences in circulating leukocyte populations631. This study demonstrated that the 
circulating leukocyte profile in human blood is neutrophilic, composed of 
approximately 50–70% neutrophils (3500–7000 cells/μl) and 20–40% lymphocytes 
(1400–4000 cells/μl) in comparison to CD-1 mice which is lymphocytic, composed 
of approximately 50–70% lymphocytes (1000–7000 cells/μl) and 15–20% 
neutrophils (300–2000 cells/μl). Neutrophil function and activity can also vary 
between humans and mice, with differences in mechanisms of leukocyte recruitment 
and composition of neutrophil granules632. As neutrophils are required in the initial 
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acute inflammatory phase167 and lymphocytes are transiently present in the chronic 
phase of the FBR193, these species differences in circulating leukocyte number and 
function could potentially result in altered FBR initiation and progression. 
The pathological equivalence between human xenografts in nude mice and 
naturally occurring human tumours needs to be considered, as changes in tumour 
characteristics such as proliferation rates, histological classification and cell type 
distribution patterns within the tumour can occur post-transplantation218,219. In 
humans, TAMs are typically distributed uniformly throughout the tumour633; while 
this distribution pattern was identified in approximately 50% of xenograft tumours in 
our study, the remainder were characterised by macrophages localising towards the 
periphery of the xenograft tumour. This type of macrophage distribution has been 
documented previously and may be due to macrophage-associated fibrous capsule 
formation around the tumour633. Whether the distribution of immune cells within 
human xenograft tumours could influence the FBR is unknown; however, as similar 
numbers of implanted and control xenograft tumours were observed to present both 
macrophage distribution types, the effect is likely to be minimal551. 
When developing the percutaneous biomaterial implantation and NT injury 
techniques, the risks of introducing endogenous cutaneous bacteria or endotoxins 
into the tumour were considered, as these factors alone could induce an immune 
reaction within the tumour. The potential for these issues occurring was reduced by 
the use of aseptic skin preparation and wire sterilisation, along with minimal 
anaesthesia and surgery time634. As all mice remained healthy throughout the 
experiments, with no visible signs of inflammation occurring at the implant sites, 
combined with similar levels of inflammation occurring in both implanted and 
control tumours our results suggest that these potential confounding factors were not 
an issue. One previous murine study has used a similar percutaneous method to 
evaluate the FBR to a subcutaneously implanted nylon mesh613. This study used a 
16G needle as the implantation device and for the creation of a NT injury in control 
tumours. The advantage of our model over this study is that smaller gauge 
biomaterial wires and needles were used for implantation and in the creation of NT 
injuries; this is an important consideration in any model for investigating the FBR, as 
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the extent of the acute inflammatory response is related to the initial trauma caused 
by the insertion device169. 
The potential for each biomaterial to induce a FBR was evaluated up to 7 
days post-implantation. This length of time is long enough to evaluate the acute 
inflammatory response and the initial phases of chronic inflammation. Full 
evaluation of chronic inflammation would require biomaterials to be implanted for a 
minimum of 3 weeks. This increased experimental time frame is difficult to achieve 
using murine xenograft models, as continuous tumour growth typically leads to skin 
ulceration causing localised inflammation and ethical concerns. However, we were 
able to evaluate Parylene-C up to 14 days post-implantation, providing evidence that 
the model can be extended for longer periods. Parylene-C was chosen for this 
extended evaluation as functional sensors were initially designed to be covered with 
a layer of this material (except for the active sensing area); Parylene-C would 
therefore be in direct contact with surrounding tumour tissue (subsequent 
modifications to sensor design finally resulted in the device been encased in 
biocompatible epoxy resin). Unfortunately, time and resources were not available to 
evaluate all biomaterials up to 14 days post-implantation. Further investigation of the 
FBR and biomaterial biocompatibility within a solid tumour, could involve using 
functional sensors implanted into naturally occurring solid tumours in 
immunocompetent large animal models. This would enable longer implantation 
periods to be achieved whilst overcoming the perceived disadvantages of using 
immunocompromised mice models. These experiments would provide further 
confidence in the intra-tumoural biocompatibility of these biomaterials. 
6.5 Conclusion 
This chapter has described the development of a novel in vivo murine 
xenograft biocompatibility model whereby biomaterials can be safely, reliably and 
quickly implanted into xenograft tumours. IHC protocols were also developed that 
allowed biomaterial implanted tumours to be sectioned in a way as to identify the 
implant site. These experiments document, for the first time in the literature, the 
biocompatibility assessment of SiO2, Si3N4, Parylene-C, Nafion, OG116-31 resin and 
Pt within a human xenograft tumour. The results demonstrated that these 
biomaterials had no significant effects on tumour viability and did not trigger a 
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significant FBR. These results have provided evidence for the use of these 
biomaterials in the construction of medical devices for implantation within solid 
tumours and have justified the progression of experiments to use working IMPACT 
sensors in in vivo models to investigate sensor functionality and begin to evaluate 
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for Clinical Applications 
This results chapter is an expanded version of a published research article: Gray 
M, Marland JRK, Dunare C, Blair EO, Meehan J, Tsiamis A, Kunkler IH, Murray A, 
Argyle A, Dyson A, Singer M, Potter MA. In Vivo Validation of a Miniaturised 
Electrochemical Oxygen Sensor for Measuring Intestinal Oxygen Tension. American 
Journal of Physiology - Gastrointestinal and Liver Physiology 2019; 317: 242-252. 
This article is open access with the authors retaining copyright to their work with 
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7.1 Abstract 
Background: An anastomotic leak is a life-threatening complication that can occur 
following an intestinal resection and anastomosis. Although its aetiology is complex, 
a leak can occur through tissue hypoxia from compromised anastomotic blood flow. 
This can impair intestinal healing, resulting in anastomotic dehiscence. Post-
operative monitoring of anastomotic oxygenation would provide a means by which 
intestinal hypoperfusion could be detected allowing the provision of treatments to 
improve intestinal perfusion and possibly prevent anastomotic breakdown. Methods: 
A novel murine intestinal ischaemic and hypoxic model was developed for validation 
of the ability of the IMPACT O2 sensor to provide real-time measurements of 
intestinal oxygenation. The sensor was placed onto the serosal surface of the small 
intestine of anaesthetised (non-recovery) rats that underwent ischaemic, hypoxaemic 
and haemorrhagic insults. Results: Sensor readings identified decreased intestinal O2 
tension following occlusion of the superior mesenteric artery and reduction in 
inspired O2 concentrations. Sensor readings increased back to baseline levels after 
reinstating blood flow or increasing inspired O2 concentrations. Conclusion: These 
results demonstrate in vivo validation of the ability of the IMPACT O2 sensor to 
detect dynamic changes in intestinal O2 tension through ischaemia and hypoxaemia 
and provide evidence for their use as O2 tension monitoring devices. Sensors placed 
and left in situ at an anastomotic site during surgery would provide a means of 
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monitoring post-operative intestinal perfusion. This approach, combined with current 
post-operative monitoring techniques, could allow for early detection of peri-
anastomotic tissue hypoxia and enable goal-directed treatments to be provided to 
restore intestinal oxygenation and prevent anastomotic dehiscence. 
7.2 Introduction 
Following biocompatibility assessment of sensor materials, in vivo functional 
validation of working IMPACT O2 sensors was undertaken to assess their suitability 
for clinical applications. To achieve this, we developed an in vivo murine model to 
investigate the sensor’s potential for measuring intestinal and muscular tissue O2 
tension (ptO2). If successful, these sensors could be developed for use in clinical 
situations where monitoring tissue perfusion would improve patient outcome. One 
situation where assessment of tissue perfusion would be advantageous is in the peri-
operative management of patients undergoing intestinal surgery. 
Intestinal resection and anastomosis is an abdominal procedure used in the 
treatment of various diseases including diverticulosis, ulcerative colitis, Crohn’s 
disease and cancer. Surgery involves removal (resection) of the diseased segment of 
intestine followed by re-joining (anastomosis) of the healthy, disease-free intestinal 
ends, thus restoring intestinal mural and luminal integrity635. Surgery can be 
performed via an open or laparoscopic approach using hand placed sutures or with a 
stapling device. The procedure is commonly performed, with estimates from the 
Association of Coloproctology of Great Britain and Ireland (ACPGBI) indicating 
that every year in the UK and Ireland approximately 20,000 large bowel anastomoses 
are performed. Regardless of the underlying disease, patient outcomes for those 
undergoing this procedure have improved through advances in peri-operative 
management, neoadjuvant and adjuvant radiotherapy and chemotherapy and through 
refinement of the procedure itself. However, no matter how safe the procedure is 
regarded to be, surgical complications can still occur. 
An anastomotic leak (AL) is a life-threatening complication that occurs as a 
result of failure of the anastomosis to heal. Anastomotic dehiscence can result in 
significant increases in morbidity636-638 and 30-day mortality rates639 and can result in 
higher local colorectal cancer recurrence rates and decreased long-term survival for 
cancer patients640-643. Patients that develop an AL are also at an increased risk of 
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developing post-operative complications such as pneumonia, multi-organ failure, 
renal and cardiac complications, localised or generalised sepsis, enterocutaneous 
fistula, wound infections and dehiscence637. Revision surgery will be required in 
approximately 85–95% of patients who develop an AL, of which 50% will need 
permanent stoma formation644. The additional surgery and intensive care needed for 
the treatment of these patients will increase hospitalisation length645 and overall 
treatment costs646,647. 
AL aetiology is complex, with both patient specific and surgical factors being 
involved (Table 7.1)643,648. An important factor involved in AL development is 
intestinal ptO2, which is a measure of the partial pressure of O2 within the interstitial 
space and is dependent on the balance between O2 supply and utilisation. If local 
intestinal O2 requirements cannot be met due to compromised tissue perfusion from 
anastomotic tension and disruption of the peri-anastomotic blood supply, then 
intestinal ischaemia and necrosis can develop649-652. 
Table 7.1. Risk factors associated with the development of an anastomotic leak. 












American Society of 
Anaesthesiologists score 
Diverticulitis 
Suboptimal anastomotic blood supply 
Concurrent surgical procedures 
Poor colonic preparation 
Peri-operative blood transfusion 
Anastomotic ischaemia or tension 








Although AL rates can be as high as 24% for surgery performed in the distal 
rectum, combined rates for surgery performed at any level of the intestinal tract are 
approximately 6-7%643,648. Comprehensive peri-operative patient management is 
crucial, especially in the early post-operative period, as septic complications 
following an AL will cause the majority of patients to become clinically ill at 5-8 
days post-surgery653. Factors that can decrease morbidity and improve patient 
outcome after abdominal surgery include the preservation of normovolaemia654, 
normothermia655, provision of supplemental O2
656 and goal-directed fluid 
therapy657,658. These factors, acting largely through improvements in local tissue 
perfusion and ptO2, are all applicable to the post-operative care of intestinal resection 
and anastomosis patients659. One major influencer of tissue perfusion is intravenous 
fluid therapy and although there is debate about the volume and type of peri-
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operative fluids that should be administered, intravenous colloid therapy has been 
shown in a pig model to significantly increase colonic ptO2 and perfusion in healthy 
and peri-anastomotic sites660. These peri-operative patient management strategies 
may help promote anastomotic healing and possibly decrease AL rates. 
If anastomotic dehiscence does occur, then early diagnosis is critical in 
improving patient outcomes and decreasing mortality rates653,661-663. A delay of 2.5 
days for definitive AL treatment can increase mortality rates from 24% to 39%639 
whereas every hour of delay from septic shock onset to the administration of 
antibiotics is associated with a 7.6% decrease in survival664. Research into 
anastomotic healing and dehiscence has been identified as a priority by the UK NHS 
National Institute for Health Research, Colorectal Therapies Healthcare Technology 
Co-operative and the ACPGBI. Unfortunately, no methods are currently available 
that allow monitoring of post-operative intestinal healing and there is no consensus 
as to the best approach to diagnose an AL. 
AL has no pathognomonic signs and therefore diagnosis cannot be based 
solely on clinical symptoms. Symptoms range from pyrexia, ileus and 
cardiorespiratory abnormalities to acute sepsis with multi-organ failure or even 
faeces draining from the surgical wound. Although blood tests for AL diagnosis 
based on raised inflammatory markers such as C-reactive protein (CRP) levels may 
be helpful, these tests are non-specific and can point to a wide range of post-
operative complications such as urinary, chest or surgical wound infections. Using a 
combination of clinically measurable parameters such as temperature, leukocyte 
count, CRP and creatinine levels as well as systemic inflammatory response 
syndrome components and urine output has been shown to decrease the delay from 
the first symptoms of AL to its treatment from 4 to 1.5 days639. Current practice for 
AL diagnosis remains imaging-based, predominantly through contrast-enhanced CT 
scans. Unfortunately, this technique has variable sensitivity and specificity665, with 
false negative rates as high as 47%666. These false negative results are likely from CT 
scans being performed prior to a leak been radiologically visible. Reluctance to 
perform multiple scans due to cost, logistics and radiation exposure in combination 
with inherent delays incurred from the time of imaging to the interpretation of results 
can significantly hinder prompt AL diagnosis667. 
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As a result of the deficiencies in the current methods used for AL diagnosis, 
there is a need for novel monitoring and diagnostic techniques to overcome this 
unmet clinical issue. A device capable of detecting post-operative peri-anastomotic 
hypoperfusion could allow early remedial intervention to be instigated to improve 
tissue perfusion and potentially reduce the risk of an AL from developing. Devices 
which allow an AL to be diagnosed quicker than current tests allow could also enable 
repeat surgery to be performed before local sepsis makes surgical revision 
impossible. The use of an implantable sensor to provide real-time information on 
spatial and temporal changes in intestinal ptO2 would be a novel approach to meet 
these diagnostic needs. Although the principle aim of the IMPACT O2 sensor is to 
monitor tissue O2 levels within a solid tumour, the technology is suitable to multiple 
applications in which monitoring visceral surface ptO2 is clinically important and 
would appear well suited to monitoring peri-anastomotic ptO2. 
This chapter describes the development and use of a murine intestinal 
ischaemic and hypoxic model for functional validation of the IMPACT O2 sensor. 
Following sensor placement onto the serosal surface of a segment of small intestine, 
we investigated the sensor’s ability to detect changes in intestinal ptO2 following 
occlusion of the superior mesenteric artery (SMA), manipulation of the inspired 
fractional oxygen concentration (FiO2), creation of acute haemorrhage and after 
euthanasia. This is, to the best of our knowledge, the first time that this developed 
murine model has been used for validation of a miniaturised Clark O2 sensor to 
measure dynamic changes in intestinal ptO2 which was further evaluated though 
measuring muscular ptO2. These results provide robust evidence for further 
development of the IMPACT O2 sensor towards clinical applications in man. 
7.3 Results 
7.3.1 Development of a model to measure intestinal tissue oxygen 
tension 
To develop an in vivo model whereby sensor validation for measuring 
intestinal ptO2 could be performed, 3 experimental groups were required. One acted 
as the control group designed to assess sensor longevity and drift, whereas 2 
treatment groups were designed to assess the sensor’s potential for detecting changes 
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in intestinal ptO2 following local (SMA occlusion) or systemic (manipulation of 
blood O2 levels and circulating blood volume) insults (Figure 7.1). 
All rats underwent general anaesthesia, arterial and venous cannulation and 
tracheostomy tube placement as described in section 3.3.2. Following a routine 
ventral midline celiotomy, extending from the manubrium to the pubis, a tube 
cystotomy was performed. A stab incision was made at the apex of the bladder which 
was then cannulated with 1.57 mm external diameter polythene tubing (Portex Ltd, 
Hythe, UK) and sutured in place with a purse string suture. Urine was collected by 
placing the free end of the tubing into a 1.5 ml Eppendorf tube. To gain access to the 
abdominal vasculature and to allow sensor placement, the small intestine and caecum 
were exteriorised and placed to the left-hand side abdominal wall. To reduce 
evaporative fluid and convective heat loss these exteriorised organs were wrapped in 
cling film and kept moist via regular topical applications of saline. Using a proximal 
section of small intestine, the IMPACT O2 sensor was placed on the antimesenteric 
serosal surface at the midpoint between small serosal blood vessels (Figure 7.2). 
Tissue adhesive (Vetbond, 3M, Bracknell, UK) was used to temporarily attach the 
lead wire to the intestine ensuring close contact between the sensor’s central active 
sensing area and the serosal surface was achieved. Following instrumentation, a 
stabilisation period of at least 30 min was provided to allow stable baseline 
physiological variables to be achieved, after which rats were randomly divided into 
control or treatment groups. Continuous sensor recordings were made throughout 
each experiment, commencing after the initial stabilisation period and continuing for 




Figure 7.1. Outline of experimental protocols and interventions. Protocol 1: 
Control animals with no interventions. Protocol 2: SMA occlusion. Protocol 3: 
Alterations in FiO2, haemorrhage and autotransfusion (resuscitation). 
Instrumentation includes anaesthesia induction, surgical preparation, arterial and 
venous cannulation, tracheostomy, celiotomy and tube cystotomy. 
 
Figure 7.2. Intra-operative photograph depicting intestinal placement of the 
sensor. Placement of the sensor can be seen on the serosal surface of a section of 
small intestine. 
7.3.2 Protocol 1: Control group 
The control group consisted of instrumented rats that received no 
physiological challenges. Continuous sensor recordings were performed for 165 min. 
Arterial blood samples were obtained immediately prior to the commencement of 
sensor recordings, every hour thereafter and then just before euthanasia. 
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7.3.3 Protocol 2: Intestinal tissue responses to superior mesenteric 
arterial occlusion 
The SMA was identified as a vessel originating from the left side of the aorta 
at the level of the right renal vein. The artery was isolated, close to the aortic origin, 
from its associated vein and surrounding soft tissues. A loose suture of 1 metric 
braided silk (Ethicon, UK) was placed round the artery to aid vessel manipulation 
and localisation. Following SMA isolation, the vessel was temporarily and reversibly 
occluded with the use of a haemostatic clamp (Fine Science Tools, Linton, UK). 
Each occlusion lasted for 5 min with a 10 min reperfusion period between 
occlusions. Vessel occlusion was confirmed through the development of intestinal 
pallor with the loss of mesenteric arterial pulsations; these changes were reversible 
following removal of the haemostatic clamp. The occlusion-reperfusion cycle was 
performed 3 times. Arterial blood samples were obtained immediately prior to the 
start of continuous sensor readings and just before euthanasia. 
 
Figure 7.3. Intra-operative photographs depicting SMA isolation, occlusion and 
release. (a) SMA identification. (b) Haemostatic clamp placed across the SMA 
providing temporary mechanical occlusion. Intestinal pallor was immediately evident 
upon vessel occlusion. (c) Following removal of the haemostatic clamp and re-
instigation of blood flow, a hyperaemic intestinal flush was evident. 
7.3.4 Protocol 3: Intestinal tissue responses to alterations in inspired 
oxygen concentrations, progressive haemorrhage and 
autotransfusion 
Alterations in FiO2 (1.0, 0.21, 0.1) were performed at 15 min intervals with 
each different O2 concentration delivered through a flowmeter via the isoflurane 
vaporiser. The cycle of FiO2 alterations was: 0.21 for 15 min (baseline), 0.1 for 15 
min (inducing hypoxaemia), 0.21 for 15 min, 1.0 for 15 min (inducing 
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hyperoxaemia) before finally returning to 0.21 for 15 min. Arterial blood samples 
were taken at the end of each FiO2 change. 
Following completion of FiO2 alterations, progressive haemorrhage was 
achieved by removing 15% of the circulating blood volume (estimated as 70 ml/kg) 
over a period of 5 min. Following a 10 min stabilisation period a further 15% was 
removed. The exsanguinated blood was collected into a heparinised syringe and 
maintained at 37oC. Ten min after completion of the second haemorrhage procedure 
autotransfusion was performed by administering the blood intravenously back to the 
rat over 10 min. Arterial blood samples were taken at the end of each haemorrhage 
procedure and just before euthanasia. 
7.3.5 Current generated by the sensor remained stable in control 
rats 
To assess the physiological stability of rats throughout the duration of 
anaesthesia that encompassed the longest experimental protocol, data from blood-
gas, biochemical and haematological analysis was combined with variables such as 
heart rate (HR), respiratory rate (RR), core temperature (CT) and mean arterial blood 
pressure (MAP). All physiological parameters, blood-gas analysis and electrolytes 
remained stable throughout anaesthesia. Although blood glucose levels began to 
decrease towards the end of the procedure this was not statistically significant (p= 
0.9304) and was consistent with the fasting state and metabolic demands of the rat 
during anaesthesia (Figure 7.4a). 
To assess stability of sensor measurements over a time period that 
encompassed the longest experimental protocol, continuous sensor recordings were 
performed in rats which were not subjected to physiological interventions. Results 
showed that currents generated in the O2 sensors were extremely stable over 165 
min, with mean currents ranging from -1.14 ± 0.03 nA at 15 min to -1.44 ± 0.15 nA 
at 135 min. Although a trend towards increasing currents over time was observed, 




Figure 7.4. Sensor currents and physiological data remain stable in control rats. 
(a) Physiological data (Hb, haemoglobin; ABE, arterial base excess; SaO2, 
haemoglobin O2 saturation; PaO2, arterial O2 partial pressure; PaCO2, arterial CO2 
partial pressure; CT, core temperature; RR, respiratory rate; HR, heart rate) (data 
expressed as mean ± SEM, n=3). (b) Current generated at the working electrode of 
the sensor during continuous sensor readings over a period of 165 min; results show 
mean current recordings from the final 5 min of each 15 min period (one-way 
ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± 
SEM, n=3, p= 0.7244). 
7.3.6 Current generated by the sensor rapidly decreased following 
occlusion of the superior mesenteric artery which was 
reversible upon reinstatement of blood flow 
To assess the ability of the sensors to detect changes in intestinal ptO2 
through the generation of temporary and reversible intestinal ischaemia, we 
performed 3 cycles of SMA occlusion and release. Results showed an almost 
instantaneous decrease in sensor current after each occlusion, reducing from non-
occluded recordings of -1.85 ± 0.05 nA to occluded recordings of -0.27 ± 0.08 nA 
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(mean current ± SEM) (Figure 7.5a). Changes between the pre- and post-occlusion 
current measurements for each of the cycles were statistically significant (p= 
0.0082). Current reductions were maintained throughout the majority of each 
occlusion which quickly rose back to non-occluded current values following removal 
of the haemostatic clamp and re-instigation of blood flow (Figure 7.5b and Table 
7.2). Following euthanasia, sensor recordings fell to the lowest recorded current 
measuring 0.04 ± 0.16 nA, which was statistically significant when compared to non-
occluded currents (p= 0.0025). 
 
Figure 7.5. Sensor currents rapidly decrease following superior mesenteric 
artery occlusion. (a) Representative graph showing current generated at the working 
electrode of the sensor during continuous sensor recordings over a period of 70 min. 
Three cycles of 5 min occlusion followed by 10 min of reperfusion were performed 
in each animal before euthanasia. (b) Combined analysis comparing current 
generated at the working electrode of the sensor during periods of SMA occlusion 
and intestinal reperfusion; results show mean current recordings from the final 5 min 
of each occlusion and reperfusion period (one-way ANOVA with Holm-Šídák 
multiple comparisons test; data expressed as mean ± SEM, n=4, **p≤0.01). 
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Table 7.2. Current recordings during each SMA occlusion/reperfusion and 
euthanasia. (n=4; mean ± SEM). 





























0.04 ± 0.16 
7.3.7 Current generated by the sensor responded rapidly to 
alterations in inspired oxygen concentrations 
To assess the ability of the sensors to detect changes in intestinal ptO2 
through changes in blood oxygenation we performed sequential alterations in FiO2 
ranging from 0.1-1.0 (Figure 7.6a). Baseline current recordings were first obtained 
using FiO2 of 0.21. The mean sensor current during this baseline period was -1.35 ± 
0.18 nA. Following a FiO2 reduction to 0.1, sensor recordings decreased by more 
than 50%, to -0.60 ± 0.10 nA. This current reduction occurred over a period of 1-2 
min, which was maintained throughout the hypoxaemic challenge and was 
statistically significant when compared to current recordings obtained during 
baseline measurements (p= 0.0396). Reversal of FiO2 from 0.1 to 0.21 resulted in an 
increase in sensor current recordings back to baseline values. Upon increasing FiO2 
to 1.0 sensor currents rapidly increased to -6.53 ± 0.46 nA, which was statistically 
significant when compared to baseline currents (p< 0.0001). This increase in current 
was maintained throughout the hyperoxaemic challenge. A final reduction in FiO2 
back to 0.21 resulted in sensor currents returning to baseline levels. Following 
euthanasia, sensor recordings fell to the lowest recorded current measuring -0.08 ± 
0.17 nA, which was statistically significant when compared to baseline currents (p= 
0.0006) (Figure 7.6b and Table 7.3). At the end of each FiO2 alteration arterial 
blood-gas analysis confirmed the expected physiological changes induced by each 
challenge. Haemoglobin O2 saturation (SaO2) and arterial O2 partial pressure (PaO2) 
both decreased at 0.1, increased at 1.0 (more prominent with PaO2), and returned to 
baseline levels at 0.21. Expectedly, total haemoglobin (Hb) concentration remained 




Figure 7.6. Sensor currents change in accordance with alterations in FiO2. (a) 
Representative graph showing current generated at the working electrode of the 
sensor during continuous sensor recordings over a period of 150 min. Each FiO2 
challenge was performed in 15 min blocks before removal of 30% of the circulating 
blood volume. (b) Combined analysis comparing current generated at the working 
electrode of the sensor during each FiO2 challenge; results show mean current 
recordings from the final 5 min of each 15 min period (one-way ANOVA with 
Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=5, 
****p≤0.0001; ***p≤0.001; *p≤0.05). (c&d) Arterial O2 partial pressure, total 
haemoglobin and haemoglobin O2 saturation measured at the end of each FiO2 
challenge. 
Table 7.3. Current recordings during each FiO2 challenge and euthanasia. (n=5; 
mean ± SEM). 
FiO2 21% (1) 10% 21% (2) 100% 21% (3) Euthanasia 
Current (nA) -1.35 ± 0.18 -0.60 ± 0.10 -1.37 ± 0.12 -6.53 ± 0.46 -1.55 ± 0.20 -0.08 ± 0.17 
7.3.8 Current generated by the sensor remained stable following 
haemorrhage 
Following completion of FiO2 challenges, the ability of the sensors to detect 
changes in intestinal ptO2 through acute haemorrhage was assessed by performing 
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progressive removal of 30% of the circulating blood volume (performed in 2 x 15% 
removal periods) (Figure 7.7a). Physiological data and arterial blood-gas analysis 
obtained 10 min after the end of each haemorrhage procedure confirmed the 
expected physiological changes induced by acute haemorrhage. Hb concentration, 
HR and MAP all showed moderate decreases following 15% haemorrhage which 
became more pronounced after 30% haemorrhage. Baseline values compared to 
those following 30% haemorrhage showed that Hb concentration decreased from 
13.3 ± 0.6 g/dl to 11.4 ± 0.4 g/dl, HR decreased from 405 ± 22 bpm to 348 ± 16 bpm 
and MAP decreased from 118 ± 12 mmHg to 56 ± 3 mmHg. All these parameters 
returned to baseline levels following autotransfusion (Figure 7.7b & c). SaO2 levels 
remained constant throughout each haemorrhage procedure. 
Although physiological responses to acute haemorrhage were induced, only 
small decreases in sensor current measurements were observed, which were not 
statistically significant compared with baseline recordings. Baseline measurements at 
FiO2 of 0.21 were -1.55 ± 0.20 nA; however, following 15% and 30% haemorrhage 
currents only decreased to -1.39 ± 0.13 nA and -1.33 ± 0.13 nA respectively. 
Following autotransfusion, sensor currents failed to increase back to baseline levels, 




Figure 7.7. Sensor currents remain stable following progressive haemorrhage 
and autotransfusion. (a) Combined analysis comparing current generated at the 
working electrode of the sensor during the preceding 15 min baseline period at FiO2 
of 0.21 and 2 subsequent cycles of removal of 15% circulating blood volume 
followed by autotransfusion; results show mean current recordings from the final 5 
min of each period (one-way ANOVA with Holm-Šídák multiple comparisons test; 
data expressed as mean ± SEM, n=5, ****p≤0.0001). (b&c) Mean arterial blood 
pressure, heart rate, total haemoglobin and haemoglobin O2 saturation measured at 
the end of each of intervention period. 
Table 7.4. Current recordings during each haemorrhage procedure and 
euthanasia. Baseline recordings were made at FiO2 of 0.21 (n=5; mean ± SEM). 





Current (nA) -1.55 ± 0.20 -1.39 ± 0.13 -1.33 ± 0.13 -1.22 ± 0.14 
7.3.9 Development of a model to measure muscular tissue oxygen 
tension 
To develop an in vivo model whereby sensor validation for measuring 
muscular ptO2 could be performed, 1 experimental group was required. The 
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treatment group was designed to assess the sensor’s potential for detecting changes 
in muscular ptO2 following systemic insults (manipulation of blood O2 levels). 
All rats underwent general anaesthesia, routine arterial and venous 
cannulation and tracheostomy tube placement as described in section 3.3.2. An 
incision was made through the skin and subcutaneous tissues of the lateral aspect of 
the thigh, mid-way between the patella and greater trochanter of the femur. The 
vastus lateralis was identified and fascia covering a small area of the muscle was 
removed. The IMPACT O2 sensor was placed onto these muscular fibres and the lead 
wire temporarily attached to the surface of the biceps femoris using tissue adhesive 
(Figure 7.8), ensuring close contact between the sensor’s central active sensing area 
and the muscular surface was achieved. To reduce evaporative fluid and convective 
heat loss exposed muscular tissues were covered in cling film and kept moist via 
regular topical applications of saline. Following instrumentation, a stabilisation 
period of at least 30 min was provided to allow stable baseline physiological 
variables to be achieved. Continuous sensor recordings were made throughout each 
experiment, commencing after the initial stabilisation period and continuing for 15 
min following confirmation of death post-euthanasia. 
 
Figure 7.8. Intra-operative photographs depicting muscular placement of the 
IMPACT sensor. (a-c) A cranial-to-caudal skin incision was made mid-way 
between the patella and the grater trochanter of the femur. The vastus lateralis 
(cranial) and biceps femoris (caudal) muscles were identified. (d) Fascia was 
removed from the vastus lateralis exposing the underlying muscular fibres. (e) 
Placement of the sensor on the muscular surface of the vastus lateralis. 
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7.3.10 Muscular tissue responses to alterations in inspired oxygen 
concentrations 
Alterations in FiO2 (1.0, 0.21, 0.1) were performed at 15 min intervals with 
each different O2 concentration delivered through a flowmeter via the isoflurane 
vaporiser. The cycle of FiO2 alterations was: 0.21 for 15 min (baseline), 0.1 for 15 
min (inducing hypoxaemia), 0.21 for 15 min, 1.0 for 15 min (inducing 
hyperoxaemia) before finally returning to 0.21 for 15 min. Arterial blood samples 
were taken at the end of each FiO2 challenge. 
7.3.11 Current generated by the sensor responded to alterations in 
inspired oxygen concentrations 
To assess the ability of the sensors to detect changes in muscular ptO2 
through changes in blood oxygenation, we performed sequential alterations in FiO2 
ranging from 0.1-1.0 (Figure 7.9a). Baseline current recordings were first obtained 
using FiO2 of 0.21. The mean sensor current during this baseline period was -1.46 ± 
0.25 nA. Following a FiO2 reduction to 0.1, sensor current recordings decreased to -
1.06 ± 0.18 nA. This current reduction occurred over a period of 5 min but was not 
statistically significant when compared to current recordings obtained during 
baseline measurements (p= 0.934). Reversal of FiO2 from 0.1 to 0.21 resulted in an 
increase in sensor current recordings back to baseline values, again occurring over a 
period of 5 min. Upon increasing FiO2 to 1.0, sensor currents rapidly increased to -
3.47 ± 0.71 nA, which was statistically significant when compared to current 
recordings obtained during baseline measurements (p= 0.0282) and at FiO2 of 0.1 
(p= 0.0075). This increase in current was maintained throughout the hyperoxaemic 
challenge. A final reduction in FiO2 back to 0.21 resulted in sensor currents returning 
to baseline levels of -1.74 ± 0.36 nA, which was statistically significant when 
compared to current recordings obtained at FiO2 of 1.0 (p= 0.0393) (Figure 7.9b and 
Table 7.5). At the end of each FiO2 alteration, arterial blood-gas analysis confirmed 
the expected physiological changes induced by each challenge. SaO2 and PaO2 both 
decreased at FiO2 of 0.1, increased at 1.0 (more prominent with PaO2) and returned 
to baseline levels at 0.21. Expectedly, Hb concentration remained the same 




Figure 7.9. Sensor currents change in accordance with alterations in FiO2. (a) 
Representative graph showing current generated at the working electrode of the 
sensor during continuous sensor recordings over a period of 80 min. A 20 min 
baseline recording at FiO2 of 0.21was performed prior to 15 min blocks of each FiO2 
challenge. (b) Combined analysis comparing current generated at the working 
electrode of the sensor during each FiO2 challenge; results show mean current 
recordings from the final 5 min of each 15 min period (one-way ANOVA with 
Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=4, 
**p≤0.01; *p≤0.05). (c&d) Arterial O2 partial pressure, total haemoglobin and 
haemoglobin O2 saturation measured at the end of each FiO2 challenge. 
Table 7.5. Current recordings during each FiO2 challenge. (n=4; mean ± SEM). 
FiO2 21% (1) 10% 21% (2) 100% 21% (3) 
Current (nA) -1.46 ± 0.25 -1.06 ± 0.18 -1.59 ± 0.29 -3.47 ± 0.71 -1.74 ± 0.36 
7.4 Discussion 
An AL is a serious complication that can occur following intestinal resection 
and anastomosis. The condition is life-threatening and can have long-term life 
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changing consequences. Unfortunately, there is no ‘perfect’ post-operative diagnostic 
test for an AL or a device that can monitor anastomotic healing. Although AL 
aetiology is complex, it has been associated with peri-anastomotic tension and 
interruption of microvasculature blood flow. This situation can cause peri-
anastomotic necrosis and poor intestinal healing through compromised tissue 
perfusion and decreased ptO2
668. In accordance with this, our experiments focused on 
validating the ability of the IMPACT O2 sensor to measure intestinal ptO2 which 
could be developed as a means of assessing anastomotic healing. 
Various intra-operative techniques are available to assess intestinal tissue 
perfusion (visible light and near infrared spectroscopy and laser fluorescence 
angiography)669,670 and O2 tension (laser Doppler flowmetry and wireless hand held 
pulse oximeters)668,671, which have been shown to predict leak occurrence. An 
ongoing clinical trial is also currently assessing the potential benefits of measuring 
intra-operative anastomotic perfusion, using intravenous indocyanine green with 
near-infrared laparoscopy, to minimise leak occurrence compared with conventional 
white-light laparoscopy672. Unfortunately, these techniques are only applicable to 
intra-operative use and as yet have failed to gain interest with clinicians. Currently, 
surgeons typically rely on subjective macroscopic tissue appraisal to assess intra-
operative intestinal perfusion. Adequate perfusion is deemed present if the intestine 
has a healthy pink colouration with the presence of intestinal bleeding and palpable 
mesenteric pulses. Unfortunately, these subjective techniques are only applicable to 
intra-operative use and are unable to predict the risk of a leak occurring635. 
Clark O2 electrodes have been previously investigated as a means of 
measuring intra-operative intestinal ptO2 using pre-clinical rabbit and dog intestinal 
devascularisation models673,674. These studies created gradual reductions in intestinal 
perfusion through the sequential ligation of a marginal intestinal artery and 
demonstrated that intestinal serosal ptO2 measured immediately before performing 
an anastomosis could predict leak occurrence. In humans, Clark O2 electrodes have 
been used intra-operatively to provide ptO2 reference ranges for the majority of the 
gastrointestinal tract (stomach, ileum, caecum and colon)675 and have been 
investigated in clinical trials for their ability to predict AL occurrence676. This 
clinical study measured peri-anastomotic colonic ptO2 before, during and 
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immediately after performing a resection and anastomosis. The results demonstrated 
that colonic ptO2 of less than either 20 mmHg, 50% of the pre-resection values, 15% 
of the PaO2 or 40% of the ptO2 at a control site were all associated with a post-
operative AL. Adequate ptO2 is required for collagen production, with levels lower 
than 15-20 mmHg associated with impaired synthesis. As submucosal collagen is the 
major holding layer for sutures/staples in the early stages of anastomotic healing, 
inadequate collagen synthesis due to low ptO2 could lead to AL occurrence
676. 
Although, these pre-clinical and clinical studies have provided evidence that 
Clark O2 electrodes can be used intra-operatively to measure intestinal ptO2 and 
predict AL occurrence, they fail to consider their potential post-operative use. The 
use of novel techniques such as an implantable device that can continuously measure 
intra- and post-operative peri-anastomotic ptO2
 would not only improve a surgeon’s 
intra-operative ability to identify sites at increased risk of dehiscence670, but also 
provide a means for monitoring post-operative anastomotic healing. This concept 
would be an ideal clinical application for the IMPACT O2 sensor. 
For in vivo functional validation and proof-of-concept that the IMPACT O2 
sensor could measure changes in intestinal ptO2, a rat model was developed. 
Physiological challenges through either manipulation of intestinal blood flow 
(through SMA occlusion) to induce ischaemia, alterations in blood oxygenation 
status (through changes in FiO2) to cause hypoxaemia and hyperoxaemia and finally 
creation of a state of acute haemorrhage were developed for use in the model. We 
suspected that these physiological challenges would cause a change in intestinal ptO2 
that could be detected by the IMPACT O2 sensor. 
Control experiments were first performed to investigate whether the rats 
could remain physiologically stable for the duration of the longest experimental 
protocols. Through monitoring physiological variables and evaluating arterial blood-
gas, biochemical and haematological data, results demonstrated that the rats could 
cope with the physiological demands from general anaesthesia for the duration of our 
experimental protocols; this was in accordance with a previous study677. Using the 
same control group of rats, sensor recordings were performed to evaluate stability of 
the currents generated by the sensors and investigate any detrimental effects that the 
tissue environment and anaesthetic gases might have on sensor functionality. These 
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considerations are important, as halothane anaesthesia has been shown to affect 
Clark electrode function678,679. Our results demonstrated, for the first time in the 
literature, continuous in vivo recordings made using a miniaturised Clark-type 
electrochemical O2 sensor for 165 min. No statistically significant changes in 
measured current were recorded during this period, suggesting that the tissue 
environment or anaesthetic gases had no effect on sensor function. This result was 
important in providing confidence that current changes observed in the experimental 
protocols were due to alterations in intestinal ptO2 caused by the physiological 
challenges rather than from sensor drift/inaccuracy. Potential effects of anaesthetic 
agents and tissue metabolites on the functionality of the IMPACT O2 sensor are 
likely to have been minimised/prevented through its design and packaging, 
predominantly using Nafion as the outer protective coating of the active sensing area. 
Pore size within Nafion membranes is small enough to exclude proteins that may 
contaminate the electrode surface, while the presence of charged sulphonate groups 
causes the electrostatic exclusion of small anions680. 
In all control and experimental groups, intestinal ptO2 measurements were 
performed by positioning the sensors on the serosal surface of the small intestine and 
securing them in place with tissue adhesive. This technique ensured direct contact of 
the active sensing area with the intestinal serosal surface without the use of excessive 
pressure which could affect local microvascular blood supply, leading to alterations 
in ptO2
675. The size of the central active sensing area is also an important factor when 
considering the use of Clark O2 electrodes for clinical applications, as large sensing 
areas have the potential to reduce tissue O2 levels in the process of generating 
measurable currents. As the sensing area of the IMPACT O2 sensor is only 50 µm in 
diameter, its potential for depleting tissue O2 levels will be minimal. In clinical 
situations the small sensor size also would allow surgeons to place single or multiple 
sensors accurately on specific tissue areas. Placement of multiple miniaturised 
sensors in the case of anastomotic surgery would be particularly advantageous as 
they could be placed on either side and around the circumference of the anastomosis 
enabling detailed peri-anastomotic ptO2 information to be obtained. This could not 
be achieved with a single sensor with a large sensing area that can only provide mean 




Initial physiological challenges to validate sensor functionality were 
performed through intestinal blood flow manipulation to induce ischaemia. To do 
this, a SMA occlusion and reperfusion technique was developed. The SMA, a direct 
branch of the aorta, is the principle blood supply to the majority of the 
gastrointestinal tract, extending from the distal duodenum to the proximal two-thirds 
of the transverse colon. SMA identification is straightforward due to defined 
anatomical landmarks; with the small intestine and caecum exteriorised to the left-
hand side of the abdomen the artery can be seen originating from the ventral aspect 
of the aorta at the level of the right renal vein. SMA identification was confirmed by 
observing small intestinal pallor immediately following vessel occlusion and a 
hyperaemic flush following vessel release. 
SMA occlusion is the most direct way of causing intestinal ischaemia with 
significant histological changes occurring in the small intestine within 40 min of 
occlusion681. Previous studies have used various SMA occlusion techniques to study 
ischaemia-reperfusion injuries682,683, cytokine production and bacteria/endotoxin 
translocation684; however, to our knowledge, this is the first report of the model 
being used for the validation of a miniaturised Clark O2 sensor to measure intestinal 
ptO2. Our technique of temporary SMA ligation as close to its aortic origin as 
possible ensured no collateral blood supply to the small intestine could occur from 
SMA subsidiary branches (inferior pancreaticoduodenal, intestinal, ileocolic, right 
and middle colic). Our results demonstrated that sensor currents fell to almost 0 nA 
within 1-2 min of SMA occlusion, indicating a severely hypoxic state as a result of 
tissue utilisation of the residual available O2. Upon removal of the SMA occlusion, a 
rapid increase in sensor current was observed indicating a return of normal intestinal 
oxygenation as a direct consequence of intestinal reperfusion and flooding of the 
intestinal capillary beds with oxygenated blood. These results showed that the 
IMPACT O2 sensor could quickly, reliably and reproducibly detect changes in 
intestinal ptO2 through ischaemic and reperfusion challenges induced by SMA 
occlusion and release. 
Further sensor validation was performed by manipulating intestinal ptO2 
through alterations in blood oxygenation levels, achieved through FiO2 challenges. 
Arterial blood-gas analysis was used to confirm the expected physiological responses 
237 
 
to these FiO2 alterations. Hypoxia caused reductions in both PaO2 and SaO2, whereas 
hyperoxia caused their levels to increase. Changes in sensor currents occurring with 
FiO2 challenges matched the same pattern of results obtained using arterial blood-gas 
analysis with statistically lower and higher currents generated in hypoxaemic and 
hyperoxaemic conditions respectively. Time taken for sensor currents to change 
following a FiO2 alteration was similar to that seen using the SMA model, with 
typical response times of 1-2 min. These results showed that the sensor could 
quickly, reliably and reproducibly detect changes in intestinal ptO2 through 
hypoxaemic and hyperoxaemic challenges caused by changes in blood oxygenation. 
Although significant changes in intestinal ptO2 were detected through both 
ischaemic, hypoxaemic and hyperoxaemic challenges, similar results were not 
demonstrated with acute haemorrhage. Physiological parameters were used to 
confirm the expected responses caused by acute haemorrhage, which showed 
significant reductions in HR and MAP following acute removal of 30% of the 
circulating blood volume. This response is consistent with increased vagal activity 
and reduced sympathetic input (Bezold–Jarish-like reflex) resulting in a decrease in 
total peripheral resistance. HR typically only increases during continued and severe 
circulating blood volume loss in an attempt to maintain tissue perfusion and 
represents a transition from reversible to irreversible shock685. Arterial blood-gas 
analysis at the end of 30% haemorrhage did identify a slight decrease in Hb 
concentration. However, SaO2 levels remained consistent due to the haemorrhage 
procedures being performed with a FiO2 of 0.21. It is likely that in our induced 
model of acute haemorrhage that decreased peripheral resistance combined with 
stable SaO2 could have maintained intestinal ptO2 at normal levels, which is why no 
changes in sensor current measurements were observed635. 
Although the main aim of these experiments was to investigate the use of the 
IMPACT O2 sensor for measuring intestinal ptO2, we also investigated its potential 
for measuring ptO2 in other tissues. Using our developed FiO2 model we assessed 
changes in muscular ptO2 to hypoxaemic and hyperoxaemic challenges. The results 
showed changes similar to those documented in the intestinal experiments and 
provided evidence that the sensor may be used for measuring ptO2 in various tissues. 
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One significant advantage of our developed in vivo model over previous 
studies using Clark O2 electrodes is that it allowed not only the assessment of 
whether the IMPACT sensor could detect changes in intestinal and muscular ptO2 
following the initial physiological challenge, but also whether sensor readings would 
return to baseline levels upon challenge removal. Previous studies have only reported 
on Clark O2 electrodes being used for making individual intestinal ptO2 
measurements at specific time points673-676; the continuous recording of data 
performed in our experiments provided an opportunity to dynamically measure 
changes in ptO2 before, during and after each challenge. Our results clearly 
demonstrated that currents measured by the IMPACT O2 sensor returned to baseline 
levels following repeated temporary ischaemic insults and reversible changes in 
FiO2. The ability to dynamically measure changes in intestinal ptO2 could have a 
significant impact on the peri-operative management of patients undergoing 
intestinal resection and anastomosis. Miniaturised Clark O2 sensors placed around 
the anastomotic site and left in situ following surgery could provide post-operative, 
minimally-invasive, rapid and highly localised continuous real-time data regarding 
transitory changes in peri-anastomotic intestinal ptO2. This method of monitoring 
ptO2 could detect early peri-anastomotic tissue hypoxia and identify patients that 
may benefit from treatments aimed at improving local ptO2 to prevent a leak, or 
failing that, diagnose a leak earlier than current diagnostic methods allow. The 
sensor’s ability to detect dynamic intestinal ptO2 changes could also be used to 
assess treatment responses and, when combined with information gained from 
conventional monitoring systems, would provide a more accurate assessment of the 
patient’s condition. 
7.5 Conclusion 
This chapter has described the development of a novel in vivo murine 
ischaemic, hypoxic and haemorrhagic model in which acute and reversible changes 
in intestinal and muscular ptO2 were produced. The results demonstrated that the 
IMPACT O2 sensor can accurately detect dynamic changes in intestinal ptO2 through 
ischaemic insults, alterations in FiO2 and euthanasia, with similar results also 
identified in muscular tissues in response to alterations in FiO2. These results have 
provided initial functional in vivo validation of the IMPACT O2 sensor and is the 
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first step in the process of evaluating its potential to be used as an advanced ptO2 
monitoring device. Justification for progressing sensor validation experiments into 






8 Development of a Pre-Clinical Ovine Pulmonary 
Adenocarcinoma Model for Human Lung Cancer 
and Validation of Intra-Tumoural Functionality 
of the IMPACT Oxygen Sensor 
This results chapter is an expanded version of a published research article: Gray 
M, Sullivan P, Marland JRK, Greenhalgh SN, Meehan J, Gregson R, Clutton RE, 
Cousens C, Griffiths D, Murray A, Argyle D. A Novel Translational Ovine 
Pulmonary Adenocarcinoma Model for Human Lung Cancer. Frontiers in Oncology 
- Molecular and Cellular Oncology 2019; 9(534): 1-17. This article is open access 
with the authors retaining copyright to their work with permission to use published 
figures in this thesis. Sections of text and figures used from this article have been 
referenced accordingly. 
8.1 Abstract 
Background: Large animal models that accurately reflect human disease are 
regarded as excellent translational models which can be used in pre-clinical research. 
Ovine pulmonary adenocarcinoma (OPA) is a naturally occurring lung cancer that 
has a similar histological classification and oncogenic pathway activation with that 
of human lung adenocarcinomas; similarities such as these make it a valuable model 
for studying human lung cancer. Methods: A novel OPA model was developed for 
validation of the ability of the IMPACT O2 sensor to provide real-time measurements 
of intra-tumoural O2 tension. Sensors were implanted into OPA tumours of 
anaesthetised (non-recovery) sheep using a CT-guided trans-thoracic percutaneous 
implantation procedure. Results: Nine sheep underwent single or double sensor 
implantations. For single sensor implantations the time taken from initial CT scans to 
sensor placement was 45 ± 5 min. All implantations resulted in successful sensor 
delivery into OPA tumours. Post-implantation pneumothorax occurred in 4 sheep. 
Sensor recordings identified decreased intra-tumoural O2 tension following a 
reduction in inspired O2 concentrations, although these changes were not statistically 
significant. Conclusion: These results demonstrate the in vivo validation of the 
ability of the IMPACT O2 sensor to detect dynamic changes in intra-tumoural O2 
tension caused by hypoxaemia. Through the integration of techniques used in the 
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treatment of human lung cancer patients, including ultrasound, general anaesthesia, 
CT and surgery into the OPA model, we have shown its translational potential. We 
believe this model can be used for a variety of other pre-clinical applications. 
8.2 Introduction 
Following initial validation of the ability of the IMPACT O2 sensor to detect 
changes in intestinal and muscular ptO2 in healthy tissues, our aim was to investigate 
its potential for measuring ptO2 within a solid tumour. To achieve this, we developed 
a novel translational large animal ovine model whereby sensors were implanted into 
naturally occurring OPA tumours. If successful, the aim would be to develop the 
sensors for use in clinical situations where a patient’s cancer treatment could be 
influenced by the assessment of intra-tumoural ptO2. Although applicable to many 
solid tumours, one situation where assessment of intra-tumoural O2 levels could be 
advantageous is in the treatment of lung cancer. 
Lung cancer is the most commonly diagnosed cancer in the world, with 
approximately 2 million new cases and 1.8 million cancer-related deaths occurring 
per year6. Historically lung cancer research has largely relied on in vivo mouse 
models. Although these models have increased our molecular understanding of the 
disease, they have failed to lead to breakthrough advancements in lung cancer 
treatment. If progress is to be made in improving lung cancer prognosis, then the 
limitations with current in vivo models must be addressed. One solution would be to 
use complex models that more accurately represent the disease293. Similarities in 
clinical presentation, activated signalling pathways and histological classification 
between OPA and human lung adenocarcinomas, combined with the availability of 
several in vitro and in vivo OPA model systems, has led to the disease being 
regarded as a valuable translational model for studying human lung cancer309. 
In vitro OPA models typically use either immortalised cell lines or primary 
cultures from OPA tumours331,686,687. Unfortunately, the lack of an in vitro cell line 
that can support JSRV replication when cells are grown in 2D systems has limited 
the amount of research that has been performed in this manner. To overcome this 
limitation, in vitro JSRV expression has been shown to be possible by culturing cells 
using 3D systems686,688 or by using OPA lung tissue explants689,690. These 3D model 
systems may more accurately recreate the oncogenic events that occur in OPA and 
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represent transitional models between in vitro and in vivo systems273. In vivo small 
animal OPA models have been developed using immunodeficient327 and 
immunocompetent mice691. These studies show that intra-nasal administration of 
adeno-associated virus vectors encoding JSRV Env leads to the formation of lung 
adenocarcinomas that are comparable to those found in sheep and humans. Although 
these small animal systems are more widely available than large animal models and 
do not require specialised animal facilities, they suffer from the same limitations as 
other in vitro cancer mouse models, as described in section 1.9. 
To improve complexity and translational ability of OPA models there are 2 in 
vivo ovine models available which use either experimentally induced tumours or 
naturally occurring disease273. The first documented in vivo OPA model 
demonstrated that the formation of lung tumours in healthy sheep could be induced 
following intra-tracheal injections of either OPA tumour homogenates or JSRV 
purified from lung fluid692,693. Later studies using neonatal lambs improved infection 
rates and decreased the time required for tumours to develop351,694. These improved 
results are likely due to JSRV preferentially infecting dividing cells, which are more 
common in younger animals695. This model has been constantly refined, most 
recently through sequencing and cloning of the JSRV genome322,696 and through the 
generation of an oncogenic and infectious molecular clone. This has enabled in vitro 
virus production to be achieved through the transfection of cell lines697, which can be 
used to infect neonatal lambs. The main advantage of using the in vivo lamb model is 
that it provides the opportunity for studying tumourigenesis and early stage disease. 
This is an important area of research in human lung cancer as clinical tissue from 
early cases is generally unavailable. However, while this model is useful for studying 
tumourigenesis and pathogenesis from infection to the formation of small tumours, 
for welfare reasons the disease cannot be allowed to reach advanced stages. The use 
of naturally occurring OPA cases provides the opportunity for studying advanced 
disease and overcomes the ethical concerns associated with the lamb model. 
As OPA is endemic in the UK, this disease population represents a valuable 
translational research opportunity for assessing human lung cancer treatment 
strategies. Unfortunately, the lack of reliable ante-mortem, pre-clinical OPA 
diagnostic tests has limited the use of these naturally occurring cases for research. 
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Pre-clinical OPA diagnosis is difficult as clinical signs are often lacking. Although 
JSRV can be detected in blood347, bronchoalveolar343 and lung fluid349 samples 
through PCR, these tests can suffer from poor sensitivity and are not easily 
applicable to routine large-scale on-farm testing. To overcome these issues, imaging 
techniques such as radiography, CT and now ultrasound are being investigated for 
use in pre-clinical OPA diagnosis273. In human thoracic medicine, CT is the imaging 
modality of choice that allows detailed evaluation of lung tissue which can identify 
smaller lesions compared to conventional radiography. Its use in OPA models has 
been demonstrated for monitoring the development and progression of tumours in 
both naturally occurring698 and experimentally infected animals339. Unfortunately, 
radiography and CT are cost prohibitive for commercial flocks and require 
specialised equipment and sedation/general anaesthesia341. 
Trans-thoracic ultrasonography has been proposed as a useful OPA diagnostic 
technique. One study performed trans-thoracic ultrasound examinations on 100 sheep 
as part of a series of diagnostic tests for the investigation of weight loss. Based on 
ultrasound examination alone, 41 sheep were diagnosed as OPA positive, with all 
cases having the diagnosis confirmed at post-mortem. All remaining sheep had no 
ultrasonographic changes characteristic of OPA and were diagnosed as OPA 
negative at post-mortem. These results demonstrated that diagnostic ultrasound was 
highly specific, producing no false positive or negative results282. Trans-thoracic 
ultrasound can be performed in a sheep in less than 1 minute699 and can differentiate 
chronic lung lesions and detect OPA lesions as small as 1-2 cm282. As trans-thoracic 
ultrasound can be performed quickly and in conscious animals the procedure lends 
itself to routine large-scale on-farm OPA diagnosis programmes273. It is also an ideal 
method for identifying pre-clinical cases for experimental use as individual cases can 
be selected based on size and location of OPA lesions. These are the reasons why 
trans-thoracic ultrasound was chosen to select OPA cases for use in our study. 
Until now the majority of in vivo and in vitro OPA models have focused on the 
investigation of JSRV biology and oncogenesis. One study however has investigated 
the impact of nutritional selenium on tumourigenesis and progression using naturally 
occurring OPA cases698. Although this study demonstrated the potential for the OPA 
model to be integrated with techniques such as CT, post-mortem examination, trace 
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element and liver enzyme activity analysis to provide comprehensive information on 
tumour pathogenesis, the use of OPA as a pre-clinical model for monitoring the 
TME, evaluation of chemotherapeutic agents or as a surgical model has yet to be 
documented. 
This chapter describes the development, refinement and use of an anaesthetised 
OPA model for functional validation of the IMPACT O2 sensor within a TME. A 
novel CT-guided trans-thoracic percutaneous implantation procedure was developed 
for sensor placement into OPA tumours. Following sensor implantation, we 
investigated the sensors ability to detect changes in intra-tumoural ptO2 following 
manipulation of FiO2. This is, to the best of our knowledge, the first description of 
the use of naturally occurring OPA cases as a pre-clinical surgical model for the 
validation of the ability of a miniaturised Clark O2 sensor to measure dynamic 
changes in intra-tumoural ptO2. Through the successful integration of techniques 
used in the treatment of human lung cancer patients, including ultrasound, general 
anaesthesia, CT and surgery into the OPA model, we have shown its translational 
potential. These results provide robust evidence for further development of the 
IMPACT O2 sensor towards clinical applications in man. 
8.3 Results 
8.3.1 Development of a percutaneous technique for sensor 
implantation into lung tissue 
To develop a technique whereby IMPACT O2 sensors could be safely and 
reliably implanted into an OPA tumour we began to investigate protocols using 
sheep carcasses. Although these sheep did not have any lung pathology, we were 
able to develop the surgical protocol before moving onto experimental animals. 
Post-mortem sheep were placed in lateral recumbency and the entire 
hemithorax was clipped. A 1 cm vertical skin incision was made approximately 1-2 
intercostal spaces caudal to the desired site of penetration into the thoracic cavity. 
Artery forceps were used to develop a subcutaneous tunnel from the skin incision 
extending cranially to the desired intercostal space. An 8G x 15 cm Jamshidi biopsy 
needle (Carefusion, France), with its stylet in place, was introduced through the 
subcutaneous tunnel, then redirected perpendicular to the thoracic wall in the middle 
of the selected intercostal space. The needle was advanced to enter the thoracic 
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cavity, with the penetration of the parietal pleura appreciated as the feeling of a 
‘pop’. Once the parietal pleura had been penetrated the needle was advanced through 
the visceral pleura and into lung parenchyma. Following penetration into lung tissue 
the stylet was removed, and the sensor and lead wire were introduced down the bore 
of the needle. The obturator was then introduced down the bore of the needle, 
advancing the sensor past the tip of the needle and positioning it within lung tissue. 
Once in place, the obturator and implantation needle were withdrawn, leaving the 
sensor and lead wire in situ. A purse string suture of 3 metric braided silk (Ethicon, 
UK) was placed around the incision, which continued as a Chinese finger trap suture 
around the lead wire, securing the sensor in place (Figure 8.1). Following sensor 




Figure 8.1. Photographs depicting development of a percutaneous implantation 
technique. (a-c) A skin incision was made through which the Jamshidi needle was 
introduced. The needle was placed perpendicular to the thoracic wall, introduced into 
the thoracic cavity and advanced into lung tissue. (d-g) The stylet was removed, and 
the sensor introduced down the bore of the needle. The obturator advances the sensor 
to position it within the lung tissue. (h-j) Removal of the obturator and implantation 




Figure 8.2. Photographs depicting sensor placement through the thoracic wall 
into lung tissue. The rib cage has been removed to assess sensor position within (a) 
lung tissue and (b) within the intercostal space. 
8.3.2 Post-mortem cases allowed mapping of accessible regions of 
the thoracic cavity for sensor implantations 
Using post-mortem cases, we performed simulated surgeries on 8 sheep 
cadavers with multiple implantations in each carcass. These surgeries allowed the 
development of the implantation procedure and investigation of the potential 
accessible regions of the thoracic cavity and lung lobes which could be safely 
implanted into during experimental cases. 
The ovine thorax is composed of 13 ribs and 12 intercostal spaces; access to 
the cranial rib spaces (1-4) was almost entirely prevented by the appendicular 
skeleton and musculature of the forelimbs, making access to the cranial thoracic 
cavity impracticable through a lateral approach. Caudally the ovine thoracic cavity 
does not extend over the whole thorax, and access gained through intercostal spaces 
caudal to the 8th space resulted in implantation into the costodiaphragmatic recess or 
penetration through the diaphragm into the abdominal cavity. The 4th-8th intercostal 
spaces on both sides of the thorax were all used successfully to implant sensors into 
lung tissue; implants were placed most reliably into the caudal lobes and right middle 
lung lobe using the 5th and 6th intercostal spaces (Figure 8.3). During implantation 
the Jamshidi needle caused significant elastic deformation of lung tissue prior to 
visceral pleural penetration, after which the needle could be advanced through the 




Figure 8.3. Photographs depicting lung lobes which can be accessed through a 
lateral percutaneous approach for sensor implantations. (a) Right hemithorax. 
(b) Left hemithorax. Yellow circles outline sensor implantation sites. 
8.3.3 Development of a CT-guided trans-thoracic percutaneous 
technique for sensor implantation into OPA tumours 
To refine the initial procedure used in post-mortem cases we used 3 sheep 
diagnosed with OPA (Table 8.1). Following induction of anaesthesia as described in 
section 3.4.2, the sheep were placed in lateral recumbency with the OPA affected 
lung uppermost. The thorax was clipped in preparation for surgery; this area 
extended cranially from just beyond the last rib to the caudal border of the scapula 
with the dorso-ventral margins extending from the dorsal spinous process of the 
thoracic vertebrae to the sternum. Following an initial thoracic CT scan, OPA lesion 
localisation was performed; lesions were localised cranio-caudally based on 
intercostal spaces and dorso-ventrally based on measurements from the dorsal 
spinous process of thoracic vertebrae to the OPA lesion. A mark was drawn on the 
skin to identify the position of thoracic wall penetration for sensor implantation. 
Table 8.1. OPA cases used for initial refinement of the CT-guided implantation 
technique. 
Case Signalment Weight 
(kg) 









56 Right caudal lobe: 2 focal lesions (1 






76 Right cranial lobe: entire lobe affected 200 
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Case A underwent an initial CT scan for lesion localisation, with subsequent 
sensor implantation performed using the same technique as was developed in the 
post-mortem cases. The sensor was implanted without CT guidance with one single 
needle advancement. Although penetration of the parietal and visceral pleura was 
easily appreciated, this blind technique made it difficult to judge how deep the needle 
had penetrated into OPA tissue. Post-implantation CT scans identified a severe 
pneumothorax, and although the sensor was positioned within OPA tissue, it was at 
the deep margins of the lung lobe (Figure 8.4a). The iatrogenic severe pneumothorax 
was likely due to the needle passing through a large volume of lung tissue or from air 
tracking into the thoracic cavity through the subcutaneous tunnel. 
To improve accuracy of sensor implantations cases B and C were performed 
under CT guidance. Following lesion localisation, as performed in case A, repeat CT 
scans were performed following the initial placement of the needle through the chest 
wall and following each needle advancement, until the needle was positioned at the 
desired point within OPA tissue. Post-implantation CT scans of case B identified a 
small pneumothorax in the region of the implant site, with the sensor positioned in 
the pneumothorax and not within OPA tissue (Figure 8.4b). Post-implantation CT 
scans of case C identified the sensor positioned in subcutaneous tissue outside the 
thoracic cavity (Figure 8.4c). In both cases sensor ‘back out’ was likely due to the 
sensor not been fully pushed past the tip of the needle into OPA tissue, or the sensor 




Figure 8.4. Axial CT images documenting surgical complications in the initial 3 
OPA cases. CT scans were taken immediately post-sensor implantation. (a) Case A. 
Severe pneumothorax with extensive retraction of the lung lobes away from the chest 
wall. The sensor is positioned deep within OPA tissue. A small amount of air can be 
seen in the subcutaneous tissues just proximal to the rib. (b) Case B. Mild 
pneumothorax localised to the implantation site. The sensor and lead wire have 
‘backed out’ during implantation and are positioned within the pneumothorax. (c) 
Case C. The sensor and lead wire have ‘backed out’ during implantation and are 
positioned within subcutaneous tissues. 
Table 8.2. Results from OPA cases used for initial refinement of the 
implantation technique. Number of needle advancements, implantation time and 
complications are provided. 
Case No. of CT 
scans/needle 
advancements 
Time from initial 







A 1 50 Yes Immediate: Severe 
pneumothorax 
B 2 32 No Immediate: Mild 
pneumothorax with sensor 
positioned within 
pneumothorax 
C 4 29 No Immediate: Sensor positioned 




8.3.4 Refined procedure for OPA lesion localisation and CT-guided 
trans-thoracic percutaneous sensor implantation 
Following the initial 3 cases, further refinement of OPA lesion localisation 
and CT-guided sensor implantation was performed (Table 8.3). Sheep were 
anaesthetised as described in section 3.4.2, clipped, prepared and positioned for CT 
scanning and surgery as described in section 8.3.3. 
Table 8.3. OPA cases used following refinement of the CT-guided implantation 
technique. Signalment, CT localisation and total anaesthesia time (time from 
induction of anaesthesia to euthanasia) are provided. 
Case Signalment Weight 
(kg) 






65 Left caudal lobe: 1 focal lesion at cranial aspect, 





51 Right caudal lobe: diffuse area affecting caudal 













57 Right cranial lobe: almost entire lobe affected 
Left caudal lobe: 1 focal lesion at caudal aspect, 









55 Right cranial lobe: entire lobe affected 
Left cranial lobe: entire lobe affected, extending 





58 Right middle lobe: entire lobe affected 
Left cranial lobe: entire lobe affected, extending 





64 Right cranial lobe: almost entire lobe affected 195 
To improve the accuracy of OPA lesion localisation and the site for 
percutaneous sensor implantation a self-adhesive sheet of non-metallic, radiopaque 
grid lines (GuideLines, Oncology Imaging Systems, UK) was placed on the thoracic 
wall skin surface in the centre of the clipped area. An initial thoracic CT scan was 
obtained to assess intra-thoracic pathology and identify OPA lesion(s) (Figure 8.5). 
OPA lesions for implantation were selected so the needle path would avoid bullae, 
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fissures, blood vessels and large bronchioles. Peripheral tumours of at least 4 cm in 
diameter were also preferred to limit the volume of normal aerated lung the needle 
would pass through and improve sensor implantation into the centre of a lesion. The 
distance between the skin and pleura was measured at the anticipated penetration 
site. OPA lesions were localised dorso-ventrally based on the grid lines and cranio-
caudally based on intercostal spaces. A mark was drawn on the skin surface to 
identify the position of thoracic wall penetration for sensor implantation (Figure 8.6). 
The grid lines were removed, and the skin was aseptically prepared for surgery using 
chlorohexidine solution before the area was four quarter draped for surgery. 
 
Figure 8.5. Initial CT scan performed to assess intra-thoracic pathology and 
localise OPA lesions. (a) Axial. (b) Coronal. (c) Sagittal planes. Large areas of 
increased radiopacity can be seen affecting the ventral regions of the left cranial and 
caudal lung lobes and the ventral regions of the right caudal lung lobe (outlined in 
black). Air bronchograms are visible within this consolidated region (white arrows). 
A patchy and hazy increased opacity (ground glass appearance) within the dorsal 
regions of the lung, with preservation of bronchial and vascular margins, suggest the 
presence of interstitial pneumonia or small foci of neoplastic tissue (outlined in 
white). The radiopaque circles on the skin surface seen on the axial plane are the grid 




Figure 8.6. OPA lesion localisation. (a) The hemithorax has been clipped for 
surgery and the radiopaque grid lines placed on the skin surface prior to the initial 
CT scan. (b-d) Following the CT scan the skin was marked both dorso-ventrally and 
cranio-caudally at the desired point of thoracic wall penetration for sensor 
implantation. 
All sensors were implanted using a trans-thoracic percutaneous technique 
under CT guidance based on the developed protocol described in section 8.3.1. A 
skin incision was made 1-2 intercostal spaces caudal to the desired thoracic wall 
entry point. The Jamshidi biopsy needle, with its stylet in place, was introduced 
through the skin incision and tunnelled cranially to the desired intercostal space. The 
tunnel was made long enough to minimise the risk of air entering the thoracic cavity 
from the external environment following sensor implantation. Once at the desired 
intercostal space the needle was positioned at 90 degrees to the thoracic wall in the 
centre of the intercostal space. The needle was then advanced the distance measured 
from the initial CT scan (approximately 1 cm) through the chest wall so that the 
needle was just within the thoracic cavity, penetrating the parietal pleura, but not 
entering lung/OPA tissue. A second CT scan was performed to ensure accurate 
placement of the needle at the desired position. If the needle position was suboptimal 
it could be re-positioned with minimal risk of lung damage. Once correctly 
positioned, the needle was advanced through the visceral pleura into OPA tissue; 
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repeat CT scans were taken following each needle advancement to ensure correct 
needle trajectory and accurate localisation of the needle tip. Measurements were 
taken from each CT scan from the needle tip to the point of desired sensor 
implantation to make needle advancements more accurate. Once the needle tip was 
positioned centrally within OPA tissue the stylet was removed, and the sensor and 
lead wire were introduced down the bore of the needle. The obturator was then 
introduced to advance the sensor past the tip of the needle into OPA tissue. Once in 
place, the obturator and implantation needle were withdrawn, leaving the sensor and 
lead wire in situ. Care was taken to ensure the lead wire did not catch on the needle, 
risking sensor displacement. The lead wire had been previously marked at 1 cm 
intervals to verify that it was not ‘backing out’ during needle removal. The lead wire 
was then sutured in place as described in section 8.3.1 (Figure 8.7 & Figure 8.8). 
Following implantation, CT scans were performed to evaluate sensor 
positioning and assess the presence of any immediate or delayed post-operative 
complications such as pneumothorax or haemorrhage; these CT scans were 
performed immediately after implantation and suturing and also following euthanasia 
(Figure 8.8 & Figure 8.9). If a pneumothorax developed the decision to drain it was 
made on severity and whether ventilation was compromised. Intermittent 




Figure 8.7. Intra-operative photographs depicting trans-thoracic percutaneous 
sensor implantation. (a&b) A skin incision was made through which the Jamshidi 
needle was introduced. (c-e) Following successive CT scans the needle was 
progressively advanced into OPA tissue. (f-h) Once the needle was in position the 
stylet was removed and the sensor introduced down the bore of the needle. (i) The 
obturator was used to push the sensor past the tip of the needle into OPA tissue. (j-l) 
The Jamshidi needle was removed, leaving the sensor and lead wire in place. (m-o) 
The skin was closed, and the lead wire secured in place with a purse string and 




Figure 8.8. Serial CT images taken during sensor implantation. Coronal, axial 
and sagittal planes are viewed following initial needle placement and after successive 
needle advancements. The needle was advanced until the tip was at the desired 
position within the OPA lesion. CT images taken immediately post-implantation 




Figure 8.9. CT images taken immediately post-sensor implantation. Images are 
from 3 separate cases. The sensor and lead wire (red arrows) can be seen within the 
area of increased radiopacity, consistent with a large consolidated OPA tumour. 
Repeat CT scans were taken following completion of sensor measurements and 
euthanasia; these showed no evidence of complications and confirmed the sensor had 
remained within OPA tissue throughout sensor recordings. 
8.3.5 Refined procedure for CT-guided implantation of multiple 
sensors 
Following procedure refinement for single sensor implantations the technique 
was modified to allow 2 sensors to be implanted into a single lesion. The initial CT 
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scan verified that the lesion was large enough to accommodate 2 sensors and allowed 
for sensor implantation planning. Sensors were placed through the same intercostal 
space 2-3 cm apart. The first needle was placed as previously described, penetrating 
the parietal pleura. Following CT confirmation of correct needle positioning the 
needle was advanced into OPA tissue and a second needle was placed, again only 
penetrating the parietal pleura. A CT scan confirmed placement of the first needle 
into OPA tissue and the second at the correct position. Both needles were then 
advanced simultaneously based on sequential CT scans and the sensors implanted as 
previously described (Figure 8.10). 
 
Figure 8.10. CT images taken immediately post-sensor implantation. The sensors 
and lead wires (red arrows) can be seen within the area of increased radiopacity, 
consistent with a large consolidated OPA tumour. Sensor 1 is placed centrally within 
the tumour whereas sensor 2 has been placed further towards the deep margin of the 
lung lobe. Repeat CT scans were taken following completion of continuous sensor 
measurements and euthanasia; these documented no evidence of complications and 
confirmed the sensors had remained within OPA tissue throughout sensor recordings. 
8.3.6 CT-guided trans-thoracic percutaneous sensor implantation 
resulted in a high success rate of delivery of sensors into OPA 
lesions 
A total of 7 OPA sheep underwent CT-guided single sensor implantations 
(Table 8.4). Time taken from the initial CT scan to sensor placement was 45 ± 5 min 
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(mean ± SEM). The number of sequential CT scans and needle advancements 
required from initial needle placement to obtaining the desired position within the 
OPA lesion ranged from 3–5; however, 4 advancements were required in 5 of the 7 
cases. All implantation procedures resulted in sensor placement within OPA tissue. 
No immediate or delayed complications were identified in 4 of the cases. 
Two sheep underwent CT-guided 2 sensor implantations (cases 8 & 9). Time 
taken from the initial CT scan to sensor placement was 73 and 50 min for each case. 
The number of sequential CT scans and needle advancements required from the 
initial placement to correct positioning within OPA tissue was 4 for each needle. In 
both cases all implantation procedures resulted in sensor placement within OPA 
tissue. No immediate or delayed complications were identified in 1 of the cases. 
Table 8.4. Results from the OPA cases used in CT-guided implantation 
procedures. Number of needle advancements, implantation time and complications 
are provided (cases 1-7 are single sensor implantations, cases 8 and 9 are double 
sensor implantations). 
Case No. of CT 
scans/needle 
advancements 
Time from initial 







1 4 31 Yes Immediate: Mild 
pneumothorax – not treated 
2 3 58 Yes Immediate: Mild 
pneumothorax – treated 
successfully with a single 
thoracocentesis 
3 4 46 Yes None 
4 4 56 Yes None 
5 4 26 Yes None 
6 4 60 Yes Immediate: Mild 
pneumothorax – not treated 
Delayed: Progression of 
pneumothorax with severe lung 
lobe collapse and development 
of subcutaneous emphysema. 
Final sensor position was within 
the pneumothorax 
7 5 43 Yes None 
8 4 73 Yes None 
9 4 50 Yes Immediate: Mild 
pneumothorax – treated 




8.3.7 Iatrogenic pneumothorax is a potential complication following 
percutaneous sensor implantation 
Sensor implantation in 4 cases was associated with iatrogenic pneumothorax. 
One case (case 1) developed a mild pneumothorax immediately post-sensor 
implantation; this did not require thoracocentesis and did not progress over the 
course of the experiment. Two cases (case 2 and 9) also developed a mild 
pneumothorax immediately post-sensor implantation; each case received a single 
percutaneous thoracocentesis immediately following pneumothorax detection. CT 
scans post-thoracocentesis confirmed lung lobe re-expansion with removal of most 
of the air from within the thoracic cavity. Continuous sensor recordings were 
performed for approximately 2 h before each sheep was euthanised and a post-
mortem CT scan performed. These scans identified no pneumothorax recurrence and 
confirmed that the sensor had remained within OPA tissue throughout sensor 
recordings (Figure 8.11). 
A final case (case 6) also developed a mild pneumothorax immediately post-
sensor implantation, with evidence of a small amount of air surrounding the lead 
wire in the thoracic wall musculature and subcutaneous tunnel. Thoracocentesis was 
not performed as only a small volume of air was initially present within the thoracic 
cavity. Continuous sensor recordings were performed for approximately 4.5 h before 
the sheep was euthanised and a post-mortem CT scan performed. This CT scan 
identified pneumothorax progression with further retraction of the lung margins 
away from the chest wall in the region of the implantation site. Lung lobe retraction 
was associated with sensor displacement causing both the sensor and lead wire to be 
situated within the pneumothorax. Significant progression of subcutaneous 




Figure 8.11. CT images documenting iatrogenic pneumothorax. CT images are 
from case 2. The OPA target lesion is seen as a patchy area of increased radiopacity 
affecting the ventral region of the right caudal lung lobe. CT scans were taken 
immediately post-sensor implantation and following euthanasia (2 h post-sensor 
implantation). A mild pneumothorax was evident immediately post-sensor 
implantation, predominately localised to the region of the implantation site. The 
sensor can be seen within OPA tissue (red arrows). Thoracocentesis was performed 
immediately post-sensor placement, which resulted in lung lobe re-expansion and 
removal of most of the air from within the thoracic cavity. Following euthanasia, CT 
scans confirmed successful management of the pneumothorax with reinflation of the 
collapsed caudal lung lobe and confirmed the sensor had remained within OPA tissue 




Figure 8.12. CT images documenting iatrogenic pneumothorax. CT images are 
from case 6. CT scans were taken immediately post-sensor implantation and 
following euthanasia (4.5 h post-sensor implantation). A mild pneumothorax was 
evident immediately post-sensor implantation. A small amount of air can be seen in 
subcutaneous tissues where the lead wire is exiting the thoracic cavity. The sensor 
can be seen positioned within OPA tissue (red arrows). Thoracocentesis was not 
performed. Following euthanasia CT scans identified significant progression of the 
subcutaneous emphysema and pneumothorax. In the axial and coronal planes, the 
sensor can now be seen positioned on the lung surface within the pneumothorax. 
8.3.8 Appropriate anaesthetic protocols enable OPA sheep to 
remain physiologically stable throughout anaesthesia 
To assess physiological stability of OPA sheep throughout anaesthesia, 
blood-gas, biochemical and haematological data was combined with variables such 
as HR, RR, CT, and MAP. Results from sheep maintained at FiO2 of 1.0 showed that 
physiological and arterial blood variables remained stable with no statistically 
significant changes occurring over time. Elevated blood lactate levels were identified 
throughout anaesthesia but showed a tendency to reduce at later time points. 
Although PaO2 levels showed marked individual variation and were lower than 
expected given the FiO2 of 1.0 (suggesting compromised alveoli O2 uptake), it was 
possible to maintain SaO2 levels above 95%. Peak inspiratory pressure increased 
throughout anaesthesia, with values at 180 min almost 1.5 times greater than that 




Figure 8.13. Physiological parameters remained stable throughout anaesthesia. 
Physiological data obtained from OPA cases maintained at FiO2 of 1.0 throughout 
anaesthesia (data expressed as mean ± SEM, n=3-5 per time point; times indicate 
min post-induction of anaesthesia) (Hb, haemoglobin; ABE, arterial base excess; 
HCO3
-, bicarbonate; SaO2, haemoglobin O2 saturation; PaO2, arterial O2 partial 
pressure; PaCO2, arterial CO2 partial pressure; CT, core temperature; PIP, peak 
inspiratory pressure; RR, respiratory rate; HR, heart rate). 
8.3.9 Current generated by the sensor responded to alterations in 
inspired oxygen concentrations 
To assess the ability of the sensors to detect changes in intra-tumoural ptO2 
through changes in blood oxygenation we performed sequential alterations in FiO2, 
ranging from 0.21-1.0 (Figure 8.14a). Each FiO2  alteration was performed at 20 min 
intervals delivered through a flowmeter via the isoflurane vaporiser. The cycle of 
FiO2 alterations was: 1.0 for 20 min (baseline), 0.5 for 20 min (inducing mild 
hypoxaemia), 0.21 for 20 min (inducing moderate hypoxaemia) before finally 
returning to 1.0 for 20 min. Arterial blood samples were taken at the end of each 
FiO2 challenge. 
Baseline current recordings were first obtained using FiO2 of 1.0. The mean 
sensor current recorded during this baseline period was -1.67 ± 0.80 nA. Following 
FiO2 reductions to 0.5 and then to 0.21 sensor recordings decreased to -1.27 ± 0.59 
nA and -0.78 ± 0.30 nA respectively. Upon increasing FiO2 back to 1.0 sensor 
recordings rose to -1.24 ± 0.69 nA (Figure 8.14b & Table 8.5). Alterations in sensor 
currents occurred over a period of 10-15 min following each change in FiO2 and 
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although trends were identified, these current changes were not statistically 
significant when compared with baseline recordings. At the end of each FiO2 
challenge arterial blood-gas analysis confirmed the expected physiological changes 
induced by each challenge. SaO2 and PaO2 both decreased at 0.5 and 0.21 and 
increased back to baseline levels at 1.0. Hb concentration remained the same 
throughout each challenge, as expected (Figure 8.14c & Figure 8.14d). 
 
Figure 8.14. Sensor currents change in accordance with alterations in FiO2. (a) 
Representative graph showing current generated at the working electrode of the 
sensor during continuous sensor recordings over a period of 100 min. Each FiO2 
challenge was performed in 20 min blocks. (b) Combined analysis comparing current 
generated at the working electrode of the sensor during each FiO2 challenge; results 
show mean current readings from throughout each 20 min period (one-way ANOVA 
with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=4). 
(c&d) Arterial O2 partial pressure, total haemoglobin and haemoglobin O2 saturation 
measured at the end of each FiO2 challenge. 
Table 8.5. Current recordings generated during each FiO2 challenge. (n=4; mean 
± SEM). 
FiO2 100% (1) 50% 21% 100% (2) 
Current (nA) -1.67 ± 0.80 -1.27 ± 0.59 -0.78 ± 0.30 -1.24 ± 0.69 
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8.3.10 All implantation sites were identified during post-mortem 
examination 
Following completion of sensor recordings, euthanasia and final CT scans all 
sheep underwent post-mortem examination. Gross pathology allowed the assessment 
of lung pathology, identification of the implant site and provided the opportunity to 
obtain biopsy specimens for histopathological analysis. 
Upon entering the thoracic cavity OPA affected regions failed to collapse. 
Gross pathology identified lesions that were in accordance with those identified on 
the CT scans in terms of number of lesions, location and size. The majority of 
tumours were extensive, often involving the majority or entire lung lobe (Figure 
8.15a & Figure 8.15b); however occasional multifocal discrete lesions affecting 
different lung lobes were seen (Figure 8.15c). OPA tumours typically caused 
distortion of the normal architecture of the affected lung lobe and had a grey 
colouration, with clear boundaries between tumour tissue and adjacent pink aerated 
lung. Although the smooth contour of the overlying pleura typically remained intact, 
several cases had the presence of fibrinous adhesions between the visceral pleura and 
chest wall. No evidence of intra-thoracic metastasis was identified, with all 
tracheobronchial and mediastinal lymph nodes appearing grossly normal in all cases. 
All sensor implantation sites were successfully identified with an entry site seen in 
the visceral pleura overlying OPA tissue. In 1 case an area of petechial haemorrhage 
was evident to the lung surface in the region of the implantation site; however, the 





Figure 8.15. Photographs depicting gross pathology seen in typical OPA cases. 
These photographs are from the implantation cases presented in Figure 8.9. Each 
implantation site is highlighted with a black arrow. (a) Large grey consolidated mass 
affecting the majority of the left caudal lung lobe. An area of petechial haemorrhage 
can be seen on the surface of the lung surrounding the needle entry point. (b) Large 
grey consolidated mass affecting the majority of the left cranial lung lobe. Fibrous 
tissue can be seen adherent to the lung surface just cranial and ventral to the needle 
entry point. (c) One large dark coloured mass affecting the right cranial lung lobe 
containing the implant site with a further focal lesion within the left caudal lung lobe. 
8.3.11 Histopathology of OPA tissue and implant site identified 
variable amounts of intra-pulmonary haemorrhage 
Following gross pathology, the implant site was dissected from OPA tissue. 
The biopsy specimen was used for both OPA diagnosis and to assess the effects of 
the implantation procedure on OPA/lung tissue. Histological examination confirmed 
OPA diagnosis in all cases used for implantations, identifying non-encapsulated 
neoplastic foci forming acinar and papillary proliferations. In advanced cases 
separate foci had coalesced into a single large tumour (Figure 8.16a). The extent of 
inflammation varied considerably between cases and between different tumour areas 
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in the same case. In all cases large numbers of alveolar macrophages were identified 
within alveolar spaces (Figure 8.16b). Mononuclear cells including plasma cells and 
lymphocytes were also common, with some showing prominent lymphofollicular 
aggregates (Figure 8.16c). Neutrophilic infiltration was also seen, but not to the same 
extent as lymphocyte numbers. In all tumours, fibrovascular connective tissue was 
identified surrounding tumour cells (Figure 8.16d). 
 
Figure 8.16. Histological appearance of OPA tumours. (a-c) H&E stained 
sections. (a) Columnar tumour cells can be seen lining the alveolar septa (black 
arrows). Two groups of neutrophils (red arrows) can be seen between the tumour 
cells. (b) Alveolar macrophages are present at the top right-hand side of the image. 
(c) Mononuclear cells, lymphocytes and plasma cells can be observed at the top left-
hand side of the image. (d) Masson’s trichrome stained section. Collagen is stained 
blue (yellow arrow heads) and can be identified surrounding the tumour cells. 
Histopathology identified tumour cells immediately adjacent to the implant 
site in all cases; however, the percentage area composed of tumour cells varied 
ranging from 50% in 2 cases up to 80-95% in the remaining 7 cases. Evidence of 
haemorrhage within the needle tract and implantation site was identified in all cases; 
however, there was marked variation in the extent of haemorrhage seen between 
cases. Cases in which the needle passed through areas predominantly composed of 
tumour cells had evidence of bleeding restricted to within the needle tract itself, 
whereas cases in which the needle passed through areas of more normal lung showed 




Figure 8.17. Histological appearance of OPA tissue and implantation site. H&E 
stained sections. The top image shows the needle tract penetrating through the 
visceral pleura and into OPA tissue. Large numbers of erythrocytes can be seen 
within the needle tract. Higher magnification images document smaller numbers of 
erythrocytes extending up to 250 µm from the implant site, predominately located 




Figure 8.18. Histological appearance of OPA tissue and implant site with 
minimal and moderate intra-parenchymal haemorrhage. H&E stained sections. 
(a) The implant site is contained within an area consisting predominantly of tumour 
cells. The needle tract contains large numbers of erythrocytes; however, only small 
numbers are identified within OPA tissue adjacent to the implant site. (b) The 
implant site is contained within an area consisting of both tumour cells and more 
normal aerated lung tissue. The needle tract contains large numbers of erythrocytes; 
however, large numbers of erythrocytes are also identified within alveolar spaces and 
stromal tissue adjacent to the implant site. 
8.4 Discussion 
Similarities between OPA and human lung adenocarcinomas, in terms of 
disease presentation, progression and histological classification, has led to OPA 
becoming regarded as an excellent model for studying various aspects of human lung 
cancer biology. In vitro and in vivo OPA experimental models are well documented 
and have been used to elicit molecular pathways involved in lung cancer 
pathogenesis. However, if the disease is to be used as a pre-clinical research tool for 
human lung cancer, then techniques used in human medicine must be incorporated 
into the OPA model to demonstrate its translational ability. In order to achieve this, 
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our novel OPA model, used for validation of the IMPACT O2 sensors, was 
developed from protocols currently used in human thoracic medicine700. 
Human lung cancer diagnosis and staging is typically performed from 
aspirates or biopsy specimens taken using a flexible bronchoscope701 or via a trans-
thoracic approach702-704. As both techniques provide an accurate way to obtain a 
diagnosis705,706 the choice of which technique to use is largely dependent on lesion 
location. Central lesions that involve bronchi are readily assessible with a 
bronchoscope. Peripheral lesions, not visible on endobronchial examination705, or are 
less than 3 cm in diameter that do not show a bronchus entering the lesion on CT 
images, are diagnosed more accurately by minimally invasive trans-thoracic needle 
biopsy (TTNB)702,703,707. Modified techniques of both endoscopic and percutaneous 
biopsy approaches could have been used in our OPA model for sensor implantations; 
however, the trans-thoracic percutaneous approach was chosen for several reasons. 
Initial OPA lesions from naturally occurring cases typically begin at the peripheral 
regions of the lung lobes. Only as neoplastic foci enlarge and coalesce do the central 
regions of the lobes become affected. Although bronchioles will frequently be 
surrounded by tumour tissue the larger bronchi may remain largely unaffected. 
Although endoscopy can be performed in sheep275, successful endoscopic sensor 
implantation would only be possible in tumours which involved bronchi of sufficient 
diameter that can accommodate the endoscope. This selection criteria would 
significantly limit the number of cases that could be used and realistically would 
only be able to be assessed once sheep are anaesthesied and CT images have been 
obtained. Significant volumes of lung fluid produced by OPA tumours, present in the 
large and small airways, would also hamper endoscopic airway visualisation and 
make sensor implantation challenging. The presence of the endoscope within the 
airway could also hinder the delivery of fresh airflow and hamper attempts to suction 
away lung fluid. The IMPACT O2 sensor is also currently wired, and endoscopic 
delivery would mean that the lead wire would be required to run up through the large 
airways and out through the larynx; the presence of the endotracheal tube would 
make this almost impossible. These limitations directed us to develop the trans-
thoracic percutaneous approach for sensor implantations700. 
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For the development of our OPA model we undertook a staged series of 
experiments. Each development stage increased the complexity of the model; 
initially beginning with post-mortem cadavers and finally resulting in a refined 
protocol used in experimental sheep. Although the cadavers did not have lung 
pathology, these experiments allowed the initial development and refinement of the 
surgical procedure and provided information on accessible lung regions through each 
intercostal space. Using cadavers, we were able to successfully implant sensors into 
lung tissue using the 4th-8th intercostal spaces on both sides of the thorax. An 
important consideration is that in live, anaesthetised sheep the positions of accessible 
regions of the lungs are likely to be slightly different from the results gathered using 
post-mortem cases. In ruminants the costodiaphragmatic recess can enlarge 
following death due to atelectasis (causing the caudal border of the lung to move 
cranially) and from cranial displacement of the diaphragm due to ruminal bloat. 
These factors are likely to have reduced the implantation window seen using these 
post-mortem cases. Sensor implantation in these experiments was performed blind, 
without any image guidance; consequently, assessment of sensor implantation into 
lung parenchyma was difficult as there was little perceptible tactile feedback from 
penetration of the visceral pleura. Significant elastic deformation of the lung 
occurred prior to Jamshidi penetration; this degree of lung deformation could 
increase the risk of undesirable lung contusions surrounding the implantation site. 
However, as OPA tumours are likely to be consolidated with areas of fibrosis and 
adhesions to the parietal pleura, elastic deformation of the visceral pleura as seen 
using these cadavers was likely to be less of an issue. Following completion of post-
mortem experiments, the next stage in model development was identifying an 
appropriate image guidance technique to aid sensor implantation. 
In human medicine TTNB requires the use of image guidance. Fluoroscopy 
was once the preferred imaging modality of choice as it enabled needle 
advancements to be visualised in real-time708; however, access to deep lesions and 
avoidance of vascular structures and bullae proved difficult with this method709. 
Ultrasound has the advantage that needle movements can be monitored precisely and 
extremely quickly during the procedure and can improve the accuracy of obtaining 
samples from necrotic lesions710,711 whilst avoiding radiation exposure; however, its 
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use is restricted to peripheral lesions that produce an acoustic window. CT is now the 
most commonly used image guidance technique for TTNB. Samples obtained using 
this procedure have excellent diagnostic accuracy rates ranging from 66–
96%706,712,713. CT has the advantage over fluoroscopy in that it allows accurate 
planning of needle path trajectories that avoid aerated lung, bullae, fissures or blood 
vessels. The procedure can also be used to sample central lesions and those less than 
1 cm in diameter714. As with ultrasound, CT images can distinguish between necrotic 
and solid regions of a lesion, allowing for better diagnostic samples to be obtained. 
CT can be combined with fluoroscopy (CTF) to allow needle adjustments to be made 
in almost real-time. The technique is primarily used for very small lesions located in 
difficult to access thoracic regions such as in the costodiaphragmatic recess, or those 
close to the mediastinum or critical at-risk structures. The procedure can also be 
performed quickly, which is advantageous in high risk or un-cooperative patients715. 
Although any of these image techniques could have been used in our OPA 
model, CT was chosen for several reasons. CTF was not considered necessary for 
our cases and would have required the use of lead aprons and radiation shields for 
safety purposes. Although ultrasound guidance could have been used for sensor 
implantations into OPA lesions affecting pleural surfaces, it cannot provide an 
assessment of pathological lesions occurring throughout the entire thorax. These 
factors directed us to use CT guidance for sensor implantations700. 
During implantation procedures each CT scan was carefully reviewed. The 
initial scan allowed for lesion selection for sensor implantation with sequential scans 
being used to accurately assess needle trajectory and position. Lesion selection and 
needle path planning was based on risk factors associated with the development of 
TTNB complications such as pneumothorax and haemorrhage. Risk factors that 
contribute to TTNB complications include lesion characteristics and underlying 
disease pathology such as small lesions and the presence of emphysema716 or chronic 
obstructive pulmonary disease717. Technical factors when performing TTNB 
including increased amounts of normal aerated lung crossed by the needle718,719, a 
small oblique needle angle with the thoracic pleura720, multiple needle 
repositionings721, a greater number of sampling procedures722, the absence of 
previous ipsilateral surgery723, using a trans-fissure approach719 and damage to 
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thoracic vasculature can also increase complication rates. In accordance with these 
known risk factors, lesions were chosen so that the needle path avoided passing 
through bullae, large vessels, bronchi and interlobar fissures. If possible, a short 
straight path from the skin to the lesion, that crossed the pleura into the lung at 90 
degrees was planned. If more than 1 lesion was present, a peripheral lesion was 
chosen to decrease the amount of lung tissue that would be traversed724. 
The length of time required to perform CT-guided TTNB in human patients is 
1 potential limitation of the procedure, even though procedural length or needle 
dwell time within the lung has not been associated with increased risk of 
pneumothorax722. In our model single sensor implantations were performed in a time 
of 45 ± 5 min (mean ± SEM), which is similar to studies in human patients that have 
documented CT-guided TTNB procedure times of up to 66 min. The radiation risk 
associated with CT-guided TTNB is a potential concern as the patient effective dose 
is often greater than standard thoracic CT scans725. In our study we did not consider 
radiation exposure as experiments were performed as non-recovery procedures. 
However, future studies to investigate if the radiation dose received by these sheep is 
comparable with that used in human TTNB procedures could be performed. 
TTNB in humans is commonly performed under local anaesthesia; however, 
general anaesthesia was mandatory in our OPA model to ensure sheep and personnel 
safety. General anaesthesia of OPA sheep can be challenging due to respiratory 
compromise originating from OPA lesions, lung lobe consolidation, increased 
respiratory tract secretions, secondary infections and anaesthesia-induced atelectasis. 
These factors have the potential to lower PaO2 levels by decreasing the effective 
movement of inspired O2 into the blood. In our cases adequate haemoglobin oxygen 
saturation was achieved by increasing FiO2 in combination with mechanical 
ventilation. Although OPA cases may require additional anaesthetic monitoring with 
respiratory and cardiovascular support, all our cases were successfully managed 
throughout sensor validation experiments, providing evidence that OPA cases can be 
used in procedures that require general anaesthesia. 
The surgical procedure itself underwent several refinements until the final 
protocol was defined. From our initial 3 cases the major refinements included the use 
of radiopaque grid lines for improved accuracy of lesion localisation and performing 
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serial CT scans to aid needle positioning and sensor implantation. Careful handling 
of the implantation needle was essential to reduce the risk of iatrogenic lung damage 
during the surgical procedure, both during its initial insertion and subsequent 
advancements. One hand placed at the needle tip, near the skin surface, was used to 
stabilise the needle and prevent excessive needle advancement, while the other hand 
held the needle hub and provided downward pressure to advance the needle. The 
needle trajectory was maintained with each advancement as small deviations at the 
needle hub would produce large deviations at the needle tip. One issue that was 
encountered was the hub weight of the Jamshidi needle, which had the potential to 
cause the needle to list/move to one side until it was advanced sufficiently into OPA 
tissue to support its weight. To reduce the risk of needle movement causing lung 
damage it was only advanced to the level of the parietal pleura during its initial 
placement. Only when the needle position was confirmed on CT images was it 
advanced through the pleura, to the pre-measured depth, seating the needle 
sufficiently within lung/OPA tissue to prevent listing. Between each subsequent 
needle advancement, the needle was allowed to move with respiratory motions to 
prevent damage to lung tissue. Only following CT confirmation of the desired 
position of the needle tip in the OPA lesion was sensor implantation performed. 
Following sensor implantation an immediate CT was performed to evaluate 
sensor positioning and assess for complications. Known TTNB associated 
complications are pneumothorax, bleeding (haemoptysis, haemothorax), infection, 
air embolism, lung lobe torsion and needle tract metastasis. Estimated TTNB 
mortality rates are very low (approximately 0.02%) and are mainly caused by air 
embolism or massive haemoptysis726. By far the most common complications 
associated with TTNB are pneumothorax and haemorrhage700. 
Pneumothorax is the most common complication seen following TTNB. 
Although rates as high as 54% have been documented727,728, accepted occurrence 
rates are more likely to be in the region 17–26%, of which only 14% will require 
treatment through percutaneous aspiration or chest tube insertion720,723,729,730. 
Although most cases will be evident within 60 min following the procedure, serial x-
rays up to 3 h post-procedure are usually performed to ensure that a delayed 
pneumothorax has not occurred731,732. In our series of experiments 4 out of 9 cases 
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(44%) developed an immediate pneumothorax. Three of these cases were classified 
as mild, with 2 requiring percutaneous needle thoracocentesis. The 2 cases that 
received thoracocentesis fully resolved and did not show any pneumothorax 
recurrence; this was likely due to removal of all the excess pleural air from around 
the implant site, allowing apposition of visceral and parietal pleural surfaces. The 
remaining case also developed a mild immediate pneumothorax which was not 
severe enough to warrant drainage. However, following 4.5 h of sensor recordings 
the post-mortem CT scan identified progression of the pneumothorax with significant 
subcutaneous emphysema. This case demonstrated the need for repeat CT scans to 
detect delayed complications. Measures that were taken to reduce the risk of 
pneumothorax included the use of a coaxial technique to allow the sensor to be 
placed with a single pleural puncture, and as described above, careful needle path 
planning. Other techniques which may help reduce pneumothorax occurrence is the 
technique of obliterating, or ‘patching’ the needle track by injecting 2–3 ml of blood 
during withdrawal of the needle704. Although this would have been possible to 
perform it may have interfered with the lead wire and caused the sensor to move 
whilst the needle was being removed. Following sensor placement, the sheep could 
also have been repositioned with the puncture site down; however, this would have 
made connections from the lead wire to recording instrumentation difficult. 
Haemorrhage is the second most common TTNB complication occurring in 
approximately 4-10% of cases729,733. Bleeding may be evident as fresh blood passing 
up through the bore of the needle, or as a ground-glass appearance in CT images in 
the area of the biopsy or along the needle tract. Fortunately, haemothorax is 
exceedingly rare, with an incidence of less than 1%726. Measures that were taken to 
reduce the risk of haemorrhage included the avoidance of large pulmonary vessels by 
the needle path and directing the needle away from the aorta and the heart. Placing 
the needle through the centre of the intercostal space also reduced the risk of damage 
to intercostal neurovascular bundles. In our series of experiments no cases were 
identified as having post-implantation haemorrhage based on CT image evaluation; 
however, following post-mortem examination and implant site histopathology 
erythrocytes were identified within the needle tract in all cases. Variable amounts of 
erythrocytes were also identified in OPA tissue away from the needle tract itself, 
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possibly to a greater extent in cases where the needle passed through more normal 
areas of lung tissue. This observation is likely due to OPA affected regions having 
reduced compliance compared with normal lung tissue, with OPA tissue potentially 
acting as a tamponade preventing the escape of erythrocytes into the tumour tissue, 
whereas alveolar spaces would act as reservoir for the erythrocytes. The under 
reporting of alveolar haemorrhage based on the CT scans is likely due to the 
appearance of the OPA lesions themselves. All cases had large OPA lesions 
involving the visceral pleura that were characterised as having increased radiopacity, 
frequently with the presence of air bronchograms. This OPA CT appearance would 
have likely obscured any haemorrhage that occurred within the needle path. 
One factor that could have contributed to the complication rate seen in our 
model is the choice of needle that was used for sensor implantations. Needle 
selection was dictated by the dimensions of the IMPACT sensors; a needle with an 
internal bore diameter of sufficient size was therefore needed to accommodate the 
sensor and lead wire. As a result of this an 8G Jamshidi needle was required. This 
size of needle is considerably larger than the 18-22G needles that would be routinely 
used in human TTNB procedures. Further development and miniaturisation of the 
IMPACT O2 sensor will ultimately allow smaller diameter needles to be used, which 
will reduce complication rates, especially as bleeding complications are thought to be 
minimised by using needles smaller than 18G. 
Following successful development of the implantation procedure we wished 
to investigate the functionality of the IMPACT O2 sensor within the OPA TME. In 
order to achieve this, we determined if alterations in blood oxygenation levels, 
through changes in FiO2, would cause changes in intra-tumoural ptO2 that could be 
detected by the sensor. Arterial blood-gas analysis was used to confirm the expected 
physiological responses to FiO2 alterations. Hypoxia caused reductions in both PaO2 
and SaO2, whereas hyperoxia caused their levels to increase. Changes in sensor 
currents occurring with FiO2 challenges matched the same pattern of results obtained 
using arterial blood-gas analysis, with lower and higher currents generated in 
hypoxaemic and hyperoxaemic conditions respectively. Although, these current 
changes were not statistically significant when compared to baseline currents 
generated at FiO2 of 1.0, they demonstrated that the IMPACT O2 sensor could detect 
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changes in intra-tumoural ptO2. The large variation seen in the results between sheep 
is likely due to the underlying dynamic nature and heterogeneity of the TME, 
highlighting the need to spatially map O2 levels within a tumour. These results 
document, to the best of our knowledge, the first time that a sensor capable of 
monitoring intra-tumoural ptO2 in real-time has been implanted into a solid tumour. 
8.5 Conclusion 
This chapter has described the use of naturally occurring OPA cases in the 
development of a novel in vivo ovine model for the CT-guided trans-thoracic 
percutaneous implantation of IMPACT O2 sensors into lung tumours. This model 
was further developed to produce acute and reversible changes in intra-tumoural 
ptO2 through alterations in FiO2. These dynamic changes were detectable by the 
IMPACT O2 sensors implanted into OPA tumours. Through the integration of 
techniques such as ultrasound, general anaesthesia, CT and surgery into the OPA 
model, we have shown the models translational potential and effectiveness as a pre-
clinical research tool for human lung cancer. These results have provided evidence 
for further development of the IMPACT O2 sensor towards clinical applications in 
cancer therapy. Our results also demonstrate that the model could be developed 
further for other pre-clinical uses, such as the procurement of biopsy specimens, the 
development of medical devices for the local delivery of chemotherapeutic agents, 
monitoring the TME and to assess the effectiveness of RT or systemic 
chemotherapeutic agents.  
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9 Future work 
The development and characterisation of our novel human and canine breast and 
ovine lung cancer radioresistant cell lines in combination with the preliminary data 
obtained from the secretomic experiments has created numerous opportunities for 
future research. We envisage these 2 areas of research running both as standalone 
projects and in combination with each other. 
Although genotypic, phenotypic and functional characterisation of the novel 
human ER- and ER+ radioresistant breast cancer cell lines was undertaken, time 
restrictions prevented analysis of the animal cell lines. Using transcriptomic data 
from the REM-134 and JS7 parental and RR cell lines, characterisation could be 
performed using similar analysis criteria as was applied to the human cell line 
datasets. This could provide important data, as this study is the first to describe the 
development of radioresistant canine mammary and ovine lung cancer cell lines. This 
may prove useful in the case of the REM-134 cell line, as canine mammary tumours 
are seen as excellent models for human mammary tumours and so could represent an 
excellent comparative model of human disease734. In particular, canine mammary 
tumours show homology to human mammary tumours in the activation of numerous 
pathways such as PI3K/AKT, KRAS, PTEN, WNT-β-catenin and MAPK735, some of 
which were found to be differentially activated in our human parental and RR breast 
cancer cell lines. Characterisation of the JS7 RR cell line would also investigate the 
effects that chronic radiation exposure has on in vitro JSRV production. Evidence 
that suggests JS7 RR produces JSRV either in 2D or 3D cultures would provide an 
exciting and novel model to study virus production and radioresistance. 
As stocks of the RR cell lines have been created and stored in liquid nitrogen 
this will allow future studies to be performed aimed at targeting the differentially 
activated pathways that we have identified in the RR cell lines. These studies would 
ultimately focus on radioresistance reversal. Although out-with the scope of this PhD 
study, these types of experiments are the logical next phase in the use of our 
radioresistance model. These types of models will likely be instrumental in the 
development of new therapeutic strategies for patients that either fail to respond to 
treatment or develop recurrent disease. 
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One area of research could involve the use of inhibitors against EGFR or its 
downstream targets. Several phase I and II trials have investigated the use of 
gefitinib with RT as a means of improving patient outcomes736. Although conflicting 
reports regarding the clinical benefit of using EGFR inhibitors have prevented the 
routine clinical use of these drugs, some studies have shown they can improve 
survival rates and quality of life737,738. As our results have reported that RR cell lines 
derived from ER+ cells showed a shift from ER to EGFR signalling, with a 
corresponding increase in sensitivity to EGFR inhibition, it would seem logical to 
investigate inhibition of this pathway, including its downstream targets such as 
MAPK and PI3K as a means of overcoming radioresistance. 
Another area of research would be to investigate WNT signalling, as this 
pathway was also found to be upregulated in RR cell lines derived from ER+ cells. 
WNT and its downstream effectors regulate various processes that are important for 
tumourigenesis, progression, differentiation and metastasis739 and further dissection 
of the pathway may identify targets that can be inhibited to reverse radioresistance. 
The global approach taken using multiple techniques for characterisation of our 
radioresistance model identified numerous pathways that were differentially 
expressed or activated between paired parental and RR cell lines. Although only 2 
potential areas of future work have been highlighted here, multiple other pathways 
could be investigated in order to further characterise the mechanisms of acquired 
radioresistance and identify possible ways of targeting its development. 
The secretomic pilot study has generated a vast amount of data that has yet to be 
fully analysed. Future work involving the secretomic-based biomarker experiments 
could be broken down into 4 primary areas: continued biomarker in-lab validation, 
biomarker detection in blood, mechanisms of biomarker secretion and the 
development of a potential biomarker signature predictive of RT response. The use 
of the developed RR cell lines could also continue for the identification of 
differentially secreted biomarkers as a means of determining radiosensitivity. 
Secretome characterisation of untreated and radiation-treated MCF-7 cells 
identified 9 candidate biomarkers of which we have only started to validate 4. Future 
in-lab validation would investigate the remaining 5 biomarkers by assessing their 
secretion levels in CM from parental and RR cell lines 24 h after radiation treatment. 
281 
 
Further secretomic experiments could also be performed using MTS, as we have 
shown that MCF-7 RR, ZR-751 RR, MDA-MB-231 RR and REM-134 RR all form 
MTS. Although MTS are a more complex model compared with 2D cultured cells, 
they still suffer from the same limitations as 2D cultured cells in that they fail to 
account for the TME and the influence that stromal cells can have on cancer cells 
and their secretion profiles. Currently, our results are restricted to biomarkers 
released from cancer cells up to 24 h post-radiation. In order to assess biomarker 
secretion profiles in response to multiple fractions of radiation, experiments would 
need to include longer post-radiation time points. In order to overcome some of the 
aforementioned limitations of 2D and 3D MTS models, further experiments could 
include not only cancer cell line models, but also tumour explants. Precision cut lung 
slices of OPA tumours is a well-documented in vitro OPA model system689,690. This 
technique could be used in a variety of tissue types such as canine and human breast 
tumours. These experiments would begin to validate the biomarkers in a more 
complex model system. Currently, we have no evidence regarding biomarker 
secretion profiles from cells that have received multiple radiation fractions or how 
these profiles change beyond 24 h post-radiation. Further experiments continuing 
this work could begin to answer these questions and help move towards biomarker 
validation in real cancer tissue. Time course experiments would also allow for 
fixation of tumour samples after each radiation fraction in order to assess gene 
expression and intra-cellular protein levels. 
Detection of biomarkers in CM of cancer cells or explants could provide robust 
evidence of their secretion in response to radiation. However, these biomarkers will 
need to be shown to be detectable in blood before they can be used clinically. 
Detection protocols and methods would need to be developed for use with either 
plasma or serum, using techniques such as immunoprecipitation or ELISA. If in-lab 
detection of biomarkers in blood samples can be achieved, then this could increase 
the scope of experiments further to include obtaining blood samples from human and 
veterinary cancer patients undergoing RT. Further in vivo validation experiments 
could be performed using our novel paired sensitive and RR cell lines grown in a 
xenograft tumour model. Although the generation of xenograft tumours using our RR 
cell lines has not been attempted before, this would provide an excellent model to 
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identify differentially secreted biomarkers from known sensitive and RR tumours. 
Tumours could be radiated and 24 h post-treatment blood samples could be obtained 
for biomarker analysis. 
In order to investigate mechanisms of biomarker secretion, further work could 
also assess extra-cellular vesicle secretion pathways, as literature searches identified 
that all 33 candidate biomarkers are known to be secreted in exosomes or 
microvesicles. Experimental work could include microvesicle and exosome isolation 
and biomarker detection from the CM following radiation of cells, MTS and 
explants. The UPR also warrants further investigation, as we showed that the 3 
pathways (PERK, IRE1α and ATF6) are differentially activated in ER+ parental and 
RR cell lines and that several of our candidate biomarkers are involved with 
translation or protein trafficking. Using parental and RR cell lines, inhibition of each 
of the 3 pathways and through inducing ER stress and the UPR would indicate if 
these pathways play roles in radioresistance development or if they are involved in 
the secretion of our candidate biomarkers. 
As we have shown that there is differential gene and intra-cellular protein 
expression between parental and RR cell lines, a further area of research would be to 
investigate whether these biomarkers could be used to produce a predictive signature 
of RT response. Validation of a panel of biomarkers with a gene signature that can 
differentiate between our parental and RR cell lines could initially be performed 
using publicly available datasets of breast cancer cell lines with a range of inherent 
radiosensitivities and by using clinical samples where follow up data on tumour 
recurance and survival is known. 
Running in parallel to the in vitro experiments, the animal work conducted in 
this PhD project was aimed at producing pre-clinical data on the safety and 
functionality of the IMPACT O2 sensor. 
The successful validation of the ability of the IMPACT O2 sensor to accurately 
detect dynamic changes in intestinal ptO2 through ischaemic insults and alterations in 
FiO2 in our murine model has provided justification for progressing the experiments 
into more complex translational large animal anastomotic leak models. Pigs are 
regarded as excellent gastrointestinal translational models, as they are similar to 
humans in size, anatomy and physiology. A porcine anastomotic leak model using a 
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low rectal resection and anastomosis, performed with a double-stapled anastomosis 
without protective ileostoma, has previously been described in the literature740. This 
model shows anastomotic leak rates of up 30% within 9 days following surgery, 
which is similar to that reported in the human literature. Development of this model 
could be used in future experiments using the IMPACT O2 sensors. Initial 
experiments using a porcine model could involve a staged series of experiments like 
those used in the development of our ovine model. Experiments would progress from 
post-mortem cases to develop the surgical technique and assess the feasibility of 
placing sensors around a low rectal anastomotic site, through to non-recovery and 
recovery procedures. Porcine non-recovery models could be performed in which 
sensors are placed on normal bowel, bowel rendered ischaemic by vascular ligation 
and in proximity to a rectal resection and anastomosis. The resection and 
anastomosis could also be made to leak through the creation of a full thickness 
incision through the intestinal wall across the anastomotic site. These experiments 
would provide data on the ability of the sensors to detect ptO2 in normal, ischaemic 
and peri-anastomotic intestine, as well as assessing their suitability for surgical 
implantation. Clinical, haematological and biochemical data with regards to 
anastomotic leakage and septic peritonitis could also be obtained. If these initial 
experiments provide encouraging results, then studies could progress into recovery 
models providing further evidence of the in vivo safety and performance of the 
IMPACT O2 sensors. 
One question that needs to be answered if the IMPACT O2 sensor is to be used 
for resection and anastomotic applications in patients is how these sensors might be 
placed at the anastomotic site during surgery so that they remain at the site to 
measure post-operative intestinal ptO2. Solutions to this issue would include their use 
akin to a surgical drain or through their incorporation into surgical staples. 
Drains are used commonly in anastomotic surgery; although their effectiveness 
at reducing the occurrence of an anastomotic leak remains open to debate741-743 they 
are not associated with any significant complications. Drains are placed in the region 
of the anastomotic site and exit the body through a skin incision to be connected to 
external drainage bags. These drains can be easily removed when no longer required, 
typically several days post-surgery. Drains have been used to obtain post-operative 
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peritoneal samples from anastomotic sites for measuring bacterial colonisation, 
cytokines744 and metabolites745 that might serve as indicators of early anastomotic 
leakage. We envisage that designing the IMPACT O2 sensor in a similar 
configuration to a surgical drain would allow easy clinical use. The sensors, along 
with an electrical lead (similar in design to the current IMPACT O2 sensor and lead 
wire), could be positioned on the intestine next to the anastomosis site at the time of 
surgery. The electrical lead would then pass out through the skin in a similar manner 
to a surgical drain allowing the sensor to be connected to the end-of-bed monitor in 
the surgical high-dependency unit, providing the surgical team with post-operative, 
real-time data on peri-anastomotic intestinal ptO2 levels. The sensors could then be 
removed in a similar manner to the surgical drains. The advantage of this application 
would be that the IMPACT O2 sensor would not require significant further 
development. Incorporation of IMPACT O2 sensors into staples would have the 
advantage that peri-anastomotic ptO2 could be measured around the entire 
circumference of the intestine, thus providing detailed spatial information. However, 
further technological development of the sensor through miniaturisation and the 
development of wireless technology would be required in order to achieve sensor 
integration into surgical staples. 
The development of our novel OPA model was aimed at validating functionality 
of the IMPACT O2 sensor within a solid tumour. However, as the model successfully 
incorporated techniques commonly used in the management of human lung cancer 
patients, we have demonstrated the model’s translational potential and effectiveness 
as a pre-clinical model for human lung cancer. The use of the model for sensor 
implantation was associated with a complication rate similar to that seen in human 
medicine for TTNB, with pneumothorax being the most commonly encountered 
complication. We suspect that the size of the sensor and needle required for 
implantations were major contributing factors related to the complication rate seen. 
The potential for iatrogenic damage to alveolar spaces and small airways will be 
increased by using larger diameter implantation devices, which may then promote 
larger volumes of air to escape from airways within the lung into the pleural space. 
As the current IMPACT O2 sensor is also wired, this meant that the lead wire had to 
run from the sensor (implanted within the tumour) through the chest wall to be 
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connected to external instrumentation. Although a subcutaneous tunnel was created 
to reduce the chances of air entering the thoracic cavity from the external 
environment, we did identify in a couple of cases air within subcutaneous tissues, 
suggesting that air was able to track within the needle tract created for sensor 
implantation. Further engineering development of the sensor, rather than modifying 
the model itself, will be needed to overcome these issues. 
Further miniaturisation of the sensor will allow smaller gauge implantation 
needles to be used, which should reduce the volume of tissue damaged during 
implantation. Wireless technology would also eliminate the need for the lead wire 
and subcutaneous tunnel. If these technological advances could be achieved, then 
they could be utilised in experiments that require sheep to be recovered from 
anaesthesia following sensor implantation. Although we did investigate the use of 
wired sensors in recovery procedures by means of connecting the lead wire to a 
battery pack which was then secured to the sheep using a ram harness, this proved 
difficult to maintain for long periods of time and was not taken forward. The use of 
wireless sensors would overcome the need for external devices and make recovery 
procedures feasible. This would not only advance the OPA model but also provide a 
means by which new areas of research could be investigated, such as intra-tumoural 
biocompatibility and modelling of RT treatment programmes. 
Our work to date did not investigate the effects of RT on in vivo sensor function; 
this will need to be addressed in the future as the primary aim of the IMPACT O2 
sensor is to monitor intra-tumoural ptO2 throughout a patient’s RT treatment 
programme. From initial CT scan images, before sensor implantation, RT treatment 
planning could be carried out in our model as is done in human medicine. Following 
routine sensor implantation, sheep could be allowed to recover from anaesthesia, and 
over a period of 2-3 weeks, undergo repeated anaesthetics and external beam RT. 
Clinically relevant fractionated dose regimes could be delivered to the OPA tumour 
which would validate the IMPACT O2 sensor under clinically relevant conditions. 
Although this type of experiment would not be designed to assess the clinical 
response of the OPA tumour to RT, if they could be performed on multiple occasions 
over a period of several weeks then this would provide further evidence for the use 
of the IMPACT O2 sensor towards clinical applications in cancer therapy. 
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Incorporating RT into the OPA model could also enable validation of the biomarkers 
released from OPA cancer cells in response to radiation. Blood samples taken before 
and 24 h after a radiation dose could be used to investigate the biomarkers identified 
through our in vitro secretomic experiments. 
One of the limitations of the murine biofouling experiments was that the model 
was unable to be extended for periods that would include the entire chronic 
inflammatory phase of the FBR. Using OPA recovery procedures would overcome 
this limitation and would have the advantage of using functional sensors composed 
of all the biomaterials that were tested individually in the murine model. This would 
assess for any interactions between the individual biomaterials that could affect the 
FBR whilst using solid tumours in immunocompetent animals and provide further 
confidence in the intra-tumoural biocompatibility of the functional sensor and its 
constituent biomaterials. 
The OPA model holds potential to be used for other pre-clinical applications 
beyond functional validation of the IMPACT O2 sensor, especially as the disease 
itself is similar to human lung adenocarcinomas. The model could be adapted for the 
assessment of either systemically or locally delivered (image-guided injection or 
implantable drug release device) chemotherapeutic agents, with clinical effectiveness 
evaluated through a combination of imaging, on-treatment biopsies and post-mortem 
examination with sample collection. 
The in vivo work described in this PhD study, ranging from small animal murine 
models to large animal ovine models, aimed to produce initial pre-clinical data to 
establish the safety and functionality of an implantable sensor that could be used to 
monitor in vivo environments in human medicine. While not specifically considered 
in this study, these implantable devices would be equally applicable for use in 
veterinary patients. Although significant progress has been made towards sensor 
validation for multiple clinical applications, further engineering development of the 
sensor with continued large animal validation is required. The ultimate goal of the 
project would be to apply to the Medicines and Healthcare products Regulatory 
Agency for approval for use in humans which would allow sensor validation to 
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11.1 Gene lists used in chapter 4 for characterisation of the 
parental and radioresistant cell lines 
Table 11.1. Epithelial and mesenchymal gene lists. Epithelial and mesenchymal 
genes are taken from a pan-cancer EMT-associated gene expression signature345. 
Epithelial   Mesenchymal  
AFTPH ELMO3 LOC440335 SH3YL1  ACOT9 LGALS1 
AIM1L ELOVL7 LPAR2 SLC15A2 ANXA5 LOC100505634 
ANKRD5 EPCAM LSR SLC22A23 AP1M1 MAP7D3 
ANXA9 EPN3 MAL2 SLC29A2 AP1S2 MRC2 
AP1M2 ESRP1 MAP7 SLC39A9 ASAP1 MSN 
ARHGEF16 ESRP2 MAPK13 SLC44A1 C14orf149 MSRB3 
ARHGEF5 EXPH5 MARVELD2 SPINT1 C17orf51 NMT2 
ATP2C2 F11R MARVELD3 SPINT2 C6orf225 OSTM1 
ATXN7L3B FA2H MKL2 SPPL3 C9orf21 P4HA3 
BLCAP FAAH MYH14 SSH3 CCDC88A PDLIM4 
BSPRY FAAH2 MYLIP ST14 CCDC99 PGBD1 
C17orf28 FAM108C1 MYO1D SYNGR2 CFL2 PPM1F 
C1orf172 FAM83H MYO5B TLCD1 CHST10 PTRF 
C1orf210 FUCA1 MYO5C TM9SF2 CTGF RAB11FIP5 
C2orf15 FUK OVOL1 TMC4 DBN1 RAB32 
C6orf132 FXYD3 OVOL2 TMEM125 DENND5A RRAS 
CAMSAP3 GALNT3 PKP3 TMEM184A EIF5A2 RWDD1 
CBLC GGCT PLEKHG6 TMEM30B EMP3 SACS 
CCDC64B GRHL1 PPL TMEM79 ETS1 SCARF2 
CDH1 GRHL2 PROM2 TNK1 FAM101B SGCB 
CDH3 HOOK1 PRR15L TSPAN13 FAM127A SH2B3 
CDS1 HOOK2 PRRG2 TSTD1 FERMT2 ST3GAL2 
CLDN7 ICA1 PRRG4 WIBG FEZ2 STX2 
CMTM4 IDH1 PRSS8 XBP1 FGFR1 SYDE1 
CNKSR1 IGSF9 PTPN6 ZFP62 FMNL3 TGFB1I1 
CRB3 ILDR1 PVRL4 ZNF552 GLIPR1 TMEM158 
CTSH INADL RAB11FIP4 
 
GNAI2 TTC7B 
CYB561 IRF6 RASEF GNG11 TTL 
DDR1 ITPKC RBM47 GSTO1 TTL 
DENND2D JUP REL HABP4 TWF2 
DSP LENG9 ROD1 IKBIP UROD 
DTX4 LIMK2 RREB1 KATNAL1 VIM 
EFNA1 LLGL2 S100A14 KIAA1949 WTIP 
ELF1 LNX1 SDR42E1 LATS2 WWC2 




Table 11.2. WNT signalling and WNT target gene lists. WNT signalling pathway 
members and their down-stream targets were taken from the KEGG database342. 
WNT Signalling   WNT Targets  
DVL2 LEF1  PLAUR SOX9 
DKK3 PRICKLE1 CD44 SIX1 
RHOA WNT9A CDH1 FST 
LRP6 SKP2 CDON MYC 
FBXW11 TCF7L1 BIRC5 LEF1 
GSK3B FZD7 EFNB1 WNT9A 
NLK FZD1 NRP1 EGFR 
EP300 CTBP1 JAG1 GJA1 
DAAM1 LRP5 MET FZD7 
PORCN FZD5 AHR PPAP2B 
AXIN1 FZD6 DKK1 BTRC 
FZD3 FRAT1 CCND1 ANGPTL4 
DVL1 BTRC PPARD AXIN2 
MAPK8 CTNNB1 VEGFA IRS1 
DKK1 AXIN2 WNT5A ANTXR1 
CCND1 FZD4 FN1 FOSL1 
WNT5B FOSL1 ID2 SOX2 
PPARD RUVBL1 CTGF PTCH1 
CSNK1A1 FZD8 EGR1 TLE1 
WNT5A JUN TWIST1 
NFATC1 CTNNBIP1 LRP1 
APC FZD2 RUNX2 




11.2 Protein lists generated in chapter 5 for characterisation 
of MCF-7 secretome 
Table 11.3. The total 927 secreted proteins identified in the conditioned media of 
untreated MCF-7 cells up to 24 h post-serum starvation. 
CON P02769 HSPA4 HIST1H4A CNDP2 NPEPL1 
PPIA TXNDC17 YWHAQ G6PD PTMA 
ENO1 GDI1 MTPN AKR1A1 TMA7 
ALDOA RPL11 FANCD2 CON__P02668 HMGN1 
HSPA8 GLO1 CON P00978 PPP1CA FAHD1 
TPI1 YWHAG UBE2I CKAP4 RRM2 
CFL1 EIF5A CS HSPH1 NUDT2 
GAPDH CON Q3SZR3 YWHAH CON P02663 DDT 
HSPA1B ADH5 ALDH9A1 ADK GMFB 
KRT8 DPP3 NUTF2 TTN HSPB11 
PGK1 PGLS RNPEP LRRCC1 GLUD1 
ACTB KRT1 PGP KARS CON 24466 
FBP1 ATIC FABP5 NEDD8 MDP1 UBE2L3 
PEBP1 PDIA3 C1orf123 HPRT1 ACO2 
CALM1 APEX1 PGD SHMT1 TFF1 
MIF PA2G4 PEPD DLD LSM2 
MDH2 NPEPPS LXN PCNA CON P06868 
GPI HMGN2 DNPEP NLN GNPDA1 
TMSB4X HSPA6 ERH CON REFSEQ OTUB1 
PGAM1 SORD CON P02662 DDAH2 CBS 
YWHAZ TALDO1 SH3BGRL3 GCLC TRPV1 
LDHA COTL1 ESD DCTPP1 TFRC 
MDH1 PNP CON Q95121 CKMT1A TATDN1 
CON P00761 SUMO2 HIST1H2AJ LSM3 PPP1CC 
SOD1 CON Q2KJF1 KRT19 GSTM3 BOLA2 
CON Q3SZ57 GGCT PRDX6 PGM2 SHMT2 
YWHAE DDB1 WDR1 HIST2H3A MAT2B 
TKT GLOD4 GOT2 PHPT1 PDLIM1 
CON Q0IIK2 CON P02754 RBBP4 TARS MYH9 
PFN1 CBR1 PKM ENO2 PCBD1 
UBA52 TXNRD1 THOP1 MAT2A GYG1 
NAPA TPT1 ASS1 RAB11A CON 18229 
CLIC1 CON P12763 NME2 IDH1 EIF4H 
KRT18 LAP3 AIMP1 GCSH NUDT1 
GNB2L1 KRT10 APEH S100A11 TXN 
PPIB FBP2 CON Q58D62 MYDGF TBCA 
DUT GSR RCC2 GNPNAT1 DDAH1 
GDI2 KRT9 CSTB CON P41361 TSN 
RAN DSTN LTA4H CON P28800 ACTG1 
TMSB10 HIST1H2BM DBI EIF6 PPIF 
CON Q3MHN5 CON Q3SZV7 SFN ACLY DYNC1LI2 
CON P34955 GSS Streptavidin PPIL3 ME1 
ALDOC YWHAB FH CMPK1 TXNL1 
PARK7 SELENBP1 SCRN1 MT2A HMCN1 
TSTA3 DNASE2 PDAP1 EEF1A1P5 SPTAN1 
CON P21752 PSMA7 RAC1 FLNB PPP2R1A 
HN1 DPYSL2 GORASP2 ALB UGP2 
WDR5 NT5DC1 PLS3 F11 FKBP2 
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TRIM28 GSTO1 REXO2 PRDX1 ABCE1 
MSN ADSS ANXA5 ACTN1 RANBP1 
ECI1 COX17 PTRHD1 VCP GABARAPL2 
OLA1 ANXA3 CSDE1 CANX UFM1 
PFAS NANS TCEB2 CLTC AARS 
CON P50448 HN1L LMAN2 RCN1 VAPA 
CPPED1 YTHDF2 ABAT HSPE1 RAB21 
FLNA FKBP4 HSPB1 SGTA CRYZ 
OAT MAPRE1 RPSA RAB7A NQO1 
ARHGDIA PPIH CON P17690 RABIF ARMT1 
HSPA4L ISOC1 CON Q3Y5Z3 TUBA1B TAGLN2 
EIF2A ENOPH1 COX4I1 AHCY FSCN1 
FDPS HIF1A ACTN4 CYCS PPA1 
NIF3L1 SERF2 SH3BGRL HSPA9 CDH1 
PPP1CB DTD2 MAGOHB EEF2 SLC9A3R1 
APRT MVD HNRNPA1 HNRNPA2B1 ACAA2 
CON P02672 IDI1 CON Q3KUS7 NME1 UBA1 
OVCA2 CON Q1RMN8 LGALS3BP P4HB S100A16 
PROSC POLR2H NIT2 TPM4 PYCARD 
FAH PIR RAB6B HNRNPAB PLOD3 
CON 38329 VCL CTSB QSOX1 PSMB2 
BLMH WDR12 KRT2 ECH1 PSPH 
CBR3 CALU PSMB1 EIF5 ACTA1 
VAPB EIF2S2 CON Q9TRI1 ARPC4 PSMA1 
MAP4 GRPEL1 HSPA5 OXCT1 PIN4 
BASP1 BPNT1 DTD1 ERP29 CNBP 
S100A13 GLRX CTSD CON 15497 A0A0U1RRE5 
PPP2R4 ZNF300 PCMT1 HPDL VPS26A 
UFC1 HEBP2 PLEC BANF1 CORO1B 
PFN2 VPS29 UBE2V1 AIFM1 PSMA2 
LAMB1 ANXA2 TP53I3 C21orf33 SPARC 
EPPK1 AAMP UBE2V2 MAPK1IP1L ARPC2 
CON Q2UVX4 HSPD1 PSAT1 PSAP ACTR3 
ACYP1 NAGK CMBL MANF IGHA2 
MIPOL1 NRBP1 PROCR PSMA6 RAD23B 
RBBP9 ADI1 CON Q9QWL7 WARS KRT5 
IMPA1 DENR RAP1B PARS2 APOA1BP 
FKBP1A PPIL1 CTTN HDGF CTSL 
FASN HRSP12 LMNB1 PRDX2 RAB1A 
VIM EML2 TPD52L2 STARD10 TXNDC12 
NR2C2AP GART SPINT2 DSG2 PSMA4 
CLIC4 NUP37 PRRC2C PDXK RNH1 
BLVRB SUMO1 EIF4A1 PAFAH1B3 ACP1 
RPL19 CNPY2 B2M TUBB RSU1 
EEF1G CON Q9TT36 CST3 LDLR IGHG1 
PRKCSH CSTF1 AP1G1 EEF1A2 FKBP3 
PSMB5 DYNLL2 C11orf54 GGH KRT16 
PAICS ZNF706 NBEA UCHL1 EIF4EBP1 
KPNA2 BAG3 NUDT14 COPB2 GCLM 
ATP5B TAX1BP3 MCAM MB GLA 
PSMA5 EZR RBMX CCT3 LRRC59 
SLC7A5 CON Q2KIT0 ALAD NUDT3 PCNP 
MTDH PAFAH1B1 C1QBP NASP TWF1 
LAMC1 DCPS PDCD5 TCP1 CD44 
CKS1B CLEC3B ASNS RNASET2 VBP1 
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RBM8A PVRL4 ETF1 PMM2 GFRA1 
PPP1R14B UBE2A TPM3 CON 2777 CIRBP 
SCIN CON 735 PRTFDC1 HEXB RPS3 
PKIB CON P19001 HMGN3 MCM4 ABHD14B 
PGM1 DHX38 PLIN3 XRCC6 UBE2N 
SERPINB1 CAPN1 CFL2 RUVBL2 NLE1 
ARPC5 CCT8 TMSB15B SUPT5H UBAP2L 
UCHL3 MYL6 PTPRK IQGAP1 GOLM1 
GRB2 Sep-02 ARFIP1 HIST1H1B KRT7 
PPP2CA PVRL1 KRT6A HPX MAVS 
CUTA WDR92 NUP107 GARS TLN1 
RARS EEF1B2 HNRNPM EPRS EFNA1 
KIAA1279 CAPZA1 EIF3G CON 81644 EIF3A 
LANCL1 CDV3 EPCAM GSN TMPO 
ARCN1 RPIA CARHSP1 CCT5 RPL27A 
CON 3SZH5 RAB14 BTD CORO1C PABPC1 
DAG1 PSME1 LACTB2 GNS LDHB 
EIF1AX SUMO3 PPP5C SKP1 DSP 
HIST1H1C KATNAL2 HAGH STMN1 PITHD1 
BCAT2 ESYT1 SHROOM2 HSP90AA1 MARCKSL1 
GMPS EIF4B CAPRIN1 FREM2 ACACA 
EDF1 AK2 PIN1 RPL10A PC 
ISG15 AK1 CTSC GLRX3 CCT6A 
CALR SFPQ LMNA SLC3A2 PCCB 
ITPA COPG1 PUF60 EIF4G2 KRT6B 
CRK SRP9 LCP1 MAP7 PCCA 
DDX39B CRABP2 SEC23B SART3 KRT14 
PSMA3 RPS28 TOP1 SRRM2 SDC1 
TXN2 PAWR PCBP1 EIF2B1 CON 8VED5 
CLSTN1 GOT1 PSMB7 HTATSF1 TWSG1 
PCK2 CON 7350 YBX1 DDR1 S100A6 
PREPL CBX3 CAP1 LSM6 FUCA2 
RPE CON V8M9 MYOD1 GALNS ZBTB8OS 
PSMB6 ADPRHL2 ALCAM DLST GNB4 
XPNPEP1 HARS CON Q2KJ62 HIST1H1D KRT74 
TXNDC5 STIP1 FKBP15 CRKL CON 1252647 
LGALS1 CON 7665 MSRA COL5A1 KRT6C 
MYH15 UBE2K CAST ENSA CON Q95M1 
HMGN4 USP8 RPL5 MARCKS CSNK1A1 
MT1E STMN2 PTK7 DBN1 RABEP1 
TPP2 SEC24C PCBP2 NPW S100A8 
AMY1A MYO1C XRCC5 PPP2R5E TOR1AIP1 
DYNC1H1 CON Q32PI4 SCAMP3 SNRPD3 SUCLG1 
CON P01966 HNRNPU SLC25A5 AP2B1 SF3B4 
COX7C KIF5A CAPZB CCT7 SNRPC 
THBS1 F11R CON Q3SX09 EIF4G1 PSMD6 
RBBP7 BID SF3B3 DARS SNRPA 
CON P08730-1 IGFBP4 PRPF19 PITPNB LASP1 
HNRNPD CAD PTBP1 AP1B1 RPS10 
PSMB3 CLEC3A ILF3 SEC13 CCDC124 
SORT1 THUMPD1 LGMN AREG NRP1 
SERBP1 KHDRBS1 TNFRSF12A IARS DDX17 
NAGLU SERPINB9 DDX21 CON 3ZBS7 EFHD1 
ALYREF HSP90AB1 HK1 SEC23A BROX 
TSNAX NUCB1 PSMC2 PCSK1N PHGDH 
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CANT1 SPINT1 AIMP2 PSMD9 CARS 
CA12 CLU HMGA1 CCT2 TIMP2 
CSRP1 SDC4 PDIA6 VAMP8 HMGB3 
UBE2D3 TUBB4B NAP1L2 CON 16046 PSMD14 
FUCA1 BCAM IMPDH2 AKAP1 ACTR2 
GRN CTSA ANXA1 KHSRP DCXR 
PDE6D ILF2 CON 01045-1 SERPINH1 FN1 
SHISA5 EWSR1 CALML5 ITPK1 AHNAK 
HNRNPK DDX6 PRMT1 LRRN2 L1CAM 
CAT LSR TIMP1 POLDIP2 UBLCP1 
PPIC PFDN2 TUBA1C SF3B2 GCN1L1 
VASN SYNCRIP PDIA4 PSMB4 RRBP1 
RUVBL1 RPL12 TMOD3 USP14 FUBP1 
CON Q3T052 RAB5C PSMD11 FAM107B AGRN 
CON P05784 CAPNS1 TRAP1 SND1 ADRM1 
LSM8 RBM3 Sep-09 NUDC 
 
COL1A1 RPS12 HSP90AB2P TPD52 
FUS NCAM2 PABPN1 GAA 
HNRNPH1 RCN2 CRIP2 HSP90B1 
NUDT9 RAB2A COMT SEC31A 
PFDN4 M0QZD8 NPC2 RPS11 
NUDT5 MDK HEXA PSME3 
PPT1 ANP32A ARPP19 ATRN 
PPP6R3 LRRFIP1 TMEM132A CXCL12 
COA3 TAF15 IGF2 LAMTOR5 
CDC37 CHORDC1 HDLBP MGMT 
PLOD1 COX6B1 CTH LGALS7 
PRDX3 FLNC PAK2 GNAS 
IGFBP2 COA4 PPP4C SPTBN1 




Table 11.4. The 239 secreted proteins common to all time points in the 
conditioned media of untreated MCF-7 cells up to 24 h post-serum starvation. 
CON 2769 LDHA ALDOC SORD HIST1H2BM 
PPIA MDH1 PARK7 TALDO1 CON Q3SZV7 
ENO1 CON P00761 HSPA4 COTL1 GSS 
ALDOA SOD1 TXNDC17 PNP YWHAB 
HSPA8 CON Q3SZ57 GDI1 SUMO2 SELENBP1 
TPI1 YWHAE RPL11 CON Q2KJF1 HIST1H4A 
CFL1 TKT GLO1 GGCT YWHAQ 
GAPDH CON Q0IIK2 YWHAG DDB1 MTPN 
HSPA1B PFN1 EIF5A GLOD4 FANCD2 
KRT8 UBA52 CON Q3SZR3 CON P02754 CON P00978 
PGK1 NAPA ADH5 CBR1 UBE2I 
ACTB CLIC1 DPP3 TXNRD1 CS 
FBP1 KRT18 PGLS TPT1 YWHAH 
PEBP1 GNB2L1 KRT1 CON P12763 ALDH9A1 
CALM1 PPIB ATIC LAP3 NUTF2 
MIF DUT PDIA3 KRT10 RNPEP 
MDH2 GDI2 APEX1 FBP2 PGP 
GPI RAN PA2G4 GSR FABP5 
TMSB4X TMSB10 NPEPPS CON 24146 C1orf123 
PGAM1 CON Q3MHN5 HMGN2 KRT9 PGD 
YWHAZ CON P34955 HSPA6 DSTN PEPD 
LXN G6PD CON 28800 EIF4H ADSS 
DNPEP AKR1A1 EIF6 TXN COX17 
ERH CON P02668 ACLY DDAH1 YTHDF2 
CON 02662 PPP1CA PPIL3 TSN FKBP4 
SH3BGRL3 CKAP4 CMPK1 PPIF SERF2 
CON 95121 HSPH1 MT2A ME1 IDI1 
HIST1H2AJ CON P02663 NPEPL1 TSTA3 CON 1RMN8 
KRT19 TTN PTMA CON P21752 POLR2H 
PRDX6 LRRCC1 TMA7 HN1 HEBP2 
GOT2 KARS HMGN1 WDR5 ADI1 
RBBP4 NEDD8-MDP1 FAHD1 OLA1 PPIL1 
PKM HPRT1 NUDT2 CON P50448 SUMO1 
THOP1 DLD DDT ARHGDIA REXO2 
ASS1 NLN GLUD1 FDPS HSPB1 
NME2 CON 585019 CON 24466 NIF3L1 COX4I1 
AIMP1 DDAH2 UBE2L3 CON P02672 ACTN4 
APEH GCLC TFF1 PROSC MAGOHB 
CON 58D62 DCTPP1 CON P06868 FAH HNRNPA1 
RCC2 CKMT1A GNPDA1 BLMH LGALS3BP 
CSTB PGM2 OTUB1 CBR3 CTSB 
LTA4H PHPT1 CBS VAPB KRT2 
DBI ENO2 TFRC BASP1 HSPA5 
SFN RAB11A TATDN1 EPPK1 CTSD 
Streptavidin IDH1 BOLA2 CON Q2UVX4 UBE2V1 
FH GCSH MYH9 FKBP1A B2M 
SCRN1 S100A11 PCBD1 DNASE2 EEF1A1P5 




Table 11.5. The 147 secreted proteins which had greater than 2-fold increase in 
secretion levels in radiation treated MCF-7 cells compared to untreated controls 
at 24 h post-treatment. 
CSRP1 C11orf54 SUMO3 FSCN1 DDAH2 
EIF3G ASNS BLVRB GNB2L1 ISG15 
RAC1;RAC3;RAC2 SUPT5H NIT2 KARS CBR3 
GNPNAT1 NUDT3 GAPDH HNRNPA1 ADH5 
CAP1 SEC24C EIF2A MGMT TALDO1 
MIPOL1 FAM49B PGD GSTM3 CCDC124 
TP53I3 RAP1B;RAP1A EIF6 PGK1 CBR1 
OVCA2 NAP1L4 WDR1 CRIP2 TMPO 
PIN4 YBX3 PA2G4 PKIB PDCD5 
TK1 ATXN7L3B CLIC1 RPIA SORD 
RPE;RPEL1 DKK1 ESD TMA7 EIF4G1 
EIF4EBP2 DCTN2 RAN ARMT1 HNRNPAB 
TRPV1;SHPK MAP7 AHCY CFL1 RBMX;RBMXL1 
FKBP2 CON 2777 ASS1 PPIA RNPEP 
LANCL1 FUBP1 NUTF2 ACP1 PHPT1 
TMSB15B TIGAR AKR1A1 ALDH9A1 GART 
VPS29 IDH1 YWHAH PKM ATIC 
CORO1B OLA1 S100A11 MAPRE1 SUMO2 
GSTO1 RAD23B HMGN3 HMGN1 VAPA 
PIN1 FABP5 EDF1 ENO1 CAT 
VAPB ALDOC IDI1 GSR AIMP1 
ANXA2;ANXA2P2 ERH DTD1 NUDT1 HRSP12 
NAGK COTL1 RBBP9 POLR2H MTDH 
CDV3 PARK7 BASP1 LTA4H TPI1 
DSTN DDT;DDTL OTUB1 ESYT1 CDH1 
FAM107B CLIC4 PGP SUMO1 EFHD1 
EPPK1 SH3BGRL3 HMGN2 TCEB2 ABHD14B 
ENSA MAP4 ITPA EIF4H 
 
HNRNPM NT5DC1 CTTN TSTA3 
ALDOA CMBL SERBP1 PPP2R4 
Table 11.6. The 33 secreted proteins which had up to 12-fold increase in 
secretion levels in radiation treated MCF-7 cells compared to untreated controls 
at 24 h post-treatment. 
CSRP1 PIN4 TK1 IDH1 NUDT3 
EIF3G RPE EIF4EBP2 SUPT5H YBX3 
GNPNAT1 TRPV1 ASNS RAP1B MAP7 
MIPOL1 LANCL1 DKK1 VPS29 TIGAR 
TP53I3 C11orf54 DCTN2 ATXN7L3B SUMO3 
OVCA2 RAC1 TMSB15B SEC24C 
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